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Abstract 
Tumour Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) is a protein belonging to the TNF 
family of ligands. TRAIL is able to induce apoptosis in tumour cells, whilst leaving normal cells 
unaltered, representing therefore an attractive anti-cancer agent. In breast cancer, however, 
different cell lines are resistant to TRAIL. Moreover, many studies have demonstrated that breast 
cancer stem cells (bCSCs), the cells that are the most responsible for relapses and metastasis 
development, are resistant to TRAIL. Cellular FLICE-Like Inhibitory Protein (c-FLIP) plays a crucial role 
in TRAIL-resistance due to its ability to interfere with the TRAIL pathway, preventing therefore the 
apoptosis. In the course of a previous study, the homology model of c-FLIP has been constructed 
and using a structure-based virtual screening of commercially available compounds, one hit 
compound (3) able to inhibit c-FLIP at micromolar concentrations has been identified. Starting from 
the structure of the hit compound, several new derivatives belonging to four different structural 
families were designed and synthesised: sulfonamide derivatives, amine derivatives, amide 
derivatives and methylene derivatives. All the newly synthesised compounds were tested in an in 
vitro assay for their ability to sensitise TRAIL-resistant MCF-7 breast cancer cell line to TRAIL. 
Different derivatives retained the ability to increase TRAIL sensitisation showing a similar or slightly 
improved activity compared to the original hit. Some of the most promising compounds were 
further evaluated in in vitro pharmacokinetic assays, dose-response and cytotoxicity studies. The 
results obtained from these studies suggested the identification of a novel hit compound (88) which 
showed the ability to increase TRAIL sensitisation with an IC50 value in the range of 15-19 μM and 
improved metabolic stability compared to 3. Additionally, molecular docking analyses suggested a 
potential ability of the newly synthesised derivatives to occupy the pocket of c-FLIP. Taking into 
consideration all these results, a series of novel potential small molecule c-FLIP inhibitors showing 
ability to increase TRAIL sensitisation in resistant breast cancer cells and breast cancer stem cells 
was developed. Although further studies are needed to confirm the role of the newly synthesised 
compounds as c-FLIP inhibitors, these early results obtained are promising for the development of 
new therapeutic strategies in breast cancer treatment.
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Chapter 1: Introduction 
1.1Breast Cancer  
Breast cancer is a disease caused by a proliferation of breast cells which are exposed to mutations 
in genes that control cell growth and survival. 
 
Fig 1.1: Tumour development. 
In the UK, in 2014, 55,222 new cases of breast cancer were diagnosed (54,833 in women and 389 in 
men). (1) In 2012, breast cancer affected around 1,676,000 people worldwide. (2) According to these 
data, breast cancer is categorised as the most prevalent form of cancer in the UK, and the second 
most common cancer worldwide. Although the breast cancer survival rate has increased in the last 
forty years, in 2012, around 522,000 women worldwide died from breast cancer. (2)  In the UK, it is 
estimated that breast cancer killed around 11,400 women in 2014, 31 women every day on average. 
(1) Therefore, considering the mortality rates, breast cancer represents one of the most common 
causes of cancer death overall. 
1.1.1 Risk factors 
Although the causes of breast cancer are not exactly understood, different risk factors have been 
identified over the years. The primary risk factor is the female sex. The latest breast cancer incidence 
statistics for the UK show a female:male ratio of 141:1. (3) This is due to the activity of the female 
oestrogen hormones that stimulate breast cell proliferation, thus promoting errors in DNA 
replication. (4) This explains also why even early menarche and late menopause, which expose 
women to a higher level of hormones, increase the risk of developing breast cancer. (5) Age is an 
additional important risk factor with those over 65 years old representing the highest percentage 
(40%) of affected people. (6) The probability to develop breast cancer is highly influenced by genetic 
predisposition as well. (8) The most common hereditary genetic mutation in breast cancer is on genes 
BRCA1 (BReast CAncer gene 1) and BRCA 2 (BReast CAncer gene 2). Physiologically, these genes are 
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involved in repairing DNA damage, contributing to the normal breast cell growth. Therefore, 
mutations on BRCA1 or BRCA2 are associated with genomic instability. (8) Women who have 
mutations on BRCA1 and BRCA2 have a 72% and a 69% risk of developing breast cancer, respectively. 
(9) Although less common, changes in genes such as p53, PTEN and others can also represent 
important risk factors, due to their important role in supressing tumours. (10,11) The chance of breast 
cancer is also associated with lifestyle. Obesity, for example, increases the risk of postmenopausal 
breast cancer. (12) Consumption of alcohol has been assessed as a breast cancer risk factor, whilst 
cigarettes smoking does not influence the probability to develop breast cancer. (13) On the other 
hand, additional dietary components such as vitamins A, C, E and soy, and also regular physical 
activity are suggested to reduce breast cancer risk. (13) 
1.1.2 Signs, Symptoms and Diagnosis 
Several signs and symptoms can occur during a breast cancer onset. In most cases the first sign is a 
lump which may appear in the breast or in the armpits. (13) Additional symptoms are: a change in 
the size or in the shape of a breast or of a nipple, fluid leaking from the nipple, irritation of the skin 
around the breast. (13) 
    
Fig 1.1.2: Breast Cancer signs. (14) 
Whenever one or more of these symptoms occur, further analyses are highly recommended. There 
are different examinations used to diagnose breast cancer. (15) The first one is the Mammogram, an 
X-ray of the breast, which allows an accurate analysis for any suspicious areas. (16) Ultrasound is 
another exam that uses sound waves to penetrate and scan the breast. (17) MRI (Magnetic 
Resonance Imaging), using magnetic energy and radio waves, is an additional analysis useful to 
understand better the difference between normal and abnormal tissue. (18) Most frequently, the last 
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test is the biopsy which, by aspiration of the tissue and microscopic examination is the only 
procedure that can accurately determine if the suspicious area is cancerous. (19) 
1.1.3 Breast Cancer subtypes 
Breast cancer categorisation into different subtypes is often useful in order to identify the best 
therapeutic strategy. Due to the high heterogeneity, breast cancer can be classified on the basis of 
multiple factors.  
1.1.3.1 Histopathology 
Breast cancers are generally divided into invasive carcinoma and non-invasive (in situ) carcinoma. 
(20).  The non-invasive carcinoma can be additionally classified as ductal carcinoma in situ (DCIS) or 
lobular carcinoma in situ (LCIS). Among the two subtypes, the ductal carcinoma is the most common 
one and it has been divided into 5 different classes: Comedo, Cribiform, Micropapillary, Papillary 
and Solid. (20) On the other hand, invasive carcinoma have been sub-classified into tubular, ductal 
lobular, invasive lobular, infiltrating ductal, mucinous and medullary. Among these, infiltrating 
ductal carcinoma (IDC) represents the most common form (70-80%) and it can be subdivided into 
three distinct grades on the basis of the difference between cancer cells and normal breast cells. (20, 
21) When the tumours are well differentiated, with high tubule formation, low nuclear pleomorphism 
and low mitotic process, they are classified as grade 1. Grade 2 tumours are moderately 
differentiated, whereas when cancer cells are poorly differentiated, with a tubule formation less 
than 10%, a high mitotic rate and nuclear pleomorphism, they are defined as grade 3. (21) The three 
different grades are shown in figure 1.1.3.1. 
 
 Fig 1.1.3.1: The three different grades. (21) 
1.1.3.2 Hormone Receptor Status 
The hormone receptor status is a common criterion used to classify breast cancer. In this case 
tumours are separated as receptor 'positive' and 'negative'. When cancer cells overexpress the 
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oestrogen or progesterone receptor, they are defined as receptor positive (ER+, PR+). (22) This class 
of tumours shows a strong response when treated with specific anti-hormonal therapy and they 
represent the most common breast cancer subtype. (23) In contrast, this therapy is not applicable to 
negative receptor tumours because they do not display the receptor for the appropriate hormone 
(ER-, PR-). The expression of the human epidermal growth factor receptor 2 (HER-2) allows a further 
classification into HER-2 positive (HER-2+) and HER-2 negative (HER-2-) tumours. (24) 
1.1.3.3 Molecular Subtypes   
The molecular classification is based on the different gene expression pattern and allows the 
definition of at least three distinct subtypes: luminal, basal and HER-2+. (25) The first subtype includes 
tumours that express oestrogen and progesterone receptors and they are divided into luminal A 
and luminal B, according to the HER-2 expression. (26) Luminal A tumours are HER-2 negative and 
they represent the 50% of invasive breast cancers, whilst luminal B tumours are characterised by a 
variable expression of HER-2 and they account for 20% of cases. (26) The HER-2+ tumours are ER/PR 
negative, however they overexpress the HER-2 gene and additional oncogenes, such as ERBB2, and 
they represent the 15% of invasive breast cancers. (26, 27) Finally, the remaining 15% is represented 
by basal tumours which are characterised by the lack of HER-2 and hormone receptor expression, 
thus they are also called triple negative breast cancer (TNBC). (26) Graph 1.1.3.3 summarises the four 
different breast cancer subtypes. 
 
Graph 1.1.3.3: Molecular Breast Cancer Subtypes.  
This categorisation is helpful in order to improve the accuracy of the diagnosis and to plan 
individualised treatments.  
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1.1.4 Breast Cancer Treatment 
The early detection of the cancer is fundamental in order to reach a successful result in breast cancer 
treatment. Currently, the UK breast cancer screening programme offers a breast cancer screening 
every three years to women aged 50-70 years. (28) The aim of this programme is the diagnosis and 
the following treatment of breast cancer in its early stage, in order to increase the probability of 
treatment success. In the UK, it has been estimated that the screening programme reduced the 
relative risk of dying from breast cancer by 20%. (29) Mammography is the most useful method in 
breast cancer screening, it is a technique that, using X-ray, takes images of the breast allowing an 
accurate analysis. Breast Self-Examination (BSE), a self-made inspection, and the clinical 
examination, a full inspection of the breast, also represent important techniques in early cancer 
investigation. (30) After the diagnosis, the appropriate therapeutic strategy will be selected according 
to the grade, the stage and the subtype of the tumour. Currently, five main categories of treatment 
are available: surgery, radiotherapy, chemotherapy, hormone therapy and targeted therapy. (31) 
1.1.4.1 Surgery 
Surgery is, usually the first approach in breast cancer treatment and aims to remove completely the 
tumour mass and to discover whether any spread has occurred. Two different types of surgical 
procedure can be considered, mastectomy and breast conservations surgery, the choice depending 
on factors such as the size or the degree of the tumour. (32)  
1.1.4.2 Radiotherapy 
Radiotherapy is the use of high-energy beam in order to destroy cancer cells in the part of the body 
treated with radiation. (33) In general, it is combined with surgery with the aim to reduce the 
possibility of breast cancer relapse. A study conducted on 11,000 women has reported that patients 
treated with postoperative radiation have a 16% lower risk of breast cancer recurrence. (34)  
1.1.4.3 Hormone therapy 
Hormonal treatment is a therapeutic strategy suitable for receptor positive tumours and is based 
on the use of agents able to inhibit the proliferative action of female hormones. Currently, endocrine 
therapy is mostly based on drugs belonging to two main classes: the selective estrogen receptor 
modulators (SERM) and the aromatase inhibitors (AI). (35) Tamoxifen is the most common drug of 
the SERM family and it represents the first-line therapy, especially in premenopausal women. (31) 
Tamoxifen acts as oestrogen receptor antagonist in the breast, preventing the oestrogen-induced 
proliferative response in breast cells. (36)  Different studies have shown that the risk of breast cancer 
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recurrence and the risk of mortality is significantly decreased after 5/10 years of Tamoxifen 
treatment. (37,38) The second class of drugs, represented by the aromatase inhibitors, is often the 
treatment of choice in postmenopausal women. (39) Anastrozole, letrozole and exemestane are the 
most common aromatase inhibitors and they act via inhibition of the aromatase, that is the enzyme 
responsible for the oestrogen synthesis. (40) A combination of these two classes of drugs is often 
used in order to increase the efficacy of the treatment. Since lower risk of breast cancer recurrence 
and higher chance of survival have been demonstrated by the combination of the two therapies, 
current guidelines recommend the use of tamoxifen for the first 2-5 years followed by the 
administration of an AI. (41) 
1.1.4.4 Targeted therapy 
Targeted therapy is based on the possibility to hit cancer cells selectively by targeting specific 
molecular pathways which are involved in cancer cell proliferation and survival. Tumours which are 
classified as HER-2+ are characterised by the overexpression of the human epidermal growth factor 
receptor-2, which is a transmembrane tyrosine kinase receptor and controls cell growth, survival 
and migration (42). Those patients with HER-2+ tumours are currently treated with targeted therapies 
such us monoclonal antibodies directed against HER-2 or other members of the epidermal growth 
factor receptor family (EGFR), or small molecule tyrosine kinase inhibitors. Trastuzumab is a 
monoclonal antibody that binds the HER-2 extracellular domain interfering with the signalling 
pathway. (42) More recently other monoclonal antibodies binding different sites of the HER-2 
extracellular domain or other EGFRs have been developed, such as pertuzumab and cetuximab. (43,44) 
Additional targeted treatments are represented by small molecule inhibitors of the tyrosine kinases. 
The most common one is lapatinib, which is an ErbB1 and ErbB2 inhibitor and interferes with 
different pathways involved in cell growth and migration. (45) Although trastuzumab represents the 
first-line therapy for HER-2+ tumours, a combination with lapatinib or other chemotherapeutic drugs 
is often used. In particular, a combination with doxorubicin and cyclophosphamide induces a 
mortality risk reduction of 37%. (46) 
1.1.4.5 Chemotherapy 
Chemotherapy implicates the use of anti-cancer drugs and is defined "adjuvant chemotherapy" 
when it is given after surgery, whereas when the drug administration precedes the surgery it is 
defined "neoadjuvant chemotherapy". In both cases, the purpose of this treatment is to kill cancer 
cells and to prevent the tumour recurrence, however, the neoadjuvant therapy has an additional 
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benefit, indeed drugs can reduce the tumour size permitting a less invasive surgery. (47) Several anti-
cancer agents have been developed over the years: alkylating agents (e.g. cyclophosphamide and 
cisplatin), antimetabolites (e.g. methotrexate and 5-fluorouracil), taxanes (e.g. paclitaxel and 
docetaxel), anthracyclines (e.g. doxorubicin). All these drugs act via inhibition of cell division. (48) 
Despite the highly unselective mechanism of action, chemotherapeutic agents represent the 
treatment of choice for triple negative breast cancers (TBNCs). Usually anthracyclines (doxorubicin) 
and taxanes (paclitaxel) as single agents are the first line therapy. (49) However, a sequential 
combination of these agents gives a 20-25% lower breast cancer mortality. (31) More recently, 
several agents which aim to hit specific pathways, such as PI3K inhibitors, PARP inhibitors, MEK 
inhibitors, HDAC inhibitors and HSP 90 inhibitors have been developed and are under investigations. 
(50)  Unfortunately, the overall survival among patients diagnosed with TNBC is currently very low, 
with only less than 30% of women surviving 5 years after the diagnosis. (50) 
A summary of the most common therapeutic strategies is shown in table 1.1. 
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Cancer Targets Type Mechanism of action Examples 
 
 
Luminal 
SERM 
 
 
 
AI 
Oestrogen receptor 
antagonist 
 
 
Inhibition of 
oestrogen synthesis 
Tamoxifen, 
Raloxifene, 
Toremifene 
 
Anastrozole, letrozole, 
exemestane 
 
 
HER-2+ 
Monoclonal 
Antibodies 
 
 
TK inhibitors 
Interfere with EGFRs 
signalling pathways 
 
 
Interfere with tyrosine 
kinases signalling 
pathways 
Trastuzumab, 
pertuzumab, 
cetuximab 
 
Lapatinib 
 
 
 
 
 
 
Basal 
Alkylating agents 
 
 
Antimetabolites 
 
 
 
Anthracyclines 
 
 
 
 
 
Taxanes 
 
DNA damage 
 
 
Interfere with the S 
phase of cell growth 
 
 
Generation of free 
radicals that break 
DNA 
 
 
 
Interfere with the M 
phase of cell cycle 
stopping cell division 
Cyclophosphamide, 
Cisplatin 
 
5-fluorouracile, 
Fludarabine, 
Methotrexate 
 
Doxorubicin, 
Epirubicin 
 
 
 
 
Paclitaxel, Docetaxel 
 
 
Table 1.1.4: Summary of breast cancer therapeutic strategies. 
1.1.4.6 Limitations of current treatments 
One of the most important limitation of the therapeutic strategies developed so far is the high 
cytotoxicity associated with the lack of tumour selectivity. (51) Commonly, patients undergoing 
chemotherapy experience an incredible variety of side effects which significantly reduce the quality 
of life during the treatment: nausea, vomiting, loss of hair, highest risk to acquire infections, 
anaemia, weight gain, fatigue. (52,53) Hormonal treatment for luminal breast cancers is also 
associated with several side effects such as insomnia, weight gain, hot flashes, joint aches. (54) 
Different side effects have been associated with trastuzumab and tyrosine kinases inhibitors used 
for the treatment of HER-2+ tumours. Cardiac toxicity is the biggest problem for patients treated 
with trastuzumab, whilst symptoms such as nausea, vomiting, diarrhoea and rash are common in 
patients treated with lapatinib. (55)  Therefore, despite the decreased mortality rate in breast cancer 
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patients reached over the years, the development of more selective targets and novel therapeutic 
strategies represents a relevant issue. 
1.1.5 Challenges in Breast Cancer treatment 
Most certainly breast cancer screening and the different therapeutic strategies developed over the 
years, achieved important results in reducing breast cancer mortality, (56) however, resistance to 
treatment and relapses are common events. (57) Therefore, an accurate analysis of the reasons 
behind these phenomena is required in order to delineate the challenges in breast cancer 
treatment. 
1.1.5.1 Drug resistance in breast cancer 
Although several therapeutic agents have been developed, resistance to these drugs still represents 
a relevant problem in breast cancer treatment. Drug resistance can either occur at the very 
beginning of the treatment, in this case defined as de novo, or it can be acquired when patients, 
initially responding to the treatment, become refractory. (58) Drug resistance concerns all different 
types of breast cancer. Adjuvant endocrine therapy for patients diagnosed with luminal cancer 
significantly contributed to reduce breast cancer mortality, however resistance to the treatment 
occurs in one third of the cases. (59) Although several factors such as different catalytic activity of the 
enzymes responsible for tamoxifen or other drugs metabolism, or modifications in the 
phosphorylation events that regulate ERs activity, have been identified, generally the mechanisms 
of endocrine resistance are still poorly understood. (60) Drug-resistance represents an important 
limitation also for the treatment of HER-2+ tumours. A very high percentage of patients develop de 
novo or acquired resistance to trastuzumab: 65% and 70% respectively. (60) Activation of other 
tyrosine kinase signalling pathways that overcome the trastuzumab-induced inhibition of HER-2 
pathway, is commonly the main mechanism behind trastuzumab resistance. (60) The problem of drug 
resistance in the treatment of TNBCs is also very well-known. Unfortunately, the only therapeutic 
option for TNBCs is the administration of chemotherapeutic agents. However, resistance to these 
drugs occurs in most of the cases. (61) Although a range of 30-70% of patients initially respond to the 
two most common classes of drugs used for the treatment, anthracyclines or taxanes, this response 
is not long-lasting. Commonly, patients acquire resistance to these agents and a progression of the 
tumours usually occurs after 6-10 months. (61) Combination therapies, that involve the combined 
use of chemotherapeutic agents belonging to different classes, have been developed in order to 
overcome the problem of resistance. However, cross-resistance, also known as multidrug resistance 
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(MDR), where patients which have been exposed to a single drug develop resistance to several other 
agents, is very common. (61) Different mechanisms involved in chemotherapy resistance have been 
identified. The expression of membrane pumps (P-gp or MRP1) that promote the efflux of drugs 
from the cell is one of the most common, but other events such as changes in the expression of the 
drug targets, altered functionality of the enzymes responsible for DNA repair or modifications in the 
apoptotic signalling pathway, also contribute to drug resistance. (61) As discussed above, a lot of 
progress in understanding the mechanisms involved in drug resistance have been made, 
nevertheless it still represents one of the main challenges in breast cancer treatment.   
1.1.5.2 Breast Cancer Heterogeneity 
Breast cancer heterogeneity represents an important explanation for the inefficiency of some 
treatments and is based on the idea that several subpopulations with a different sensitivity to drugs 
contribute to tumour formation. (62) The heterogeneity is due to multiple factors. The several 
subtypes of breast cancer, defined according to different characteristics that tumours show, have 
already been mentioned. However, additional aspects are also involved in breast cancer 
heterogeneity. The type of genetic alteration that converts a normal cell to cancerous cell (mutation, 
fusion, amplification), and the different susceptibility of genes to breast cancer, are additional 
examples of the causes of heterogeneity. (63) 
1.1.5.3 Breast Cancer Stem Cells (BCSCs) 
The nature of the cell, which is originally transformed in a cancer cell, is an additional important 
factor that contributes to heterogeneity and relapse occurrence. 
1.1.5.3.1 Cancer Stem Cell (CSC) Hypothesis 
During the last 10-15 years a novel theory on cancer initiation has been developed: the cancer stem 
cell hypothesis. (64) This theory states that only a small subpopulation of cells, known as cancer stem 
cells is responsible for cancer development and progression. (65)  This concept is mainly based on the 
fact that cancer cells show important stem-cell like properties: self-renewal ability, capacity to 
differentiate into different cell types, resistance to programmed cell death and high metastatic 
potential. (66)  Additionally, the probability to accumulate multiple mutations that are responsible 
for the initiation of the tumour is higher in stem cells due to their enduring nature. (66) According to 
the CSC model, cancer stem cells, as well as normal stem cells, during the self-renewal process, can 
either generate daughter cancer stem cells (symmetric self-renewal), which are responsible for the 
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progression of the tumour, or differentiate into the heterogeneous bulk of cancer cells (asymmetric 
self-renewal), which do not show stem-cell like properties. (66,67)  
 
Fig 1.1.5.3.1: Cancer Stem Cells Hypothesis. 
Over the years different evidences have supported this theory for a variety of cancers. These studies 
have demonstrated that only cancer stem cells, identified by the expression of specific markers 
associated with self-renewal and differentiation properties, were responsible for tumour initiation. 
(65)  
1.1.5.3.2 BCSCs Hypothesis 
The hypothesis that breast tumours originate from cancer stem cells has been demonstrated for the 
first time in 2003. (68) This study showed that only cancer stem cells, defined by specific surface 
markers such as CD44+CD24-/low were responsible for tumour initiation. On the contrary, the 
majority of cancer cells expressing CD44-CD24+ markers did not show ability to initiate tumours 
when transplanted in mice. Furthermore, this study demonstrated that tumour initiating cells have 
stem-cells like properties such as self-renewal and differentiation, indeed those cells expressing 
CD44+CD24-/low   showed the ability to re-induce tumour formation when passaged and transplanted 
in new mice, and to generate nontumorigenic cancer cells with different phenotypes. (68)  
1.1.5.3.3 BCSCs-resistance to treatment and relapse 
The idea that breast cancer stem cells are responsible for tumour initiation and progression also 
plays an important role in explaining phenomena such as resistance to treatment and relapse 
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occurrence.  As discussed in paragraph 1.1.4.5, current chemotherapeutic drugs target cells that 
rapidly undergo cell division. On the contrary, cancer stem cells are quiescent and long-lived cells. 
(69). Additionally, BCSCs are characterised by the high expression of anti-apoptotic proteins and ABC-
transporters, also recognised as multi-drug resistance transporters. (65)  As a result of these 
properties, BCSCs do not respond to conventional treatments. (65)  BCSCs resistance to treatment 
has also relevant implications in the occurrence of relapses, which represents an important problem 
in breast cancer treatment. Indeed, although current therapeutic strategies have been successful in 
inducing tumours regression, the self-renewing breast cancer stem cells that survive after the 
treatment will likely support tumour reoccurrences. (70) For all these reasons, breast cancer stem 
cells, represent, nowadays, an important and attractive therapeutic target in order to develop novel 
therapeutic strategies able to eradicate all the cancer cells within the tumour.  
 
Fig 1.1.5.3.3: Therapeutic strategies of treating cancer. 
1.1.5.3.4 BCSCs experimental models 
In order to identify novel therapeutic agents able to target breast cancer stem cells, specific in vivo 
and in vitro experimental models have been developed. The most reliable in vitro assay for the 
identification of breast cancer stem cells is the mammosphere assay. (71) The assay is based on the 
selective ability of breast cancer stem cells to form clusters of undifferentiated cells, termed 
mammospheres, when cultured in non-adherent conditions. Indeed, in these particular conditions 
most of the cells will die due to anoikis, whilst stem cells will survive and proliferate. In a second 
passage, mammospheres previously formed will be broken-up and treated in the same conditions 
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in order to evaluate the self-renewal ability of the breast cancer stem cells, which will result in the 
formation of new mammospheres. (72) The Colony Forming Assay (CFA) or clonogenic assay is an 
additional assay used to identify breast cancer stem cells. As well as the mammosphere assay, CFA 
is based on the ability of a single cell to replicate indefinitely and form colonies composed of at least 
50 cells. (73) However, although these in vitro assays are convenient in terms of time and resources 
needed, further in vivo studies are often required. The gold standard for in vivo study is the serial 
transplantation assay. (67) This assay involves the transplantation of human cancer cells in 
immunocompromised mice which are assessed at different times for tumour formation. 
Subsequently cells are isolated from the tumour and transplanted into a second animal, in order to 
evaluate the ability of these cells to self-renew and re-induce tumour formation. (67) Ideally, the 
development of novel agents targeting breast cancer stem cells should be supported by initial in 
vitro assays, which are suitable for high-throughput screens for compounds, followed by in vivo 
studies.  
1.1.5.3.5 Targeting BCSCs 
Different strategies are currently under exploration for developing specific breast cancer stem cell 
therapies. (74) One of the most common approaches is to target the different signalling pathways 
which are involved in survival and self-renewal of breast cancer stem cells, such as Wnt, Notch, 
Hedgehog, PI3K/Akt/mToR. (75) Several agents, which are currently in clinical trials, showed the 
ability to affect mammospheres formation in vitro and to reduce tumour growth in in vivo studies: 
MK-0752 (gamma-secretase inhibitor), vismodegib (hedgehog inhibitor), PKF118-310 (Wnt 
inhibitor), everolismus (PI3K/Akt/mToR inhibitor). (75) Other agents, such as salinomycin, or ATRA 
(All Trans Retinoic Acid) have been evaluated due to their ability to induce cancer stem cells 
differentiation, but they showed poor clinical results. (75) Additionally, existing agents are currently 
being studied for their ability to affect breast cancer stem cells when combined with conventional 
chemotherapeutic drugs, lapatinib, trastuzumab and bevacizumab represent a few examples. (75) 
Interestingly, recent studies are also exploring the effect on breast cancer stem cell populations of 
drugs which have not been used in cancer treatments, such as metformin, or disulfiram. (75) Although 
clinical results for these agents are currently unknown, all these studies prove the importance of 
the advances made in identifying the molecular pathways involved in breast cancer stem cells 
survival and in developing in vitro and in vivo experimental models. This progress is fundamental for 
the development of more selective targets in order to overcome problems such as relapses and drug 
resistance and achieve better results in breast cancer treatment. 
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1.2 Apoptosis 
Apoptosis, or programmed cell death, is a physiological process necessary for normal organism 
development and for the conservation of tissue homeostasis. Alterations in this process are involved 
in several pathologies: immunological diseases, neurodegenerative diseases, cardiovascular 
diseases and cancer. (76) Immune reactions, pathologies, chemical agents, drugs, and hormones are 
the most common stimuli that cause the apoptosis initiation. (77) Afterwards two different molecular 
pathways may carry on this process: the intrinsic pathway and the extrinsic pathway. 
The intrinsic pathway involves mitochondria and a protein family known as the BCL-2 family. The 
proteins belonging to this family are characterised by the presence of a BCL-2 homology domain (BH 
domain). Anti-apoptotic (Bcl-2, Bcl-xl) and pro-apoptotic (Bax, Bak, Boc) proteins are both part of 
this family. When stressing conditions occur, the pro-apoptotic factors initiate the formation of 
pores on the mitochondrial membrane, increasing its permeability. This event leads to the 
conclusion of ATP production due to the variation in mitochondrial membrane potential and finally 
to the release of multiple proteins, such as Cytochrome C (Cyt C) or the apoptotic protease activating 
factor-1 (Apaf-1), which recruit the pro-caspase 9, forming the apoptosome that is able to activate 
the caspase-cascade. (77)  
On the other hand, the extrinsic pathway involves the Tumour Necrosis Factor (TNF) family of 
proteins. Receptors belonging to this family are generally known as death receptors (DRs). Multiple 
ligands that show a specific domain, the death domain, bind these receptors, leading to the 
formation of the Death Inducing Signalling Complex (DISC). (78) The DISC generation involves 
recruitment of adapter proteins which show a particular domain defined as Death Effector Domain 
(DED). This domain interacts with the DED of the pro-caspase-8 thus leading to the activation of the 
caspase-cascade. (77) 
Figure 1.2 summarises the two apoptotic signalling pathways.  
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Fig 1.2: Apoptotic Signalling Pathways. 
1.2.1 Tumour necrosis factor-Related Apoptosis Inducing Ligand (TRAIL) 
TRAIL or the Apo-2 ligand is a type II transmembrane protein composed of 281 amino acids 
belonging to the TNF family of proteins. (79) TRAIL is naturally expressed on cells of the immune 
system such as dendritic cells, macrophages, T cells and natural killer cells. TRAIL is produced in a 
pro-form which, after cleavage, results in a soluble homotrimeric molecule. (80) As homotrimer, 
TRAIL is able to bind five different receptors: Death Receptor 4 (DR4), Death Receptor 5 (DR5), Decoy 
Receptor 1 (DcR1), Decoy Receptor 2 (DcR2), and the last one called Osteoprotegerin (OPG). The 
two DRs exhibit the Death Domain (DD) which is crucial for initiation of apoptosis, whereas DcRs 
lack this domain, therefore when overexpressed, they inhibit the activation of the death pathway. 
(80) Although the main function of TRAIL is represented by its role in inducing apoptosis, rarely TRAIL 
is also able to interfere with other pathways involved in cell survival, such as NF-кB, MAPKs, PI3K 
and Akt. (81) The role of TRAIL in these pathways is still not completely understood, however, a 
combination of different proteins such as FADD, Caspase-8, c-FLIP, TNFR-type1, TNFF-type2 and 
others are thought to be involved in this process. (81)    
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1.2.1.1 TRAIL-induced apoptosis 
As discussed in paragraph 1.2.1, as homotrimer TRAIL is able to activate the extrinsic apoptotic 
pathway via interaction with the Death Receptors (DRs). When activated by TRAIL, DRs change their 
conformations, acquiring a trimeric form, initiating the formation of the DISC (death inducing 
signalling complex). The intracellular death domain (DD) of the DRs recruits FADD (Fas-Associated 
Death Domain), an adapter protein which shows a Death Effector Domain (DED). DED of FADD 
recognises and binds the DED on procaspase-8. The following procaspase-8 dimerization converts 
this protein into the active form caspase-8 thus leading to caspase cascade and apoptosis. (82)  
 
Fig 1.2.1.1: TRAIL-induced apoptosis. 
1.2.1.2 Regulation of TRAIL and TRAIL signalling 
As endogenous ligand involved in the apoptotic process, the expression of TRAIL is highly regulated 
by different transcription factors. Interferons, and other transcription factors such as NFAT and 
NFкB, or p53 and Foxo3a, which are involved in tumour suppression, promote TRAIL expression, 
whilst factors such as SP-1 negatively modulate TRAIL gene transcription. (83) The response to TRAIL 
may be controlled by all the different components belonging to the TRAIL signalling pathway. One 
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of the main factors that modulates the sensitivity to TRAIL is the expression level of the TRAIL 
receptors. Lack of DR4 and DR5 is associated with TRAIL resistance. In particular, in breast cancer, 
endocytosis of the DRs and consequent lack of expression on the cell surface, significantly decrease 
the response to TRAIL. (79, 84) Overexpression of decoy receptors (DcRs) also contribute to TRAIL 
resistance. These receptors do not show the DD required for the formation of the DISC, therefore, 
when overexpressed, they prevent the binding between TRAIL and DRs and consequently the 
activation of the apoptotic signalling pathway. (85) Additionally to TRAIL receptors, several other 
proteins may influence the response to TRAIL. The cellular FLICE-like inhibitory protein (c-FLIP) is a 
protein involved in the apoptotic process. As well as procaspase-8, c-FLIP shows two death effector 
domains (DEDs), although lacking caspase activity. When overexpressed, c-FLIP can compete with 
procaspase-8 for binding to FADD, therefore preventing the activation of the caspase cascade. (86)  
Caspases may also be directly inactivated by the presence of caspase-inhibiting proteins such as 
XIAP, thus preventing the TRAIL-induced cell death. (87)  Up-regulation of the transcription factor 
NFкB, that regulates the expression of genes codifying for the antiapoptotic proteins mentioned 
above, also promotes TRAIL resistance. (88) On the other side, overexpression of the oncogenic factor 
c-Myc is associated with increased TRAIL sensitivity. The ability of c-Myc to inhibit the NFкB-induced 
expression of anti-apoptotic proteins and to upregulate the expression of the DR5, represent the 
main mechanisms involved in the enhancement of the TRAIL response. (86, 89)   
1.2.1.3 TRAIL and non-transformed cells 
Nowadays TRAIL is considered one of the most promising anticancer agents due to the ability to 
induce apoptosis in cancer cells whilst leaving normal cells unaltered. (90) Although different 
hypotheses have been proposed, the complete mechanism behind TRAIL resistance in non-
transformed cells is currently unknown. (90) Multiple proteins such as the anti-apoptotic Bcl-2 
proteins, c-FLIP, and the caspase-inhibitor XIAP, might be involved. (90) However, the suppression of 
one of these proteins only, do not sensitise normal cells to TRAIL, indicating that these proteins 
regulate the TRAIL-resistance according to a redundant mechanism. Interestingly, redundancy 
seems to be lost in different TRAIL-resistant cancer cells, where inhibition of a single anti-apoptotic 
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protein is sufficient to increase the response to TRAIL. (90) Surprisingly, no correlation has been found 
between the expression of decoy receptors in normal cells and TRAIL resistance. (90)  
1.2.1.4 TRAIL as anti-cancer agent 
Since one of the most relevant limitations of the current treatments is the lack of tumour selectivity, 
the ability of TRAIL to hit cancer cells only is the most significant reason for the increasing interest 
in TRAIL as an anti-cancer agent. (91) In order to evaluate TRAIL as potential anticancer treatment, 
recombinant human TRAIL (rhTRAIL) and agonistic monoclonal antibodies specific for TRAIL death 
receptors have been developed. (92) Among the different forms of rhTRAIL which have been explored 
over the years, only one form, known as dulanermin, has been developed for clinical application. (93) 
In different phase-I clinical trials, dulanermin demonstrated little antitumor activity as monotherapy 
in advanced cancers, whilst it showed better efficacy when combined with chemotherapeutic 
agents, bevacizumab or rituximab in colorectal cancer, lung cancer and lymphoma. Moreover, in all 
these trials, dulanermin was well-tolerated and generally safe. However, dulanermin failed in 
randomised controlled trials during phase-II studies, where the rhTRAIL did not show any significant 
anticancer activity. (93)  Agonistic antibodies specific for the death receptors have also been clinically 
evaluated. Currently four of them, mapatumumab (DR4 agonist), conatumumab, tigatuzumab, DS-
8273a (DR5 agonists), are in clinical trials. (94) In preclinical models, mapatumumab was effective in 
advanced cancers when combined with chemotherapy, and in lymphoma as single agent, whilst the 
DR5 agonists showed efficacy in lung, colorectal, pancreatic and advanced cancers, but only when 
combined with chemotherapy. (93) Furthermore, in these studies they demonstrated general safety 
and higher pharmacokinetic stability compared to rhTRAIL. (94) However, although these promising 
results, in phase-II studies, little anticancer activity was observed for this class of agents. (93)  In order 
to increase the efficacy of this therapy, an alternative approach may be represented by the 
combined administration of rhTRAIL and agonistic antibodies specific for the DRs. In particular the 
combination of dulanermin and conatumumab was evaluated in primary ovarian cancer cells. (95) 
This study showed that both agents are able to bind DR5, via different epitopes, leading to increased 
formation of the DISC and improved ability in killing cancer cells. (95)  
Therefore, although TRAIL is emerging as very desirable anti-cancer agent, the latest data obtained 
from phase-II clinical trials indicate the need to develop further strategies in order to improve the 
efficacy of TRAIL and, additionally, to overcome the problem of TRAIL resistance in cancer cells 
which represents one of the most relevant limitation associated with TRAIL therapy.   
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1.2.1.5 TRAIL resistance in breast cancer 
One of the most important limitations for the use of TRAIL as an anticancer agent is represented by 
the fact that approximately the 60-70% of cancer cells are resistant to TRAIL-induced apoptosis. (90) 
In breast cancer, in vitro studies revealed that most of cell lines derived from TNBCs are TRAIL 
sensitive, whereas the majority of cell lines isolated from ER+ and HER-2+ tumours do not respond 
to TRAIL. (96) Unfortunately, the molecular mechanisms that determine this different behaviour 
between breast cancer cell lines have not been identified. (96) In general, the whole mechanism 
behind TRAIL resistance is not completely understood, however, all the proteins and receptors 
belonging to the TRAIL pathway may be involved. (97) For instance, mutations or lower expression of 
the death receptors, higher expression of the decoy receptors, dysfunction of FADD, 
downregulation of caspase-8 may be implicated. (97) Moreover, other signalling pathways, such as 
NF-ĸB or PI3K-AKT may also contribute to TRAIL resistance. Upregulation of NF-ĸB is common in 
different TRAIL-resistant cancers and, as discussed in paragraph 1.2.1.2, NF-ĸB regulates the 
expression of anti-apoptotic proteins such as XIAP, Bcl-xl or Bcl-2. (97) TRAIL-resistant cancers also 
express high levels of constitutively activated AKT (caAKT). Activation of AKT might result in 
upregulation of c-FLIP, which is one of the most significant proteins involved in regulation of the 
apoptotic pathway and it will be discussed in section 1.3. (97) 
1.2.1.6 Combinational therapies 
In order to overcome the problem of TRAIL resistance in cancer cells, novel therapeutic strategies 
involving the combination of TRAIL with inhibitors of the different anti-apoptotic factors implied in 
TRAIL resistance, are currently being evaluated. So far, the data obtained from clinical trials 
exploring the combination of TRAIL with different chemotherapeutic agents such as paclitaxel, 
doxorubicin, gemcitabine or cisplatin, revealed that these drugs are able to enhance TRAIL-induced 
apoptosis in different cancers. (93) Upregulation of the DRs and activation of p53 which positively 
modulates expression of DR5, are deemed to be the reasons behind this synergising effect. (81) 
However, in order to avoid the cytotoxicity associated with chemotherapeutic drugs, more selective 
agents that inhibit specific factors involved in the apoptotic pathway, such as NF-ĸB and PI3K-AKT 
inhibitors, inhibiting-apoptotic protein (IAP) antagonists and Bcl-2 antagonists are under evaluation. 
(81, 93) Currently, YM155, LY2181308 and AEG35156 which downregulate the expression of inhibiting-
apoptotic proteins XIAP and survivin, are in clinical trials. (98) Bcl-2 antagonist, ABT-199 and ABT-263 
which targets Bcl-2 and BCL-xL have also entered clinical studies, ABT-263 in particular showed 
promising TRAIL-sensitising effect in pancreatic and hepatic cancer cells in in vitro studies. (93)   
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Therefore, these encouraging data indicate that overcoming TRAIL-resistance using selective agents 
interfering with specific proteins involved in the apoptotic pathway, represents a valid therapeutic 
strategy which may lead to the development of cancer cell-selective anticancer treatments. 
1.3 Cellular-FLICE-Like Inhibitory Protein (c-FLIP) 
Cellular FLICE-Like Inhibitory Protein (c-FLIP) is a member of the extrinsic apoptotic signalling 
pathway which interferes with the formation of the DISC.  The first form of FLIP, a viral form known 
as v-FLIP, was identified in 1997 and it was discovered in molluscum contagiosum virus (MCV). (99) 
In the same year, the mammalian cellular homolog, called c-FLIP, was characterised. (100) 
1.3.1 c-FLIP structure 
To date, thirteen different spliced variants of c-FLIP have been reported, even though only three 
isoforms are expressed as proteins: c-FLIPS, 26 kDa short form, c-FLIPR, 24 kDa form and c-FLIPL, 55 
kDA long form. (101)  All three isoforms exhibit two death effector domains (DEDs) at the N-terminus. 
The C-terminus of c-FLIPR is slightly shorter than c-FLIPS, however these two isoforms are very similar.  
On the contrary c-FLIPL shows a longer C-terminus, which contains two caspase-like domains (p20 
and p12), and is highly similar to caspase-8 (101) However, c-FLIPL is not catalytically active, due to 
the lack of the amino acids required for the caspase activity, and in particular to the substitution of 
the crucial cysteine residue by a tyrosine residue. (101, 102) Moreover, c-FLIPL shows two cleavage sites 
at positions Asp-376 and Asp-196 which can be processed by caspase-8 to generate the two cleaved 
fragments p43 and p22 respectively. (103) The three isoform structures and the cleaved fragments 
are shown in figure 1.3.1.  
 
Fig 1.3.1: Structures of the three c-FLIP isoforms and cleaved fragments.  
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1.3.2 c-FLIP-expression regulation 
The expression of c-FLIP can be modulated at different levels. Transcriptionally, c-FLIP expression is 
induced by several factors such as NF-kB, p63, EGR1, AR, SP1 whereas factors such as c-myc, c-Fos, 
SP3, FOXO3a prevent c-FLIP transcription. (101) Translationally, c-FLIP expression is mainly regulated 
by the Akt-mTOR kinase pathway that stimulates c-FLIP-expression. (101) Degradation of c-FLIP 
primarily occurs via ubiquitin-proteasome degradation pathway, however JNK activation and 
phosphorylation events are also involved in the control of c-FLIP levels. (101) 
1.3.3 c-FLIP function 
c-FLIP is an important protein involved in different cellular processes such as regulation of apoptosis, 
necroptosis and autophagy and activation of proliferation pathways. (104) Additionally, c-FLIP is 
involved in human Th cell differentiation and in embryonic development. (105, 106, 107)     
1.3.3.1 c-FLIP and proliferation pathways 
Different studies have demonstrated that, when overexpressed, c-FLIP acts as activator of signalling 
pathways associated with properties such as survival and proliferation. (104) c-FLIPL, when 
overexpressed, activates the NF-ĸB signalling pathway and the MAP kinase Erk by interacting with 
factors such as TNFR-associated factors 1 and 2 (TRAF1/2), RIP and Raf-1. (108) Co-
immunoprecipitation studies in cancer cells have shown that c-FLIP interacts with Akt, increasing its 
anti-apoptotic function. (109) Additionally, c-FLIP is able to inactivate signalling pathways involved in 
the activation of apoptosis, such as JNK pathway. (110)  Furthermore, an ability of c-FLIP to induce 
cancer cell proliferation has been demonstrated in prostate cancer, where overexpression of c-FLIP 
is associated with reduced degradation of β-catenin and following higher levels of the proliferative 
factor cyclin D1. (111) 
1.3.3.2 c-FLIP in necroptosis and autophagy 
Necroptosis and autophagy are programmed cellular mechanisms which are activated by 
inflammatory conditions or damage to cytoplasmic components. Several studies have 
demonstrated that c-FLIP is involved in the activation or suppression of these processes. (104) In 
necroptosis, the different c-FLIP isoforms play two distinct roles during the formation of the 
ripoptosome, which is a complex of several cell death-inducing proteins: c-FLIPL blocks the 
ripoptosome assembly, whilst c-FLIPS promotes its formation. (112) On the contrary, in autophagy, c-
FLIP only acts as an inhibitory protein, binding and blocking Atg3 which is an essential factor for the 
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formation of the autophagosome and the following degradation of damaged cytoplasmic 
components. (113)   
1.3.3.3 c-FLIP in apoptosis 
The role that c-FLIP plays as apoptosis regulator represents one of the most important c-FLIP 
functions. Although c-FLIP is recognised as an anti-apoptotic protein, many studies have 
demonstrated that the two major protein isoforms, c-FLIPs and c-FLIPL, have different regulative 
functions. (104, 114, 115)   The short isoform, c-FLIPs, only blocks caspase-8 activation, while c-FLIPL shows 
a dual functionality, promoting the caspase-8 activation at lower concentration and acting as 
caspase-8 antagonist at higher concentration. (115) The reasons behind this bifunctional role of c-
FLIPL are not completely understood, however the mechanism of caspase-8 activation seems to 
involve the cleaved fragments of c-FLIP (p43/p22FLIP) and their ability to heterodimerise with 
caspase-8 forming a complex which enhances caspase-8 activation. (116) Contrarily, c-FLIPS that lacks 
the pseudo-caspase domain and the cleavage sites, only shows anti-apoptotic functions. (116)  
Although the important role of c-FLIP in preventing apoptosis is widely recognised, the mechanism 
by which c-FLIP interferes in this process is not clear. Initially a competitive binding between the 
DED of c-FLIP and the DED of procaspase-8 to FADD was proposed. (117) According to this model, c-
FLIP and procaspase-8 compete for binding to the DED of FADD, as shown in figure 1.3.3.3a (117)  
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Fig 1.3.3.3a: Competitive Model. 
However, more recently, two independent immunoprecipitation and mutational studies, have 
demonstrated that c-FLIP might interfere with the formation of the DISC in a non-competitive way. 
(118, 115) Although in both cases the results obtained challenge the initial vision of c-FLIP competing 
with procaspase-8, these studies propose two different potential mechanisms of action: the two-
step model and the co-operative and hierarchical model. (118, 115) The two step-model suggests that 
both proteins, c-FLIP and procaspase-8, bind the two faces of the DED of FADD to form a tripartite 
complex. In this complex, c-FLIPL/S and procaspase-8 can interact via DEDs. When c-FLIPL is recruited 
to the complex, the caspase-like domain of c-FLIPL interacts with the caspase domain of procaspase-
8, generating a catalytically active complex, which promotes procaspase-8 dimerization and 
following caspase-8 activation. On the other side, c-FLIPS, lacking the caspase-like domain, interacts 
with procaspase-8 via DEDs without inducing the conformational changes required for the activation 
of the enzyme. (118) 
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Fig 1.3.3.3b: Two-step Model. 
A different mechanism of action is proposed in the co-operative and hierarchical model. According 
to this model, the amount of c-FLIP that directly binds FADD is limited, whereas the main form of c-
FLIP recruitment to the DISC occurs via interaction with procaspase-8. At physiological levels, c-FLIPL 
interacts with procaspase-8, forming FLIPL/procaspase-8 heterodimers, which induce activation of 
caspase-8. Procaspase-8 preferentially binds c-FLIP molecules, however, when the levels of c-FLIPL 
decrease, additional procaspases-8 are recruited to form homodimers that, after proteolytic 
cleavage, activate caspase-8. Contrarily, c-FLIPS does not induce DED-mediated procaspase-8 
oligomerization, therefore, when recruited, c-FLIPS forms heterodimers with procaspase-8 which are 
catalytically inactive. (115)  
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Fig 1.3.3.3c: Co-operative and hierarchical Model. 
1.3.4 c-FLIP in cancer 
The ability of c-FLIP to inhibit the extrinsic apoptotic pathway might play an important role in cancer 
cells TRAIL resistance. Multiple cancer cell lines, resistant to TRAIL-induced apoptosis, show 
elevated levels of c-FLIP. Gastric carcinoma, melanoma, cervical carcinoma, ovarian carcinoma, 
colorectal carcinoma, Hodgkin's lymphoma, prostate carcinoma, pancreatic carcinoma are all 
examples of tumours where c-FLIP is overexpressed. (104) In breast cancer, the association between 
c-FLIP and TRAIL resistance has been demonstrated by a siRNA study, where inhibition of c-FLIP 
expression using siRNA in different breast cancer cells, sensitise these cells to TRAIL treatment. (1119)  
1.3.5 c-FLIP as a therapeutic target: current inhibitors 
Considering its ability to prevent apoptosis leading to the survival of breast cancer cells, c-FLIP-
inhibition is now recognised as a valid and promising therapeutic target. (120) Initially, the first 
attempts to modulate the expression of c-FLIP involved the use of siRNA or agents stimulating c-
FLIP degradation. (121, 122) Although these approaches have been efficient in sensitising breast cancer 
cells to TRAIL, the several off-target effects which may occur, and the lack of carriers for the delivery 
into the cells, preclude any possible in vivo action. (122)  A broad class of compounds able to reduce 
the expression of c-FLIP is represented by histone deacetylase inhibitors (HDACi). SAHA (Suberoyl 
anilide hydroxamic acid) and CMH (4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide) are 
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examples of this class. (123, 122) These agents induce an increased response of cancer cells to TRAIL 
because of their ability to downregulate c-FLIP at the transcriptional level. (122) However, CMH for 
instance, is active at 100 μM, and at the same concentration it causes the degradation of poly(ADP-
ribose) polymerase (PARP), which is an off-target effect. (122) Additional agents which interfere with 
c-FLIP levels are the Akt inhibitors. Among them, API-1 (pyrido[2,3-d]pyrimidine) for example, 
stimulates c-FLIP degradation. (124)  Celecoxib is a known COX-2 inhibitor which is also able to inhibit 
Akt, promoting c-FLIP degradation. (125)  However additional Akt inhibitors, such API-2, are not 
associated with the ability to modulate c-FLIP levels, therefore it is likely that the way these agents 
work is non-specific for c-FLIP. (123) 
 
Fig 1.3.5 Chemical Structure of current c-FLIP inhibitors. 
Therefore, several agents are recognised as effective at increasing TRAIL sensitivity through the 
modulation of c-FLIP expression, nevertheless none of these agents can be defined as a specific c-
FLIP inhibitor. For this reason, novel small molecules able to inhibit specifically c-FLIP are needed. 
(101) 
1.4 Previous Molecular Modelling Studies 
Computational techniques represent an important tool in the drug discovery process. (126) In general, 
computer-aided drug design methodologies are based on two different approaches: the ligand-
based drug design and the structure-based drug design. (127) Structure-based drug design techniques 
(SBDD) can be used when the three-dimensional structure of the biological target has been 
experimentally determined, or a model based on the crystal structure of homologous proteins can 
be built using homology modelling techniques. (127) In order to identify compounds that can bind 
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into the binding site of the protein, virtual screenings of libraries of compounds, followed by 
molecular docking analyses, are usually performed. (128) The ligand-based drug design (LBDD) 
approach can be adopted when the structure of the biological target is not available, and the 
structure of known active compounds can be used to perform ligand-based virtual screening studies. 
(129)  
In the course of a previous study performed in our research group by Dr Olivia Hayward, following 
a structure-based drug design approach, molecular modelling techniques were used in order to 
analyse the interactions occurring between the DED domains of FADD, c-FLIP and caspase-8. The 
final purpose was to identify the features responsible for the interaction FADD:c-FLIP and 
FADD:caspase-8 in order to develop novel small molecule inhibitors able to target c-FLIP selectively. 
(130) 
1.4.1 c-FLIP and Caspase-8 homology models 
At the beginning of the study, the crystal structures for c-FLIP and caspase-8 were not available. A 
homologous protein had been identified in MC159 (PDB ID: 2BBR), a viral form of c-FLIP, which has 
been used in different studies in order to model DED interactions. (115, 118) This protein showed a 
sequence identity of 33% and 29% with c-FLIP and caspase-8, respectively. Considering also the 
highly conserved nature of the DEDs regions, the MC159 crystal structure was chosen as template 
to build the homology models of the DED structures of c-FLIP and caspase-8. (118, 130) The two models 
are shown in figure 1.4.1.1 A and B. 
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Fig 1.4.1.: Homology Models of c-FLIP (A) and caspase-8 (B). In both proteins DED1 is in blue and DED2 is in yellow.                                                                                                  
The interactions between the DEDs of FADD and c-FLIP/caspase-8 were then modelled. A previous 
study had demonstrated the importance of a particular motif, the FL motif (Phe25/Leu26), in 
FADD/Caspase-8 binding. (130) Mutations in this motif generate a relevant reduction of caspase-8 
activation due to the decreased caspase-8 recruitment to the DISC. Furthermore, it has been shown 
that the FL motif causes an intramolecular interaction between DED1 and DED2 in all the proteins 
that exhibit the two domains. Specifically, the FL motif situated on DED1 interacts with the 
hydrophobic surface of DED2. This interaction does not occur in FADD because of the presence of 
only one DED, therefore the FL motif of FADD is available to interact with DEDs of c-FLIP and caspase-
8. (131) On the basis of this known intramolecular interaction between DED1 and DED2, the 
intermolecular interactions between the DED of FADD and the hydrophobic pockets located on the 
DED1 of c-FLIP and caspase-8 were modelled. (130)  
1.4.2 c-FLIP:FADD  interaction 
According to the c-FLIP-FADD model generated in the previous study, the Phe25 of FADD, which is 
deemed to have a crucial role for the recruitment of c-FLIP and procaspase-8, fits a small 
hydrophobic pocket on the DED1 of c-FLIP, as shown in figure 1.4.2. (130) 
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Fig 1.4.2: Model of the interactions occurring between FADD (pink) and c-FLIP (blue). 
1.4.3 Pharmacophore generation and Virtual Screening 
The interacting c-FLIP pocket was used to generate a pharmacophore model in order to identify 
features which may be used as targets for possible inhibitors. Once the pharmacophore was 
developed, it was used to run a structure-based virtual screening, starting from a database of 
350,000 known compounds (Specs Database, Delft). (132) Among them, 14,000 compounds satisfied 
the pharmacophore query, and they were docked in the pocket of c-FLIP. Following scoring and 
rescoring steps, 2,000 compounds were selected. An additional selection step was performed by 
docking the 2,000 compounds in the pocket of caspase-8. The final aim was to select those 
compounds potentially able to bind c-FLIP selectively, with a poor predicted ability to fit the pocket 
of caspase-8. Therefore, according to the docking scores obtained, 100 common compounds with 
the highest and lowest score for c-FLIP and caspase-8 respectively, were selected and visually 
inspected. After visual inspection, 19 compounds were selected for testing. (130)  
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1.5 In vitro assays and lead compound identification 
All the 19 selected compounds were tested in different in vitro assays. (130) Two TRAIL-resistant 
breast cancer cell lines were used to assess the compounds: MCF-7 (ER+) and BT474 (ER+). (119) The 
Cell Viability Assay was used as first screening. This assay allowed the selection of those compounds 
that did not affect cell viability when administered alone, demonstrating lack of toxicity, whilst 
inducing a significant reduction in cell viability when associated with TRAIL, showing ability in 
sensitising the TRAIL-resistant cancer cells to TRAIL-induced cell death. From this assay, the three 
best compounds were selected and evaluated in two additional in vitro assays: the Mammosphere 
Assay (72) and Colony Forming Assay. (73) Both these tests are specific for cancer stem cells, therefore 
they were used to investigate the ability of the selected compounds to induce TRAIL-sensitisation in 
breast cancer stem cells. In both cell lines and in both assays, one compound in particular, 
compound 3, gave the best results. This compound reduced the ability of cancer cells to form 
mammospheres or colonies when administered in association with TRAIL at low micromolar 
concentrations, indicating that the increased TRAIL-sensitisation observed in the cell viability assay 
concerns also breast cancer stem cells. The chemical structure of 3, its predicted binding mode in 
the pocket of c-FLIP as well as some of the results obtained in this part of the study are shown in Fig 
1.5 A and B. (130)  
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Fig 1.5 A: Chemical structure of 3 and its predicted binding mode in the pocket of c-FLIP. B: Mammosphere Assay in BT474 cells. 
Blue bars represent compound 3 tested alone, red bars represent compound 3 in association with TRAIL. Different molarities 
were used. At 100 µM concentration, compound 3 showed the best activity in reducing the number of mammospheres formed, 
measured as mammosphere forming units (MFU). (130) 
1.6 Evaluation of purchased analogues of 3 
The identification of the hit compound 3 was followed by biological evaluation of additional eight 
analogues of 3, which were purchased from SPECS. Table 1.6.1 illustrates the chemical structures of 
these compounds. 
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Table 1.6.1: Analogues of 3 tested. 
Analogues 3.1 and 3.7 show a different position of the carboxylic acid which is placed on the ring 
substituted with hydrophobic groups, while in 3.4 the carboxylic function is replaced by the alcohol 
group. In all other analogues the hydrophobic ring is modified with different hydrophobic groups at 
different positions. The Colony Forming Assay and Mammosphere Assay on MCF-7 and BT474 cells 
were performed in order to assess whether these compounds showed an improved efficacy 
compared to the original hit. The molecules were tested at 100 µM concentration. In both assays 
and cell lines, the analogues showed a decreased ability to reduce the number of colonies and 
mammospheres formed compared to 3. (130)  
1.7 Mechanism of action of 3 
Several experiments have been performed in the previous work in order to investigate the 
mechanism of action of 3, with the final aim to confirm its role as selective c-FLIP inhibitor. (130) In 
order to assess the ability of 3 to induce TRAIL sensitisation via the caspase-8 mediated extrinsic 
apoptotic pathway, the caspase-glo 8 luminescence assay, which measures caspase-8 activity, was 
performed. (133) The results obtained showed a significant increased caspase-8 activity when MCF-7 
cells were treated with the combination 3-TRAIL, whilst 3 alone did not induce any relevant changes 
in caspase-8 activity. Furthermore, the FRET (Fluorescence Resonance Energy Transfer) assay, a 
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specific method used to evaluate protein-protein interactions, was performed. This assay is based 
on the possibility to detect the energy transfer occurring between two interacting proteins, via 
fluorophore-labelling these proteins and measuring the changes in fluorescence emission which are 
observable when the two proteins interact. (134) Preliminary data obtained from this experiment 
gave promising results: while c-FLIP:FADD interaction was detected in cells treated with TRAIL only, 
in cells treated with the combination TRAIL-3 no interaction between the two proteins was 
observed, suggesting the ability of 3 to disrupt c-FLIP:FADD interaction. (130) Similar early results were 
obtained in the co-immunoprecipitation assay (Co-IP), which is currently being performed by Dr 
Richard Clarkson’s research group (European Cancer Stem Cells Research Institute, Hadyn Ellis 
Building, Cardiff University). The Co-IP technique is based on the precipitation of complexes formed 
by two interacting proteins via using specific antibody and antibody-binding proteins attached to a 
beaded support. (135) In accordance with the FRET results, the early data obtained from the Co-IP 
assay suggested the ability of 3 to promote the interaction between FADD and caspase-8. Therefore, 
all these data together confirmed that 3 is able to induce TRAIL sensitisation via the specific TRAIL-
caspase-8-mediated apoptotic pathway. Moreover, the preliminary observation that in presence of 
3, the c-FLIP:FADD interaction is disrupted, while the interaction between FADD and caspase-8 is 
promoted, is very promising in order to confirm the potential role of 3 as selective c-FLIP inhibitor. 
Additionally, a concomitant study performed in Dr Richard Clarkson’s research group, exploring the 
effect of a combined 3-paclitaxel therapy, had demonstrated that 3 is able to induce paclitaxel 
sensitisation in resistant cancer stem cells. These preliminary in vitro results were confirmed by in 
vivo studies that showed the ability of 3 to reduce tumour size, when associated with paclitaxel, 
and, more importantly, to prevent tumour recurrence. (136)  
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1.7 Project aims 
Although c-FLIP is recognised as an interesting target in breast cancer therapy, currently all 
therapeutic strategies available aim to reduce the protein expression, acting as c-FLIP transcription 
inhibitors or increasing c-FLIP degradation. The primary inhibition of c-FLIP using small molecules 
has not been explored before because of the high similarity with caspase-8. Effectively, a non-
selective inhibitor may likely also inhibit caspase-8 preventing apoptosis. However, previous studies 
performed in our research group have demonstrated that, with the support of computational 
modelling techniques, the identification of novel small molecules that selectively inhibit c-FLIP may 
be an achievable result. Therefore, the purpose of this project will be the design and development 
of analogues of 3. The synthesis of new compounds will aim to improve the chemical and physical 
properties of the original hit in order to enhance its ability to cross the cellular membrane. 
Furthermore, all variations made on the original scaffold will be used to investigate the structure-
activity relationships. Molecular docking techniques will be used to visualise the predicted binding 
mode of the compounds in the pocket of c-FLIP in order to estimate the activity potential and the 
selectivity of the future analogues. New synthetic pathways will be designed and optimised. The 
synthesised molecules will then be tested in specific in vitro assays to evaluate their ability to 
sensitise breast cancer cells and breast cancer stem cells to TRAIL-induced apoptosis and in addition 
the lack of toxicity in non-cancerous cells.  
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Chapter 2: Computational Studies 
2.1 Introduction 
At the beginning of this study the analysis of the features involved in c-FLIP:FADD binding and in c-
FLIP:hit 3 was performed according to the homology modelling studies previously performed in our 
research group. (1) The aim was to investigate the chemical and structural properties of the c-FLIP 
pocket in order to design new molecules hypothetically able to block the interaction between c-FLIP 
and FADD while promoting the FADD:Caspase-8 binding. Following these computational studies, 
several new compounds were designed and synthesised. For all the new derivatives molecular 
docking studies were performed, and a brief description of the general methods used is reported in 
this chapter. Moreover, additional computational studies were performed in order to investigate 
whether further amino acid residues of c-FLIP may be involved in the interaction with FADD.  
2.2 c-FLIP:FADD interaction and c-FLIP pocket analysis 
As mentioned in section 1.4.2, in previous studies carried out in our research group, the homology 
model of FADD interacting with the DED1 of c-FLIP was built. (1) Previous mutational studies have 
demonstrated the important role of the Phe25/Leu26 motif of FADD, which is responsible for the 
interaction occurring with caspase-8, and it is deemed to have a crucial role in c-FLIP and caspase-8 
recruitment to the DISC. (2) An analysis of the interactions occurring between this particular motif 
and the amino acid residues in the pocket of c-FLIP was therefore performed using MOE as visualiser 
software. According to our model, the Phe25 located on the DED of FADD occupies a small pocket 
on the DED1 of c-FLIP, forming Van der Waals interactions with the His7 and an H-bond with the 
Arg45. The interactions occurring between the amino acid residues and the corresponding distances 
are shown in figure 2.2.1. 
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Fig  2.2.1: Phe25 of FADD (pink) forms an H-bond (2.01 Å), indicated by a black dot line, with Arg45 and Van der Waals 
interaction (2.83 Å), indicated with a red dot line, with His7  in the DED1 of c-FLIP (blue). 
The pocket accommodating Phe25 of FADD is a small hydrophobic cavity. As shown in figure 2.2.2, 
the central portion of the pocket is occupied by two amino acid residues, Glu10 and Arg38. Behind 
these residues, the pocket bends inward creating a curved-shaped hydrophobic cavity. Arg45, which 
is responsible for the binding with Phe25 of FADD, is exposed to the surface of the pocket, in 
proximity to the entrance of the cavity.  
 
Fig 2.2.2: The c-FLIP pocket. 
Arg45 
Phe25 
His7 
2.01 Å 
2.83 Å 
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Considering the features described above, novel small molecules able to fit the curved-shaped 
hydrophobic cavity in the pocket of c-FLIP might be able to prevent the binding to FADD. 
2.3 Hit 3:c-FLIP interaction 
In order to investigate the features required for the occupation of c-FLIP pocket, the predicted 
binding mode of hit 3 was analysed. Looking at figure 2.3.1, which shows the interaction between 3 
and c-FLIP, it is possible to outline important relationships between the structural properties of the 
compound and its binding mode. 
 
Fig 2.3.1: Predicted binding mode for 3 (dark blue) and its interaction with the amino acid residues. The two amino acid residues 
Glu10 and Arg38 are not shown in order to provide a better visualisation of the predicted binding mode. 
The structure of 3 can be divided into three portions, each of which plays an important role in the 
binding within the c-FLIP pocket. Figure 2.3.2, which includes the two amino acid residues Arg38 
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and Glu10, shows the predicted ability of the compound to fit the small pocket. The presence of the 
sulfonamide linker, located behind the residues Glu10 and Arg38, allows the molecule to acquire a 
tetrahedral geometry, thus promoting its arrangement in the curved-shaped cavity. The 2,4-
dichloro-3-methyl phenyl ring occupies the hydrophobic region of the pocket, whilst the carboxylic 
acid moiety, on the other aromatic ring, forms an H-bond with Arg45 of c-FLIP.  
 
Fig 2.3.2: The small figure represents the predicted ability of the hit compound 3 (surface dark blue) to adapt to the curved-
shaped cavity (surface grey). The big figure is an enlargement of the binding pocket which shows how the sulfonamide goup 
(yellow) of 3 (dark blue), occupying the area behind the residues Arg38 and Glu10, allows the molecule to fit the curved-shaped 
c-FLIP pocket.  
The analysis of the structural properties of the c-FLIP pocket and the investigation of the features 
required for the binding of the original hit 3 within the c-FLIP pocket, in combination with the 
biological results obtained in the previous work, were used to design new potential c-FLIP inhibitors.   
2.4 Design of new derivatives 
In order to investigate structure-activity relationships and to improve the activity and the 
pharmacokinetic properties of 3, new derivatives were designed. As mentioned in section 2.3, the 
linker between the two aromatic rings plays a crucial role in the binding within the c-FLIP pocket. 
Therefore, on the basis of the linker group, four new series of compounds were designed: 
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sulphonamide derivatives, amine derivatives, methylene derivatives and amide derivatives. The 
general scaffold of the new series of analogues is represented in table 2.4. 
DERIVATIVES SCAFFOLD 
Sulphonamide 
 
Amine 
 
Methylene 
 
Amide 
 
Table 2.4: General Scaffold of the new derivatives. 
For each series different modifications on the two aromatic rings were also explored.  
2.5 Molecular Docking Studies 
Molecular docking techniques represent an important tool in medicinal chemistry due to their 
ability to predict the binding mode of a ligand to its molecular target. (3) In general, molecular 
docking algorithms generate different conformations (poses) for each ligand in the binding site of 
the biological target. The binding affinity of each pose for the binding site is then estimated using 
different scoring functions. (4) In this work, molecular docking studies were performed in order to 
investigate the predicted behaviour of all the newly designed derivatives in the pocket of c-FLIP. All 
molecular docking analyses were performed using Glide SP. (5) As a first step, a database containing 
the structure of the newly designed compounds was created using MOE 2015. (6) Using the LigPrep 
tool in Maestro, (5) the ligands included in the database were prepared for docking. The c-FLIP pocket 
was selected as receptor, and a maximum length of 12Å from the centre of the site, defined by the 
position predicted to be occupied by hit 3, was set up to dock the compounds. 15 poses for each 
compound were included in the post-docking minimisation. The results obtained were exported in 
MOE, which was used for the visual inspection of all poses and the analysis of the predicted 
interactions between the ligands and the amino acid residues belonging to the binding pocket.  
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2.6 New potential interaction sites 
In a recent study published in 2016, a new model of c-FLIP recruitment to the DISC was proposed. 
(7) According to the results obtained in this study, based on the reconstitution of the TRAIL DISC, only 
a small amount of c-FLIP is recruited to the DISC in the absence of procaspase-8, while, interestingly, 
the amount of c-FLIP recruited is significantly increased when the reconstituted DISC is pre-
assembled with procaspase-8. Therefore, this model supports a potential co-operative recruitment 
of procaspase-8 and c-FLIP to the DISC, thus indicating that c-FLIP and procaspase-8 do not compete 
for binding to FADD. Furthermore, mutational studies were performed, in order to identify the 
amino acids involved in the formation of the complexes FADD:procaspase-8 and FADD:c-FLIP. 
According to the results obtained, Tyr8 in the DED1 of procaspase-8 is the key residue involved in 
the interaction with FADD, suggesting that FADD recruits procaspase-8 via DEDPhe25:DED1Tyr8 
binding, while additional procaspase-8 molecules interact via the DED1 domain with the exposed 
DED2 of the FADD-bound procaspase-8. On the other side, the mutational studies performed on the 
complex c-FLIP:FADD revealed the residues Phe114/Leu115 in the DED2 of c-FLIP and His9 of FADD 
as the crucial amino acids for the interaction between the two proteins. However, the formation of 
the complex c-FLIP:FADD which occurs via the DED2 of c-FLIP is limited in the absence of procaspase-
8, suggesting that c-FLIP may be indirectly recruited to FADD via DED-mediated c-FLIP:procaspase-
8 heterodimerization. Therefore, the model suggested in this study involves the initial recruitment 
of procaspase-8 to Phe25 of FADD via DED1. When c-FLIP is overexpressed, procaspase-8 
heterodimerizes with c-FLIP via DED2:DED1 interaction. Thus, c-FLIP is indirectly recruited to the 
DISC and the exposed DED2 interacts with His9 of FADD. According to the proposed model, c-FLIP 
blocks the activation of procaspase-8 preventing the dimerization required for the conversion into 
the active form caspase-8, and additionally inhibiting the recruitment of other pro-caspase-8 
molecules to FADD. (7)  
Taking into consideration this information, further molecular modelling analyses were performed in 
order to explore the potential sites of interaction described above. 
2.6.1 Protein:Protein Docking 
The suggested interaction between the DED of FADD and the DED2 of c-FLIP was computationally 
investigated performing a protein:protein docking analysis. The protein-protein docking method is 
a technique used in computational chemistry to predict the possible interactions which occur 
between two proteins. (8) In this work, the protein-protein docking analysis was performed using 
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MOE 2015. (6) The crystal structure of FADD (PDB ID: 1A1W) was defined as desired receptor, while 
His9 of FADD, which was the crucial amino acid identified in the study previously mentioned, (7) was 
selected as the binding site. The c-FLIP model was marked as the ligand to dock and all the amino 
acids of the protein were defined as ligand site in order to explore all the potential interactions 
deriving from the computational analysis. The docking results were then visually inspected. 
Interestingly, several results suggested the potential interaction of His9 of FADD with Leu115 of 
DED2 of c-FLIP, which is one of the key residues involved in the formation of the complex c-
FLIP:FADD according to the work previously described. (7) Furthermore, among all the poses 
analysed, one in particular, shown in fig 2.6.1, predicted the interaction between His9 of FADD and 
both the amino acid residues Phe114 and Leu115 of c-FLIP, revealing a potential correlation with 
the mutational studies recently published. (7) Therefore, this pose was chosen as the best result from 
protein:protein docking studies.  
 
Fig 2.6.1: Protein:protein docking result: The predicted interaction (indicated by the pink cloud) between the His9 of FADD (pink) 
and the Phe114/Leu115 of c-FLIP (blue). 
Following the protein:protein docking, a molecular dynamics simulation was performed in order to 
analyse the stability of the system over time.  
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2.6.2 Molecular Dynamics Simulation 
A Molecular Dynamics (MD) simulation analyses the spatial coordinates of each atom of the 
molecular system, through the simultaneous solution, in short time steps, of Newton’s second law 
of motion (equation 2.6.2). (9) 
𝐹𝑖 = 𝑚𝑖 ∗ 𝑎𝑖 = 𝑚𝑖 ∗  
𝛿2𝑟𝑖
𝛿𝑡2
 
Equation 2.6.2: Newton’s equation of motion. 
F=force, m=mass, a=acceleration, r=distance, t=time, i= 1 to N (9) 
MD simulations also calculate potential energy and forces between particles using force field 
functions. (9) Therefore, MD simulations represent an important technique in computational 
chemistry in order to analyse the dynamic behaviour of a molecular system as a function of time, 
thus acquiring information about the motion of the different atoms and about the stability of the 
molecular system. (10) 
In this study, a MD simulation was performed using DESMOND (11). The simulation time was set to 
100 ns and constant values of number of atoms, temperature (300K) and pressure (1 atm) were 
selected. The specific protocol applied is reported in the Experimental Section. The results obtained 
were analysed using Maestro. The MD simulation was monitored with C-alpha RMSD evaluation in 
order to analyse the stability of the system. Graph 2.6.2 shows an increase of the RMSD values from 
0 to 50 ns, and the system appears to be stabilised between 50 and 100 ns, indicating also that the 
MD duration was appropriate.  
 
Graph 2.6.2: RMSD time variations of the protein C-alpha. 
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The visual inspection of the molecular dynamics results was performed using MOE. The MD result is 
shown in figure 2.6.2. The predicted interaction between Phe114/Leu115 of c-FLIP and His9 of FADD 
was retained during the MD simulation, thus supporting the docking results previously obtained and 
suggesting stability for the predicted interaction over time.      
A 
 
B 
 
Fig 2.6.2: MD simulation result. A: Before MD simulation B: after MD simulation. 
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These computational studies suggest the potential involvement of Phe114/Leu115 located on the 
DED2 of c-FLIP in the binding to FADD, indicating that additional sites as well as the hydrophobic c-
FLIP pocket located on the DED1 may be explored as new potential target sites. 
2.7 Conclusions 
At the beginning of this work, computational studies were performed in order to explore the 
features required for the binding between c-FLIP and FADD, to investigate the chemical and 
structural properties of the c-FLIP pocket and eventually to analyse the interactions occurring 
between c-FLIP and the hit 3. These studies were used to design four series of analogues of 3 with 
the final aim to develop novel c-FLIP inhibitors showing improved activity and a better 
pharmacokinetic profile compared to the original hit. Furthermore, following the publication of a 
new model of c-FLIP recruitment to the DISC, (7) protein:protein docking and molecular dynamics 
studies were performed, in order to investigate whether additional target sites may be identified. 
According to the results obtained, two residues located on the DED2 of c-FLIP might be involved in 
the binding to FADD, Phe114 and Leu115, indicating that, additionally to the DED1, the DED2 of c-
FLIP might be also explored as potential target site. This work however will focus on the hydrophobic 
pocket located on the DED1 of c-FLIP. 
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Chapter 3: Sulfonamide Derivatives 
3.1 Design of sulfonamide derivatives 
In order to develop novel analogues able to improve the efficacy of 3, changes on the original 
structure were considered on the basis of the molecular modelling studies performed and the 
results previously obtained. At the beginning, given the importance of the sulfonamide linker for 
the arrangement in the c-FLIP pocket, this functional group was retained. However, in some of the 
designed derivatives the original linker was elongated by adding one carbon atom. On the other 
hand, changes on both aromatic rings were contemplated. The original 2,4-dichloro-3-methyl 
substituent was replaced with numerous hydrophobic groups at different positions of the ring with 
the aim to investigate whether other hydrophobic substituents may improve penetration and 
stability of the molecule in the pocket. Moreover, the replacement of the phenyl ring with different 
heterocycles and bigger rings such as naphthalene and quinoline was explored. Since previous 
biological data had shown a reduction of activity for compounds lacking the carboxylic acid group 
or compounds having the carboxylic acid moiety on the hydrophobic ring, this functional group was 
retained on the original anthranilic ring. The carboxylic acid group is deemed to be crucial for the 
activity of 3 because of its proposed ability to interact with Arg45 of c-FLIP, thus preventing the 
binding between this amino acid and Phe25 of FADD. However, the presence of a carboxylic acid 
moiety is often associated with limitations such as reduced ability to cross the lipophilic layers of 
the cellular membrane or potential toxicity derived from metabolism. (1) Replacement of the 
carboxylic acid group with bioisoster groups such as tetrazole and oxadiazole, or different alkyl 
esters was therefore considered. Carboxamide and N-alkyl-carboxamides were also explored as 
substituents of the carboxylic acid in order to investigate how these functional groups may affect 
activity of the original hit. Several new analogues of 3 were designed as listed in table 3.1. All 
molecules conserve a central scaffold characterised by the sulfonamide group which connects the 
two aromatic rings (Fig 3.1). In order to explore whether changes in the hydrophobic ring only or 
changes in the carboxylic acid moiety only may affect activity of the compounds, for some of the 
analogues the carboxylic acid moiety was retained and only the hydrophobic ring was modified, 
whilst for other analogues the hydrophobic ring was kept unchanged while the carboxylic acid was 
replaced with alkyl esters and tetrazole group in ortho, meta and para position, and oxadiazole and 
different alkyl carboxamide groups in the ortho position. For all the other analogues changes on 
both sides of the molecule were considered.     
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Fig 3.1: Central scaffold of the new analogues. 
Molecule R1 R 
21 2-methyl ester (2,4-dichloro-5-methyl)phenyl 
22 3-methyl ester (2,4-dichloro-5-methyl)phenyl 
23 4-methyl ester (2,4-dichloro-5-methyl)phenyl 
24 2-methyl ester (4-trifluoromethyl)phenyl 
25 2-methyl ester (3,4-dimethyl)phenyl 
26 2-methyl ester (3,4-dichloro)phenyl 
27 2-methyl ester (2,4-dichloro)phenyl 
28 2-methyl ester (2,4-dimethyl)phenyl 
29 2-methyl ester (2,5-dimethyl)phenyl 
30 2-methyl ester (2,5-dichloro)phenyl 
31 2-methyl ester (4-tert-butyl)phenyl 
32 2-methyl ester (3,5-bis(trifluoromethyl))phenyl 
33 2-methyl ester 1-phenylmethane 
34 2-methyl ester 3-pyridine 
35 2-methyl ester 2-naphtalene 
36 2-methyl ester 1-napthalene 
37 2-methyl ester cyclohexane 
42 2-methyl ester (5-chloro-2-methyl)phenyl 
43 2-methyl ester (4-methyl-3-chloro)phenyl 
50 2-ethyl ester (2,4-dichloro-5-methyl)phenyl 
51 3-ethyl ester (4-trifluoromethyl)phenyl 
52 2-methyl ester (4-iodo)phenyl 
53 3-methyl ester (4-iodo)phenyl 
54 2-ethyl ester (2-methyl-3-chloro)phenyl 
55 3-ethyl ester (2-methyl-3-chloro)phenyl 
56 2-methyl ester 1-(p-tolyl)methane 
57 2-methyl ester 2-furan 
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63 2-carboxylic acid benzene 
64 2-carboxylic acid 1-(4-(trifluoromethyl)phenyl)methane 
65 2-carboxylic acid 2-thiophene 
66 2-carboxylic acid 8-quinoline 
67 2-carboxylic acid 3-quinoline 
69 2-carboxylic acid (4-methyl-3-chloro)phenyl 
70 2-carboxylic acid (4-pentafluorosulfanyl)phenyl 
71 2-methyl ester (4-pentafluorosulfanyl)phenyl 
72 2-carboxylic acid 3-pyridine 
73 2-carboxylic acid 2-napthalene 
74 2-carboxylic acid 1-naphtalene 
75 2-carboxylic acid cyclohexane 
76 2-carboxylic acid 2-furan 
78 2- isopropyl ester (2,4-dichloro-5-methyl)phenyl 
79 2- isopropyl ester (4-methyl-3-chloro)phenyl 
80 2- tert-butyl ester (2,4-dichloro-5-methyl)phenyl 
81 2- tert-butyl ester (4-methyl-3-chloro)phenyl 
86 4-(1H-tetrazol) (2,4-dichloro-5-methyl)phenyl 
87 4-(1H-tetrazol) (4-methyl-3-chloro)phenyl 
88 2-(1H-tetrazol) (2,4-dichloro-5-methyl)phenyl 
89 2-(1H-tetrazol) (4-methyl-3-chloro)phenyl 
90 2-(1H-tetrazol) (4-trifluoromethyl)phenyl 
91 2-(1H-tetrazol) 2-naphtalene 
92 2-(1H-tetrazol) 8-quinoline 
93 2-(1H-tetrazol) 2-quinoline 
97 2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol) (2,4-dichloro-5-methyl)phenyl 
98 2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol) (4-methyl-3-chloro)phenyl 
101 2-N-methyl carboxamide (4-methyl-3-chloro)phenyl 
102 2-N-methyl carboxamide (2,4-dichloro-5-methyl)phenyl 
103 2-N-ethyl carboxamide (2,4-dichloro-5-methyl)phenyl 
104 2-N,N-dimethyl carboxamide (2,4-dichloro-5-methyl)phenyl 
105 2-N-isopropyl carboxamide (2,4-dichloro-5-methyl)phenyl 
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106 2-carboxamide (2,4-dichloro-5-methyl)phenyl 
Table 3.1: Designed sulfonamide derivatives. 
3.2 Synthesis of hit 3 
Compound 3 tested in the previous study (2) had been purchased from the SPECS company, 
therefore in order to confirm the activity demonstrated, the hit compound was resynthesised. 
Scheme 3.3 shows the reaction scheme. 
 
Scheme 3.2: Synthesis of hit 3. 
The hit 3 was obtained by the reaction between anthranilic acid and 2,4-dichloro-5-methylsulfonyl 
chloride. The reaction occurs through nucleophilic attack by amine on the sulfonyl chloride which 
leads to Cl- elimination. The base NaOH is used to remove the HCl formed during the reaction. The 
desired product was obtained, and the yield of the reaction was optimised from 28% to 50% 
increasing the reaction temperature to 70°C instead of 25°C.  
3.3 Synthesis of sulfonamide derivatives 
3.3.1 Synthesis of methyl(arylsulfonamidobenzoates) (21-37, 42-43) 
Given the commercial availability of most of the sulfonyl chlorides required for the synthesis of the 
new analogues, the one step reaction with methyl aminobenzoates 18-20 was carried out to obtain 
the analogues 21-37 and 42-43. The general scheme is shown in scheme 3.3.1. 
 
Scheme 3.3.1: General scheme for the synthesis of compounds 21-37. 
The procedure followed is the General Procedure 2 reported in the Experimental Section. The 
reaction mechanism involves the nucleophilic attack by the amino group of anthranilic ester on the 
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electrophilic sulfur atom, which is followed by elimination of Cl-. The base used is pyridine which 
removes HCl formed as well as being used as solvent.  
Table 3.3.1 shows all the compounds synthesised and the corresponding yields obtained. 
Starting Sulfonyl 
Chloride 
R1 R Product Yield% 
1 (2,4-dichloro-5-methyl)phenyl 2-methyl (18) 21 49% 
1 (2,4-dichloro-5-methyl)phenyl 3-methyl (19) 22 56% 
1 (2,4-dichloro-5-methyl)phenyl 4-methyl (20) 23 46% 
4 (4-trifluoromethyl)phenyl 2-methyl (18) 24 60% 
5 (3,4-dimethyl)phenyl 2-methyl (18) 25 29% 
6 (3,4-dichloro)phenyl 2-methyl (18) 26 65% 
7 (2,4-dichloro)phenyl 2-methyl (18) 27 68% 
8 (2,4-dimethyl)phenyl 2-methyl (18) 28 55% 
9 (2,5-dimethyl)phenyl 2-methyl (18) 29 47% 
10 (2,5-dichloro)phenyl 2-methyl (18) 30 56% 
11 (4-tert-butyl)phenyl 2-methyl (18) 31 75% 
12 (3,5-bis(trifluoromethyl))phenyl 2-methyl (18) 32 70% 
13 1-phenylmethane 2-methyl (18) 33 28% 
14 3-pyridine 2-methyl (18) 34 79% 
15 2-napthalene 2-methyl (18) 35 58% 
16 1-napthalene 2-methyl (18) 36 48% 
17 Cyclohexane 2-methyl (18) 37 26% 
Table 3.3.1: Compounds 21-37. 
In general, this reaction worked well for every product, with only compounds 25, 33 and 37 being 
obtained with a low yield of 29%, 28% and 26% respectively, due to the loss of the product during 
the purification process. After the characterisation of each compound by 1H-NMR, 13C-NMR and 
HPLC, they were subjected to biological evaluation. 
3.3.2 Synthesis of methyl(arylsulfonamido)benzoate (42-43) 
The synthesis of the last two analogues required the preparation of the two starting sulfonyl 
chlorides. The reaction scheme used to obtain the two starting materials is shown in scheme 3.3.2. 
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Scheme 3.3.2: First step for the synthesis of compounds 40-41. 
The chlorosulfonation which occurs between chlorosulfonic acid and the two different substituted 
toluenes complies with the electrophilic aromatic substitution mechanism. Initially, a self-
protonation of chlorosulfonic acid occurs to form water. Afterwards, an electron pair of the toluene 
ring attacks the sulphur atom of the acid, leading to the formation of the aromatic sulfonyl chloride 
after elimination of water.  
Table 3.3.2 illustrates the two starting materials used and corresponding sulfonyl chlorides obtained 
with the yield of the reactions. 
Starting Material Structure 
Sulfonyl 
Chloride 
Structure Yield 
38 
 
40 
 
35% 
39 
 
41 
 
19% 
Table 3.3.2: Starting materials used and corresponding sulfonyl chlorides obtained. 
In order to obtain the selective chlorosulfonation on the desired position, the starting toluenes were 
chosen analysing the influence of the different substituents on the reactivity. In fact, in this reaction 
the methyl and chlorine groups act as activating and deactivating substituents respectively and both 
orientate the substitution at ortho and para positions. The two starting material structures are 
shown in figure 3.3.2.1 
 
Fig 3.3.2.1: Starting toluene structures. 
Since starting 38 is para-substituted, both substituents can orientate the chlorosulfonation only at 
the ortho positions; however, since the methyl group, which is an activating substituent, has a 
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stronger influence than the chlorine group, the methyl ortho-orientation is the most likely. In 39 
both ortho and para postions are available, however also in this case the methyl effect prevails over 
the chlorine. Moreover, generally in the chlorosulfonation reaction the percentage of the para-
substituted product formed is higher than the ortho substituted, therefore the sulfonyl chloride 
expected was the one with the methyl and chlorine at positions para and meta respectively. The 
two sulfonyl chloride structures and the corresponding 1H-NMR spectra are shown in figure 3.3.2.2  
 
 
Fig 3.3.2.2: Sulfonyl chloride structures and corresponding 1H-NMR spectra. 
According to 1H-NMR experiments, both desired sulfonyl chlorides were obtained. The splitting and 
the ppm values of the signals were crucial for the determination of the compounds structures. In 
particular, the correspondence between the ppm value and the electron-withdrawing effect on the 
surrounding protons was evaluated. In both cases, using the splitting of signals and the J coupling 
values, it was possible to identify all three protons belonging to the aromatic ring. Considering only 
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these three protons, in the 1H-NMR spectra of compound 40 the doublet signal corresponding to 
proton 1 resonance was the most downfield because of the strong electron-withdrawing effect, 
whilst the low ppm value of the doublet generated by proton 3 was due to the shield of the methyl 
group. The doublet of doublet representing proton 2 occupied an intermediate position between 
the other two protons resulting from the electron-withdrawing effect of the chlorine. An analogous 
situation occurred in the 1H-NMR spectrum of compound 41, with the doublet signal of proton 3 
which resonated at the lowest ppm value, followed by the doublet of doublet of proton 2, whilst 
the doublet of proton 1 was the last signal downfield. Therefore, the synthesis of the two desired 
compounds was confirmed. However, the two reactions exhibited two different trends. In the 
synthesis of 40, the desired sulfonyl chloride was the major product of the reaction, thereby it was 
used for the next step. Nevertheless, small percentages of side products occurred explaining the 
low yield of the reaction (35%). On the contrary, the second sulfonyl chloride (41) was obtained in 
equal percentage with three different side products, therefore a flash column chromatography was 
performed in order to isolate the desired compound. Unfortunately, the formation of greater 
amounts of additional compounds decreased the yield to 19%. Afterwards in order to obtain the 
corresponding final sulfonamides, compounds 40 and 41 were reacted with the methyl 2-
aminobenzoate, using the same reaction shown in the scheme 3.3.1. Products 42 and 43 were 
obtained and table 3.3.2.2 displays their structures and reaction yields. 
Product Structure Yield 
42 
 
9% 
43 
 
24% 
Tab 3.3.2.2: Compounds 42-43. 
Despite the fact that both the two final products were obtained, in both cases they were associated 
with low yields. 42 showed the lowest yield. Two different reasons caused a reduction of the amount 
of product obtained. The first reason involved the reaction that occurred between the anthranilic 
ester and the small amounts of impurities coming from the starting material, thus leading to the 
formation of additional side products. The second reason concerned the purification processes, in 
fact several recrystallisations were attempted in order to remove the impurities shown by the 1H-
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NMR spectrum. However, it was impossible to completely purify the product by recrystallisation 
only, therefore also a flash column chromatography was performed. All these factors contributed 
to the decrease of yield.  The slightly improved yield in the synthesis of compound 43 was probably 
due to the cleaner starting material used. However also in this case recrystallisation, followed by 
flash column chromatography, was performed, thus decreasing the yield obtained (24%).  
3.3.3 Synthesis of alkyl(arylsulfonamido)benzoates (50-57) 
The general scheme of the reaction used to synthesise analogues 50-57 is shown in scheme 3.3.3, 
and the reaction follows the same mechanism explained in paragraph 3.3.1.   
 
Scheme 3.3.3: General scheme for the synthesis of compounds 50-57. 
 
Table 3.4.3 lists all the analogues obtained following the General Procedure 4 reported in the 
Experimental Section. 
Starting Sulfonyl 
Chloride 
R1 R Product Yield% 
1 (2,4-dichloro-5-methyl)phenyl 2-ethyl ester (44) 50 43% 
4 (4-trifluoromethyl)phenyl 3-ethyl ester (45) 51 65% 
46 (4-iodo)phenyl 2-methyl ester (18) 52 25% 
46 (4-iodo)phenyl 3-methyl ester (19) 53 12% 
47 (2-methyl-3-chloro)phenyl 2-ethyl ester (44) 54 40% 
47 (2-methyl-3-chloro)phenyl 3-ethyl ester (45) 55 82% 
48 1-(p-tolyl)methane 2-methyl ester (18) 56 15% 
49 2-furan 2-methyl ester (18) 57 57% 
Table 3.3.3: Compounds 50-57. 
Generally, compounds which show the ester group in ortho position were obtained in lower yields 
compared to compounds with the ester group in meta position. This might be explained by the 
bigger steric hindrance around the nitrogen atom that makes the amino group less reactive. 
Nevertheless, compounds 50, 51, 54, 55 and 57 were obtained in moderate yields. On the other 
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hand, low yields were obtained for compounds 52, 53 and 56. In all cases the reaction did not reach 
completion even after 24 hours, thus explaining the low yields obtained. Moreover, in order to 
facilitate the formation of 53 the temperature was increased to 40°C. Although this strategy 
promoted the formation of 53, an undesired product was also obtained. Unfortunately, considering 
the highly similar retention factor of the side product, the complete isolation of 53 was not achieved, 
leading to the 12% yield obtained. Similarly to 53, different purification processes were required for 
56, thus contributing to the low yield obtained.  
3.3.4 Synthesis of (arylsulfonamido)benzoic acids (63-67, 69-70, 72-76) 
As mentioned in section 3.1, some of the designed derivatives retain the carboxylic acid function 
whilst different modifications are introduced on the hydrophobic ring. The several 
(arylsulfonamido)benzoic acid derivatives were obtained using different reactions.  
3.3.4.1 Synthesis of compounds 63-67 
Analogues 63-67, shown in table 3.3.4.1, were obtained using the reaction reported in paragraph 
3.3 and the reaction scheme is shown in scheme 3.3.4.1. 
 
Scheme 3.3.4.1: General scheme for the synthesis of compound 63-67. 
 
Starting Sulfonyl Chloride R Product Yield% 
58 benzene 63 59% 
59 1-(4-(trifluoromethyl)phenyl)methane 64 23% 
60 2-thiophene 65 22% 
61 8-quinoline 66 28% 
62 3-quinoline 67 35% 
Table 3.3.4.1: Compounds 63-67. 
In general, this reaction worked well with the starting sulphonyl chlorides reacting completely. All 
the products obtained with this method were purified by recrystallisation and the moderate yields 
obtained can be explained by the loss of product during this process.   
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3.3.4.2 Synthesis of compounds 69-70, 71 
Analogues 69-70 are characterised by the presence of different substituents on the hydrophobic 
phenyl ring. The reaction scheme is shown in scheme 3.3.4.2. 
 
Scheme 3.3.4.2: General scheme for the synthesis of compounds 69-70. 
The reaction follows the same mechanism explained in paragraph 3.3, however a different base was 
used to obtain 69 and 70. This is due to the fact that when the same reaction was performed using 
NaOH the yields obtained were extremely low (< 5%). The use of an alternative base, sodium 
carbonate, allowed optimisation of the yields. 
Compounds and corresponding yields obtained are shown in table 3.3.4.2 
 
Starting Sulfonyl Chloride R Product Yield% 
41 3-chloro-4-methyl 69 61% 
68 4-pentafluorosulfanyl 70 40% 
Table 3.3.4.2: Compounds 69-70. 
69 was synthesised in order to investigate whether retaining the carboxylic acid moiety may 
improve the activity of the corresponding methyl ester derivative (43). In 70 instead a new 
hydrophobic substituent was introduced, the 4-pentafluorosulfanyl (SF5). This group has been 
reported to impart lipophilicity, chemical resistance, thermal stability and low surface energy to 
molecules, therefore the synthesis of new analogues containing this moiety was considered. (3) 
Moreover, the methyl ester derivative (71) of 70 was also synthesised. The analogue 71 was 
obtained through a Fisher esterification and the reaction scheme is shown in scheme 3.3.4.2.2. 
 
Scheme 3.3.4.2.2: Synthesis of compound 71. 
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Following the General Procedure 7 reported in the Experimental Section, compound 71 was 
obtained with 43% yield. 
3.3.4.3 Synthesis of compounds 72-76 
Derivatives 72-76 were obtained via hydrolysis of the corresponding methyl esters 34-37, 57. The 
structures of the carboxylic acid derivatives are shown in table 3.3.4.3 while scheme 3.3.4.3 reports 
the general reaction scheme.   
 
Scheme 3.3.4.3: General scheme for the synthesis of compounds 72-76. 
Hydrolysis, performed in basic conditions, afforded products 72, 75, and 76 in moderate yields and 
products 73 and 74 in good yields. The General Procedure applied is reported in the Experimental 
Section. 
Starting Ester R Product Yield% 
34 3-pyridine 72 30% 
35 2-napthalene 73 67% 
36 1-napthalene 74 90% 
37 cyclohexane 75 26% 
38 2-furan 76 32% 
Table 3.3.4.3: Compounds 72-76. 
3.3.5 Synthesis of alkyl(arylsulfonamido)benzoates (78, 80-82) 
In 78, 80-82 alternative esters such as the isopropyl ester and the tert-butyl ester were considered 
as substituents instead of the methyl group. These two groups aim to explore whether bigger alkyl 
groups, which show higher stability to hydrolysis compared to the methyl ester, may influence the 
activity of the compounds. In order to make a direct comparison between the different alkyl esters, 
the isopropyl derivative and the tert-butyl derivative of 21 and 43 were synthesised. 
Scheme 3.3.5.1 shows the synthetic strategy applied to obtain 78, the isopropyl derivative of 21.   
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Scheme 3.3.5.1: Synthesis of compound 78. 
The isopropyl 2-aminobenzoate was obtained via Fisher esterification of the anthranilic acid. The 
procedure followed is the General Procedure 7, however in this case the time of the reaction was 
increased to 48 hours. Nevertheless, only a partial conversion of the starting material into the 
corresponding isopropyl ester was reached, probably due to the low reactivity of the isopropyl 
alcohol. Considering the low yield obtained, an alternative strategy which aims to increase the 
reactivity of the starting acid was also attempted. Consequently, the chlorination of the anthranilic 
acid by reaction with thionyl chloride and the following reaction with i-PrOH was performed. 
However, this approach was unsuccessful giving an even lower yield (11%). Therefore, the 19% yield 
obtained through the Fisher esterification was the best result achieved. The following step involves 
the reaction with sulfonyl chloride 1 to give the final product 78. The procedure applied is General 
Procedure 2. In this case, the reaction did not reach completion, probably because of the decreased 
reactivity of the amino group which is sterically hindered by the isopropyl group, thus explaining the 
low yield obtained.   
Compound 79, the isopropyl derivative of 43, was obtained via esterification of the carboxylic acid 
derivative 69. Two different synthetic strategies were applied. The first attempt was the Fisher 
esterification shown in scheme 3.3.5.2 
 
Scheme 3.3.5.2: Synthesis of compound 79. 
Unfortunately, also in this case the conversion to the isopropyl ester was extremely low, and after 
48 hours only the 6% of product was formed. An alternative synthetic approach which involves the 
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use of the coupling agent 2-(1H-benzotriazol-1-yl)-N,N,N’,N’tetramethylaminium tetrafluoroborate 
(TBTU) was considered. The reaction scheme is shown in scheme 3.3.5.3 
 
Scheme 3.3.5.3: Synthesis of compound 79. 
The procedure followed for this reaction is reported in the Experimental Section. The mechanism of 
the reaction implicates different steps. The first step is the formation of the carboxylate anion which 
reacts with TBTU. The following decomposition of the resulting tetrahedral intermediate promotes 
the addition of the benzotriazole derivative to the carbonyl centre generating the activated carbonyl 
group which reacts with the alcohol, eventually leading to the formation of the corresponding ester 
and a by-product soluble in water. Figure 3.3.5.1 illustrates the reaction mechanism. 
 
Fig 3.3.5.1: Esterification mechanism using the coupling reagent TBTU. 
Although the percentage of product formed was much higher compared to the Fisher esterification, 
only 22% yield was obtained. This low value is due to the formation of different impurities which 
did not allow the complete isolation of the pure product, although several purification processes 
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were performed. However, using this alternative synthetic strategy, a slight optimisation of the yield 
was achieved.   
The tert-butyl derivatives 80 and 81 were synthesised following the General Procedure 8 reported 
in the Experimental Section. The reaction scheme is shown in scheme 3.3.5.4. 
 
Scheme 3.3.5.4: Synthesis of compounds 80-81. 
The procedure applied is commonly used for the synthesis of tert-butyl esters and it involves the 
reaction between the carboxylic acid and the tertiary alcohol in the presence of H2SO4 absorbed on 
MgSO4. Compounds and corresponding yields obtained are shown in table 3.3.5.1. 
Product Structure Yield 
80 
 
20% 
81 
 
22% 
Table 3.3.5.1: Compounds 80-81. 
In both reactions, only a partial conversion of the starting material was observed, thus explaining 
the low yields obtained. 
3.3.6 Synthesis of (arylsulfonamido)N-(1H-tetrazol-5-yl)phenyls (86-93) 
The replacement of the carboxylic acid moiety with a tetrazole group characterises compounds 86-
93. Tetrazoles are the most common carboxylic acid bioisosteres. (1) Compared to the carboxylic acid 
groups, tetrazoles show similar planarity and acidity. However, the higher lipophilicity of the 
tetrazolate anions might result in a better permeability across the cellular membrane. (4) Moreover, 
the metabolic product deriving from the N-glucuronidation of the tetrazole group is less reactive 
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than the O-glucoronidated derivatives generated from carboxylic acids, thus implying minor 
cytotoxicity effects. (5) Different tetrazole derivatives were synthesised. Scheme 3.3.6.1 shows the 
synthetic pathway. 
 
Scheme 3.3.6.1: Synthetic pathway applied for the synthesis of the tetrazole derivatives. 
The first step involves the synthesis of the ortho and para substituted (1H-tetrazol-5yl)anilines. The 
reaction, carried out the in presence of sodium azide and ammonium chloride, is shown in scheme 
3.3.6.2 and General Procedure 9 applied is reported in the Experimental Section.   
 
Scheme 3.3.6.2: Synthesis of compounds 84-85. 
The reaction occurs via a concerted 1-3 dipolar cycloaddition where the dipolarophile is represented 
by the aminobenzonitrile, whilst the azide is the 1-3 dipolar species. The mechanism of reaction is 
shown in figure 3.3.6.1.  
 
Fig 3.3.6.1: Concerted 1-3 dipolar cycloaddition mechanism. 
Following this reaction, the ortho (84) and para (85) substituted (1H-tetrazol-5-yl) anilines were 
obtained with a yield of 53% and 33% respectively. The low yield obtained for 85 is mainly due to 
the loss of product in the aqueous layer during the extraction process. For 84, an alternative method 
involving solvent evaporation and purification by column chromatography was attempted and the 
yield was increased to 53%. The final tetrazole derivatives 86-93 were obtained by reaction of 84 
and 85 with the corresponding sulfonyl chlorides, following the reaction described in paragraph 
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3.4.1. The reaction scheme is shown in scheme 3.3.6.3, while table 3.3.6.1 reports the structure of 
86-93 and the corresponding yields obtained. 
 
Scheme 3.3.6.3: Synthesis of compounds 86-93. 
(1H-tetrazol-5yl)aniline R1 Product Yield% 
4-(1H-tetrazol-5yl)aniline (85) (2,4-dichloro-5-methyl)phenyl (1) 86 46% 
4-(1H-tetrazol-5yl)aniline (85) 3-chloro-4-methyl (41) 87 18% 
2-(1H-tetrazol-5yl)aniline (84) (2,4-dichloro-5-methyl)phenyl (1) 88 18% 
2-(1H-tetrazol-5yl)aniline (84) 3-chloro-4-methyl (41) 89 16% 
2-(1H-tetrazol-5yl)aniline (84) (4-trifluoromethyl)phenyl (4) 90 42% 
2-(1H-tetrazol-5yl)aniline (84) 2-napthalene (15) 91 38% 
2-(1H-tetrazol-5yl)aniline (84) 8-quinoline (62) 92 26% 
2-(1H-tetrazol-5yl)aniline (84) 3-quinoline (63) 93 46% 
Table 3.3.6.1: Compounds 86-93. 
Although this reaction worked well in terms of amount of product formed, some of the derivatives 
were obtained with poor yields (<20%). This is mostly due to the fact that some derivatives required 
different recrystallisation steps, which contributed to reduce the amount of product obtained.   
3.3.7 Synthesis of (arylsulfonamido)N-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-
yl)phenyls (97-98) 
In 97-98 the carboxylic acid group was replaced with a 5-oxo-1,2,4-oxadiazole ring. This moiety is 
characterised by a planar acidic heterocycle and it has been reported to be more lipophilic than the 
tetrazole ring, representing therefore a good carboxylic acid surrogate. (1, 6) In order to explore 
whether the replacement of the carboxylic acid function with the 5-oxo-1,2,4-oxadiazole ring may 
improve the cell membrane permeability, the synthesis of the oxadiazole derivatives of 3 and 43 
was performed. Scheme 3.3.7.1 shows the reaction scheme for the synthesis of 97-98. 
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Scheme 3.3.7.1: Synthetic pathway applied for the synthesis of compounds 97-98. 
The 5-oxo-1,2,3-oxadiazole intermediate (96) was obtained reacting the 2-aminobenzamidoxime 
(94) with diethyl carbonate (95) in basic conditions, as reported in scheme 3.3.7.2, following the 
procedure reported in the Experimental Section. 
 
Scheme 3.3.7.2: Synthesis of compound 96. 
The reaction mechanism, shown in figure 3.3.7.1, involves the initial deprotonation of the -OH 
group, which is followed by attack of the anion generated at the oxygen atom, on the carbonyl 
group. The formation of the tetrahedral species and the subsequent loss of EtOH, generate an 
intermediate which, following the attack of the nitrogen atom on the carbonyl group, and the loss 
of another molecule of EtOH, cyclises to give the desired product 96, with a yield of 58%. (7) 
 
Fig 3.3.7.1: Reaction mechanism for the synthesis of compound 96. 
Reaction of 96 with sulfonyl chlorides 1 and 41 was performed in order to obtain the desired final 
products 97-98, following the reaction described in paragraph 3.3.1 and reported in scheme 3.3.7.3, 
while table 3.3.7.1 illustrates the structure of the two 5-oxo-1,2,4-oxadiazole derivatives.  
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Starting Sulfonyl Chloride R Product 
1 2,4-dichloro-5-methyl 97 
41 3-chloro-4-methyl 98 
Table 3.3.7.1: Compounds 97-98. 
 
 
Scheme 3.3.7.3: Synthesis of compounds 97-98.  
When the synthesis of 97 and 98 was attempted, the formation of several by-products was 
observed. Although, following a series of chromatographic purifications, 97 and 98 were isolated 
with a yield of 7% and 2% respectively, 1H-NMR, HPLC and mass spectrometry analyses revealed 
degradation of the 5-oxo-1,2,4-oxadiazole ring. According to the results obtained from the analyses 
performed, in both cases, the decarboxylation of the 5-oxo-1,2,4-oxadiazole ring occurs, leading to 
the formation of the corresponding amidine. Degradation of the two products was assessed by 
repeating 1H-NMR, HPLC and MS analyses of the isolated compounds 97 and 98 after 24 hours. Table 
3.3.7.2 summarises the data obtained, and the structure of the degraded products is shown in figure 
3.3.7.2. 
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Figure 3.3.7.2: Compounds 97-98 and corresponding amidine species 99-100.  
Before 24h After24  
Ratio (%) Ratio (%) MS (ESI)+ 
97 (95.86):99 (4.14%) 97 (92.41):99 (7.59%) 402.07:358.06 
98 (95.96%):100 (3.30%) 98 (85.72%):100 (12.94%) 366.18:324.12 
Table 3.3.7.2: HPLC and MS analyses. 
Interestingly, the decarboxylation of the oxadiazole ring seems to be promoted by the presence of 
a sulfonamide group, indeed, when the sulphonamide linker was replaced by an amine moiety, 
which will be discussed in Chapter 4, this phenomenon was not observed. Therefore, considering 
the stability problems associated with the 5-oxo-1,2,4-oxadiazole ring, this series of derivatives was 
discarded.    
3.3.8 Synthesis of alkyl(arylsulfonamido)benzamides (101-106) 
Analogues 101-106 are characterised by the replacement of the methyl ester of compounds 21 and 
43 with differently substituted carboxamides in order to increase the hydrolytic stability of these 
molecules. The synthetic strategy applied to obtain the carboxamide derivatives involves the use of 
the coupling reagent N-N’ carbonyldiimidazole (CDI), which allows the direct amidation of carboxylic 
acids, and the reaction mechanism is shown in figure 3.3.8.2. Initially the carboxylic acid reacts with 
CDI generating the acyl carboxy imidazole and imidazole. The two intermediates immediately react 
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together to form the activated acylimidazole which will be attacked by the nitrogen atom of the 
amine giving the desired product.  
 
Fig 3.3.8.1: General scaffold of the carboxamide derivatives (101-106). 
 
 
Fig 3.3.8.2: Reaction mechanism for the synthesis of the carboxamide derivatives.  
The starting carboxylic acid and CDI were stirred overnight in order to allow the formation of the 
activated species, and then the desired amine was added following General Procedure 10 reported 
in the Experimental Section. The scheme of the reaction for the synthesis of the substituted 
carboxamide derivatives is reported in scheme 3.3.8.1, products obtained and their corresponding 
yields are shown in table 3.3.8.1. 
 
Scheme 3.3.8.1: Synthesis of derivatives 101-105. 
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Starting 
carboxylic acid 
R R’ Product Yield% 
69 3-chloro-4-methyl -methyl 101 30% 
3 2,4-dichloro-5-methyl -methyl 102 49% 
3 2,4-dichloro-5-methyl -ethyl 103 44% 
3 2,4-dichloro-5-methyl -dimethyl 104 35% 
3 2,4-dichloro-5-methyl -isopropyl 105 53% 
Table 3.3.8.1: Compounds 101-105. 
Generally the reaction worked well, with only two compounds (101 and 105) giving poor yields 
(<40%.) The low yield obtained for 101 can be explained by the loss of product during the different 
purification techniques (flash column chromatography and recrystallisation) required for the 
complete purification of the compound. In the case of 104 the reaction was slow and even after 
stirring the reaction overnight the activated species did not react completely, giving only 35% of the 
desired product. 
In order to obtain the primary carboxamide derivative of 3 the conditions of the reaction were 
slightly changed. The organic solvent was replaced by the 1-butyl-3-methylimidazolium 
tetraﬂuoroborate ([bmim]BF4) ionic liquid in order to promote the solubility of the ammonium 
acetate which was used as source of ammonia. The scheme of the reaction is shown in scheme 
3.3.8.2, and the procedure applied is reported in the Experimental Section. 
 
Scheme 3.3.8.2: Synthesis of derivative 106. 
Although this procedure has been reported as an effective method for the synthesis of the primary 
carboxamide, (8) the product was obtained in a very low yield (10%). Unfortunately, the starting 
carboxylic acid and the activated acylimidazole were the main species obtained from the reaction, 
while only a small amount of product, corresponding to the 10 % yield, was formed.  
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3.4 Conclusions 
Starting from the structure of the hit 3, 60 sulfonamide derivatives were designed, with the aim of 
obtaining new molecules showing a better pharmacokinetic profile and improved activity compared 
to hit 3. Several modifications on the original structure were considered. The carboxylic acid moiety 
was replaced by different groups such as alkyl esters, tetrazole, oxadiazole and carboxamide groups. 
On the other side changes on the hydrophobic ring were also explored, including the introduction 
of various hydrophobic substituents, as well as the replacement with different heterocycles and 
bigger aromatic rings. Different synthetic strategies were developed, and all the designed 
derivatives were synthesised. Unfortunately, compounds belonging to the 5-oxo-1,2,4-oxadiazole 
series showed stability issues, therefore this family was discarded. The newly synthesised 
derivatives were biologically evaluated in order to assess their ability to sensitise breast cancer cells 
and breast cancer stem cells to TRAIL. The results obtained will be discussed in the Biological 
Evaluation chapter.  
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Chapter 4: Amine Derivatives 
4.1 Design of amine derivatives 
This series of analogues was developed in order to investigate whether the replacement of the 
sulfonamide linker by an amine group affects the activity of the compounds. The general scaffold of 
this new series of derivatives, represented by an amine group which links two differently substituted 
aromatic rings, is shown in figure 4.1. The new amine linker retains the original tetrahedral geometry 
required for the adjustment of the molecules to the curved-shaped cavity of the c-FLIP pocket, as 
well as the original distance between the two aromatic rings. However, in order to explore whether 
increasing the length and the flexibility of the linker might affect the ability of the two rings to 
occupy the pocket of c-FLIP, molecules showing an elongated linker were also designed. Moreover, 
with the aim to carry out structure-activity relationships studies, a further modification to the linker, 
involving the inversion of the -NH group (R-NH-CH2-R’), was considered. All the designed amine 
derivatives retain the carboxylic acid function in the ortho or meta position of the original anthranilic 
ring. However, using the same criteria discussed in chapter 3, the substitution of the carboxylic acid 
moiety with a methyl ester group, or with the carboxylic acid bioisosteres, tetrazole and oxadiazole 
rings, was also considered. On the other side, modifications designed for the hydrophobic ring were 
mostly selected according to the early biological data obtained for the sulfonamide derivatives, 
which will be discussed in the Biological Evaluation chapter. Those hydrophobic substituents that 
gave the best biological results were introduced in the amine series. The replacement of the original 
phenyl ring with bigger aromatic rings such as naphthalene and quinoline, and with the heterocycle 
pyridine was also explored. Considering the features described above, 33 new derivatives were 
designed, and they are listed in table 4.1. 
 
Fig 4.1: Central scaffold of the amino derivatives 
Molecule R R’ 
113 (4-trifluoromethyl)phenyl 2-carboxylic acid 
114 (4-trifluoromethyl)phenyl 3-carboxylic acid 
115 (3,4-dimethyl)phenyl 2-carboxylic acid 
116 (3,4-dimethyl)phenyl 3-carboxylic acid 
117 (3-chloro-4-methyl)phenyl 2-carboxylic acid 
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118 (3-chloro-4-methyl)phenyl 3-carboxylic acid 
119 8-quinoline 2-carboxylic acid 
120 2-quinoline 2-carboxylic acid 
121 (4-trifluoromethyl)phenyl 2-methyl ester 
122 (4-trifluoromethyl)phenyl 3-methyl ester 
123 (3,4-dimethyl)phenyl 2-methyl ester 
124 (3,4-dimethyl)phenyl 3-methyl ester 
129 (3-chloro-4-methyl)phenyl 2-methyl ester 
130 (3-chloro-4-methyl)phenyl 3-methyl ester 
131 3-pyridine 2-methyl ester 
132 4-pyridine 2-methyl ester 
133 2-naphtalene 2-methyl ester 
134 1-naphtalene 2-methyl ester 
137 benzyl 2-methyl ester 
138 (4-trifluoromethyl)phenyl 2-methyl ester 
139 3-pyridine 2-carboxylic acid 
140 4-pyridine 2-carboxylic acid 
141 2-naphtalene 2-carboxylic acid 
142 1-naphtalene 2-carboxylic acid 
143 (4-trifluoromethyl)phenyl 2-carboxylic acid 
144 (4-trifluoromethyl)phenyl 2-(1H-tetrazole) 
145 (3-chloro-4-methyl)phenyl 2-(1H-tetrazole) 
146 (3-chloro-4-methyl)phenyl 4-(1H-tetrazole) 
147 8-quinoline 2-(1H-tetrazole) 
148 2-quinoline 2-(1H-tetrazole) 
149 2-naphtalene 2-(1H-tetrazole) 
150 (3-chloro-4-methyl)phenyl 2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol) 
155 2-methylbenzoic acid 3-chloro-4-methyl 
156 2-methylbenzoic acid 5-chloro-2-methyl 
157 2-methylbenzoic acid 4-(trifluoromethyl) 
Table 4.1: Designed amine derivatives. 
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4.2 Synthesis of amine derivatives 
4.2.1: Synthesis of (aryl)amino)benzoic acids (113-120) 
Some of the carboxylic acid derivatives of the amine series were obtained via reductive amination 
of the appropriate aldehyde using ortho or meta aminobenzoic acid, and sodium borohydride 
(NaBH4) as reducing agent. The reaction scheme is shown in scheme 4.2.1, and the mechanism of 
the reaction is illustrated in figure 4.2.1. Initially, the aldehyde and the aminobenzoic acid react to 
form a Schiff base intermediate which will be reduced by NaBH4 in the presence of acetic acid.   
 
Scheme 4.2.1: Synthesis of compounds 113-120. 
 
 
Figure 4.2.1: Reductive amination mechanism. 
Following General Procedure 11 reported in the Experimental Section, derivatives 113-120 were 
obtained. The substituents belonging to each analogue, and the corresponding yields obtained are 
shown in table 4.2.1. 
Starting aldehyde R -COOH Product Yield 
107 4-(trifluoromethyl)phenyl 2-COOH (2) 113 17% 
107 4-(trifluoromethyl)phenyl 3-COOH (112)  114 20% 
108 (3,4-dimethyl)phenyl 2-COOH (2) 115 52% 
108 (3,4-dimethyl)phenyl 3-COOH (112) 116 26% 
109 (3-chloro-4-methyl)phenyl 2-COOH (2) 117 21% 
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109 (3-chloro-4-methyl)phenyl 3-COOH (112) 118 28% 
110 8-quinoline 2-COOH (2) 119 43% 
111 3-quinoline 2-COOH (2) 120 41% 
Table 4.2.1: Compounds 113-120. 
Unfortunately, poor yields were obtained for most of the new compounds. All the derivatives 
showing a yield less than 30% required at least two flash column chromatography purifications 
followed by recrystallisation. Therefore, the low yields obtained were mainly due to the loss of 
product during the several purification processes.  
4.2.2 Synthesis of methyl((aryl)amino)benzoates (121-124, 129-134, 137-138) 
Derivatives 121-124 and 129-134 are characterised by the replacement of the carboxylic acid 
function with a methyl ester group. This modification was carried out with the aim to increase the 
lipophilicity of the compounds in order to enhance their ability to cross the cellular membrane. Two 
main reactions were used to obtain the methyl ester derivatives.  
4.2.2.1 Synthesis of methyl((aryl)amino)benzoates (121-124) 
Methyl ester derivatives 121-124 were synthesised via esterification of the corresponding carboxylic 
acids 113-116. The procedure used is General Procedure 11 reported in the Experimental Section 
and it involves the use of the coupling agent TBTU in the presence of DIPEA. The reaction scheme is 
shown in scheme 4.2.2.1 and the reaction follows the same mechanism explained in paragraph 3.3.5 
in Chapter 3.  
 
Scheme 4.2.2.1: Synthesis of derivatives 121-124. 
In table 4.2.2.1 are listed the derivatives synthesised and the corresponding yields obtained. 
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Product R R’ Yield 
121 4-trifluoromethyl 2-COOCH3 44% 
122 4-trifluoromethyl 3-COOCH3 38% 
123 3,4-dimethyl 2-COOCH3 13% 
124 3,4-dimethyl 3-COOCH3 26% 
Table 4.2.2.1: Compounds 121-124. 
Although all the desired products were obtained, the reaction did not give a complete conversion 
of the starting carboxylic acids, even after the reaction time was increased from 7 hours to 15 hours. 
Moreover, the complete purification of 123 and 124 required repeated flash column 
chromatography, thus contributing to the decrease of the yield to 13% and 26% respectively. 
4.2.2.2: Synthesis of methyl((aryl)amino)benzoates (129-134) 
Scheme 4.2.2.2. shows the reaction scheme for the synthesis of the derivatives 129-134, which were 
obtained via reductive amination of the appropriate aldehydes, following General Procedure 11 and 
the reaction explained in paragraph 4.2.1.  
 
Scheme 4.2.2.2: Synthesis of derivatives 129-134. 
In most cases this reaction worked well and the desired products were obtained in good yields. Only 
compound 129 was obtained with a yield of 26% due to the different purification processes 
required.   
Starting aldehyde R -COOCH3 Product Yield 
109 (3-chloro-4-methyl)phenyl 2-COOCH3 (18) 129 26% 
109 (3-chloro-4-methyl)phenyl 3-COOCH3 (19)  130 83% 
125 3-pyridine 2-COOCH3 (18) 131 96% 
126 4-pyridine 2-COOCH3 (18) 132 95% 
127 2-napthalene 2-COOCH3 (18) 133 76% 
128 1-napthalene 2-COOCH3 (18) 134 79% 
Table 4.2.2.2: Compounds 129-134. 
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4.2.2.3 Synthesis of methyl((aryl)amino)benzoates (137-138) 
In derivatives 137-138 the amine linker was elongated by adding an additional carbon atom. As 
shown in scheme 4.2.2.3, these derivatives were obtained via nucleophilic substitution occurring 
between the methyl-2-amino benzoate and differently substituted bromides, following the 
procedures reported in the Experimental Section. Table 4.2.2.3. reports the structure of the two 
compounds obtained and the corresponding yields.  
 
Scheme 4.2.2.3: Synthesis of compounds 137-138. 
Starting bromide R Product Yield 
135 benzyl 137 5% 
136 4-(trifluoromethyl)phenyl 138 26% 
Table 4.2.2.3: Compounds 137-138. 
Compounds 137 and 138 were obtained in low yields. Unfortunately, in both cases, even after the 
time of the reaction was increased to 48 hours, the T.L.C showed the presence of the two unreacted 
starting materials with only a small amount of the desired products formed. Therefore, 137 was 
isolated and obtained in 5% yield, whilst only traces of 138 were collected after the purification 
process. In order to obtain a higher amount of compound 138, the same reaction was carried out in 
basic conditions, which increased the percentage of product formed, giving a yield of 26%.   
4.2.3 Synthesis of (aryl)amino)benzoic acids (139-143) 
The carboxylic acid derivatives 139-143 were obtained via hydrolysis of the corresponding methyl 
esters. The reaction scheme is shown in scheme 4.2.3 and the procedure followed is General 
Procedure 13 in the Experimental Section. The structure of the derivatives obtained and the 
corresponding yields are reported in table 4.2.3. In the majority of the cases, the hydrolysis of the 
starting methyl ester reached completion, therefore, the low yields obtained are mainly due to the 
loss of product during the purification process.   
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Scheme 4.2.3: Synthesis of compounds 139-143. 
Starting aldehyde R Product Yield 
131 3-pyridine 139 28% 
132 4-pyridine 140 26% 
133 2-napthalene 141 89% 
134 1-napthalene 142 41% 
136 (4-trifluoromethyl)benzyl 143 16% 
Table 4.2.3: Compounds 139-143. 
4.2.4 Synthesis of derivatives 144-149, 150 
As discussed in Chapter 3, the advantage of replacing a carboxylic acid with bioisostere groups such 
as a tetrazole or oxadiazole ring is represented by their higher lipophilicity compared to the 
carboxylic acid function and the less reactivity of their metabolic products, whilst retaining similar 
acidity and planarity. (1) A few amine derivatives showing the tetrazole and the oxadiazole group 
were designed.  
4.2.4.1 Synthesis of ((aryl)amino)N-(1H-tetrazol-5-yl)phenyl (144-149) 
The tetrazole derivatives were obtained via reductive amination of the appropriate aldehyde with 
the (1H-tetrazole-5-yl)anilines, previously synthesised and discussed in paragraph 3.3.6, following 
General Procedure 11. The reaction scheme is shown in scheme 4.3.4.1, while the derivatives 
obtained are shown in table 4.2.4.1 
 
Scheme 4.2.4.1: Synthesis of compounds 144-149. 
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Starting 
aldehyde 
R (1H-tetrazol-5yl)aniline Product Yield 
107 4-(trifluoromethyl)phenyl 2-(1H-tetrazol-5yl)aniline (84) 144 32% 
109 (3-chloro-4-methyl)phenyl 2-(1H-tetrazol-5yl)aniline (84) 145 25% 
109 (3-chloro-4-methyl)phenyl 4-(1H-tetrazol-5yl)aniline (85) 146 15% 
110 8-quinoline 2-(1H-tetrazol-5yl)aniline (84) 147 12% 
111 2-quinoline 2-(1H-tetrazol-5yl)aniline (84) 148 11% 
127 2-napthalene 2-(1H-tetrazol-5yl)aniline (84) 149 75% 
Table 4.2.4.1: Compounds 144-149. 
Despite the complete reductive amination of the starting aldehydes 107, 109-111 and 127, assessed 
by T.L.C., different purification processes were required to isolate the final products from the 
starting anilines 84 and 85, thus explaining the low yields obtained. 
4.2.4.2 Synthesis of (arylamino)N-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl (150) 
The derivative 150, which is characterised by the presence of the oxadiazole ring, was obtained via 
reductive amination of aldehyde 109 with the 3-(2-aminophenyl)-1,2,4-oxadiazol-5(4H)-one (96) as 
shown in scheme 4.2.4.2.  
 
Scheme 4.2.4.2: Synthesis of compound 150. 
Considering the stability issues observed for the corresponding sulfonamide derivatives 97-98, 
further 1H-NMR, HPLC and MS analyses were performed in order to assess whether degradation of 
the oxadiazole ring occurs for compound 150. Interestingly, according to the results obtained from 
these analyses, no changes in the structure of 150 was observed after 24 hours and 7 days. These 
results suggest a potential role of the sulphonamide group in promoting this phenomenon. 
Therefore, considering the stability of 150, this derivative was biologically evaluated. 
4.2.5: Synthesis of 2-(((aryl)amino)methyl)benzoic acids (155-157) 
In order to investigate whether changing the disposition of the -CH2-NH- linker may affect the ability 
of compounds to occupy the cavity of c-FLIP, the inversion of the amine linker was considered. 
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Therefore, a small series of derivatives showing the -NH group bound to the hydrophobic aromatic 
ring (figure 4.2.5.1) was designed. Table 4.2.5.1 shows the structure of the designed derivatives. 
 
Fig 4.2.5.1: General scaffold of derivatives showing an inverted amine linker. 
R Product 
3-chloro-4-methyl 155 
5-chloro-2-methyl 156 
4-(trifluoromethyl) 157 
Table 4.2.5.1: Designed derivatives. 
Initially, in order to obtain derivatives 155-157, a nucleophilic displacement of the 2-
(bromomethyl)benzoic acid by differently substituted anilines was attempted, as shown in scheme 
4.2.5.1.  
 
Scheme 4.2.5.1: Synthesis of compounds 155-157. 
Unfortunately, using these conditions, the synthesis of the desired derivatives was not achieved. 
Indeed, in all cases, this reaction promoted the formation of a different product, which was analysed 
by 1H-NMR and mass spectrometry. The 1H-NMR data obtained revealed the absence of the two 
peaks corresponding to the protons belonging to the -OH and -NH groups. With the help of MS 
analyses, which suggested the loss of a water molecule, the undesired species obtained were 
identified as the corresponding lactams (figure 4.2.5.2). 
 
Figure 4.2.5.2: By-products formed. 
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However, although this strategy was unsuccessful for the synthesis of the desired derivatives, the 
three by-products were conserved in order to investigate whether the lactam scaffold might show 
biological activity. 
On the other side, in order to obtain the desired derivatives, an alternative synthetic pathway was 
developed as shown in scheme 4.2.5.2. The first step involves a nucleophilic substitution reaction 
occurring between the methyl 2-(bromomethyl)benzoate (161) and the appropriate anilines, with 
the aim to obtain the ester intermediates, which, following hydrolysis, generate the desired 
carboxylic acid derivatives.  
 
Scheme 4.2.5.2: Alternative synthetic pathway for the synthesis of derivatives 155-157. 
Initially, the synthesis of the starting material methyl 2-(bromomethyl)benzoate (161), was 
attempted through esterification of the corresponding carboxylic acid 151. Two different reactions 
were performed, as shown in scheme 4.2.5.3. 
 
Scheme 4.2.5.3: Synthesis of starting material 161. 
The first reaction (a), involves the TBTU-mediated esterification and follows General Procedure 12 
in the Experimental Section. Unfortunately, this reaction led to the formation of a single by-product, 
which, by 1H-NMR and 13C-NMR analyses, was identified as the cyclic ester (figure 4.3.5.3) deriving 
from the intramolecular reaction between the oxygen of the carboxylic acid and the electrophilic -
CH2. Considering the basic conditions used in reaction (a) which may promote the intramolecular 
interaction, the acid catalysed Fisher esterification (b) was also attempted. Also in this case, the 
main product obtained was the undesired lactone. However, using acid conditions, a small amount 
of desired product, corresponding to the 10% yield, was obtained.  
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Fig 4.2.5.3: By-product formed during the esterification. 
Therefore, an alternative synthetic strategy, involving the benzylic bromination of the starting 
methyl 2-methylbenzoate, using N-bromosuccinimide (NBS) as a bromine source, in the presence of 
azobisisobutyronitrile (AIBN) as a radical initiator, was attempted. The procedure followed is 
reported in the Experimental Section and the mechanism of the reaction is shown in figure 4.2.5.4, 
while the scheme of the reaction is illustrated in scheme 4.2.5.4. The reaction occurs via a free 
radical-based bromination. The AIBN acts as the radical initiator and generates the bromine radical 
which carries out the propagation step. The termination step is represented by the formation of 
succinimide and bromine. 
 
Scheme 4.2.5.4: Synthesis of the starting material 161. 
 
Figure 4.2.5.4: General mechanism of the bromination. 
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The described strategy was successful, giving the desired product in 83% yield. Once the starting 
161 was obtained, the ester intermediates were obtained by reacting 161 with the different anilines, 
in presence of MeOH and NEt3, as shown in scheme 4.2.5.5 and reported in General Procedure 14. 
The derivatives obtained and the corresponding yields are illustrated in table 4.2.5.2. 
 
Scheme 4.2.5.5: Synthesis of intermediates 162-164. 
Aniline R Product Yield 
152 3-chloro-4-methyl 162 74% 
153 5-chloro-2-methyl 163 38% 
154 4-(trifluoromethyl) 164 43% 
Table 4.2.5.2: Intermediates 162-164. 
The synthesis of the corresponding acid derivatives was attempted via basic hydrolysis of derivatives 
162-164, as shown in scheme 4.2.5.6. 
 
Scheme 4.2.5.6: Synthesis of derivatives 155-157. 
Although this strategy was successful in order to achieve the synthesis of 156, which was obtained 
in 53% yield, derivatives 155 and 157 were not obtained due to the formation of the corresponding 
lactams 158 and 160 as main products of the reaction. The different trend observed for 156 might 
be determined by the presence of the chlorine atom in alpha position to the nitrogen which, 
creating steric hindrance, may decrease the reactivity of the nitrogen and prevent the cyclisation of 
the molecule. Stability tests were performed after a period of one week. Interestingly, no stability 
issues were observed for 156, whilst the two methyl ester derivatives 162 and 164 showed 
cyclisation with formation of the corresponding lactams 158 and 160. Therefore, although the 
different attempts performed in order to obtain the three designed derivatives 155-157, only the 
synthesis of 156 was successful. 
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4.3 Conclusions 
In order to investigate whether the replacement of the original sulfonamide moiety may affect the 
activity of the compounds, a new series of analogues, characterised by an amine group that links 
two differently substituted aromatic rings, was designed. 33 new derivatives, characterised by 
several changes on the hydrophobic ring and different functional groups as replacement of the 
carboxylic acid moiety, were synthesised. The synthetic strategies applied were successful for most 
designed derivatives. Unfortunately, for the compounds belonging to the family of 2-
(((aryl)amino)methyl)benzoic acids, out of three designed derivatives, only 156 was obtained. 
Indeed, although different attempts were performed, these compounds showed a tendency to 
cyclise to form the corresponding lactams. However, the cyclised derivatives obtained were 
biologically evaluated together with the other amine derivatives and the results obtained will be 
discussed in the Biological Evaluation chapter. 
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Chapter 5: Methylene and Amide Derivatives 
5.1 Design of methylene and amide derivatives 
With the aim to further explore structure-activity relationships, the role played by the distance 
between the two aromatic rings, and by the molecular geometry, was investigated with the design 
of two additional small series of analogues, characterised by the replacement of the original 
sulfonamide moiety with a methylene and an amide group. The central scaffold of the new series of 
compounds is represented in figure 5.1A-B. The methylene linker shortens the distance between 
the two aromatic rings, whilst retaining the desired molecular geometry for the correct arrangement 
of the molecule in the pocket of c-FLIP. On the contrary, the introduction of an amide linker, induces 
molecules to acquire a planar conformation, allowing to investigate how changes in the molecular 
geometry might affect the activity of the compounds. A few derivatives for each series were 
designed and as shown in table 5.1. The substituents introduced on the hydrophobic ring were 
selected on the basis of the preliminary data obtained for the sulfonamide analogues, whilst the 
carboxylic acid moiety and the corresponding alkyl ester groups were inserted in ortho and meta 
position of the original anthranilic ring.  
 
Fig 5.1: Central scaffold of the methylene(A) and amide (B) derivatives. 
Molecule Linker R R’ 
169 Methylene 4-trifluoromethyl 2-methyl ester 
170 Methylene 3-chloro-4-methyl 3-methyl ester 
171 Methylene 3-chloro-4-methyl 2-methyl ester 
172 Methylene 3-chloro-4-methyl 3-carboxylic acid 
173 Methylene 3-chloro-4-methyl 2-carboxylic acid 
178 Amide 4-trifluoromethyl 3-ethyl ester 
179 Amide 4-trifluoromethyl 2-methyl ester 
180 Amide 4-trifluoromethyl 3-methyl ester 
181 Amide 4-iodo 3-ethyl ester 
182 Amide 3-chloro-2-methyl 2-methyl ester 
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183 Amide 3-chloro-2-methyl 3-methyl ester 
186 Amide 3-chloro-4-methyl 2-carboxylic acid 
Table 5.1.: Different substituents on the methylene derivatives. 
5.2 Synthesis of methylene derivatives 
The synthetic strategy applied for the synthesis of the new methylene derivatives is shown in 
scheme 5.2. The methylene linker was synthesised via a Miyaura-Suzuki cross-coupling reaction 
between the desired aryl halides and ((methoxycarbonyl)phenyl)boronic acids. The corresponding 
carboxylic acids were obtained by hydrolysis of the synthesised methyl ester derivatives. 
 
Scheme 5.2.: Synthetic strategy for the synthesis of the methylene derivatives. 
5.2.1 Synthesis of methyl(benzyl)benzoates (169-171) 
The mechanism of the Miyaura-Suzuki cross-coupling, which allows the formation of the methylene 
linker between the two aromatic rings, is represented in figure 5.2.1. The reaction is a palladium-
catalysed reaction which requires three steps: oxidative addition, transmetalation and reductive 
elimination. In the oxidative addition the palladium is oxidised from palladium(0) to palladium(II), 
which forms an organopalladium complex with the aryl halide. The next step, the transmetalation, 
promotes the transfer of the ligand from the organoboronic acid to the palladium(II) complex. This 
step requires the presence of the base, represented by NaOH in figure 5.2.1, which activates the 
boronic species. Reductive elimination leads to the formation of the desired product, and the 
regeneration of palladium(0).  
 
Fig 5.2.1.: Miyaura-Suzuki cross-coupling mechanism. (1) 
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Considering the wide range of palladium catalysts available, and additionally several bases and 
multiple solvent systems which may be used, this reaction was performed following different 
procedures, in order to find the optimal conditions for the synthesis of this series of analogues. 
Following General Procedure 15 reported in the Experimental Section, which involves the use of the 
catalyst Pd(OAc)2 plus PPh3 ligand, and the base K3PO4, two of the methylene derivatives were 
synthesised (169-170). Scheme 5.2.1.1. illustrates the general scheme of the reaction, while the 
derivatives obtained, with the corresponding starting materials are listed in table 5.2.1. 
 
Scheme 5.2.1.1: General scheme for the synthesis of compounds 169-170. 
Aryl 
Bromide  
(R) Boronic 
Acid 
(R’) Product Yield 
165 4-trifluoromethyl 167 2-methylester 169 37% 
166 3-methylester 168 3-chloro-4-methyl 170 58% 
Table 5.2.1: Compounds 169-170. 
The low yield obtained for 169 can be explained by the fact that the starting aryl halide did not react 
completely, thus leading to a small amount of product formed. Moreover, the complete isolation of 
the desired compound during the purification process, was not possible because of the highly similar 
RF shared between the starting bromide 165 and the final product 169. A better yield was obtained 
for 170, mainly because of the easier purification process required for the isolation of the final 
product.  
In order to obtain the derivative 171, initially, the same reaction between the synthesised bromide 
161 (discussed in Chapter 4) and the boronic acid 168 was attempted. Also in this case, the reaction 
was slow and the starting bromide did not react completely. However, although different 
purification processes were attempted, the isolation of the desired product from the remaining 
starting bromide was not possible. Therefore, the conditions of the reaction were changed, in order 
to investigate whether using a different catalyst the reaction may reach completion. The procedure 
applied is reported in the Experimental Section. The scheme of the reaction is shown in scheme 
5.2.1.2. 
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Scheme 5.2.1.2: Synthesis of 171. 
Interestingly, changing the catalyst, the base and the solvents system, the starting bromide 161 
completely reacted. However, although the desired product was the main species formed, the 
isolation of the pure product was not possible due to the formation of the by-product 2-ethyl ester 
derivative, promoted by the presence of EtOH and base at high temperature. Therefore, the mixture 
of ethyl and methyl esters obtained was used for the next step in order to obtain the carboxylic acid 
derivative. 
5.2.2 Synthesis of benzyl benzoic acids (172-173) 
The methylene derivatives showing the carboxylic acid function were obtained via hydrolysis of the 
corresponding methyl esters, following General Procedure 16 in the Experimental Section. The 
reaction scheme is shown in scheme 5.2.2. 
 
Scheme 5.2.2: Synthesis of derivatives 172-173. 
In general, the reaction worked well giving the two final products 172 and 173 in 74% and 67% yield, 
respectively. The two methylene derivatives obtained are shown in table 5.2.2. 
Starting Material R Product R’ Yield 
170 3-methylester 172 3-carboxylic acid 74% 
171 2-methylester 173 2-carboxylic acid 67% 
Table 5.2.2.: Compounds 172-173. 
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5.3: Synthesis of the amide derivatives 
5.3.1: Synthesis of alkyl 2-arylamido benzoates (178-183) 
Derivatives 178-183 were obtained through a nucleophilic acyl substitution reaction between the 
differently substituted benzoyl chlorides and the desired amines. Scheme 5.3.1 illustrates the 
general reaction scheme. 
 
Scheme 5.3.1.: Synthesis of compounds 178-183. 
The procedure followed is General Procedure 17 in the Experimental Section. The reaction 
mechanism involves the addition of the nucleophilic amine to the carbonyl group yielding a 
tetrahedral intermediate. The elimination of the leaving group -Cl- leads to the formation of the 
desired amide. The base NEt3 serves to neutralise the HCl formed during the reaction. The amide 
derivatives obtained and the corresponding yields are shown in table 5.3.1.   
Compound 
R R’ Yield 
178 4-trifluoromethyl 3-ethyl ester 45% 
179 4-trifluoromethyl 2-methyl ester 35% 
180 4-trifluoromethyl 3-methyl ester 90% 
181 4-iodo 3-ethyl ester 37% 
182 3-chloro-2-methyl 2-methyl ester 28% 
183 3-chloro-2-methyl 3-methyl ester 30% 
Table 5.3.1: Compounds 178-183. 
Most of the time the starting benzoyl chloride reacted completely, therefore the variable yields 
obtained were mainly due to the loss of product during the work-up or the purification phases. 
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5.3.2 Synthesis of the 3-chloro-2-methy benzoyl chloride (177) 
In order to obtain derivatives 182 and 183 the synthesis of the starting benzoyl chloride (177) was 
required. The reaction is shown in scheme 5.3.2. and involves the conversion of the corresponding 
carboxylic acid into the desired chloride using oxalyl chloride and DMF.  
 
Scheme 5.3.2: Synthesis of 177. 
The reaction mechanism involves the initial reaction between the DMF and the oxalyl chloride that 
generates the by-products CO2 and CO and a reactive imine intermediate which interacts with the 
starting carboxylic acid to form the desired acyl chloride as reported in figure 5.3.2. 
Fig 5.3.2: General mechanism for the conversion of carboxylic acid into acyl chloride. 
The reaction gave the desired chloride in 92% yield. 
5.3.3: Synthesis of 2-(3-chloro-4-methylbenzamido)benzoic acid (186) 
The synthetic pathway applied for the synthesis of the amide derivative showing the carboxylic acid 
moiety (186) is shown in scheme 5.3.3.1. 
 
Scheme 5.3.3.1: Synthetic pathway for the synthesis of compound 186. 
In order to obtain the desired derivative, following the procedure reported in the Experimental 
Section, the starting benzoyl chloride 185 was synthesised via conversion of the corresponding 
carboxylic acid 184 using thionyl chloride (SOCl2) as shown in scheme 5.3.3.2. 
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Scheme 5.3.3.2: Synthesis of 3-chloro-4-methyl benzoyl chloride 185. 
As shown in figure 5.3.3.1, the reaction involves the initial nucleophilic attack of the oxygen to the 
sulfur atom, which leads to the addition of the chloride to the carbonyl group. The following [1,2] 
elimination generates the desired acyl chloride, SO2 and HCl.    
 
Fig 5.3.3.1: Mechanism for the conversion of the carboxylic acid into the corresponding acyl chloride. 
Unfortunately, even after stirring the reaction for 24 hours, the conversion of the starting carboxylic 
acid was uncompleted, giving the desired benzoyl chloride 185 in 50% yield.  
The final product was obtaining by reacting benzoyl chloride 185 with anthranilic acid 2, as shown 
in scheme 5.3.3.3. 
 
Scheme 5.3.3.3: Synthesis of compound 186. 
Following a nucleophilic attack of the amine group on the carbonyl atom and subsequently 
elimination of the leaving group chlorine, the desired product 186 was obtained in 52% yield. 
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5.4 Conclusions 
The two small series of methylene and amide derivatives were designed with the aim to investigate 
whether factors such as the length and the geometry of the molecules may influence the ability of 
compounds to fit the curved-shaped cavity of the pocket of c-FLIP. The synthetic strategies applied 
led to the synthesis of 4 methylene derivatives and 7 amide derivatives, which were biologically 
evaluated and the results obtained will be discussed in the Biological Evaluation chapter.  
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Chapter 6: Biological Evaluation 
6.1 Introduction 
Due to their ability to self-renew, breast cancer stem cells (BCSCs) play a crucial role in the 
development and the spread of tumour, and in phenomena such as resistance to treatment and 
recurrence. (1, 2) Unfortunately, conventional treatments developed for breast cancer, although 
acting on the bulk tumour cells and inducing tumour regression, do not affect breast cancer stem 
cells. (2) Moreover, a further limitation associated with the common chemotherapeutic drugs is 
represented by the wide range of cytotoxic effects as a result of the lack of selectivity against cancer 
cells. (3) The development of new selective therapies, targeting both breast cancer stem cells and 
differentiated cancer cells, while sparing normal cells represents an important need. TRAIL, due to 
its ability to induce apoptosis selectively in cancer cells, while leaving normal cells unaffected, is 
considered a promising anticancer agent. (4) However, different cancer cell lines and in particular 
breast cancer cell lines are resistant to TRAIL treatment. (5) In the course of previous studies carried 
out in our research group, new potential therapeutic strategies, aiming to induce TRAIL sensitisation 
via the inhibition of c-FLIP, were identified. (5, 6) These studies have demonstrated that the inhibition 
of c-FLIP expression, using siRNA, sensitises resistant breast cancer cells and BCSCs to TRAIL 
treatment. (5) Moreover, a new potential c-FLIP small molecule inhibitor (3), able to induce TRAIL 
sensitisation in resistant breast cancer cell lines at a low micromolar concentration, was identified. 
(6) Following these previous studies, a series of analogues of 3 were designed and synthesised with 
the aim to explore structure-activity relationships and to improve the activity and the 
pharmacokinetic properties of the original hit compound. Using a specific in vitro assay, all the 
designed derivatives were evaluated for their ability to sensitise both breast cancer cells and breast 
cancer stem cells to TRAIL. 
6.2 Colony Forming Assay (CFA) 
All the compounds were tested using the Colony Forming Assay (CFA) or Clonogenic Assay. 
Generally, this in vitro assay is based on the ability of single cells to replicate indefinitely, thus 
creating "colonies" of cells. (7) A colony is composed of 50 cells minimum and each colony is counted 
as a Colony Forming Unit (CFU). (8) In a cancer cell line for instance, when cells are treated with anti-
cancer agents, a reduction of the CFU indicates the ability of these agents to reduce cancer cell 
renewal. An additional important property of the CFA is its applicability to cancer stem cells. Indeed, 
the single cancer cells generating colonies are deemed to be representative of cancer stem cells, 
mainly because of the clonogenic activity and the expression of genes such as p63, and BMI-1, which 
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are associated with properties typically belonging to stem cells such as self-renewal and survival. (7, 
9, 10)  
6.2.1 Compounds evaluation 
The protocol used to assess the activity of the compounds is reported in the Experimental Section. 
In general, cells were pre-treated with the different compounds, before adding TRAIL (soluble 
human recombinant TRAIL, SuperKiller TRAIL, Enzo Life Sciences). Colonies were left to form for 10 
days. After this period the colonies formed were counted. The ability of the test compounds to 
sensitise cancer cells to TRAIL was measured as reduction of the colony forming units (CFU) and 
normalised to the DMSO control. 3 was also evaluated, in order to compare the activity of the newly 
synthesised derivatives with the original hit compound. Additionally, in each experiment, cells were 
treated with compounds only, in order to assess the lack of cytotoxic or off-target effects. Those 
compounds inducing a CFU reduction when combined with TRAIL, without affecting colonies 
formation when administered alone, were of most interest, as they act specifically via the TRAIL-
mediated pathway.  
6.3 Breast cancer cell line 
The TRAIL resistant MCF-7, a human breast adenocarcinoma cancer cell line, was used to evaluate 
the activity of the synthesised compounds. Originally, this cell line was isolated in 1970 from a 
Caucasian woman with metastatic breast cancer and it is representative of ER positive cancer cells. 
(11) This cell line was chosen on the basis of the results obtained in previous studies carried out in 
our research group. (5, 6) These studies assessed the TRAIL resistance of the MCF-7 cell line and the 
ability to induce TRAIL sensitisation by inhibiting c-FLIP expression via siRNA. (5) Consecutively, a 
similar sensitising effect was observed after treatment of MCF-7 cells with hit 3, which was able to 
increase TRAIL sensitisation in different biological assays (Cell Viability assay, Mammosphere Assay 
and Colony Forming Assay). (6) Interestingly, according to the results obtained in these previous 
studies, while MCF-7 cells were completely resistant to TRAIL in the Cell Viability Assay, TRAIL alone 
was able to reduce the number of colonies formed in the Colony Forming Assay. (6) However, when 
MCF-7 cells were treated with the combination TRAIL/hit 3, the number of colonies formed was 
significantly lower, thus demonstrating the ability of hit 3 to increase TRAIL sensitisation in the MCF-
7 cancer cells. (6) Following these studies, all the new derivatives synthesised in this work were 
evaluated for their ability to increase MCF-7 cells TRAIL sensitisation in the Colony Forming Assay. 
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6.4 Biological Results 
All the following data are the combined results of at least three independent repetitions for each 
compound. Data were analysed using GraphPad Prism version 7.03 for Windows. (12) Each compound 
was tested alone (“minus TRAIL” graph) and in combination with TRAIL (“plus TRAIL” graph). In 
accordance with the data obtained in the previous study, (6) TRAIL alone, tested at a fixed 
concentration of 20ng/ml, induced a reduction of the colony forming units (CFU) of approximatively 
80%. Generally, the activity of the compounds was measured as the ability to reduce the number of 
colonies formed (CFU) compared to TRAIL. A reduction in colonies formation when the compounds 
were administered in the absence of TRAIL was considered as an indication of potential cytotoxic or 
off-target effects.    
6.4.1 Sulfonamide Derivatives 
6.4.1.1 Alkyl(arylsulfonamido)benzoates (21-37, 42-43, 50-57, 71, 78-81) 
The first set of compounds tested is characterised by analogues showing several modifications on 
the hydrophobic ring, as well as the replacement of the original carboxylic acid moiety with different 
alkyl ester groups. Table 6.4.1.1 reports the structure of the compounds tested, while the results 
obtained are shown in Graph 6.4.1.1. 
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Molecule Structure Molecule Structure 
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78 
 
79 
 
80 
 
81 
 
Table 6.4.4.1: Alkyl(arylsulfonamido)benzoates. 
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Graph 6.4.4.1: MCF-7 cells were treated with compounds at 10 μM, alone or in combination with TRAIL (20ng/ml). Colonies were 
counted after 10 days. %CFU was calculated from the number of cells plated and normalised to control (DMSO). Data shown is 
representative of at least 3 experiments ± SEM. * p<0.05, ** p<0.005, *** p<0.0005, **** p<0.0001 One-way ANOVA compared 
to TRAIL. Black and red dashed lines represent the effect of TRAIL and compound 3 in the presence of TRAIL respectively. 
 Compounds 21, 22, 23, 78, 80, 50 retain the original 2,4-dichloro-5-methylphenyl ring of 3, while 
different alkyl esters were introduced to replace the carboxylic acid moiety. According to the results 
obtained, analogues showing an ethyl ester in ortho position (50), as well as a tert-butyl ester group 
(80), retained the ability to increase TRAIL sensitisation, demonstrating a similar activity compared 
to hit 3. Contrarily, the introduction of an isopropyl ester (78) induced a reduction of activity, whilst 
the analogues showing a methyl ester in ortho, meta and para position (21, 22 and 23) lost their 
ability to increase TRAIL sensitisation. Among the derivatives exhibiting a different hydrophobic ring 
while maintaining the methyl ester group in the ortho position, a few compounds, showing two 
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methyl or two chlorine groups at different positions of the ring and a para tert-butyl substituted 
derivative, did not show any sensitising effect (21, 25, 26, 27, 29, 30 and 31). Interestingly, the 
number of CFU observed in the presence of these specific derivatives was higher compared to TRAIL, 
thus implying a non-specific mechanism of action of these compounds. Nevertheless, the majority 
of the newly designed derivatives were able to increase TRAIL sensitisation. The replacement of the 
phenyl ring with a 3-pyridine (34) and a furan (57) ring, as well as the introduction of the -SF5 group 
(71) and of an additional -CH2 on the sulfonamide linker (33 and 56), were associated with a CFU 
reduction similar to 3. 36 and 35, both characterised by the presence of a naphthalene ring, retained 
the ability to increase TRAIL sensitisation; however, 35, the 2-napthalene ring derivative, showed a 
potential off-target effect, causing a reduction in the number of colonies formed also in the absence 
of TRAIL. Compounds 24, which shows a trifluoromethyl group as hydrophobic substituent, 42 and 
43, showing a methyl and a chlorine group at positions ortho,para and para,meta, respectively, and 
37, characterised by the replacement of the phenyl ring with a cyclohexane, gave the best results, 
inducing a higher reduction of CFU compared to 3. Moreover, the isopropyl and tert-butyl ester 
derivatives of 43, 79 and 81, respectively, retained the activity, with compound 79 giving better 
results than the corresponding tert-butyl ester derivative. Generally, all compounds characterised 
by the presence of an ethyl ester group in position ortho or meta (51, 54 and 55) demonstrated a 
comparable activity with 3. Interesting results were obtained for 52 and 53, both showing an iodine 
group as hydrophobic substituent of the phenyl ring, which caused a reduction of the CFU even in 
the absence of TRAIL, thus suggesting potential cytotoxic or off-target effects.   
6.4.1.2 (Arylsulfonamido)benzoic acids (63-70, 72-76) 
The structures of the sulfonamide derivatives retaining the carboxylic acid group and the 
corresponding biological data obtained are reported in Table 6.4.1.2 and Graph 6.4.1.2. 
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Molecule Structure Molecule Structure 
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Table 6.4.1.2: (Arylsulfonamido)benzoic acids. 
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Graph 6.4.1.2: MCF-7 cells were treated with compounds at 10 μM, alone or in combination with TRAIL (20ng/ml). Colonies were 
counted after 10 days. %CFU was calculated from the number of cells plated and normalised to control (DMSO). Data shown is 
representative of at least 3 experiments ± SEM. * p<0.05, ** p<0.005, *** p<0.0005, **** p<0.0001 One-way ANOVA compared 
to TRAIL. Black and red dashed lines represent the effect of TRAIL and compound 3 in the presence of TRAIL respectively. 
Most derivatives retaining the carboxylic acid function maintained the ability to increase TRAIL 
sensitisation. In accordance with the results obtained for the corresponding methyl ester 
derivatives, compounds characterised by an elongated sulfonamide linker (64), or by the presence 
of a cyclohexane (75), a pyridine (72) and a furan (76) ring, as well as the -SF5 substituted derivative 
(70), showed similar or slightly improved activity compared to 3. Additional modifications were 
explored, such as the introduction of a thiophene (65) or a benzyl ring (63). Both derivatives were 
able to retain the ability to increase TRAIL sensitisation. Interestingly, the two naphthalene 
compounds 73 and 74 showed a different behaviour compared to the corresponding methyl esters. 
In fact, whilst the 2-napthalene derivative 73 maintained a moderate sensitising effect, the 1-
napthalene 74 not only lost its activity, but it also induced an increase in the number of CFU 
compared to TRAIL. Contrary to the naphthalene derivatives, the two quinoline compounds, 66 and 
67, gave similar results, both showing a slightly improved activity compared to 3. Interesting results 
were obtained for 69, the carboxylic acid derivative of 43, which induced an increase of the CFU 
compared to TRAIL, losing the sensitising effect observed with the corresponding methyl ester 
derivative (43). 
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6.4.1.3 (Arylsulfonamido)N-(1H-tetrazol-5-yl)phenyls (86-93) 
Compounds 86-93 are characterised by the presence of a 1H-tetrazole ring as substituent of the 
carboxylic acid moiety. The biological results obtained for these derivatives are shown in Graph 
6.4.1.3 and Table 6.4.1.3 reports their chemical structures. 
Molecule Structure Molecule Structure 
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Table 6.4.1.3: (Arylsulfonamido)N-(1H-tetrazol-5-yl)aryls. 
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Graph 6.4.1.3: MCF-7 cells were treated with compounds at 10 μM, alone or in combination with TRAIL (20ng/ml). Colonies were 
counted after 10 days. %CFU was calculated from the number of cells plated and normalised to control (DMSO). Data shown is 
representative of at least 3 experiments ± SEM. * p<0.05, ** p<0.005, *** p<0.0005, **** p<0.0001 One-way ANOVA compared 
to TRAIL. Black and red dashed lines represent the effect of TRAIL and compound 3 in the presence of TRAIL respectively. 
 
Compounds 86 and 88, which retain the 2,4-dichloro-5-methyl phenyl ring, differ in the position of 
the tetrazole group, which is in position para and ortho, respectively. Both derivatives retained the 
ability to increase TRAIL sensitisation, however the 2-(1H-tetrazol) analogue 88 showed a slightly 
improved activity compared to 3. In contrast with these data, analogues 87 and 89, the para and 
ortho derivatives of 43, respectively, gave different results, with 87 showing similar activity 
compared to 3, while a decrease in the TRAIL-sensitisation effect was observed for the 2-(1H-
tetrazol) derivative 89. Among the other tetrazole analogues, 91, characterised by the presence of 
a 2-napthalene ring, showed similar activity compared to the 2-methyl ester and the carboxylic acid 
derivatives (35 and 73), whilst 90, showing a trifluoromethyl group as hydrophobic substituent, lost 
the ability to sensitise cells to TRAIL compared to the methyl ester derivative 24. Similar results were 
obtained for the two quinoline compounds, 92 and 93, where the replacement of the carboxylic acid 
group with a tetrazole ring was associated with loss of activity. 
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6.4.1.4 Alkyl(arylsulfonamido)benzamides (101-106) 
Table 6.4.1.4 and graph 6.4.1.4 show the structures of the carboxamide derivatives and the 
corresponding biological results obtained. 
Molecule Stucture 
101 
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Table 6.4.1.4: Alkyl(arylsulfonamido)benzamides. 
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Graph 6.4.1.4:  MCF-7 cells were treated with compounds at 10 μM, alone or in combination with TRAIL (20ng/ml). Colonies 
were counted after 10 days. %CFU was calculated from the number of cells plated and normalised to control (DMSO). Data 
shown is representative of at least 3 experiments ± SEM. * p<0.05, ** p<0.005, *** p<0.0005, **** p<0.0001 One-way ANOVA 
compared to TRAIL. Black and red dashed lines represent the effect of TRAIL and compound 3 in the presence of TRAIL 
respectively. 
In order to evaluate whether the introduction of a carboxamide moiety may affect the activity of 
the compounds, a few derivatives retaining the original 2,4-dichloro-5-methyl phenyl ring while 
showing different N-alkyl carboxamide groups were synthesised. Generally, the free carboxamide 
group (106) was associated with a decrease in activity compared to 3, as well as the differently 
substituted carboxamide derivatives, 102, 103, 105. However, the N,N-dimethyl carboxamide 104, 
and the methyl carboxamide derivative of 43 (101), showed an ability to increase TRAIL sensitisation 
similar to 3.    
6.4.1.5 Structure-activity relationships 
Taking into consideration all the biological data obtained for the sulfonamide derivatives, an analysis 
of the potential structure-activity relationships was performed. Molecules retaining the original 
hydrophobic ring of 3, lost their activity when the carboxylic acid in ortho position of the anthranilic 
ring was replaced by a methyl ester in ortho, meta or para position. A reduction in activity was 
observed when an isopropyl ester or differently substituted carboxamide groups, including the free 
carboxamide, were introduced. However, derivative 104, which shows a N,N-dimethyl carboxamide 
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group, induced a slightly higher reduction of CFU compared to 3. Groups such as ethyl and tert-butyl 
esters, and the tetrazole group in the para position of the original anthranilic ring, retained a similar 
activity compared to 3, while the introduction of the tetrazole ring in ortho position (88) induced a 
slightly improved ability to increase TRAIL sensitisation. For all the other derivatives, changes in both 
aromatic rings were explored. In general, the replacement of the hydrophobic phenyl ring with 
heterocycles such as furan, thiophen and pyridine was associated with activity retention in both 
carboxylic acid and methyl ester derivatives. The introduction of a cyclohexane ring (37 and 75) 
induced a slight improvement in activity compared to 3. Interesting results were obtained for the 
naphthalene derivatives. In the presence of a methyl ester group, both derivatives 35 and 36 
showed a comparable activity to 3. The 2-napthalene derivative retained the activity in the presence 
of a carboxylic acid (73) or of a tetrazole ring (91), while 74, the carboxylic acid 1-napthalene 
derivative, completely lost its sensitising effect. The introduction of a 8-quinoline or 2-quinoline was 
associated with a slight improvement in activity in the presence of the carboxylic acid group (66 and 
67), whereas both quinoline derivatives in the presence of the tetrazole ring (92 and 93) lost their 
activity. All the derivatives showing an elongated sulfonamide linker (33, 56 and 64) demonstrated 
a comparable activity to 3. A similar activity was also observed with the introduction of an 
unsubstituted phenyl ring (63). The different hydrophobic substituents introduced on the phenyl 
ring gave interesting results. The two iodine derivatives 52 and 53 were considered as potentially 
cytotoxic, due to the significant reduction of CFU caused in the absence of TRAIL. On the contrary, 
groups such as the 4-trifluoromethyl (24), 5-chloro-3-methyl (42), 3-chloro-4-methyl (43) and the 4-
SF5 group (71), in the presence of a methyl ester, retained a similar or a slightly improved activity 
compared to 3. The carboxylic acid derivative of 71, 70, gave similar results, showing activity 
retention. The introduction of a tetrazole ring in the 4-trifluoromethyl derivative (90) induced a 
complete loss of activity. Interesting results were obtained for the different derivatives of 43 
synthesised. In contrast with the data obtained for hit 3, the introduction of a carboxylic acid group 
(69) or a tert-butyl ester (81) or a tetrazole ring in ortho position (89) was associated with loss or 
reduction of activity. On the contrary, the isopropyl ester derivative (79), the para-tetrazole 
derivative (87) and the methyl carboxamide derivative (101) retained a similar activity compared to 
43 and hit 3. The conflicting data obtained for 3 and 43, in addition with all the results discussed 
above, suggest that the difference in activity observed for the synthesised derivatives is not related 
to a single modification or to a particular group, but it seems to be associated with a combination 
of the changes at both aromatic rings. 
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6.4.2 Amine Derivatives 
6.4.2.1 (Aryl)amino)benzoic acids (113-120, 139-143, 156) 
The structures of the amine derivatives retaining a carboxylic acid group are shown in table 6.4.2.1 
and the biological results obtained are reported in graph 6.4.2.1. 
Molecule Structure Molecule Structure 
113 
 
118 
 
114 
 
119 
 
115 
 
120 
 
116 
 
139 
 
117 
 
140 
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141 
 
142 
 
143 
 
156 
 
Table 6.4.2.1: (Aryl)amino)benzoic acids. 
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Graph 6.4.2.1: MCF-7 cells were treated with compounds at 10 μM, alone or in combination with TRAIL (20ng/ml). Colonies were 
counted after 10 days. %CFU was calculated from the number of cells plated and normalised to control (DMSO). Data shown is 
representative of at least 3 experiments ± SEM. * p<0.05, ** p<0.005, *** p<0.0005, **** p<0.0001 One-way ANOVA compared 
to TRAIL. Black and red dashed lines represent the effect of TRAIL and compound 3 in the presence of TRAIL respectively. 
The majority of the amine derivatives showing a carboxylic acid group on the anthranilic ring 
retained the ability to increase TRAIL sensitisation. Only 113 and 114, both characterised by a 
trifluoromethyl group as hydrophobic substituent and the carboxylic acid moiety in position ortho 
and meta, respectively, significantly increased the number of colonies formed compared to TRAIL, 
thus suggesting potential off-target effects. Interestingly, different results were obtained for 143, 
which shows an elongated amine linker while maintaining the -CF3 group. In this case, the ability to 
increase TRAIL sensitisation was similar to the original hit 3. Similar results were obtained for all the 
other derivatives. Substituents such as 3,4-dimethyl groups (115 and 116), or 3-chloro-4-methyl 
groups (117 and 118) were associated with activity retention. The replacement of the phenyl ring 
by a 3-pyridine (139) or a 4-pyridine (140) ring, as well as the introduction of bigger hydrophobic 
rings such as the 2- and 1-naphthalenes (141 and 142) or the 2- and 8-quinolines (120 and 119), 
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induced an increase of TRAIL sensitisation. However, derivatives 142 and 119 induced a slight 
reduction of the CFU even in the absence of TRAIL, thus suggesting potential cytotoxic or off-target 
effects. Similarly, a sensitising effect was observed for 156, characterised by an inverted amine 
linker, although this derivative also induced a 20% reduction of colonies formation when 
administered without TRAIL. 
6.4.2.2 Methyl((aryl)amino)benzoates (121-124, 129-134, 137-138)   
Biological results obtained for the amine derivatives showing a methyl ester group in position ortho 
or meta of the original anthranilic acid are shown in Graph 6.4.2.2 and their chemical structures are 
reported in Table 6.4.2.2.   
Molecule Structure Molecule Structure 
121 
 
129 
 
122 
 
130 
 
123 
 
131 
 
124 
 
132 
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133 
 
134 
 
137 
 
138 
 
Table 6.4.2.2: Methyl((aryl)amino)benzoates. 
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Graph 6.4.2.2: MCF-7 cells were treated with compounds at 10 μM, alone or in combination with TRAIL (20ng/ml). Colonies were 
counted after 10 days. %CFU was calculated from the number of cells plated and normalised to control (DMSO). Data shown is 
representative of at least 3 experiments ± SEM. * p<0.05, ** p<0.005, *** p<0.0005, **** p<0.0001 One-way ANOVA compared 
to TRAIL. Black and red dashed lines represent the effect of TRAIL and compound 3 in the presence of TRAIL respectively. 
In most cases, the replacement of the carboxylic acid moiety with a methyl ester group was 
associated with activity retention. Analogues 123, 124, 129, 130, 131 and 133, the corresponding 
methyl ester derivatives of 115, 116, 124, 118, 139 and 141, showed an ability to increase TRAIL 
sensitisation similar to the one observed for the corresponding carboxylic acid derivatives. 
Controversial results were obtained instead for the two analogues showing the trifluoromethyl 
substituent on the phenyl ring, 121 and 122. Contrarily to the corresponding carboxylic acids (113 
and 114), both ortho (121) and meta (122) methyl ester derivatives increased TRAIL sensitisation. 
However, the effect of 121 might also be associated with cytotoxic or off-target effects, due to its 
ability to reduce colonies formation in the absence of TRAIL. In comparison with the corresponding 
carboxylic acids, the introduction of the methyl ester group in 132 and 134, showing a 4-pyridine 
ring and 1-napthalene ring, respectively, induced loss of activity. Interestingly, 134, induced CFU 
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reduction even in the absence of TRAIL, in accordance with its carboxylic acid derivative, 142. The 
loss of activity induced by the introduction of a methyl ester group was also observed for 138, the 
methyl ester derivative of 143, characterised by an elongated amine linker. The same negative 
results were obtained also for 137, showing an unsubstituted phenyl ring and a longer linker, which 
increased the number of CFU compared to TRAIL, thus indicating a non-specific mechanism of 
action.           
6.4.2.3 ((Aryl)amino)N-(1H-tetrazol-5-yl)phenyls and (arylamino)N-(5-oxo-2,5-dihydro-1,2,4-
oxadiazol-3-yl)phenyls (144-150) 
The chemical structures of compounds showing the tetrazole and oxadiazole rings are shown in 
Table 6.4.2.3 and their biological activity is reported in Graph 6.4.2.3. 
Molecule Structure Molecule Structure 
144 
 
148 
 
145 
 
149 
 
146 
 
150 
 
147 
 
  
Table 6.4.2.3: ((Aryl)amino)N-(1H-tetrazol-5-yl)phenyls and (arylamino)N-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl. 
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Graph 6.4.2.3: MCF-7 cells were treated with compounds at 10 μM, alone or in combination with TRAIL (20ng/ml). Colonies were 
counted after 10 days. %CFU was calculated from the number of cells plated and normalised to control (DMSO). Data shown is 
representative of at least 3 experiments ± SEM. * p<0.05, ** p<0.005, *** p<0.0005, **** p<0.0001 One-way ANOVA compared 
to TRAIL. Black and red dashed lines represent the effect of TRAIL and compound 3 in the presence of TRAIL respectively. 
Compounds 145 and 146 are respectively the ortho and para tetrazole derivatives of 117 and 129. 
Interestingly, according to the results obtained, while 145 showed similar activity compared to the 
previous carboxylic acid (117) and methyl ester (129) derivatives, the introduction of the tetrazole 
ring in para position (146) is associated with potential off-target effects, as shown by the reduction 
in CFU induced in the absence of TRAIL and at the same time the slightly increase of colonies formed 
compared to TRAIL. A similar potential off-target effect was observed with 149, the 2-naphthalene 
tetrazole derivative, which increased the number of CFU compared to TRAIL alone. The introduction 
of a tetrazole ring to the 8-quinoline (147) and 3-quinoline (148) derivatives, although retaining the 
TRAIL sensitisation effect, did not improve the activity compared to the corresponding carboxylic 
acid derivatives or to hit 3. Moreover, the activity of 148 might be correlated to potential off-target 
effects, due to its ability to reduce the CFU number even in the absence of TRAIL. On the contrary, 
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positive results were obtained for 144, which is the -CF3 substituted tetrazole derivative, which, 
controversially to the corresponding carboxylic acid, showed an ability to increase TRAIL 
sensitisation similar to 3. Retention of activity was also observed with the oxadiazole derivative of 
145, compound 150.  
6.4.2.4 2-(alkyl)isoindolin-1-ones (158-159) 
As mentioned in Chapter 4, the undesired lactam by-products obtained during the synthesis of 2-
(((aryl)amino)methyl)benzoic acids 158-159, were also biologically evaluated. The results obtained 
are shown in Graph 6.4.2.4 and the structures of the two lactam derivatives tested are reported in 
Figure 6.4.2.4.  
 
Fig 6.4.2.4: 2-(alkyl)isoindolin-1-ones. 
 
 
Graph 6.4.2.4: MCF-7 cells were treated with compounds at 10 μM, alone or in combination with TRAIL (20ng/ml). Colonies were 
counted after 10 days. %CFU was calculated from the number of cells plated and normalised to control (DMSO). Data shown is 
representative of at least 3 experiments ± SEM. * p<0.05, ** p<0.005, *** p<0.0005, **** p<0.0001 One-way ANOVA compared 
to TRAIL. Black and red dashed lines represent the effect of TRAIL and compound 3 in the presence of TRAIL respectively. 
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One of the two derivatives, 159, did not show any sensitising effect, whilst 158 revealed potential 
cytotoxicity or off-target effects by inducing a reduction in CFU even in the absence of TRAIL. 
6.4.2.5 Structure-activity relationships 
In accordance with the data obtained for the sulfonamide derivatives, the different biological 
activity of the amine derivatives seems to be correlated with modifications on both aromatic rings. 
129, the amine derivative of 43, which shows a 3-chloro-4-methyl phenyl ring and a methyl ester in 
ortho position of the original anthranilic ring, retained similar activity compared to the original 
sulfonamide compound and to 3. Interestingly, in contrast with the data obtained for the 
corresponding sulfonamide derivative (69), the introduction of a carboxylic acid group in 117 was 
associated with a slight improvement of activity compared to 3. Also, the 3-methyl ester and the 3-
carboxylic acid derivatives, 118 and 130, respectively, retained the ability to increase TRAIL 
sensitisation, although showing a decrease in activity compared to 3. Moreover, contrary to the 
results obtained for the corresponding sulfonamide derivative, the introduction of the tetrazole ring 
in para position (146) induced loss of activity, while a slightly higher reduction of CFU compared to 
3 was observed with the ortho tetrazole derivative 145 and the oxadiazole derivative 150. The 
introduction of a pyridine ring was associated with activity retention in the presence of a carboxylic 
acid group (139 and 140). The corresponding methyl esters, however, gave opposite results, with 
the 3-pyridine 131 retaining the activity, whereas the 4-pyridine 132 lost its sensitising effect. The 
naphthalene derivatives, as well as the quinoline derivatives, in the presence of a carboxylic acid 
group showed a similar activity compared to 3, although a slight reduction of the CFU was observed 
for the 1-napthalene (142) and the 8-quinoline (119) derivatives even in the absence of TRAIL.  
Interestingly, in the presence of a methyl ester, while the 2-napthalene 133 retained the activity, 
the 1-napthalene 134 completely lost its sensitising effect, increasing instead its ability to induce a 
reduction of CFU in the absence of TRAIL. Moreover, in contrast with the corresponding sulfonamide 
derivatives (91 and 93), the introduction of a tetrazole ring in the 2-napthalene derivative (149) 
induced a significant decrease in the ability to increase TRAIL sensitisation, whilst for the 2-quinoline 
derivative (148) the presence of a tetrazole ring was associated with a higher ability to induce a 
reduction of CFU in the absence of TRAIL. The amine analogue of 24, characterised by a 4-
trifluoromethyl phenyl ring and a 2-methy ester (121), although retaining a similar activity compared 
to 3, also induced a reduction of the CFU formed in the absence of TRAIL, indicating potential 
additional off-target effects. Interestingly, while the replacement of the methyl ester with a 
carboxylic acid group (113, 114) was associated with loss of activity, the introduction of a tetrazole 
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ring in 144 induced a reduction of the CFU comparable to 3, contrarily to the results obtained for 
the corresponding sulfonamide derivative (90). Controversial results were obtained also for the 4-
trifluoromethyl derivatives showing a longer amine linker, with the carboxylic acid derivative 143 
showing a similar activity compared to 3, while the corresponding methyl ester 138, as well as the 
unsubstituted phenyl ring (137), did not show any sensitising effect. Similarly, the inversion of the 
amine linker in 156 only showed a small sensitising effect, associated with a reduction of the CFU 
even in the absence of TRAIL. 
6.4.3 Methylene and Amide Derivatives 
6.4.3.1 Methylene Derivatives (169-170, 172-173) 
Compounds belonging to the small series of methylene derivatives synthesised are reported in table 
6.4.3.1 and the corresponding biological results are shown in graph 6.4.3.1.  
Molecule Structure Molecule Structure 
169 
 
172 
 
170 
 
173 
 
Table 6.4.3.1: Methylene Derivatives. 
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Graph 6.4.3.1: MCF-7 cells were treated with compounds at 10 μM, alone or in combination with TRAIL (20ng/ml). Colonies were 
counted after 10 days. %CFU was calculated from the number of cells plated and normalised to control (DMSO). Data shown is 
representative of at least 3 experiments ± SEM. * p<0.05, ** p<0.005, *** p<0.0005, **** p<0.0001 One-way ANOVA compared 
to TRAIL. Black and red dashed lines represent the effect of TRAIL and compound 3 in the presence of TRAIL respectively. 
The methylene derivatives 173, 172 and 170 retain the 3-chloro-4-methyl phenyl ring of compound 
43. According to the results obtained, the introduction of a methylene linker in the carboxylic acid 
(172 and 173) and the methyl ester (170) derivatives was associated with loss of activity. On the 
contrary, 169, showing a para trifluoromethyl phenyl and a 2-methyl ester group as R1, retained the 
ability to increase TRAIL sensitisation.  
6.4.3.2: Amide Derivatives (178-183, 186) 
A small series of amide derivatives was synthesised in order to explore whether changes in the 
molecular geometry affected the activity of the compounds. Table 6.4.3.2 shows the structure of 
the amide derivatives, while the biological results obtained are reported in Graph 6.4.3.2. 
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Molecule Structure Molecule Structure 
178 
 
182 
 
179 
 
183 
 
180 
 
186 
 
181 
 
  
Table 6.4.3.2: Amide Derivatives. 
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Graph 6.4.3.2: MCF-7 cells were treated with compounds at 10 μM, alone or in combination with TRAIL (20ng/ml). Colonies were 
counted after 10 days. %CFU was calculated from the number of cells plated and normalised to control (DMSO). Data shown is 
representative of at least 3 experiments ± SEM. * p<0.05, ** p<0.005, *** p<0.0005, **** p<0.0001 One-way ANOVA compared 
to TRAIL. Black and red dashed lines represent the effect of TRAIL and compound 3 in the presence of TRAIL respectively. 
Only compound 183, which shows a 2-methyl-3-chloro phenyl ring and a methyl ester in the meta 
position of the original anthranilic ring, increased TRAIL sensitisation with similar activity compared 
to 3. Derivatives 179, amide analogue of 24, and 186, amide analogue of 69, although increasing 
TRAIL sensitisation, also promoted a reduction of the CFU in the absence of TRAIL. A slight ability to 
induce a reduction of colonies formation in the absence of TRAIL was also observed for 182 and the 
iodine derivative 181, suggesting a potential off-target or cytotoxic effect associated with this series 
of derivatives. On the contrary, 178 and 180, both showing a trifluoromethyl substituent on the 
phenyl ring, and an ethyl (178) and a methyl (180) ester in meta position, did not show ability to 
increase TRAIL sensitisation. 
6.4.3.3 Structure-activity relationships 
The introduction of a methylene linker in derivatives showing a 3-chloro-4-methyl phenyl ring (173, 
170 and 172) was associated with loss of activity compared to the corresponding sulfonamide and 
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amine derivatives. On the contrary, the 4-trifluoromethyl phenyl methylene derivative 169 retained 
a similar activity compared to 3. Controversial results were obtained for the amide derivatives. A 
decrease in activity was observed for the 4-trifluoromethyl phenyl derivatives showing a 3-ethyl and 
3-methyl ester, 178 and 180, respectively, while the 2-methyl ester 179, although showing an 
increased activity compared to 3, also induced a reduction of the CFU in the absence of TRAIL. A 
similar effect was observed for the 3-chloro-4-methyl phenyl derivative, 186. 
6.4.4 Conclusions 
The ability of all the newly synthesised compounds to increase TRAIL sensitisation in the MCF-7 cells 
was evaluated and compared to the original hit 3. Although a clear identification of the features 
required for the activity was not possible due to the variable results obtained among all the 
compounds, several new derivatives were found to increase TRAIL sensitisation by reducing colonies 
formation with a similar or slightly improved activity compared to 3. The active compounds belong 
to all four series of derivatives and they show different chemical features, thus suggesting that 
multiple factors determine the ability of the compounds to stimulate the response to TRAIL. Graph 
6.4.4.A-D summarises the results obtained for all the tested compounds when administered in 
combination with TRAIL. Among the derivatives retaining the sulfonamide linker, some of the best 
compounds were identified in 24, 42 and 43, all showing the methyl ester group in ortho position 
on the original anthranilic ring and a 4-trifluoromethyl phenyl (24), 5-chloro-2-methyl phenyl (42) 
and 3-chloro-4-methyl phenyl (43) on the hydrophobic side of the molecule. The two compounds 
characterised by the presence of a cyclohexane ring, methyl ester 37 and carboxylic acid 75, also 
showed a slightly improved ability to reduce the CFU number compared to 3. Additional 
modifications such as the introduction of a furan ring (76), or a 8-quinoline (66) and a 3-quinoline 
(67), while retaining the carboxylic acid moiety, also resulted in a slightly greater ability to increase 
TRAIL sensitisation. The tert-butyl ester derivative (80), the tetrazole derivative (88) and the N,N-
dimethyl carboxamide derivative (104) of 3, all induced a slightly higher reduction of CFU compared 
to 3. The introduction of an amine linker was associated with activity retention in 129, 117 and 145, 
the amine derivatives of 43, 69, 89, respectively, as well as in the presence of an oxadiazole group 
(150). Compounds characterised by the presence of a naphthalene (141 and 142) and a quinoline 
(119 and 120) ring also retained a similar activity compared to hit 3. On the contrary, amine 
derivatives showing a 4-trifluoromethyl phenyl ring demonstrated interesting activity only in the 
presence of a tetrazole group (144).   Among the small series of methylene derivatives synthesised, 
169, showing a 4-trifluoromethyl phenyl ring, was the only compound demonstrating ability to 
                                                                                                                         Chapter 6: Biological Evaluation 
142 
 
increase TRAIL sensitisation. A few amide derivatives induced a higher TRAIL sensitisation compared 
to 3, however these compounds were also associated with a reduction of colonies formation when 
tested alone, suggesting potential cytotoxic or off-target effects. 
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Graph 6.4.4A-D: Summary of the results obtained for all the test compounds when administered in combination with TRAIL. 
A:sulfonamide derivatives; B:amine derivatives; C:methylene derivatives; D:amide derivatives.  
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6.5 In vitro pharmacokinetic studies 
In order to investigate how the newly designed chemical modifications affected the 
pharmacokinetic properties of the compounds, some of the synthesised derivatives were subjected 
to preliminary in vitro pharmacokinetic studies. These studies were performed by Cyprotex Ltd and 
they include metabolic stability, Caco2 cell permeability and hERG inhibition. The metabolic stability 
was evaluated using the microsomal stability assay which measures the in vitro intrinsic clearance. 
(13) The Caco2 cell permeability assay (14) estimates the intestinal permeability of the compounds and 
finally the hERG inhibition assay (15) evaluates their potential cardiotoxicity. Data obtained are 
reported in Tables 6.5.1, 6.5.2 and 6.5.3. 
Compound CLint (μl/min/mg protein) Standard Error CLint t1/2 (min) 
3 15.1 3.14 91.8 
24 Nd Nd Nd 
79 79.5 12.7 17.4 
117 35.6 2.85 39.0 
141 35.6 2.90 39.0 
88 10.4 1.33 134 
150 92.3 3.33 15.0 
Table 6.5.1: Microsomal Stability Assay Results. 
Compound Mean % recovery (A2B) Mean % recovery (B2A) Efflux Ratio 
3 86.3 95.6 0.660 
24 Nd nd Nd 
79 Nd nd Nd 
117 66.2 77.2 0.622 
141 61.3 73.5 0.881 
88 66.7 67.2 6.43 
150 23.1 51.7 0.768 
Table 6.5.2: Caco2 Cell Permeability Assay Results. 
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Compound IC50 (μM) 
3 >25 
24 23.6 
79 >25 
117 >25 
141 >25 
88 >25 
150 92.3 
Table 6.5.3: hERG Inhibition Assay Results. 
In general, all the compounds tested did not show any significant ability to inhibit hERG channels, 
thus suggesting lack of cardiotoxic effects. Good permeability in both directions across the Caco2 
cells was observed for all compounds, indicating a predicted oral absorption potential.  In terms of 
microsomal stability, most of the compounds showed a higher clearance and a shorter half-life time 
compared to 3, whilst 88, the ortho tetrazole derivative of 3, was found to be more metabolically 
stable, increasing the half-life time of 3 from approximatively 92 mins to 134 mins. 
6.6 Dose-response studies 
In order to further evaluate the activity of the compounds showing the best ability to increase TRAIL 
sensitisation at 10 μM concentration, dose-response studies were performed. Unfortunately, due 
to the time required fot this assay to be performed, only a few compounds were selected. 
Compound 88, the otho tetrazole derivative of 3, was the initial compound tested, mainly because 
of the slightly improved ability to reduce the number of CFU compared to 3, and the positive 
pharmakokinetic profile showed in the preliminary in vitro ADME studies. This compound was tested 
at four different concentrations (100 μM, 10 μM, 1 μM and 0.1 μM). At the same time, a dose-
response study for TRAIL was performed  in order to evaluate whether the different concentration 
of TRAIL might influence the activity of the compound. Results are shown in Graph 6.6.1. 
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Graph 6.6.1: MCF-7 cells were treated with 88 at 100 μM, 10 μM, 1 μM, 0.1 μM, alone or in combination with TRAIL at 20 ng/ml, 
15 ng/ml, 10 ng/ml. Colonies were counted after 10 days. %CFU was calculated from the number of cells plated and normalised 
to control (DMSO). Data shown is representative of at least 3 experiments ± SEM. * p<0.05, **p<0.005, ***p<0.0005, 
****p<0.0001 Two-way ANOVA compared to TRAIL. 
The dose-response curve, as well as the IC50 values calculated for the different concentrations of 
TRAIL used, is reported in Figure 6.6.1. 
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 10 ng/ml 15 ng/ml 20 ng/ml 
IC50 (μM) 17 19 16 
Fig 6.6.1: Dose-response curve and IC50 values for compound 88. IC50 was calculated using GraphPad Prism 7.03, log(inhibitor) vs 
response (three parameters). 
According to the results obtained, at the highest concentration of 100 μM, a reduction of CFU was 
observed even in the absence of TRAIL, thus indicating potential cytotoxic or non-specific effects at 
higher concentrations. Nevertheless, 88 increased TRAIL sensitisation in a dose-dependent manner, 
with an IC50 value in the range of 15-19 μM. As shown in Figure 6.6.1, the effect of TRAIL alone (left 
graph) was dose-dependent, inducing a reduction of approximately 80% when tested at 20 ng/ml 
and 60% at the lowest concentration of 10 ng/ml. However, as demonstrated by the similar IC50 
values calculated, 88 retained a similar ability to increase TRAIL sensitisation independently of the 
TRAIL concentration, thus indicating that the concentration of TRAIL does not affect the activity of 
the compound.  
A dose-response study was performed also for 144, belonging to the amine series of derivatives. 
When tested at 10 μM concentration, 144 demonstrated a similar ability to increase TRAIL 
sensitisation compared to 3. Taking into consideration the TRAIL concentration study performed for 
88, 144 was tested alone and in combination with TRAIL at 10 ng/ml. Similarly to 88, 144 increased 
TRAIL sensitisation in a dose-dependent manner with an IC50 value of 8.09 μM.  The results obtained 
are shown in Graph 6.6.2 and the dose-response curve is illustrated in Figure 6.6.2. 
TRAIL 
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Graph 6.6.2: MCF-7 cells were treated with 144 at 100 μM, 10 μM, 1 μM, 0.1 μM, 0.01 μM alone or in combination with TRAIL at 
10 ng/ml. Colonies were counted after 10 days. %CFU was calculated from the number of cells plated and normalised to control 
(DMSO). Data shown is representative of at least 3 experiments ± SEM. * p<0.05, **p<0.005, ***p<0.0005, ****p<0.0001  One-
way ANOVA compared to TRAIL. 
 
Fig 6.6.2: Dose-response curve and IC50 values for compound 144. IC50 was calculated using GraphPad Prism 7.03, log(inhibitor) vs 
response (three parameters). 
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6.7 Cytotoxicity Studies 
As discussed in the previous paragraphs, several compounds demonstrated the ability to increase 
TRAIL sensitisation showing an activity similar or slightly improved compared to hit 3. Cytotoxicity 
studies were performed for some of the best compounds in order to assess the lack of cytotoxic 
effects on non-cancerous cells. Moreover, those compounds inducing a reduction of the number of 
colonies formed in the absence of TRAIL, suggesting potential cytotoxic or off-target effects, were 
also investigated.  
6.7.1 Cell Viability Assay 
Cytotoxicity studies were performed using the CellTiter-Blue Cell Viability Assay. (16) The assay is 
based on the ability to measure the number of viable cells after treatment with different 
compounds, in order to evaluate the effects on cell proliferation and the ability to induce cell death. 
The number of viable cells is calculated according to their ability to convert resazurin into the highly 
fluorescent metabolite resofurin, which will emit a fluorescent signal. The fluorescence will be then 
measured to give the number of viable cells. (16) The assay was performed on human embryonic 
kidney cells (HEK293), which are representative of non-tumorigenic cells. (17) The protocol applied is 
reported in the Experimental Section. In general, cells were treated with the different compounds, 
alone and in combination with TRAIL at 20 ng/ml. After 24 hours viable cells were counted. The 
cytotoxicity of the compounds was measured as reduction of cell viability compared to the control, 
represented by untreated cells (minus TRAIL). The experiment was performed in the presence of a 
positive control represented by 10% DMSO. Graph 6.7.1 shows the results obtained. 
 
Graph 6.7.1: Cell Viability Assay. HEK293 cells were treated with compounds at 10 μM concentration, alone or in combination 
with TRAIL at 20 ng/ml. After 24 hours treatment the percentage of viable cells was calculated and normalised to the control 
(Untreated -TRAIL).  10% DMSO represents the positive control. Data shown is representative of at least 3 experiments ± SEM. 
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All the compounds showing ability to increase TRAIL sensitisation in the Colony Forming Assay (43, 
76, 65, 37, 88, 89, 144, 147, 150 and 169) did not induce a reduction of cell viability compared to 
the control, demonstrating lack of cytotoxic effects. Compounds 35, 52, 53, 121, 134, 170 and 186 
were also investigated due to their ability to induce a reduction of colonies formation in the absence 
of TRAIL. However, only 53 was found to be cytotoxic, inducing approximatively 30% of cell death. 
Moreover, the non-toxicity of the original hit 3 was also confirmed, as well as the inability of TRAIL 
to induce cell death in non-cancerous cells.  
6.8 Conclusions 
The ability of compounds to sensitise TRAIL resistant MCF-7 cells to TRAIL was evaluated using the 
Colony Forming Assay. This assay is based on the ability of cancer cells, in particular of cancer stem 
cells, to proliferate, forming colonies of cells. The ability of the different compounds to increase 
TRAIL sensitisation was measured as the ability to reduce the number of colonies formed compared 
to TRAIL. Initially, a screening of all the newly synthesised compounds was performed testing all 
derivatives at 10 μM concentration. Several compounds revealed a similar ability to increase TRAIL 
sensitisation compared to hit 3, while a few analogues were able to slightly increase the reduction 
of the CFU number. With the aim to investigate how the chemical changes introduced on the original 
hit structure affected the pharmacokinetic properties, preliminary in vitro ADME studies were 
performed on some of the compounds. Among the derivatives tested, 88 showed a greater 
metabolic stability and a higher half-life time compared to 3. 88 was further evaluated with dose-
response studies. These studies confirmed the ability of 88 to act in a dose-dependent manner, with 
an IC50 value that varies between approximatively 15-19 μM. Contemporarily, a dose-response study 
of TRAIL was also performed. The results obtained indicated that, although the effect of TRAIL on 
MCF-7 cells was dose-dependent, the activity of the compound to increase TRAIL sensitisation was 
not influenced by the different concentrations of TRAIL. A dose-response study was performed also 
for 144, which belongs to the amine series of derivatives and, similarly to 88, shows a tetrazole 
moiety. 144 was found to be able to increase TRAIL sensitisation with an IC50 of 8.09 μM. 
Additionally, these two compounds, together with other analogues showing a good efficacy in 
increasing TRAIL sensitisation, were evaluated in a cytotoxicity assay on non-cancerous cells. The 
results obtained confirmed the lack of cytotoxic effects of the tested compounds. Taking into 
consideration the better pharmacokinetic profile and the slightly improved activity compared to 3, 
88 was identified as a new promising hit and additional studies will be performed with the aim to 
further demonstrate the ability of 88 to increase TRAIL sensitisation in breast cancer stem cells and 
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to confirm the role of 88 as a c-FLIP inhibitor. A description of the future assays will be discussed in 
the Conclusion chapter. At the same time, dose-response studies will be performed for all the other 
derivatives that showed an ability to increase TRAIL sensitisation similarly or slightly improved 
compared to 3.  
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6.9 Pancreatic Studies 
As part of a project carried in our research group, some of the newly synthesised derivatives were 
also evaluated for their ability to induce apoptosis in a pancreatic cancer cell line (TKCC-07). This 
project followed the results obtained in a previous work, which demonstrated the ability of TRAIL 
to promote proliferation and migration of pancreatic KRAS-mutated cancer via TRAIL-R2 mediated 
activation of the RAc1/PI3K signalling pathway. (18) The project undertaken in our research group 
aimed to investigate whether c-FLIP, via blocking the activation of the apoptotic pathway, might 
indirectly contribute to the stimulation of the proliferative pathway. Preliminary results obtained 
from this study, performed by Dr Aleksandra Gruca, showed that inhibition of c-FLIP, using siRNA 
increased cell death in different pancreatic cancer cell lines in the cell viability assay. Moreover, 
treatment of cells with hit 3 at 10 μM concentration and TRAIL, induced a reduction in cell viability 
of approximatively 60-70% after 19 hours treatment. Interestingly hit 3, when administered alone, 
showed a reduction in cell viability of approximatively 30% after 19 hours treatment, which was 
increased to approximatively 40% prolonging the treatment with hit 3 to 48 hours. Therefore, 
according to the preliminary data obtained in this study, a promising ability of hit 3 to induce 
activation of the apoptotic pathway even in the absence of TRAIL was suggested. Following these 
studies, some of the newly designed derivatives were also investigated.    
6.9.1 Cell Viability Assay 
At the time when this experiment was performed, only preliminary data had been obtained from 
the colony forming assay, therefore the selected derivatives for the pancreatic studies do not 
necessarily correspond to the compounds showing the best ability to increase TRAIL sensitisation in 
the MCF-7 cells. Compounds were tested at 10 μM concentration for their ability to reduce cell 
viability of the pancreatic cancer cells after 24 and 48 hours treatment. The preliminary results 
obtained are shown in Graph 6.9.1.  
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Graph 6.9.1: TKCC-07 cells were treated with different compounds at 10 μM concentration for 24 hours (black bars) and 48 hours 
(grey bars). After this time, the viable cells were counted and the %viability was calculated and normalised to the control 
(Untreated). N=1 for 24h treatment, N=2 for 48h treatment (144 N=1). 
Compared to the data obtained in the previous experiments performed in our research group, hit 3 
showed a similar potency in reducing cell viability. 88, 89 and 92 gave the best results, showing 
approximately a 40% of reduction in cell viability after 24 hours and 48 hours of treatment. On the 
contrary, 144 did not affect the number of viable cells, which was comparable to the control. 
Controversial results were obtained for 147, which induced a higher percentage of cell death after 
24 hours than the 48 hours treatment. Although more repetitions are needed in order to confirm 
these results, the positive preliminary data obtained might be used as a starting point for further 
evaluations aiming to investigate a potential application of 3 and its derivatives in the treatment of 
pancreatic cancer. 
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Chapter 7: Molecular Docking Studies 
7.1 Molecular Docking Studies 
Following the biological evaluation, molecular docking studies were performed in order to 
investigate the predicted binding mode of the newly designed derivatives within the c-FLIP pocket 
and potentially explain the differences in activity observed between the derivatives. All molecular 
docking analyses were performed using Glide SP (1) and the methodology applied is reported in the 
Experimental Section.  
7.1.2 Sulfonamide derivatives 
According to the docking results, the majority of the sulfonamide derivatives occupy the 
hydrophobic c-FLIP pocket with a binding mode which is similar to the one predicted for hit 3. In 
general, the sulfonamide group is located behind the residues Arg38 and Glu10 and it allows the 
two aromatic rings to fit the pocket. The hydrophobic ring of the different derivatives, which in most 
molecules is represented by a phenyl ring showing different hydrophobic substituents, or in some 
cases replaced by heterocycles such as furan or thiophene, or in bigger hydrophobic rings such as 
naphthalene and quinoline rings, always occupies the deepest part of the cavity. On the contrary, 
the “hydrophilic” ring remains on the external side due to the interactions occurring between the 
carboxylic acid moiety and Arg45. These interactions are maintained in the derivatives where the 
carboxylic acid group is replaced by bioisosteres such as tetrazole and oxadiazole. On the contrary, 
different results were obtained for the carboxamide derivatives. According to the docking results, 
the introduction of the carboxamide group leads to the loss of the interaction with Arg45, while a 
new hydrogen bond is formed between the carboxyl group and Lys18, thus causing a shift of the 
aromatic ring position to the opposite site of the c-FLIP pocket. Figure 7.1.2 (A-F) shows the 
predicted binding mode for representative structures of the different chemical modifications 
mentioned above.   
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Fig 7.1.2: Predicted binding mode and ligand interactions for compounds A:43, B:76, C:73, D:88, E:106, F:102. These compounds 
(dark blue) are representative of the general binding mode. On the right are shown the interactions which occur with the amino 
acid residues. 
F 
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Taking into consideration the general scaffold of the synthesised sulfonamide derivatives, all 
characterised by the presence of two aromatic rings linked by a sulfonamide group, a similar binding 
mode was predicted for the majority of the different analogues, therefore these results cannot be 
used for explaining the different biological activity observed among the compounds. Moreover, the 
biological results obtained for the derivatives showing a carboxamide group, which, although 
showing a decrease in activity, retained the ability to increase TRAIL sensitisation, is in contrast with 
the predicted poor ability to fit the hydrophobic cavity of c-FLIP.  In conclusion, a correlation 
between the docking results and the biological activity cannot be clearly identified. 
7.1.3 Amine Derivatives 
The docking results obtained for the amine derivatives are shown in figure 7.1.3(A-E). The amine 
linker, fitting the area behind the residues Glu10 and Arg38, allows the hydrophobic rings to reach 
the deepest part of the pocket, while the anthranilic rings are located in proximity of the residue 
Arg45, which forms a H-bond with the carboxylic acid group (A-B). Derivatives showing a longer or 
inverted amine linker seem to retain the general binding mode described above (C-D), as well as the 
derivatives where the carboxylic acid group is replaced by a tetrazole ring (E).   
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Fig 7.1.3: Predicted binding mode for the compounds A:117, B:133, C:137, D:156, E:145. These compounds (dark blue) are 
representative of the general binding mode. On the right are shown the interactions which occur with the amino acid residues. 
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Similarly to the sulfonamide derivatives, all the amine analogues were predicted to fit the c-FLIP 
pocket with the general binding mode described above. Therefore, unfortunately, the docking 
results cannot be used to explain the differences in biological activity observed for the amine 
derivatives. 
7.1.3 Methylene and amide derivatives 
The general predicted binding mode for the methylene and amide derivatives within the pocket of 
c-FLIP is similar to the one described for the sulfonamide and amine series and it is shown in Figures 
7.1.3.1. and 7.1.3.2.  
 
Figure 7.1.3.1: Predicted binding mode for compound 173. This compound (dark blue) is representative of the general binding 
mode of the methylene derivatives. On the right are shown the interactions which occur with the amino acid residues. 
 
Figure 7.1.3.2.: Predicted binding mode for compound 186. This compound (dark blue) is representative of the general binding 
mode of the amide derivatives. On the right are shown the interactions which occur with the amino acid residues. 
For the methylene derivatives, despite the shorter distance between aryl groups, the two aromatic 
rings are predicted to retain their ability to occupy the c-FLIP pocket. The -CH2 linker is located in 
proximity of the residues Arg38 and Glu10, allowing the hydrophobic substituted ring to ease into 
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the internal part of the pocket, whilst, on the other side, the carboxylic acid moiety on the 
anthranilic ring forms a H-bond with Arg45. Despite the positive docking results obtained, three of 
the four methylene derivatives evaluated did not show biological activity. Moreover, according to 
the docking results for the amide derivatives, the planar geometry does not affect the ability of the 
amide linker to occupy the curved-shaped cavity, thus promoting the arrangement of the 
hydrophobic ring in the internal hydrophobic area of the pocket, whilst leaving the carboxylic acid 
moiety to interact with Arg45 (Figure 7.1.3.2). Although this general predicted binding mode does 
not allow explanation of the differences in biological activity observed for the amide derivatives, the 
predicted ability of molecules showing a planar conformation to fit the pocket of c-FLIP might 
correlate with the ability observed for some of the amide derivatives to increase TRAIL sensitisation.   
7.2 Conclusions 
All the newly synthesised derivatives show a common scaffold which can be divided into three 
different parts: a hydrophobic region represented by different aromatic rings, a more hydrophilic 
area characterised by a phenyl ring substituted with several carboxylic acid-based functional groups, 
and a short linker which connects the two aromatic rings. Taking into consideration this general 
structure, the predicted binding mode generated from the molecular docking analyses was highly 
similar among all the derivatives, with the different linkers occupying the central area of the curved-
shaped cavity of c-FLIP, the hydrophobic ring reaching the deepest part of the pocket and the 
different functional groups on the other side interacting with Arg45. Although these positive docking 
results might confirm the ability of this class of molecules to occupy the c-FLIP pocket, considering 
the generalised results obtained, a potential correlation between molecular docking predictions and  
the differences observed in the biological activity could not be clearly identified. 
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Chapter 8: Conclusion and Future Perspectives 
8.1 Conclusion 
This study aimed to develop novel and selective c-FLIP inhibitors in order to sensitise resistant breast 
cancer cells and breast cancer stem cells to TRAIL treatment. During previous work performed in 
our research group, molecular modelling techniques had been used to explore the features involved 
in the binding between c-FLIP and FADD, and a targetable pocket in the structure of c-FLIP had been 
identified. Virtual screening studies had been performed leading to the identification of one 
potential c-FLIP inhibitor, 3, active at micromolar concentrations. (1) In this work, molecular 
modelling studies were performed in order to analyse the features required for the binding between 
the potential inhibitors and the pocket of c-FLIP. Taking into consideration these studies, several 
analogues of the original hit compound were designed with the aim to develop novel small-molecule 
c-FLIP inhibitors showing improved pharmacokinetic profiles and a greater activity compared to 3. 
Four different series of derivatives were designed and they are summarised in Table 8.1. In general, 
the central scaffold of each series shows a hydrophobic region (R), which is connected to a 
substituted phenyl ring by different linkers. 
 
Sulfonamide derivatives 
 
 
Amine derivatives 
 
 
Methylene derivatives   
 
Amide derivatives 
 
Table 8.1: Central scaffold of the different series of derivatives. 
In each series different modifications were explored in order to investigate structure-activity 
relationships. Different synthetic strategies were applied and all the designed derivatives were 
successfully synthesised. The newly synthesised small molecules were biologically evaluated for 
their ability to induce TRAIL sensitisation in the TRAIL-resistant MCF-7 breast cancer cell line using 
the in vitro Colony Forming Assay. This assay is based on the ability of cancer cells, in particular 
cancer stem cells, to proliferate forming colonies of cells, counted as colony forming units (CFU). 
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The activity of the compounds was measured as the ability to reduce the number of CFU when 
administered in association with TRAIL. Most derivatives demonstrated the ability to increase TRAIL 
sensitisation when tested at 10 μM concentration, showing a similar activity compared to hit 3. 
Moreover, some of the compounds slightly increase the reduction of CFU compared to 3. Among 
these compounds, 88, the tetrazole derivative of 3, also demonstrated greater metabolic stability 
and longer half-life (when incubated with microsomes) compared to 3. Dose-response studies 
confirmed the ability of 88 to increase TRAIL sensitisation in a dose-dependent manner, with an IC50 
value in the range of 15-19 μM. A dose-dependent TRAIL sensitising effect was observed also for 
144, which showed an IC50 value of 8.09 μM. Additional dose-response studies for compounds which 
gave the best results in the initial 10 μM CFA will be performed in the future. Cytotoxicity studies 
on non-cancerous cells confirmed the lack of cytotoxic effects for the majority of the compounds 
evaluated. Taking into consideration all these data, together with the results obtained from the 
molecular docking studies which suggested the ability of the synthesised derivatives to occupy the 
pocket of c-FLIP, a series of novel potential c-FLIP inhibitors showing ability to increase TRAIL 
sensitisation in breast cancer stem cells was developed. A novel hit, 88, was identified and future 
studies will be performed to investigate its role as a c-FLIP inhibitor. Moreover, as part of a project 
undertaken in our research group, some of the synthesised derivatives were evaluated for their 
ability to activate the TRAIL-apoptotic pathway in a pancreatic cancer cell line. Although further 
confirmations are needed, positive preliminary results were obtained and they might represent the 
starting point for additional investigations of potential applications of the synthesised compounds 
in the treatment of pancreatic cancer. 
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8.2 Future Perspectives 
In order to confirm the role of the synthesised derivatives as novel c-FLIP inhibitors, a series of 
different biological assays will be performed. 
8.2.1 Biological Evaluation 
8.2.1.1 Mammosphere Assay 
The mammosphere formation assay is an in vitro assay based on the ability of cancer stem cells to 
form cluster of cells, termed “mammospheres”. (2) This assay is the most reliable in vitro assay for 
the identification of cancer stem cells. Practically, the cancer cell line will be plated in suspension in 
non-adherent conditions, using particular media and culture plates. Only cancer stem cells will be 
able to survive in these conditions, while all the other cells will die by anoikis. (3)  The mammospheres 
formed in the first passage are consequently broken-up and treated in the same conditions 
described above. The new mammospheres formed in the second passage will be representative of 
the cancer stem cells self-renewal ability. (3) A reduction of the number of mammospheres will 
indicate the compounds to hit cancer stem cells. 
8.2.1.2 In Vivo Studies 
In Vivo studies will be necessary to confirm the ability of the combined TRAIL/compounds therapy 
to reduce tumour growth and to prevent reoccurrence of the tumour, as well as to provide 
information about potential toxicity and undesired effects. 
8.2.2 Mechanism Of Action Studies 
8.2.2.1 Caspase-8 Activity Assay 
The caspase-8 activity assay measures the protease activity using specific kits containing a 
luminogenic caspase-8 substrate. (4) The assay will be performed to measure the increase of caspase-
8 activity in presence of the combined treatment using TRAIL and test compounds, in order to prove 
that the compounds are acting via the caspase-8 pathway.    
8.2.2.2 Co-immunoprecipitation 
Co-immunoprecipitation (Co-IP) is a technique used to identify protein-protein interactions. (5) The 
assay is based on the ability to precipitate the complex formed by the two interacting proteins from 
a cell lysate. Practically, the incubation of the cell lysate with an antibody against one of the two 
interacting proteins forms an immune complex. This complex is then precipitated using an antibody-
binding protein attached to a beaded support. The precipitate, constituted by the antibody bound 
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to the complex protein-protein interaction, is then fractionated by SDS-PAGE and then analysed by 
Western Blot. (5) The interaction between c-FLIP and FADD will be explored using this technique. 
Moreover, the assay will be performed treating the cells with those compounds which showed the 
most promising activity in the cellular assays, in order to demonstrate that the mechanism of action 
of the synthesised molecules effectively involves the disruption of the interaction c-FLIP:FADD. 
8.2.2.3 Fluorescence Resonance Energy Transfer (FRET) 
The Fluorescence Resonance Energy Transfer (FRET) is an additional method to investigate protein-
protein interactions. (6) The two proteins are labelled with two fluorophores, one acting as donor 
and the other acting as acceptor. When there is a physical interaction between the proteins, the 
donor, in an excited electronic state, is able to transfer energy to the acceptor. Using the appropriate 
microscope, it is possible to detect the energy transfer expressed by the increment of the acceptor 
fluorescence emission. Therefore, labelling c-FLIP, caspase-8 and FADD with donor and acceptor 
fluorophores in the presence of the compounds will enable confirmation of the selective binding 
between the compounds and c-FLIP, and the resulting interaction between caspase-8 and FADD 
which leads to apoptosis.  
The biological experiments described in this section will be performed by Dr Richard Clarkson’s 
research group (European Cancer Stem Cells Research Institute, Hadyn Ellis Building, Cardiff 
University).  
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Chapter 9: Experimental 
9.1 General Information 
9.1.1 Chemistry 
All chemicals, reagents and solvents were purchased from commercial sources, and were used 
without further purification. TLC was performed on silica gel plates (Merck Kieselgel 60F254) and was 
developed by the ascending method. After solvent evaporation, compounds were visualised by 
irradiation with UV light at 254 nm and 366 nm. Flash column chromatography was performed using 
the Biotage Isolera One system. 1H and 13C NMR spectra were recorded on a Bruker AVANCE DPX500 
spectrometer (500 MHz and 75 MHz respectively) and auto-calibrated to the deuterated solvent 
reference peak. Chemical shifts are given in  relative to tetramethylsilane (TMS); the coupling 
constants (J) are given in Hertz. TMS was used as an internal standard ( = 0) for 1H- NMR and CDCl3 
served as an internal standard ( = 77.0) for 13C- NMR. Purity and mass of compounds were 
determined by UPLC-MS analyses, performed on a Waters UPLC system provided with Diode Array 
detector and Electrospray (positive and negative ion) MS detector. Stationary phase: Waters Acquity 
UPLC BEH C18 1.7 um 2.1 × 50 mm column. Mobile phase: H2O containing 0.1% Formic acid (A) and 
MeCN containing 0.1% Formic acid (B). Column temperature: 40 °C. Samples were prepared in 
acetonitrile at 1 μg/mL concentration. Injection volume: 2 µL. A linear gradient standard method (A) 
was used: 90% A (0.1 min), 90–0% A (2.6 min), 0% A (0.3 min), 90% A (0.1 min); flow rate 0.5 mL/min. 
Purity of the compounds tested in biological assays was >95%.  
9.1.2 Biology 
9.1.2.1 Cell Lines 
Human MCF-7 cells (1) were cultured in RPMI-1640 medium (Invitrogen) supplemented with 10% v/v 
heat inactivated fetal bovine serum (FBS), 2mM L-glutamine (Invitrogen) and 50 units/mL penicillin-
streptomycin. TKCC-07 cells (2) were cultured in M199/F12 medium (Life Technologies) 
supplemented with 15 mM HEPES (Life Technologies), 2mM glutamine (Life Technologies), 20ng/mL 
EGF (Life Technologies), 40 ng/mL hydrocortisone (Sigma), 5 μg/mL apo-transferrin (Sigma), 
0.2IU/mL insulin ActRApid (Life Technologies), 0.06% glucose solution (10%) (Sigma), 7.50 % fetal 
bovine serum (FBS), 0.5 pg/mL tri-iodotyronine (Sigma), MEM vitamins (100x) (Life Technologies), 2 
μg/mL o-phosphoryl ethanolamine (Sigma), 1% penicillin-streptomycin and 0.05% gentamicin. 
Human HEK-293 cells (3) were cultured in Dulbecco’s modified eagle medium with nutrient mixture 
F12 (DMEM/F12) (Gibco), supplemented with 10% v/v heat inactivated FBS and 50 units/mL 
penicillin-streptomycin.  
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9.1.2.2 Cell Culture Maintenance  
Cells were kept in a logarithmic growth phase in 25cm2 cell culture flasks (T25) (Nunc) at 37°C in a 
sterile incubator with a humidified atmosphere of 5% CO2 and 95% air by passaging or refreshing 
media when required. Passaging was performed by removing the culture medium and adding 2mL 
of 0.05% trypsin/EDTA (Invitrogen) for MCF-7 and HEK-293 cells and 0.1 mM EDTA (Sigma) for TKCC-
07 cells. Cells were incubated at 37°C for 5-10 mins. When all cells were detached, culture medium 
was added according to the appropriate passage ratio. MCF-7 and HEK-293 cells were kept to a 
passage number of around 35, TKCC-07 cells were kept to a passage number of around 10.  
9.1.2.3 Cell Storage 
Cells were frozen at low passage number and cryo-stored in liquid nitrogen. To prepare cells for 
storage, cells were trypsinised and pelleted. Pellets were resuspended in 1mL normal media with 
10% DMSO-D6 (Sigma) in 1.5mL cryo-tubes (Nunc).  Cryo-tubes were left overnight at -80°C in an 
isopropanol cell freezing container, after which tubes were transferred to long term storage in liquid 
nitrogen container.  To revive cells, tubes were defrosted rapidly in a 37°C water bath and spun at 
1100rpm to obtain a cell pellet which was resuspended in 5mL growth medium and cultured in a 
T25 flask. 
9.1.2.4 Cell-Based Assays 
9.1.2.4.1 Cell Counting 
Cells were detached as described in section 9.1.2.2. Cells were moved to a 15 ml Falcon Tube (Nunc) 
and resuspended in culture media. Following centrifugation at 1100 RPMI for 5 mins, the pellet was 
resuspended in culture media and 10 μL of the resulting suspension were loaded into the Fastread 
10-chamber counting grid (Immune Systems). The average of the number of cells in four counting 
squares was measure and multiplied by 10,000 to obtain the number of cells/mL. 
9.1.2.4.2 Colony Forming Assay (4) 
Cells were plated in a 12 well plate at a density of 184.8 cells/mL and left to attach overnight, after 
which media was refreshed with appropriate control or test medium.  Colonies were left to form for 
10 days, after which, medium was removed and cells were gently washed with 1X PBS for 5 minutes.  
Crystal violet was then added for 15 minutes, followed by 3 x PBS washes for 5 minutes each.  
Colonies were then visualised and photographed under white light. Colonies showing a minimum 
diameter of 200 μm were counted using the GelCount plate reader (Oxford Optronix) setting 
threshold values of 200-1000 μm. 
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9.1.2.4.3 CellTiter Blue Viability Assay (5) 
Cells were plated in 96 well plate at a density of 100,000 cells/mL and left to attach overnight. When 
cells reached a confluence of approximately 70%, medium was refreshed with appropriate control 
or test medium. After 24 or 48 hours, 20 μL of CellTiter Blue reagent was added to each well (100 
μL culture media) and incubated for at 37°C with 5% CO2 for 2 hours. Following this period, 
fluorescence was measured using a FluoStar Optima plate reader (BMG Labtech) setting 
excitation/emission wavelengths to 560/590 nm.  
9.1.3 Molecular Modelling 
9.1.3.1 Molecular Docking  
All molecular docking studies were performed on a Intel Xeon (R) CPU 5150 @ 2.66 GHz x 4, running 
Ubuntu 12.04 (precise) 32-bit. Molecular Operating Environment (MOE) 2015 (6) and Glide SP-
Maestro (Shrödinger Release 2017-1) (7) were used to perform the docking analyses. MOE was 
initially used to build a database containing all synthesised compounds in their energy minimised 
status. Maestro was used to prepare the model of c-FLIP was using the Protein Preparation Wizard 
tool which allowed the assignment of bond orders, the additions of hydrogens and finally a 
restrained energy minimization of the hydrogens using OPLS_2005 force field. The receptor grid was 
generated by selecting the predicted position occupied by hit 3 as binding site, and a maximum 
length of 12Å from this site was selected to dock the compounds. Before running the molecular 
docking analyses, the database of compounds previously generated was prepared using the LigPrep 
tool in Maestro. Molecular docking analyses were performed using Glide SP precision retaining the 
default parameters and including 15 poses for each compound in the post-docking minimization. 
The docking results were exported in MOE and then visually inspected. The interactions between 
compounds and the amino acid residues were predicted using the Ligand Interaction tool in MOE. 
9.1.3.2 Molecular Dynamics (MD)  
DESMOND (8) was used with OPLS2005 force field for the molecular dynamics (MD) simulation. The 
two interacting proteins were placed in a cubic box filled with TIP 3P water. The energy of the system 
was minimised using a steepest descent minimisation algorithm. Consequently, the simulation time 
was set up at 100 ns, and the simulation was performed at NTP conditions: constant number of 
atoms (N), constant temperature of (300K) (T) and constant pressure (1atm) (P), saving the 
trajectory and energy values every 40 ps. The results were analysed using Maestro (7) and then 
exported and visually inspected using MOE (6). The MD simulation was monitored with C-alpha 
RMSD evaluation in order to analyse the stability of the system. 
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9.2 Synthesis of sulfonamide derivatives 
General Procedure 1: arylsulfonamido benzoic acids (3, 63-67) (9) 
 
2-Aminobenzoic acid (1 eq), the appropriate arylsulfonyl chloride (1 eq) and NaOH (1 eq) were 
stirred in water (10 mL/mmol) at 70°C overnight. The product was filtered, washed with water, dried 
and purified by recrystallisation or flash column chromatography. 
General Procedure 2: methyl(arylsulfonamidobenzoates) (21-37, 42-43, 78, 86-93) 
(10) 
 
To a stirred solution of the differently substituted aniline (1 eq) in anhydrous pyridine (4 mL/mmol) 
was added the appropriate arylsulfonyl chloride (1.2 eq) under an atmosphere of nitrogen. The 
reaction mixture was stirred at room temperature for 6h and was then quenched by addition of 
water (10 mL/mmol). The aqueous layer was extracted with ethyl acetate (20 mL/mmol) and the 
organic layer was then dried over anhydrous sodium sulfate. The solvent was removed under 
vacuum, and the crude product was purified by recrystallisation or flash column chromatography. 
General Procedure 3: arylsulfonyl chlorides (40-41) (11) 
 
To a cooled (0°) mixture of the appropriated substituted benzene (1eq) in chloroform (4 mL/mmol), 
chlorosulfonic acid (2.5 eq) was added dropwise. The reaction mixture was magnetically stirred at 
0° C and the chlorosulfonic acid was added at such a rate that the temperature of the reaction 
mixture did not exceed 5°C. After the complete addition of chlorosulfonic acid, the reaction mixture 
was stirred for another 45 mins at room temperature and the mixture was poured into crushed ice. 
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The product was extracted with chloroform (20 mL/mmol) and dried over anhydrous sodium sulfate. 
Chloroform was removed under vacuum. The crude product was directly used for the next step or 
purified by flash column chromatography. 
General Procedure 4:  alkyl(arylsulfonamido)benzoates (50-57) (12) 
 
To a cooled (0°) stirring solution of alkyl anthranilate (1 eq) in CH2Cl2 (4 mL/mmol) was added 
pyridine (7.5 eq). The appropriate arylsulfonyl chlorides (1.2 eq) was then added slowly. The solution 
was allowed to warm to room temperature and stirred for 1-3 hours. The reaction was poured into 
saturated NaHCO3 solution (14 mL/mmol), extracted with CH2Cl2 (3 x 5mL/mmol), and washed with 
1M HCl (15 mL/mmol). The combined organic phases were dried over MgSO4 and concentrated in 
vacuo. The desired products were purified by recrystallization or flash column chromatography. 
General Procedure 5: arylsulfonamido benzoic acids (69-70) (13) 
 
A solution of Na2CO3 (2.4 eq) in H2O (4.5 mL/mmol) was heated to 60°C, treated with anthranilic 
acid and stirred for 5 min. The appropriate arylsulfonyl chloride was added in portions, the 
temperature was raised to 70°C and the mixture stirred overnight. The temperature was raised to 
85°C and the mixture was vacuum filtered. The resulting filtrate was treated with 6 M HCl (5 
mL/mmol) and cooled down to room temperature. The resulting precipitate was isolated by vacuum 
filtration, washed with 1M HCl and water. The desired products were purified by recrystallisation or 
flash column chromatography. 
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General Procedure 6: arylsulfonamido benzoic acids (72-76) (14) 
 
To a solution of the appropriate methyl-(arylsulfonamido) benzoate (1 eq) in THF (7 mL/mmol), H2O 
(3.5 mL/mmol), MeOH (3.5 mL/mmol) was added LiOH (3 eq). The reaction was stirred at 70°C 
overnight. After the reaction was allowed to cool to room temperature, the reaction mixture was 
acidified with 2M HCl. The product was extracted with ethyl acetate (3x10 mL/mmol). The organic 
layer was dried over MgSO4 and evaporated under reduced pressure. The product was purified by 
flash column chromatography or recrystallisation. 
General Procedure 7: alkyl(aryl)esters (71, 77, 79) (15) 
 
To a solution of the appropriate aryl acid (1 eq) in isopropanol (1.9 mL/mmol) was added 1.25 M 
HCl in isopropanol solution (1.9 mL/mmol). The reaction was refluxed overnight. The solution was 
then cooled to room temperature and concentrated in vacuum. The residue was partitioned 
between sat. aq. NaHCO3 solution (30mL/mmol) and ethylacetate (3x25 mL/mmol). The combined 
organic layers were washed with sat. aq. NaHCO3 solution (25 mL/mmol) and water (10 mL/mmol), 
dried over MgSO4 and concentrated under vacuum to give the alkyl esters. The desired products 
were purified by flash column chromatography. 
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Synthesis of Isopropyl 2-((3-chloro-4-methylphenyl)sulfonamido)benzoate (79) (16) 
(C17H18ClNO4S; M.W.= 367.84) 
 
2-((3-chloro-4-methylphenyl)sulfonamido)benzoic acid (0.100 g, 0.3 mmol), TBTU (0.09 g, 0.3 mmol) 
and DIPEA (0.08 g, 0.6 mmol) were stirred in anhydrous DMF (1 mL), and the resulting mixture was 
stirred at room temperature for 30 min, under N2 atmosphere. Isopropyl alcohol (0.02 g, 0.3 mmol) 
was then injected into the reaction mixture via syringe and stirring was continued at room 
temperature until completion of the reaction. The reaction mixture was diluted with DCM (10 mL) 
and the resulting mixture was extracted with sat.aq NH4Cl (10 mL) and sat.aq NaHCO3 (10 mL). The 
organic layer was dried over MgSO4 and the solvent was evaporated under vacuum. The desired 
product was purified by flash column chromatography.  
Colourless oil;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.60; 
Purification1: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 70:30 in 10 CV); 
Purification2: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 70:30 in 15 CV); 
Purification3: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 
5g, n-hexane-DCM 100:0 increasing to n-hexane-DCM 0:100 in 11 CV); 
Yield: 0.024 g (22%); 
1H-NMR (CDCl3), δ: 1.26 (d, J= 6.2 Hz, 6H, H-16,17), 2.30 (s, 3H, H-7), 5.11-5.14 (m, 1H, H-15), 6.97-
7.00 (m, 1H, H-aromatic), 7.17-7.19 (m, 1H, H-aromatic), 7.37-7.41 (m, 1H, H-aromatic), 7.52 (dd, 
J1= 7.8 Hz, J2= 1.9 Hz, 1H, H-aromatic), 7.59 (dd, J1= 8.3 Hz, J2= 1.0 Hz, 1H, H-aromatic), 7.74-7.76 (m, 
1H, H-aromatic), 7.85 (m, 1H, H-aromatic), 10.68 (bs, 1H, NH) ppm. 
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 13C-NMR (CDCl3), δ: 20.2 (CH3, C-7), 21.7 (2xCH3, C-16,17), 69.5 (CH, C-15), 119.4, 123.2, 125.3, 
127.7, 131.1, 131.3, 134.3 (CH, C-aromatic), 116.9, 135.1, 138.3, 140.1, 141.8 (C, C-aromatic), 167.3 
(C, C-14). 
UPLC-MS: Rt 2.77 (100%) MS (ESI)+: 368.8 [M+H]+. 
General Procedure 8: tert-Butyl(arylsulfonamido) benzoate (80-81) (17) 
 
Concentrated sulfuric acid (1eq) was added to a vigorously stirred suspension of anhydrous 
magnesium sulfate (4eq) in DCM (4mL/mmol). The mixture was stirred for 15 minutes, after which 
the appropriate carboxylic acid (1eq) was added. Tert-Butyl alcohol (5eq) was added last. The 
mixture was stoppered tightly and stirred at 25°C for 18h. The reaction mixture was then quenched 
with sat.aq. NaHCO3 solution and stirred until all the MgSO4 was dissolved. The solvent phase was 
separated, washed with brine, dried over MgSO4 and concentrated to afford the crude tert-butyl 
ester, which was purified by flash column chromatography.   
General Procedure 9: (1H-tetrazol-5yl) anilines (84-85) (18) 
 
The appropriate aminobenzonitrile (1 eq), sodium azide (1.2 eq), ammonium chloride (1.2 eq) and 
DMF (0.6 mL/mmol) were mixed and heated at 120o C for 72 hours. The solvent was evaporated 
under reduced pressure. The desired products were purified by flash column chromatography. 
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Synthesis of 3-(2-aminophenyl)-1,2,4-oxadiazol-5(4H)-one (96) (19) 
(C8H7N3O2; M.W.= 177.16) 
 
 
Sodium methoxide (25wt% in MeOH, 0.534 g, 9.9 mmol) was added to a stirred solution of 2-amino-
N-hydroxy-benzamidine (0.500 g, 3.3 mmol) in ethanol (10 mL) at room temperature. The mixture 
was vigorously stirred and diethyl carbonate (1.563 g, 13.2 mmol) was added. The reaction mixture 
was refluxed overnight and then allowed to cool to room temperature. The solvent was removed 
under reduced pressure and the residue was diluted with water (5 mL). The basic solution was 
neutralised to pH 7 with 1M HCl at 0°C. The resulting precipitate was filtered under reduced 
pressure, washed with water and dissolved in ethyl acetate. The organic phase was dried over 
MgSO4, filtered and evaporated in vacuum. The crude product was used without further 
purification.  
Yellow Solid; 
T.L.C. System: N-hexane-EtOAc 6:4 v/v, Rf: 0.85; 
Yield: 0.279 g (48%); 
1H-NMR (DMSO-D6), δ: 6.63-6.66 (m, 1H, H-aromatic), 6.85 (dd, J1= 8.3 Hz, J2= 0.7 Hz, 1H, H-
aromatic), 7.22-7.25 (m, 1H, H-aromatic), 7,47 (dd, J1= 7.9 Hz, J2= 1.4 Hz, 1H, H-aromatic), 8.54 (bs, 
1H, NH).  
 13C-NMR (DMSO-D6), δ: 115.8, 116.6, 128.3, 132.6 (CH, C-aromatic), 104.6, 148.0, 159.3 (C, C-
aromatic), 160.4 (C, C-8). 
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General Procedure 10: alkyl(arylsulfonamido) carboxamide (101-105) (20) 
 
A suspension of CDI (1.2eq) and the appropriate carboxylic acid (1eq) in THF (6 mL/mmol) was 
stirred at room temperature overnight. A 2N solution of alkylamine in THF (1.5eq) was then added 
and the resulting solution was stirred at room temperature for 6 hours. The solvent was evaporated 
and the residue dissolved in ethyl acetate (10mL/mmol). The solution was washed sequentially with 
water and brine. The organic layer was dried over MgSO4 and then evaporated. The desired product 
was purified by column chromatography or recrystallisation. 
Synthesis of 2-((2,4-Dichloro-5-methylphenyl)sulfonamido) benzamide (106) (21) 
(C14H12Cl2N2O3S; M.W.= 359.22) 
 
N,N’-carbonyldiimidazole (0.050 g, 0.33 mmol) was added to a solution of 2-((2,4-dichloro-5-
methylphenyl)sulfonamido)benzoic acid (0.100 g, 0.27 mmol) in [bmim]BF4 (1 mL). The resulting 
mixture was stirred at 80°C for 2h. Ammonium acetate (0.083 g, 1.08 mmol) and triethylamine 
(0.082 g, 0.81 mmol) were added to the reaction mixture. The reaction was heated at 80°C for 3h. 
After completion of the reaction, the product was extracted with ethyl acetate (10 mL), washed with 
0.01N solution of HCl (15 mL), and dried over anhydrous MgSO4. The solvent was evaporated in 
vacuo, and the crude product was puriﬁed by flash column chromatography. 
Grey solid;  
T.L.C. System: n-hexane-EtOAc 3:7 v/v, Rf: 0.60; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane:EtOAc 100:0 increasing to n-hexane-EtOAc 0:100 in 14CV); 
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Yield: 0.010 g (10%); 
1H-NMR (CDCl3), δ: 2.32 (s, 3H, H-7), 5.87 (bs, 2H, NH2), 6.94-6.98 (m, 1H, H-aromatic), 7.29-7.32 (m, 
1H, H-aromatic), 7.36 (s, 1H, H-4), 7.39-7.41 (m, 1H, H-aromatic), 7.48-7.51 (m, 1H, H-aromatic), 
7.97 (s, 1H, H-1), 11.50 (bs, 1H, NH). 
13C-NMR (CDCl3), δ: 19.6 (CH3, C-7), 118.3, 122.7, 127.8, 131.8, 133.4, 133.5 (CH, C-aromatic), 118.4, 
130.0, 135.1, 135.5, 138.9, 139.8 (C, C-aromatic), 170.4 (C, C-14). 
UPLC-MS: Rt 2.13 (>98%) MS (ESI)+: 381.9 [M+Na]+. 
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9.2.1: Arylsulfonamido benzoic acids (3, 63-67) 
2-((2,4-Dichloro-5-methylphenyl)sulfonamido) benzoic acid (3) 
(C14H11Cl2NO4S; M.W.= 360.21) 
 
Reagent: 2-Aminobenzoic acid (2) (0.79 g, 5.78 mmol); 
Reagent: 2,4-dichloro-5-methylbenzenesulfonyl chloride (1) (1.50 g, 5.78 mmol); 
General Procedure 1; 
White solid; 
T.L.C. System: n-hexane-EtOAc 5:5 v/v, Rf: 0.48; 
Purification: recrystallisation from EtOH; 
Yield: 1.04 g (50%); 
1H-NMR (CDCl3), δ: 2.40 (s, 3H, H-7), 7.09-7.13 (m, 1H, H-aromatic), 7.41-7.43 (m, 1H, H-aromatic), 
7.49-7.53 (m, 1H, H-aromatic), 7.84 (s, 1H, H-6), 7.95-7.97 (m, 1H, H-aromatic), 8,23 (s, 1H, H-3), 
11.71 (bs, 1H, NH), 14.15 (bs, 1H, OH). 
13C-NMR (CDCl3), δ: 19.5 (CH3, C-7), 116.9, 123.5, 132.1, 132.2, 134.3, 135.2 (CH, C-aromatic), 116.1, 
128.9, 134.4, 136.7, 139.5, 140.0 (C, C-aromatic), 170.3 (C, C-14). 
UPLC-MS: Rt 2.03 (98%) MS (ESI)+: 360.9 [M+H]+. 
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2-(Phenylsulfonamido)benzoic acid (63) (22) 
(C13H11NO4S; M.W.= 277.29) 
 
Reagent: benzenesulfonyl chloride (58) (0.1 g, 0.56 mmol); 
Reagent: 2-aminobenzoic acid (1) (0.078 g, 0.56 mmol); 
General Procedure 1; 
White Solid; 
T.L.C. System: DCM:MeOH 98:2 v/v, Rf: 0.25; 
Purification: Recrystallisation from DCM/n-hexane; 
Yield: 0.053 g (59%); 
1H-NMR (DMSO-D6), δ: 7.11-7.14 (m, 1H, H-aromatic), 7.51-7.58 (m, 4H, H-aromatic), 7.63-7.67 (m, 
1H, H-aromatic), 7.81-7.83 (m, 2H, H-aromatic), 7.89-7.91 (m, 1H, H-aromatic), 11.16 (bs, 1H, NH), 
14.01 (bs, 1H, OH).  
 13C-NMR (DMSO-D6), δ: 118.97, 123.87, 127.31, 130.00, 132.00, 134.05, 134.98 (CH, C-aromatic), 
117.28, 139.05, 140.24 (C-aromatic), 170.22 (C, C- 13). 
UPLC-MS: Rt 1.91 (100%) MS (ESI)+: 278.0 [M+H]+. 
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2-(((4-(Trifluoromethyl)phenyl)methyl)sulfonamido)benzoic acid (64) 
(C15H12F3NO4S; M.W.= 359.32) 
 
Reagent: (4-(trifluoromethyl)phenyl)methanesulfonyl chloride (59) (0.150 g, 0.58 mmol); 
Reagent: 2-aminobenzoic acid (1) (0.080 g, 0.58 mmol); 
General Procedure 1; 
White Solid; 
T.L.C. System: DCM-MeOH 98:2 v/v, Rf: 0.26; 
Purification: Recrystallisation from EtOH; 
Yield: 0.034 g (23%); 
1H-NMR (DMSO-D6), δ: 4.86 (s, 2H, H-8), 7.16-7.19 (m, 1H, H-aromatic), 7.47 (d, J= 8.0 Hz, 2H, H-
aromatic), 7.55-7.60 (m, 2H, H-aromatic), 7.70 (d, J= 8.0 Hz, 2H, H-aromatic), 7.99-8.01 (m, 1H, H-
aromatic), 10.83 (bs, 1H, NH), 13.92 (bs, 1H, OH). 
13C-NMR (DMSO-D6), δ: 57.3 (CH2, C-8), 117.8, 123.1, 125.7, 132.0, 132.1, 135.1 (CH, C-aromatic), 
129.3 (d, J= 32.2 Hz, C) 116.0, 132.4, 134.2, 141.0 (C-aromatic), 170.2 (C, C- 15). 
19F-NMR (DMSO-D6), δ: -61.04 (s, 3F). 
UPLC-MS: Rt 2.12 (>98%) MS (ESI)-: 358.1 [M-H]- . 
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2-(Thiophene-2-sulfonamido)benzoic acid (65) 
(C11H9NO4S2; M.W.= 283.32) 
 
Reagent: thiophene-2-sulfonyl chloride (60) (0.2 g, 1.09 mmol); 
Reagent: 2-aminobenzoic acid (1) (0.150 g, 1.09 mmol); 
General Procedure 1; 
Grey Solid; 
T.L.C. System: n-hexane-EtOAc 6:4 v/v, Rf: 0.25; 
Purification: Recrystallisation from EtOH; 
Yield: 0.067 g (22%); 
1H-NMR (DMSO-D6), δ: 7.13-7.15 (m, 1H, H-aromatic), 7.17-7.21 (m, 1H, H-aromatic), 7.60-7.64 (m, 
2H, H-aromatic), 7.67 (dd, J1= 3.7 Hz, J2= 1.3 Hz, 1H, H-aromatic), 7.91-7.94 (m, 1H, H-aromatic), 7.96 
(dd, J1= 4.9 Hz, J2= 1.3 Hz, 1H, H-aromatic),  11.23 (bs, 1H, NH), 14.09 (bs, 1H, OH). 
13C-NMR (DMSO-D6), δ: 119.3, 124.2, 128.3, 132.0, 134.0, 134.9, 135.0 (CH. C-aromatic), 117.6, 
139.2, 139.9 (C, C-aromatic), 170.2 (C, C- 11). 
UPLC-MS: Rt 1.89 (99%) MS (ESI)+: 283.9 [M+H]+. 
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2-(Quinoline-8-sulfonamido)benzoic acid (66) 
(C16H12N2O4S; M.W.= 328.34) 
 
Reagent: quinoline-8-sulfonyl chloride (61) (0.100 g, 0.44 mmol); 
Reagent: 2-aminobenzoic acid (1) (0.040 g, 0.44 mmol); 
General Procedure 1; 
White Solid; 
T.L.C. System: DCM-MeOH 98:2 v/v, Rf: 0.10; 
Purification: Recrystallisation from EtOH; 
Yield: 0.040 g (28%); 
1H-NMR (DMSO-D6), δ: 6.93-6.96 (m, 1H, H-aromatic), 7.38-7.41 (m, 1H, H-aromati),  7.62 (dd, J1= 
8.4 Hz, J2= 0.7 Hz, 1H, H-aromatic), 7.69 (dd, J1= 8.3 Hz, J2= 4.2 Hz, 1H, H-aromatic), 7.73-7.78 (m, 
2H, H-aromatic), 8.30 (dd, J1= 8.3 Hz, J2= 1.3 Hz, 1H, H-aromatic), 8.49 (dd, J1= 8.4 Hz, J2= 1.7 Hz, 1H, 
H-aromatic), 8.52 (dd, J1= 7.3 Hz, J2= 1.3 Hz, 1H, H-aromatic), 8.95 (dd, J1= 4.2 Hz, J2= 1.7 Hz, 1H, H-
aromatic), 11.55 (bs, 1H, NH), 13.74 (bs, 1H, OH). 
13C-NMR (DMSO-D6), δ: 117.1, 122.9, 123.2, 126.1, 131.8, 133.1, 134.6, 135.3, 137.5, 151.9 (CH, C-
aromatic), 117.0, 128.8, 140.2, 142.8, 153.6 (C, C-aromatic), 169.41 (C, C- 16). 
UPLC-MS: Rt 1.87 (99%) MS (ESI)+: 329.1 [M+H]+. 
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2-(Isoquinoline-4-sulfonamido)benzoic acid (67) 
(C16H12N2O4S; M.W.= 328.34) 
 
Reagent: isoquinoline-4-sulfonyl chloride (62) (0.100 g, 0.44 mmol); 
Reagent: 2-aminobenzoic acid (1) (0.060 g, 0.44 mmol); 
General Procedure 1; 
White Solid; 
T.L.C. System: DCM-MeOH 98:2 v/v, Rf: 0.34; 
Purification: Recrystallisation from EtOH; 
Yield: 0.050 g (35%); 
1H-NMR (DMSO-D6), δ: 7.13-7.16 (m, 1H, H-aromatic), 7.54-7.59 (m, 2H, H-aromatic), 7.75-7.78 (m, 
1H, H-aromatic), 7.85-7.87 (m, 1H, H-aromatic), 7.95-7.98 (m, 1H, H-aromatic), 8.09-8.11 (m, 1H, H-
aromatic), 8.23 (dd, J1= 8.5 Hz, J2= 1.1 Hz, 1H, H-aromatic), 9.04-9.07 (m, 1H, H-aromatic), 9.14 (d, 
J= 2.3 Hz, 1H, H-aromatic), 11.29 (bs, 1H, NH), 13.72 (bs, 1H, OH). 
13C-NMR (DMSO-D6), δ: 119.8, 124.4, 128.9, 129.3, 130.2, 132.0, 133.5, 135.0, 137.4, 146.5 (CH, C-
aromatic), 118.2, 126.3, 132.2, 139.4, 148.9 (C, C-aromatic), 169.9 (C, C- 16). 
UPLC-MS: Rt 1.93 (99%) MS (ESI)+: 329.1 [M+H]+. 
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9.2.2: Methyl(arylsulfonamidobenzoates) (21-37, 42-43, 78, 86-93) 
Methyl 2-((2,4-dichloro-5-methylphenyl)sulfonamido)benzoate (21) 
(C15H13Cl2NO4S; M.W.=374.2) 
 
Reagent: 2,4-dichloro-5-methylbenzensulfonyl chloride (1) (0.3 g, 1.15 mmol); 
Reagent: methyl anthranilate (18) (0.14 g, 0.98 mmol); 
General procedure 2; 
White solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.64; 
Purification: Recrystallisation from EtOH; 
Yield: 0.176 g (49%); 
1H-NMR (CDCl3), δ: 2.33 (s, 3H, H-7), 3.86 (s, 3H, H-15), 6.93-6.96 (m, 1H, H-aromatic), 7.30-7.34 (m, 
1H, H-aromatic), 7.35 (s, 1H, H-aromatic), 7.46 (dd, J1= 8.4 Hz, J2= 0.8 Hz, 1H, H-aromatic), 7.90 (dd, 
J1= 8.0 Hz, J2= 1.4 Hz, 1H, H-aromatic), 7.99 (s, 1H, H-aromatic), 11.12 (bs, 1H, NH). 
13C-NMR (CDCl3), δ: 19.6 (CH3, C-7), 52.5 (CH3, C-15), 116.9, 122.5, 131.4, 131.9, 134.5, 135.6 (CH, 
C-aromatic), 115.2, 115.9, 129.9, 133.5, 139.7, 140.0 (C, C-aromatic), 168.1 (C, C-14). 
UPLC-MS: Rt 2.59 (100%) MS (ESI)+: 376.1 [M+H]+. 
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Methyl 3-((2,4-dichloro-5-methylphenyl)sulfonamido)benzoate (22) 
(C15H13Cl2NO4S; M.W.=374.2) 
 
Reagent: 2,4-dichloro-5-methylbenzensulfonyl chloride (1) (0.3 g, 1.15 mmol); 
Reagent: methyl-3-aminobenzoate (19) (0.145 g, 0.96 mmol); 
General Procedure 2; 
White solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.40; 
Purification: Recrystallisation from EtOH; 
Yield: 0.203 g (56%); 
1H-NMR (CDCl3), δ: 2.36 (s, 3H, H-7), 3.96 (s, 3H, H-15), 7.33-7.37 (m, 1H, H-aromatic), 7.39-7.42 (m, 
1H, H-aromatic), 7.51 (s, 1H, H-aromatic), 7.76-7.77 (m, 1H, H-aromatic), 7.80-7.82 (m, 1H, H-
aromatic), 7.89 (s, 1H, H-aromatic), 11.20 (bs, 1H, NH). 
13C-NMR (CDCl3), δ: 19.5 (CH3, C-7), 52.3 (CH3, C-15), 122.4, 125.6, 126.9, 129.6, 131.6, 133.5 (CH, 
C-aromatic), 120.5, 128.4, 135.9, 135.9, 136.1, 156.6 (C, C-aromatic), 160.6 (C, C-14).  
UPLC-MS: Rt 2.30 (100%) MS (ESI)-: 372.1 [M-H]-. 
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Methyl 4-((2,4-dichloro-5-methylphenyl)sulfonamido)benzoate (23) 
(C15H13Cl2NO4S; M.W.=374.2) 
 
Reagent: 2,4-dichloro-5-methylbenzensulfonyl chloride (1) (0.3 g, 1.15 mmol); 
Reagent: methyl-4-aminobenzoate (20) (0.14 g, 0.96 mmol); 
General procedure 2; 
Yellow powder; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.40; 
Purification: Recrystallisation from MeOH/DCM; 
Yield: 0.166 g (46%); 
1H-NMR (DMSO-d6), δ: 2.39 (s, 3H, H-7), 3.78 (s, 3H, H-15), 7.19-7.22 (m, 2H, H-aromatic), 7.80 (s, 
1H, H-aromatic), 7.81-7.84 (m, 2H, H-aromatic), 8.13 (s, 1H, H-aromatic), 11.23 (bs, 1H, NH). 
13C-NMR (DMSO-D6), δ: 19.0 (CH3, C-7), 51.8 (CH3, C-15), 117.1, 130.6, 131.5, 133.5 (CH, C-aromatic), 
124.4, 128.7, 134.7, 136.0, 139.0, 141.4 (C, C-aromatic), 165.5 (C, C-14). 
UPLC-MS: Rt 2.29 (100%) MS (ESI)-: 372.1 [M-H]-. 
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Methyl 2-((4-(trifluoromethyl)phenyl)sulfonamido)benzoate (24) 
(C15H12F3NO4S; M.W.=359.32) 
 
Reagent: 4-(trifluoromethyl)benzensulfonyl chloride (4) (0.3 g, 1.22 mmol); 
Reagent: methyl anthranilate (18) (0.15 g, 1.02 mmol); 
General procedure 2; 
White solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.46; 
Purification: Recrystallisation from EtOH; 
Yield: 0.220 g (60%); 
1H-NMR (CDCl3), δ: 3.89 (s, 3H, H-15), 7.10-7.13 (m, 1H, H-aromatic), 7.71-7.72 (m, 1H, H-aromatic), 
7.73-7.75 (m, 2H, H-aromatic), 7.95-7.97 (m, 1H, H-aromatic), 7.98-8.00 (m, 2H, H-aromatic), 10.76 
(bs, 1H, NH). 
13C-NMR (CDCl3), δ: 52.6 (CH3, C-15), 119.3, 123.6, 126.2, 127.7, 131.3, 134.5 (CH, C-aromatic), 
116.2, 134.7, 139.8, 142.8 (C, C-aromatic), 168.3 (C, C-14). 
19F-NMR (CDCl3), δ: -63.19, (s, 3F). 
UPLC-MS: Rt 2.39 (100%) MS (ESI)+: 360.1 [M+H]+. 
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Methyl 2-((3,4-dimethylphenyl)sulfonamido)benzoate (25) 
(C16H17NO4S, M.W.=319.4) 
 
Reagent: 3,4-dimethylbenzensulfonyl chloride (5) (0.3 g, 1.46 mmol); 
Reagent: methyl anthranilate (18) (0.18 g, 1.22 mmol);  
General procedure 2; 
White solid; 
T.L.C. System: n-hexane-EtOAc 8:2, v/v, Rf: 0.42; 
Purification: Recrystallisation from EtOH; 
Yield: 0.024 g (29%); 
1H-NMR (DMSO-D6), δ: 2.25 (s, 6H, 2xCH3, H-7,8), 3.83 (s, 3H, H-16), 7.14-7.18 (m, 1H, H.aromatic), 
7.31 (d, J=7.8 Hz, 1H, H-aromatic), 7.45-7.48 (m, 1H, H-aromatic), 7.52 (dd, J1= 8.0 Hz, J2= 1.7 Hz, 1H, 
H-aromatic), 7.55-7.58 (m, 1H, H-aromatic), 7.59-7.61 (m, 1H, H-aromatic), 7.85 (d, J= 7.8 Hz, 1H, H-
aromatic), 10.43 (bs, 1H, NH). 
13C-NMR (DMSO-D6), δ: 19.7, 19.9 (2xCH3, C-7,8), 53.1 (CH3, C-16), 119.9, 124.1, 124.9, 127.8, 130.6, 
131.4, 134.9 (CH, C-aromatic), 117.8, 136.4, 138.4, 139.3, 143.4 (C, C-aromatic), 168.1 (C, C-15). 
UPLC-MS: Rt 2.35 (100%) MS (ESI)+: 320.1 [M+H]+. 
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Methyl-2-((3,4-dichlorophenyl)sulfonamido)benzoate (26) 
(C14H11Cl2NO4S; M.W.=360.2) 
 
Reagent: 3,4-dichlorobenzensulfonyl chloride (6) (0.3 g, 1.22 mmol); 
Reagent: methyl anthranilate (18) (0.15 g, 1.01 mmol); 
General procedure 2; 
White solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.33; 
Purification: Recrystallisation from EtOH; 
Yield: 0.238 g (65%); 
1H-NMR (DMSO-D6), δ: 3.88 (s, 3H, H-14), 7.16-7.20 (m, 1H, H-aromatic), 7.38 (d, J= 8.5 Hz, 1H, H-
aromatic), 7.52-7.56 (m, 1H, H-aromatic), 7.67-7.70 (m, 1H, H-aromatic), 7.91 (s, 1H, H-6), 7.92-7.94 
(m, 1H, H-aromatic), 8.17 (d, J= 8.5 Hz, 1H, H-aromatic), 11.07 (bs, 1H, NH). 
13C-NMR (DMSO-D6), δ: 53.3 (CH3, C-14), 118.5, 124.2, 128.6, 131.7, 132.1, 133.7, 135.2 (CH, C-
aromatic), 127.1, 132.3, 135.0, 138.5, 139.8 (C, C-aromatic), 168.2 (C, C-13).  
UPLC-MS: Rt 2.46 (100%) MS (ESI)+: 362.1 [M+H]+. 
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Methyl 2-((2,4-dichlorophenyl)sulfonamido)benzoate (27) 
(C14H11Cl2NO4S; M.W.=360.2) 
 
Reagent: 2,4-dichlorobenzensulfonyl chloride (7) (0.3 g, 1.22 mmol); 
Reagent: methyl anthranilate (18) (0.15 g, 1.01 mmol); 
General procedure 2; 
White solid; 
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.40; 
Purification: Recrystallisation from EtOH; 
Yield: 0.247 g (68%); 
1H-NMR (DMSO-D6), δ: 3.88 (s, 3H, H-14), 7.15-7.20 (m, 1H, H-aromatic), 7.38 (d, J= 8.2 Hz, 1H, H-
aromatic), 7.52-7.56 (m, 1H, H-aromatic), 7.68 (dd, J1= 8.5 Hz, J2= 1.9 Hz, 1H, H-aromatic), 7.90-7.91 
(m, 1H, H-aromatic), 7.93 (d, J= 8.2 Hz, 1H, H-aromatic), 8.17 (d, J= 8.5 Hz, 1H, H-aromatic), 11.07 
(bs, 1H, NH).  
13C-NMR (DMSO-D6), δ: 53.3 (CH3, C-14), 118.1, 124.2, 128.6, 131.7, 132.1, 133.7, 135.3 (CH, C-
aromatic), 118.5, 132.3, 135.2, 138.5, 139.8 (C, C-aromatic), 168.1 (C, C-13). 
UPLC-MS: Rt 2.46 (>99%) MS (ESI)+: 362.1 [M+H]+. 
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Methyl 2-((2,4,-dimethylphenyl)sulfonamido)benzoate (28) 
(C16H17NO4S; M.W.= 319.4) 
 
Reagent: 2,4-dimethylbenzensulfonyl chloride (8) (0.3 g, 1.46 mmol); 
Reagent: methyl anthranilate (18) (0.18 g, 1.22 mmol); 
General procedure 2; 
White solid; 
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.48; 
Purification: Recrystallisation from EtOH; 
Yield: 0.215 g (55%); 
1H-NMR (DMSO-D6), δ: 2.30 (s, 3H, H-8), 2.51 (s, 3H, H-7), 3.87 (s, 3H, H-15), 7.09-7.14 (m, 1H, H-
aromatic), 7.20-7.23 (m, 2H, H-aromatic), 7.31 (d, J= 8.3 Hz, 1H, H-aromatic), 7.50-7.55 (m, 1H, H-
aromatic), 7.78 (d, J= 8.3 Hz, 1H, H-aromatic), 7.89-7.91 (m, 1H, H-aromatic), 10.73 (bs, 1H, NH). 
13C-NMR (DMSO-D6), δ: 19.7 (CH3, C-8), 21.2 (CH3, C-7), 53.2 (CH3, C-15), 118.3, 123.5, 127.4, 130.3, 
131.6, 133.9. 135.1 (CH, C-aromatic), 116.2, 134.2, 137.0, 139.5, 144.6 (C, C-aromatic), 168.4 (C, C- 
14). 
UPLC-MS: Rt 2.39 (100%) MS (ESI)+: 320.2 [M+H]+. 
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Methyl 2-((2,5-dimethylphenyl)sulfonamido)benzoate (29) 
(C16H17NO4S; M.W.= 319.4) 
 
Reagent: 2,5-dimethylbenzensulfonyl chloride (9) (0.3 g, 1.46 mmol); 
Reagent: methyl anthranilate (18) (0.18 g, 1.22 mmol); 
General procedure 2; 
White solid; 
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.51; 
Purification: Recrystallisation from EtOH; 
Yield: 0.183 g (47%); 
1H-NMR (DMSO-D6), δ: 2.33 (s, 3H, H-8), 2.49 (s, 3H, H-7), 3.87 (s, 3H, H-15), 7.11-7.15 (m, 1H, H-
aromatic), 7.28 (d, J= 7.7 Hz, 1H, H-aromatic), 7.33 (d, J= 7.7 Hz, 1H, H-aromatic), 7.39-7.40 (m, 1H, 
H-aromatic), 7.52-7.56 (m, 1H, H-aromatic), 7.81 (s, 1H, H-6), 7.89-7.92 (m, 1H, H-aromatic), 10.71 
(bs, 1H, NH). 
13C-NMR (DMSO-D6), δ: 19.4 (CH3, C-8), 20.7 (CH3, C-7), 53.2 (CH3, C-15), 118.5, 123.6, 130.3, 131.59, 
133.2, 134.7, 135.2 (CH, C-aromatic), 116.4, 134.0, 136.5, 136.9, 139.4 (C, C-aromatic), 168.4 (C, C-
14). 
UPLC-MS: Rt 2.39 (100%) MS (ESI)+: 342.1 [M+Na]+. 
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Methyl 2-(2,5-dichlorophenyl)sulfonamido)benzoate (30) 
(C14H11Cl2NO4S; M.W.= 360.2) 
 
Reagent: 2,5-dichlorobenzensulfonyl chloride (10) (0.3 g, 1.22 mmol); 
Reagent: methyl anthranilate (18) (0.15 g, 1.01 mmol); 
General procedure 2; 
White solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.45; 
Purification: Recrystallisation from EtOH; 
Yield: 0.205 g (56%); 
1H-NMR (DMSO-D6), δ: 3.88 (s, 3H, H-14), 7.15-7.20 (m, 1H, H-aromatic), 7.42 (d, J= 8.1 Hz, 1H, H-
aromatic), 7.55-7.59 (m, 1H, H-aromatic), 7.71 (d, J= 8.5 Hz, 1H, H-3), 7.78 (dd, J1= 8.5 Hz, J2= 2.4 Hz, 
1H, H-4), 7.91-7.94 (m, 1H, H-aromatic), 8.14 (d, J= 2.4 Hz, 1H, H-6), 11.08 (bs, 1H, NH). 
13C-NMR (DMSO-D6), δ: 53.3 (CH3, C-14), 119.0, 124.4, 131.4, 131.7, 134.3, 135.3, 135.5 (CH, C-
aromatic), 117.5, 129.8, 132.9, 137.7, 138.2 (C, C-aromatic), 168.1 (C, C-13). 
UPLC-MS: Rt 2.43 (100%) MS (ESI)-: 358.0 [M-H]-. 
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Methyl 2-((4-(tert-butyl)phenyl)sulfonamido)benzoate (31) 
(C18H21NO4S; M.W.= 347.4) 
 
Reagent: 4-(tert-butyl) benzenesulfonyl chloride (11) (0.3 g, 1.26 mmol); 
Reagent: methyl anthranilate (18) (0.16 g, 1.05 mmol); 
General procedure 2; 
White solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.45; 
Purification: Recrystallisation from EtOH; 
Yield: 0.270 g (74%); 
1H-NMR (DMSO-D6), δ: 1.26 (s, 9H, 3xCH3, H-8,9,10), 3.81 (s, 3H, H-18), 7.16-7.20 (m, 1H, H-
aromatic), 7.50 (m, 1H, H-aromatic), 7.56-7.70 (m, 3H, H-aromatic), 7.73 (m, 2H, H-aromatic), 7.85 
(dd, J1= 7.9 Hz, J2= 1.3 Hz, 1H, H-aromatic), 10.43 (bs, 1H, NH). 
13C-NMR (DMSO-D6), δ: 31.1 (3xCH3, C-8,9,10), 53.1 (CH3, C-18), 120.2, 124.2, 126.7, 127.2, 131.4, 
134.9 (CH, C-aromatic), 35.4 (C, C-7), 118.1, 136.4, 139.2, 157.0 (C, C-aromatic), 168.0 (C, C-17). 
UPLC-MS: Rt 2.53 (100%) MS (ESI)+: 348.2 [M+H]+. 
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Methyl 2-((3,5-bis(trifluoromethyl)phenyl)sulfonamide)benzoate (32) 
(C16H11F6NO4S; M.W.= 427.32) 
 
Reagent: 3,5-bis(trifluoromethyl)benzenesulfonyl chloride (12) (0.1 g, 0.32 mmol); 
Reagent: methyl anthranilate (18) (0.04 g, 0.26 mmol); 
General procedure 2; 
White solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.39; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-DCM 100:0 increasing to n-hexane-DCM 20:80 in 15CV); 
Yield: 0.096 g (70%); 
1H-NMR (CDCl3), δ: 3.88 (s, 3H, H-16), 7.16-7.19 (m, 1H, H-aromatic), 7.55-7.19 (m, 1H, H-aromatic), 
7.75 (dd, J1= 8.3 Hz, J2= 1.0 Hz, 1H, H-aromatic), 7.94-7.06 (m, 1H, H-aromatic), 8.00-8.03 (m, 1H, H-
aromatic), 8.25-8.27 (m, 2H, H-aromatic), 10.74 (bs, 1H, NH). 
13C-NMR (CDCl3), δ:  52.7 (CH3, C-16), 120.5, 124.5, 126.4, 127.5, 131.4, 132.6, 134.8 (CH, C-
aromatic), 117.0, 120.5, 124.5, 127.4, 131.4, 139.1, 141.9 (C, C-aromatic), 168.2 (C, C-15). 
19F-NMR (CDCl3), δ: -63.02, (s, 2x3F). 
UPLC-MS: Rt 2.53 (>98%) MS (ESI)-: 426.2 [M-H]-. 
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Methyl 2-((phenylmethyl)sulfonamido)benzoate (33) 
(C15H15NO4S; M.W.= 305.35) 
 
Reagent: phenylmethanesulfonyl chloride (13) (0.200 g, 1.04 mmol); 
Reagent: methyl 2-aminobenzoate (18) (0.132 g, 0.88 mmol); 
General Procedure 2; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.42; 
Purification: Recrystallisation from EtOH; 
Yield: 0.075 g (28%) 
1H-NMR (DMSO-D6), δ: 3.82 (s, 3H, H-15), 4.69 (s, 2H, H-7), 7.19-7.22 (m, 3H, H-aromatic), 7.29-7.33 
(m, 2H, H-aromatic), 7.34-7.36 (m, 1H, H-aromatic), 7.56-7,58 (m, 1H, H-aromatic), 7.60-7.74 (m, 1H, 
H-aromatic), 7.95 (dd, J1= 7.9 Hz, J2= 1.3 Hz, 1H, H-aromatic), 10.11 (bs, 1H, NH).  
 13C-NMR (DMSO-D6), δ: 40.5 (CH3, C-15), 57.9 (CH2, C-7), 118.8, 123.4, 128.8, 128.9, 131.2, 131.5, 
135.2 (CH, C-aromatic), 116.2, 129.3, 140.5 (C, C-aromatic), 168.1 (C, C-14). 
UPLC-MS: Rt 2.23 (>98%) MS (ESI)-: 304.1 [M-H]-. 
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Methyl 2-(pyridine-3-sulfonamido)benzoate (34) 
(C13H12N2O4S; M.W.= 292.31) 
 
Reagent: pyridine-3-sulfonyl chloride (14) (0.200 g, 1.12 mmol); 
Reagent: methyl 2-aminobenzoate (18) (0.141 g, 0.93 mmol); 
General Procedure 2; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.20; 
Purification: Recrystallisation from EtOH;  
Yield: 0.217 g (79%); 
1H-NMR (DMSO-D6), δ: 3.80 (s, 3H, H-13), 7.00-7.04 (m, 2H, H-aromatic), 7.29-7.33 (m, 1H, H-
aromatic), 7.40-7.45 (m, 1H, H-aromatic), 7.66 (dd, J1= 8.4 Hz, J2= 0.9 Hz, 1H, H-aromatic), 7.86 (dd, 
J1= 8.0 Hz, J2= 1,5 Hz, 1H, H-aromatic), 8.03-8.07 (m, 1H, H-aromatic), 8.65-8.68 (m, 1H, H-aromatic), 
8.98 (s, 1H, H-2), 10.71 (bs, 1H, NH).  
 13C-NMR (DMSO-D6), δ: 52.6 (CH3, C-13), 119.4, 123.6, 123.7, 131.3, 134.7, 134.9, 148.1, 153.5 (CH, 
C-aromatic), 116.3, 136.0, 139.7 (C, C-aromatic), 168.3 (C, C-12). 
UPLC-MS: Rt 2.06 (>98%) MS (ESI)+: 293.0 [M+H]+. 
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Methyl 2-(naphthalene-2-sulfonamido)benzoate (35) 
(C18H15NO4S; M.W.= 341.38) 
 
Reagent: naphthalene-2-sulfonyl chloride (15) (0.200 g, 0.89 mmol); 
Reagent: methyl 2-aminobenzoate (18) (0.113 g, 0.74 mmol); 
General Procedure 2; 
Pink Solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.38; 
Purification: Recrystallisation from EtOH; 
 Yield: 0.171 g (68%); 
1H-NMR (CDCl3), δ: 3.86 (s, 3H, H-18), 7.01-7.04 (m, 1H, H-aromatic), 7.44-7.48 (m, 1H, H-aromatic), 
7.59-7.65 (m, 2H, H-aromatic), 7.72 (dd, J1= 8.5 Hz, J2= 0.7 Hz, 1H, H-aromatic), 7.83 (dd, J1= 8.6 Hz, 
J2= 1.8 Hz, 1H, H-aromatic), 7.87 (d, J= 8.1 Hz, 1H, H-aromatic), 7.89-7.91 (m, 2H, H-aromatic), 7.95 
(d, J= 8.1 Hz, 1H, H-aromatic), 8.48 (s, 1H, H-10), 10.80 (bs, 1H, NH).  
 13C-NMR (CDCl3), δ: 52.4 (CH3, C-18), 119.0, 122.2, 122.9, 127.5, 128.8, 128.92, 128.95, 129.3, 129.4, 
131.1, 134.5 (CH, C-aromatic), 115.9, 132.0, 134.9, 136.3, 140.42 (C, C-aromatic), 168.32 (C, C-17). 
UPLC-MS: Rt 2.37 (100%) MS (ESI)+: 342.23 [M+H]+. 
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Methyl 2-(naphthalene-1-sulfonamido)benzoate (36) 
(C18H15NO4S; M.W.= 341.38) 
 
Reagent: naphthalene-1-sulfonyl chloride (16) (0.200 g, 0.88 mmol); 
Reagent: methyl 2-aminobenzoate (18) (0.111 g, 0.73 mmol); 
General Procedure 2; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.36; 
Purification: Recrystallisation from EtOH; 
Yield: 0.144 g (48%); 
1H-NMR (CDCl3), δ: 3.85 (s, 3H, H-18), 6.94-6.97 (m, 1H, H-aromatic), 7.37-7.40 (m, 1H, H-aromatic), 
7.50-7.54 (m, 1H, H-aromatic), 7.57-7.61 (m, 1H, H-aromatic), 7.63 (dd, J1= 8.4 Hz, J2= 0.8 Hz, 1H, H-
aromatic), 7.69-7.72 (m, 1H, H-aromatic), 7.84 (dd, J1= 8.0 Hz, J2= 1.4 Hz, 1H, H-aromatic), 7.91 (d, 
J= 8.4 Hz, 1H, H-aromatic), 8.04 (d, J= 8.0 Hz, 1H, H-aromatic), 8.37 (dd, J1= 7.4 Hz, J2= 1.4 Hz, 1H, H-
aromatic), 8.74-8.76 (m, 1H, H-aromatic), 11.10 (bs, 1H, NH).  
 13C-NMR (CDCl3), δ: 52.4 (CH3, C-18), 118.0, 122.4, 123.9, 124.5, 126.9, 128.4, 128.9, 130.3, 131.0, 
134.3, 134.7 (CH, C-aromatic), 115.3, 128.0, 134.2, 140.4 (C, C-aromatic), 168.3 (C, C-17). 
UPLC-MS: Rt 2.37 (100%) MS (ESI)+: 342.2 [M+H]+. 
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Methyl 2-(cyclohexanesulfonamido)benzoate (37) 
(C14H19NO4S; M.W.= 297.37) 
 
Reagent: cyclohexanesulfonyl chloride (17) (0.2 g, 1.09 mmol); 
Reagent: methyl 2-aminobenzoate (18) (0.137 g, 0.91mmol); 
General Procedure 2; 
Colourless oil; 
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.48; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
10g, n-hexane-DCM 100:0 increasing to n-hexane-DCM 50:50 in 11CV); 
Yield: 0.070 g (26%); 
1H-NMR (DMSO-D6), δ: 1.08-1.13 (m, 2H, H-cyclohexane), 1.15-1.18 (m, 1H, H-cyclohexane), 1.50-
1.57 (m, 2H, H-cyclohexane), 1.58-1.60 (m, 1H, H-cyclohexane), 1.78-1.81 (m, 2H, H-cyclohexane), 
2.06-2.08 (m, 2H, H-cyclohexane), 2.98 (tt, J1= 12.1 Hz, J2= 3.4 Hz, 1H, H-1), 3.86 (s, 3H, H-14), 6.98-
7.01 (m, 1H, H-aromatic), 7.52-7.55 (m, 1H, H-aromatic), 7.73 (dd, J1= 8.4 Hz, J2= 0.5 Hz, 1H, H-
aromatic), 7.95-7.97 (m, 1H, H-aromatic), 10.31 (bs, 1H, NH). 
13C-NMR (DMSO-D6), δ: 52.5 (CH3, C-14), 25.0, 25.1, 26.2 (CH2, C-cyclohexane), 61.1 (CH, C-1), 117.6, 
122.1, 131.4, 134.8 (CH. C-aromatic), 114.6, 141.6 (C, C-aromatic), 168.4 (C, C- 13). 
UPLC-MS: Rt 2.35 (99%) MS (ESI)-: 296.2 [M-H]-. 
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Methyl 2-((2-chloro-5-methylphenyl)sulfonamido)benzoate (42) 
(C15H14ClNO4S; M.W.= 339.8) 
 
Reagent: 5-chloro-2-methylbenzensulfonyl chloride (40) (0.6 g, 2.66 mmol); 
Reagent: methyl anthranilate (18) (0.33 g, 2.22 mmol); 
General procedure 2; 
White solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.40; 
Purification1: Recrystallisation from EtOH; 
Purification 2: Flash column chromatography (n-hexane:EtOAc 100:0 v/v increasing to n-
hexane:EtOAc 95:5 v/v); 
Yield: 0.071 g (9%); 
1H-NMR (DMSO-D6), δ: 2.51 (s, 3H, CH3, H-7), 3.84 (s, 3H, H-15), 7.18-7.21 (m, 1H, H-aromatic), 7.38-
741 (m, 1H, H-aromatic), 7.45 (d, J= 8.2 Hz , 1H, H-5), 7.56-7.60 (m, 1H, H-aromatic), 7.64 (dd, J1= 
8.2 Hz, J2= 2.2 Hz, 1H, H-4), 7.83-7.88 (m, 1H, H-aromatic), 7.89 (d, J= 2.2 Hz, 1H, H-2), 10.71 (bs, 1H, 
NH). 
13C-NMR (DMSO-D6), δ: 19.4 (CH3, C-7), 53.2 (CH3, C-15), 120.1, 124.5, 129.1, 131.3, 133.8, 135.0, 
135.2 (CH, C-aromatic), 110.1, 131.6, 134.7, 140.3, 147.9 (C, C-aromatic), 168.1 (C, C-14). 
UPLC-MS: Rt 2.49 (99%) MS (ESI)-: 338.0 [M-H]-. 
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Methyl 2-((3-chloro-4-methylphenyl)sulfonamido)benzoate (43) 
(C15H14ClNO4S; M.W.= 339.8) 
 
Reagent: 3-chloro-4-methylbenzensulfonyl chloride (41) (0.33 g, 1.33 mmol); 
Reagent: methyl anthranilate (18) (0.17 g, 1.11 mmol); 
General Procedure 2; 
White solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.40; 
Purification1: Recrystallisation from EtOH; 
Purification 2: Flash column chromatography (n-hexane:EtOAc 100:0 v/v increasing to n-
hexane:EtOAc 9:1 v/v); 
Yield: 0.091 g (24%); 
1H-NMR (DMSO-D6), δ: 2.36 (s, 3H, CH3, H-7), 3.82 (s, 3H, H-15), 7.19-7.23 (m, 1H, H-aromatic), 7.44 
(dd, J1= 8.3 Hz, J2= 1.0 Hz, 1H, H-aromatic), 7.56-7.6 0 (m, 1H, H-aromatic), 7.61-7.62 (m, 2H, H-
aromatics), 7.81-7.82 (m, 1H, H-aromatic), 7.84-7.86 (m, 1H, H-aromatic), 10.42 (bs, 1H, NH). 
13C-NMR (DMSO-D6), δ: 19.9 (CH3, C-7), 53.0 (CH3, C-15), 121.0, 124.7, 126.5, 129.7, 130.3, 131.5, 
134.8 (CH, C-aromatic), 119.1, 137.8, 138.0, 138.5, 139.0 (C, C-aromatic), 167.8 (C, C-14). 
UPLC-MS: Rt 2.45 (100%) MS (ESI)+: 340.1 [M+H]+. 
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Isopropyl 2-((2,4-dichloro-5-methylphenyl)sulfonamido)benzoate (78) 
(C17H17Cl2NO4S; M.W.= 402.29) 
 
Reagent: 2,4-dichloro-5-methylbenzenesulfonyl chloride (1) (0.650 g, 2.50 mmol); 
Reagent: isopropyl 2-aminobenzoate  (77) (0.374 g, 2.08 mmol); 
General Procedure 2; 
White solid; 
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.6; 
Purification: Recrystallisation from EtOH; 
Yield: 0.148 g (26%); 
1H-NMR (CDCl3), δ: 1.40 (d, J= 6.3Hz, 6H, H-16,17), 2.43 (s, 3H, H-7), 5.27-5.29 (m, 1H, H-15), 7.01-
7.05 (m, 1H, H-aromatic), 7.38-7.42 (m, 1H, H-aromatic), 7.44 (s, 1H, H-6), 7.53-7.56 (m, 1H, H-
aromatic), 7.99 (dd, J1= 8.0 Hz, J2= 1.5 Hz, 1H, H-aromatic), 8.09 (s, 1H, H-3), 11.35 (bs, 1H, NH). 
 13C-NMR (CDCl3), δ: 19.6 (CH3, C-7), 21.8 (2xCH3, C-16,17), 69.6 (CH, C-15), 116.9, 122.4, 131.4, 
131.8, 133.5, 134.2 (CH, C-aromatic), 115.9, 129.9, 134.9, 135. 5, 139.6, 139.9 (C, C-aromatic), 167.2 
(C, C-14).  
UPLC-MS: Rt 2.78 (100%) MS (ESI)-: 400.1 [M-H]-. 
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N-(4-(1H-Tetrazol-5-yl)phenyl)-2,4-dichloro-5-methylbenzenesulfonamide (86) 
(C14H11Cl2N5O2S; M.W.= 383.24)  
 
Reagent: 2,4-dichloro-5-methylbenzenesulfonyl chloride (1) (0.193 g, 0.74 mmol); 
Reagent: 4-(1H-tetrazol-5-yl)aniline (85) (0.100 g, 0.62 mmol); 
General Procedure 2; 
Pink Solid; 
T.L.C. System: n-hexane-EtOAc 6:4 v/v, Rf: 0.35; 
Purification: Recrystallisation from EtOH/Water; 
Yield: 0.110 g (46%); 
1H-NMR (DMSO-D6), δ: 2.39 (s, 3H, H-7), 7.30 (d, J= 8.6 Hz, 2H, H-aromatic), 7.81 (s, 1H, H-2), 7.90 
(d, J= 8.6 Hz, 2H, H-aromatic), 8.15 (s, 1H, H-5), 11.15 (bs, 1H, NH).  
 13C-NMR (DMSO-D6), δ: 14.4 (CH3, C-7), 119.3, 128.7, 132.0, 134.0 (CH, C-aromatic), 114.8, 129.2, 
135.2, 136.5, 139.5, 139.9 (C, C-aromatic). 
UPLC-MS: Rt 1.96 (>99%) MS (ESI)+: 384.1 [M+H]+. 
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N-(4-(1H-Tetrazol-5-yl)phenyl)-3-chloro-4-methylbenzenesulfonamide (87)  
(C14H12ClN5O2S; M.W.= 349.79) 
 
Reagent: 3-chloro-4-methylbenzenesulfonyl chloride (41) (0.167 g, 0.74 mmol); 
Reagent: 4-(1H-tetrazol-5-yl)aniline (85) (0.100 g, 0.62 mmol); 
General Procedure 2; 
White Solid; 
T.L.C. System: DCM-MeOH 95:5 v/v, Rf: 0.37; 
Purification: Recrystallisation from EtOH;  
Yield: 0.040 g (28%); 
1H-NMR (DMSO-D6), δ: 2.36 (s, 3H, H-7), 7.32 (d, 2H, J= 8.3 Hz, H-aromatic), 7.56 (d, J= 7.6 Hz, 1H, 
H-5), 7.68 (d, J= 7.6 Hz, 1H, H-6), 7.82 (s, 1H, H-2), 7.92 (d, J= 8.3 Hz, 2H, H-aromatic), 10.82 (bs, 1H, 
NH).  
 13C-NMR (DMSO-D6), δ: 20.1 (CH3, C-7), 120.2, 125.8, 127.1, 128.7, 132.6 (CH, C-aromatic), 131.5, 
134.4, 138.8, 140.4, 142.0 (C, C-aromatic), 175.9 (C, C-14). 
UPLC-MS: Rt 1.86 (>99%) MS (ESI)+: 350.1 [M+H]+. 
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N-(2-(1H-tetrazol-5-yl)phenyl)-2,4-dichloro-5-methylbenzenesulfonamide (88) 
(C14H11Cl2N5O2S; M.W.= 384.24) 
 
Reagent: 2,4-dichloro-5-methylbenzenesulfonyl chloride (1) (0.193 g, 0.74 mmol); 
Reagent: 2-(1H-tetrazol-5-yl)aniline (84) (0.100 g, 0.62 mmol); 
General Procedure 2; 
Off-White Solid; 
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.29; 
Purification: Recrystallisation from EtOH;  
Yield: 0.042 g (18%); 
1H-NMR (DMSO-D6), δ: 2.39 (s, 3H, H-7), 7.28-7.32 (m, 1H, H-aromatic), 7.48-7.51 (m, 2H, H-
aromatic), 7.78 (s, 1H, H-2), 7.94-7.98 (m, 1H, H-aromatic), 8.16 (s, 1H, H-5), 11.37 (bs, 1H, NH).  
 13C-NMR (DMSO-D6), δ: 19.5 (CH3, C-7), 119.2, 124.8, 129.5, 132.1, 132.7, 134.0 (CH, C-aromatic), 
113.5, 129.1, 134.7, 135.5, 136.6, 136.8 (C, C-aromatic), 172.3 (C, C-14). 
UPLC-MS: Rt 2.26 (>97%) MS (ESI)+: 386.1 [M+H]+. 
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N-(2-(1H-tetrazol-5-yl)phenyl)-3-chloro-4-methylbenzenesulfonamide (89) 
(C14H12ClN5O2S; M.W.= 349.79) 
 
Reagent: 3-chloro-4-methylbenzenesulfonyl chloride (41) (0.167 g, 0.74 mmol); 
Reagent: 2-(1H-tetrazol-5-yl)aniline (85) (0.100 g, 0.62 mmol); 
General Procedure 2; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.29; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP 10g,  
n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 0:100 in 15CV); 
Yield: 0.034 g (16%); 
1H-NMR (DMSO-D6), δ: 2.33 (s, 3H, H-7), 7.33-7.36 (m, 1H, H-aromatic), 7.45-7.48 (m, 2H, H-
aromatic), 7.51-7.55 (m, 2H, H-aromatic), 7.66-7.68 (m, 1H, H-aromatic), 7.86-7.88 (m, 1H, H-
aromatic), 10.67 (bs, 1H, NH).  
 13C-NMR (DMSO-D6), δ: 20.1 (CH3, C-7), 122.3, 125.8, 125.9 127.3, 129.7, 132.3, 132.4 (CH, C-
aromatic), 116.6, 134.6, 135.6, 138.2, 142.1 (C, C-aromatic), 179.4 (C, C-15). 
UPLC-MS: Rt 2.15 (>99%) MS (ESI)+: 350.3 [M+H]+. 
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N-(2-(1H-tetrazol-5-yl)phenyl)-4-(trifluoromethyl)benzenesulfonamide (90) 
(C14H10F3N5O2S; M.W.= 369.32)  
 
Reagent: 4-(trifluoromethyl)benzenesulfonyl chloride (4) (0.182 g, 0.74 mmol); 
Reagent: 2-(1H-tetrazol-5-yl)aniline (85) (0.100 g, 0.62 mmol); 
General Procedure 2; 
White Solid; 
T.L.C. System: DCM-MeOH 98:2 v/v, Rf: 0.45; 
Purification: Recrystallisation from EtOH/Water; 
Yield: 0.095 g (42%); 
1H-NMR (DMSO-D6), δ: 7.36-6.39 (m, 1H, H-aromatic), 7.44 (dd; J1= 8.1 Hz, J2= 1.0 Hz, 1H, H-
aromatic), 7.52-7.55 (m, 1H, H-aromatic), 7.85 (dd, J1= 7.8 Hz, J2=  1.4 Hz, 1H, H-aromatic), 7.88-7.91 
(m, 4H, H-aromatic), 10-73 (bs, 1H, NH).  
 13C-NMR (DMSO-D6), δ: 123.0, 126.2, 126.9, 128.3, 129.9, 132.5 (CH, C-aromatic), 133.2 (d, J= 37.7 
Hz, C) 117.0, 122.6, 124.8, 135.3, 143.0 (C-aromatic). 
19F-NMR (DMSO-D6), δ: -61.76 (s, 3F). 
UPLC-MS: Rt 1.81 (100%) MS (ESI)+: 370.1 [M+H]+. 
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N-(2-(1H-tetrazol-5-yl)phenyl)naphthalene-2-sulfonamide (91) 
(C17H13N5O2S; M.W.= 351.38) 
 
Reagent: naphthalene-2-sulfonyl chloride (15) (0.169 g, 0.74 mmol); 
Reagent: 2-(1H-tetrazol-5-yl)aniline (85) (0.100 g, 0.62 mmol); 
General Procedure 2; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 5:5 v/v, Rf: 0.17; 
Purification: Recrystallisation from EtOH; 
Yield: 0.083 g (38%); 
1H-NMR (DMSO-D6), δ: 7.26-7.29 (m, 1H, H-aromatic), 7.47-7.50 (m, 1H, H-aromatic), 7.54 (d, J=8.1 
Hz, 1H, H-aromatic), 7.63-7.66 (m, 1H, H-aromatic), 7.68-7.71 (m, 2H, H-aromatic), 7.82-7.84 (m, 1H, 
H-aromatic), 7.97-8.02 (m, 2H, H-aromatic), 8.10 (d, J= 8.1 Hz, 1H, H-aromatic), 8.47 (s, 1H, H-10), 
10.78 (bs, 1H, NH). 
 13C-NMR (DMSO-D6), δ: 121.5, 122.2, 125.4, 128.26, 128.29, 128.9, 129.6, 129.73, 129.78, 129.9, 
134.8 (CH, C-aromatic), 115.2, 131.9, 132.5, 136.0, 136.1(C, C-aromatic). 
UPLC-MS: Rt 2.07 (100%) MS (ESI)+: 352.1 [M+H]+. 
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N-(2-(1H-tetrazol-5-yl)phenyl)quinoline-8-sulfonamide (92) 
(C16H12N6O2S; M.W.= 352.37) 
Reagent: quinoline-8-sulfonyl chloride  (62) (0.170 g, 0.74 mmol); 
Reagent: 2-(1H-tetrazol-5-yl)aniline (85) (0.100 g, 0.62 mmol); 
General Procedure 2; 
Off-White Solid; 
T.L.C. System: n-hexane-EtOAc 5:5 v/v, Rf: 0.63; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP 25g,  
n-hexane-EtOAc 0:100 increasing to n-hexane-EtOAc 50:50 in 15CV); 
Yield: 0.056 g (26%); 
1H-NMR (DMSO-D6), δ: 7.11-7.14 (m, 1H, H-aromatic), 7.39-7.42 (m, 1H, H-aromatic), 7.55-7.58 (m, 
1H, H-aromatic), 7.72-7.76 (m, 3H, H-aromatic), 8.26-8.28 (m, 1H, H-aromatic), 8.41-8.44 (m, 2H, H-
aromatic), 8.48-8.49 (m, 1H, H-aromatic), 11.23 (bs, 1H, NH). 
 13C-NMR (DMSO-D6), δ: 112.9, 118.6, 123.1, 124.1, 128.3, 129.3, 132.4, 134.4, 136.5, 151.3 (CH, C-
aromatic), 126.1, 134.4, 137.4, 142.6 (C, C-aromatic). 
UPLC-MS: Rt 1.65 (>96%) MS (ESI)+: 353.3 [M+H]+. 
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N-(2-(1H-tetrazol-5-yl)phenyl)isoquinoline-4-sulfonamide (93) 
(C16H12N6O2S; M.W.= 352.37) 
 
Reagent: quinoline-3-sulfonyl chloride (63) (0.100 g, 0.43 mmol); 
Reagent: 2-(1H-tetrazol-5-yl)aniline (85) (0.069 g, 0.43 mmol); 
General Procedure 2; 
Brown Solid; 
T.L.C. System: DCM-MeOH 98:2 v/v, Rf: 0.15; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, DCM-MeOH 100:0 increasing to DCM-MeOH 95:5 in 10CV); 
Yield: 0.069 g (46%); 
1H-NMR (DMSO-D6), δ: 7.05-7.08 (m, 1H, H-aromatic), 7.21-7.25 (m, 1H, H-aromatic), 7.64 (d, J= 8.2 
Hz, 1H, H-aromatic), 7.69-7.72 (m, 1H, H-aromatic), 7.88-7.91 (m, 1H, H-aromatic), 8.01 (d, J= 8.5 
Hz, 1H, H-aromatic), 8.03-8.05 (m, 1H, H-aromatic), 8.09-8.11 (m, 1H, H-aromatic), 8.89 (s, 1H, H-3), 
8.97 (s, 1H, H-2), 13.23 (bs, 1H, NH). 
13C-NMR (DMSO-D6), δ: 118.8, 124.3, 127.7, 128.6, 128.8, 129.2, 130.0, 133.2, 137.0, 146.4 (CH, C-
aromatic), 120.5, 126.2, 134.9, 146.4, 148.7 (C, C-aromatic), 159.6 (C, C- 16). 
UPLC-MS: Rt 1.85 (100%) MS (ESI)+: 353.1 [M+H]+. 
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9.2.3 Arylsulfonyl chlorides (40-41) 
5-Chloro-2-methylbenzensulfonyl chloride (40) (23) 
(C7H6Cl2O2S; M.W.= 225.1) 
 
Reagent: 4-chlorotoluene (38) (1.0 g, 8.1 mmol); 
General Procedure 3; 
Pink oil; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.52; 
Yield: 0.640 g (35%); 
1H-NMR (CDCl3), δ: 2.58 (s, 3H, CH3, H-7), 7.39 (d, J= 8.2 Hz, 1H, H-3), 7.52 (dd, J1= 8.2 Hz, J2= 2.1 Hz, 
1H, H-4), 8.09 (d, J= 2.1 Hz, 1H, H-6). 
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3-Chloro-4-methylbenzenesulfonyl chloride (41) (24) 
(C7H6Cl2O2S; M.W.= 225.1) 
 
Reagent: 2-chlorotoluene (39) (1.0 g, 8.1 mmol); 
General Procedure 2; 
White Solid; 
T.L.C. System: n-hexane-EtOAcg 8:2 v/v, Rf: 0.57; 
Yield: 0. 351 g (19%); 
1H-NMR (CDCl3), δ: 2.43 (s, 3H, CH3, H-7), 7.51 (d, J= 8.5 Hz, 1H, H-3), 7.73 (dd, J1= 8.5 Hz, J2= 2.2 Hz, 
1H, H-2), 7.83 (d, J= 2.2 Hz, 1H, H-6). 
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9.2.4 Alkyl(arylsulfonamido)benzoates (50-57) 
Ethyl 2-((2,4-dichloro-5-methylphenyl)sulfonamido)benzoate (50) 
(C16H15Cl2NO4S; M.W.= 388.26) 
 
Reagent: ethyl 2-aminobenzoate (44) (0.2 g, 0.77 mmol); 
Reagent: 2,4-dichloro-5-methylbenzenesulfonyl chloride (50) (0.106 g, 0.642 mmol); 
General Procedure 4; 
Pink solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.75; 
Purification: Recrystallisation from EtOH; 
Yield: 0.106 g (43%); 
1H-NMR (DMSO-D6), δ: 1.33 (t, J= 7.1 Hz, 3H, H-9), 2.39 (s, 3H, H-16), 4.36 (q, J= 7.1 Hz, 2H, H-8), 
7.14-7.18 (m, 1H, H-aromatic), 7.40-7.42 (m, 1H, H-aromatic), 7.52-7.56 (m, 1H, H-aromatic), 7.83 
(s, 1H, H-aromatic), 7.95 (dd, J1= 7.0 Hz, J2= 1.0 Hz, 1H, H-aromatic), 8.19 (s, 1H, H-aromatic), 11.10 
(bs, 1H, NH). 
13C-NMR (DMSO-D6), δ: 14.3 (CH3), 19.5 (CH3), 62.3 (CH2, C-8), 118.0, 124.0, 131.7, 132.1, 134.1, 
134.5 (CH, C-aromatic), 116.7, 129.0, 135.3, 136.7, 138.7, 140.0 (C, C-aromatic), 167.8 (C, C-7) ppm.   
UPLC-MS: Rt 2.69 (100%) MS (ESI)-: 386.2 [M-H]-. 
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Ethyl 3-((4-(trifluoromethyl)phenyl)sulfonamido)benzoate (51) 
(C16H14F3NO4S; M.W.= 373.35) 
 
Reagent: ethyl 3-aminobenzoate (45) (0.150 g, 0.91 mmol); 
Reagent: 4-(trifluoromethyl)benzenesulfonyl chloride (4) (0.269 g, 1.1 mmol); 
General Procedure 4; 
Beige solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.3; 
Purification: Recrystallisation from EtOH; 
Yield: 0.222 g (65%); 
1H-NMR (DMSO-D6), δ: 1.29 (t, J= 7,1 Hz, 3H, H-9), 4.28 (q, J= 7.1Hz, 2H, H-8), 7.37-7.44, (m, 2H, H-
aromatic), 7.64-7.67 (m, 1H, H-aromatic), 7.69-7.70 (m, 1H, H-aromatic), 7.95-7.99 (m, 4H, H-
aromatic), 10.77 (bs, 1H, NH). 
 13C-NMR (DMSO-D6), δ: 14. 5 (CH3, C-9), 61.4 (CH2, C-8), 121.1, 125.3, 125.6, 127.16, 127.18, 128.1 
(CH, C-aromatic), 130.3, 131.4, 133.0, 138.0, 143.5 (C, C-aromatic), 165.5 (C, C-7). 
 19F-NMR (DMSO-D6), δ: -61.72 (s, 3F). 
UPLC-MS: Rt 2.26 (100%) MS (ESI)-: 372.1 [M-H]-. 
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Methyl 2-((4-iodophenyl)sulfonamido)benzoate (52) 
(C14H12INO4S; M.W.= 417.22) 
 
Reagent: methyl 3-aminobenzoate (18) (0.360 g, 1.19 mmol); 
Reagent: 4-iodobenzenesulfonyl chloride (46) (0.150 g, 0.99 mmol); 
General Procedure 4; 
Beige solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.55; 
Purification: Recrystallisation from EtOH; 
Yield: 0.104 g (25%); 
1H-NMR (DMSO-D6), δ: 3.81 (s, 3H, H-8), 7.20-7.24 (m, 1H, H-aromatic), 7.42-7.44 (m, 1H, H-
aromatic), 7.53 (d, J= 8.6 Hz, 2H, H-aromatic), 7.68-7.60 (m, 1H, H-aromatic), 7.85 (dd, J1= 6.5 Hz, 
J2= 1.5 Hz, 1H, H-aromatic), 7.95 (d, J= 8.6 Hz, 2H, H-aromatic), 10.41 (bs, 1H, NH).  
13C-NMR (DMSO-D6), δ: 53.1 (CH3, C-8), 121.2, 124.9, 128.9, 131.5, 134.8, 138.8 (CH, C-aromatic), 
102.4, 119.4, 138.3, 138.9 (C, C-aromatic), 167.8 (C, C-7). 
UPLC-MS: Rt 2.39 (100%) MS (ESI)+: 418.1 [M+H]+. 
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Methyl 3-((4-iodophenyl)sulfonamido)benzoate (53) 
(C14H12INO4S; M.W.= 417.22) 
 
Reagent: methyl 2-aminobenzoate (19) (0.062 g, 0.41 mmol); 
Reagent: 4-iodobenzenesulfonyl chloride (46) (0.150 g, 0.50 mmol); 
General Procedure 4; 
White solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.44; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 60:40 in 10CV); 
Yield: 0.02 g (12%); 
1H-NMR (CDCl3), δ: 3.84 (s, 3H, H-8), 6.79 (bs, 1H, NH), 7.27-7.30 (m, 1H, H-aromatic), 7.31-7.33 (m, 
1H, H-aromatic), 7.40 (d, J= 8.5 Hz, 2H, H-aromatic), 7.61-7.62 (m, 1H, H-aromatic), 7.72 (d, J= 8.5 
Hz 2H, H-aromatic), 7.73-7.75 (m, 1H, H-aromatic).  
13C-NMR (CDCl3), δ: 52.5 (CH3, C-8), 125.7, 126.7, 128.5, 128.8, 129.6, 138.4 (CH, C-aromatic), 100.9, 
131.5, 136.5, 138.5 (C, C-aromatic), 166.2 (C, C-7). 
UPLC-MS: Rt 2.16 (>99%) MS (ESI)+: 418.1 [M+H]+. 
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Ethyl 2-((3-chloro-2-methylphenyl)sulfonamido)benzoate (54) 
(C16H16ClNO4S; M.W.= 353.82) 
 
Reagent: ethyl 2-aminobenzoate (44) (0.150 g, 0.66 mmol); 
Reagent: 3-chloro-2-methylbenzenesulfonyl chloride (47) (0.092 g, 0.55 mmol); 
General Procedure 4; 
White solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.58; 
Purification1: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-EtOAc 100:0  increasing to n-hexane-EtOAc 60:40 in 10CV); 
Purification2: Recrystallisation from EtOH  
Yield: 0.076 g (40%); 
1H-NMR (DMSO-D6), δ: 1.31 (t, J= 7.1 Hz, 3H, H-9), 2.60 (s, 3H, H-16), 4.32 (q, J= 7.1 Hz, 2H, H-8), 
7.16-7.20 (m, 1H, H-aromatic), 7.35-7.37 (m, 1H, H-aromatic), 7.41-7.45 (m, 1H, H-aromatic), 7.52-
7.56 (m, 1H, H-aromatic), 7.75-7.77 (m, 1H, H-aromatic), 7.90 (dd, J1= 6.8 Hz, J2= 1.1 Hz, 1H, H-
aromatic), 7.95-7.97 (m, 1H, H-aromatic), 10.82 (bs, 1H, NH). 
 13C-NMR (DMSO-D6), δ: 14.3 (CH3), 16.8 (CH3), 62.1 (CH2, C-8), 119.6, 124.3, 128.1, 129.2, 131.5, 
134.8, 134.9 (CH, C-aromatic), 117.9, 136.5, 136. 6, 138.8, 139.5 (C, C-aromatic), 167.7 (C, C-7). 
UPLC-MS: Rt 2.57 (>95%) MS (ESI)+: 354.8 [M+H]+. 
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Ethyl 3-((3-chloro-2-methylphenyl)sulfonamido)benzoate (55) 
(C16H16ClNO4S; M.W.= 353.82) 
 
Reagent: ethyl 3-aminobenzoate (45) (0.150 g, 0.66 mmol); 
Reagent: 3-chloro-2-methylbenzenesulfonyl chloride (47) (0.092 g, 0.55 mmol); 
General Procedure 4; 
Pink solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.38; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-EtOAc 60:40 increasing to n-hexane-EtOAc 60:40 in 10CV); 
Yield: 0.161 g (82%); 
1H-NMR (CDCl3), δ: 1.30 (t, J= 7.1 Hz, 3H, H-9), 2.65 (s, 3H, H-16), 4.29 (q, J= 7.1 Hz, 2H, H-8), 6.99 
(bs, 1H, NH), 7.14-7.17 (m, 1H, H-aromatic), 7.22-7.26 (m, 2H, H-aromatic), 7.49 (dd, J1= 7.0 Hz, J2= 
1.1 Hz, 1H, H-aromatic), 7.60-7.61 (m, 1H, H-aromatic), 7.67-7.71 (m, 1H, H-aromatic), 7.88 (dd, J1= 
6.8 Hz, J2= 1.1 Hz, 1H, H-aromatic). 
 13C-NMR (CDCl3), δ: 14.2 (CH3), 16.9 (CH3), 61.5 (CH2), 121.2, 124.2, 125.9, 126.6, 128.7, 131.7, 
134.2 (CH, C-aromatic), 129.5, 135.2, 136.6, 137.2, 139.3 (C, C-aromatic), 165.9 (C, C-7). 
UPLC-MS: Rt 2.27 (>99%) MS (ESI)+: 354.2 [M+H]+. 
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Methyl 2-((p-tolylmethyl)sulfonamido)benzoate (56) 
(C16H17NO4S; M.W.= 319.38) 
 
Reagent: p-tolylmethanesulfonyl chloride (48) (0.200 g, 0.97 mmol); 
Reagent: methyl 2-aminobenzoate (18) (0.070 g, 0.44 mmoll); 
General Procedure 4; 
White Solid; 
T.L.C. System: n-hexane:EtOAc 8:2 v/v, Rf: 0.46; 
Purification1: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 60:40 in 15CV); 
Purification 2: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 
5g, n-hexane-DCM 100:0 increasing to n-hexane-DCM 0:100 in 15CV); 
Yield: 0.019 g (15%); 
1H-NMR (CDCl3), δ: 2.34 (s, 3H, H-7), 3.85 (s, 3H, H-16), 4.37 (s, 2H, H-8), 7.06-7.14 (m, 5H, H-
aromatic), 7.50-7.53 (m, 1H, H-aromatic), 7.73-7.75 (m, 1H, H-aromatic), 8.02 (dd, J1= 7.9 Hz, J2= 1.6 
Hz, 1H, H-aromatic), 10.28 (bs, 1H, NH). 
13C-NMR (CDCl3), δ: 21.1 (CH3, C-7), 52.4 (CH3, C-16), 58.0 (CH2, C-8), 118.0, 122.6, 129.4, 130.5, 
131.3, 134.7 (CH, C-aromatic), 115.4, 125.1, 138.7, 141.0 (C-aromatic), 167.9 (C, C- 15). 
UPLC-MS: Rt 2.30 (100%) MS (ESI)-: 318.0 [M-H]-. 
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Methyl 2-(furan-2-sulfonamido)benzoate (57) 
(C12H11NO5S; M.W.= 281.28) 
 
Reagent: furan-2-sulfonyl chloride (49) (0.250 g, 1.80 mmol); 
Reagent: methyl 2-aminobenzoate (18) (0.226 g, 1.5 mmol); 
General Procedure 4; 
Pink solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.3; 
Purification: Recrystallisation from EtOH; 
Yield: 0.280 g (57%); 
1H-NMR (DMSO-D6), δ: 3.84 (s, 3H, H-12), 6.65 (dd, J1= 3.5 Hz, J2= 1.7 Hz, 1H, H-aromatic), 7.24-7.27 
(m, 2H, H-aromatic), 7.49 (dd, J1= 8.2 Hz, J2= 0.6 Hz, 1H, H-aromatic), 7.60-7.63 (m, 1H, H-aromatic), 
7.89 (dd, J1= 7.8, J2= 1.3 Hz, 1H, H-aromatic), 7.96-7.98 (m, 1H, H-aromatic), 10.62 (bs, 1H, NH). 
13C-NMR (DMSO-D6), δ: 53.1 (CH3, C-12), 112.2, 118.6, 121.3, 125.0, 131.4, 134.7, 148.6 (CH, C-
aromatic), 119.6, 137.9, 147.1 (C-aromatic), 167.9 (C, C- 11). 
UPLC-MS: Rt 2.10 (100%) MS (ESI)+: 282.0 [M+H]+. 
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9.2.5 Arylsulfonamido benzoic acids (69-70) 
2-((3-Chloro-4-methylphenyl)sulfonamido)benzoic acid (69) 
(C14H12ClNO4S; M.W.= 325.76) 
 
Reagent: 2-aminobenzoic acid (2) (0.150 g, 1.11 mmol); 
Reagent: 3-chloro-4-methylbenzenesulfonyl chloride (41) (0.300 g, 1.33 mmol); 
General Procedure 5; 
Brown solid; 
T.L.C. System: DCM-MeOH 9:1 v/v, Rf: 0.28; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, DCM-MeOH 100:0 increasing to DCM-MeOH 80:20 in 15CV); 
Yield: 0.220 g (61%); 
1H-NMR (DMSO-D6), δ: 2.34 (s, 3H, H-14), 6.79-6.82 (m, 1H, H-aromatic), 7.19-7.23 (m, 1H, H-
aromatic), 7.30 (d, J= 7.9 Hz, 1H, H-aromatic), 7.51 (d, J= 7.9 Hz, 1H, H-aromatic), 7.55-7.57 (m, 1H, 
H-aromatic), 7.73-7.74 (m, 1H, H-aromatic), 7.84-7.86 (m, 1H, H-aromatic), 11.07 (bs, 1H, NH), 13.11 
(bs, 1H, OH). 
 13C-NMR (DMSO-D6), δ: 14.5 (CH3, C-14), 117.4, 120.2, 125.9, 129.3, 129.8, 131.3, 132.2 (CH, C-
aromatic), 121.8, 136.8, 137.0, 141.7, 144.9 (C, C-aromatic), 170.0 (C, C-7) ppm. 
UPLC-MS: Rt 2.18 (>96%) MS (ESI)+: 326.1 [M+H]+. 
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2-((4-(Pentafluorosulfanyl)phenyl)sulfonamido)benzoic acid (70) 
(C13H10F5NO4S2; M.W.= 403.34) 
 
Reagent: 2-aminobenzoic acid (2) (0.057 g, 0.41 mmol); 
Reagent: 4-(pentafluorosulfanyl)benzenesulfonyl chloride (68) (0.150 g, 0.49 mmol); 
General Procedure 5; 
Brown solid; 
T.L.C. System: n-hexane-EtOAc 2:8 v/v, Rf: 0.58; 
Yield: 0.066 g (40%); 
1H-NMR (DMSO-D6), δ: 7.17-7.21 (m, 1H, H-aromatic), 7.47-7.50 (m, 1H, H-aromatic), 7.56-7.60 (m, 
1H, H-aromatic), 7.92 (dd, J1= 7.9 Hz, J2= 1.6 Hz, 1H, H-aromatic), 8.04 (d, J= 8.8 Hz, 2H, H-aromatic), 
8.13 (d, 8.8 Hz, 2H, H-aromatic), 11.30 (bs, 1H, NH), 13.88 (bs, 1H, OH). 
 13C-NMR (DMSO-D6), δ: 119.6, 124.5, 127.8, 128.7, 132.0, 134.9 (CH, C-aromatic), 118.3, 139.3, 
142.9, 156.0 (C, C-aromatic), 169.9 (C, C-7). 
 19F-NMR (DMSO-D6), δ: 63.34 (d, J=151.6 Hz, 4F), 84.64 (m, 1F). 
UPLC-MS: Rt 2.24 (>96%) MS (ESI)-: 402.1 [M-H]-. 
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9.2.6 Arylsulfonamido benzoic acid (72-76) 
2-(Pyridine-3-sulfonamido)benzoic acid (72) 
(C12H10N2O4S; M.W.= 278.28) 
 
Reagent: methyl 2-(pyridine-3-sulfonamido)benzoate  (34) (0.1 g, 0.34 mmol); 
General Procedure 6; 
Off-White Solid; 
T.L.C. System: n-hexane-EtOAc 6:4 v/v, Rf: 0.20; 
Purification: Recrystallisation from EtOH/Water; 
Yield: 0.030 g (30%); 
1H-NMR (DMSO-D6), δ: 7.17-7.20 (m, 1H, H-aromatic), 7.52-7.54 (m, 1H, H-aromatic), 7.57-7.59 (m, 
1H, H-aromatic), 7.60-7.62 (m, 1H, H-aromatic), 7.90 (dd, J1= 7.9 Hz, J2= 1.5 Hz, 1H, H-aromatic), 
8.19-8.22 (m, 1H, H-aromatic), 8.80-8.82 (m, 1H, H-aromatic), 8.95-8.97 (m, 1H, H-aromatic), 11.23 
(bs, 1H, NH), 13.60 (bs, 1H, OH). 
13C-NMR (DMSO-D6), δ: 119.8, 124.4, 124.9, 132.0, 134.9, 135.4, 147.7, 154.4 (CH, C-aromatic), 
118.3, 125.6, 135.6 (C, C-aromatic), 169.93(C, C- 12). 
UPLC-MS: Rt 1.66 (99%) MS (ESI)+: 278.9 [M+H]+. 
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2-(Naphthalene-2-sulfonamido)benzoic acid (73) 
(C17H13NO4S; M.W.= 327.35) 
 
Reagent: methyl 2-(naphthalene-2-sulfonamido)benzoate (35) (0.080 g, 0.23 mmol); 
General Procedure 6; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.20; 
Yield: 0.051 g (68%); 
1H-NMR (DMSO-D6), δ: 7.07-7.11 (m, 1H, H-aromatic), 7.51-7.55 (m, 1H, H-aromatic), 7.57-7.59 (m, 
1H, H-aromatic), 7.66-7.69 (m, 1H, H-aromatic), 7.70-7.74 (m, 1H, H-aromatic), 7.76-7.79 (m, 1H, H-
aromatic)  7.87 (d, J= 8.0 Hz, 1H, H-aromatic), 8.01 (d, J= 8.0 Hz, 1H, H-aromatic), 8.09 (d, J= 8.7 Hz, 
1H, H-aromatic), 8.17 (d, J= 8.2 Hz, 1H, H-aromatic), 8.60 (s, 1H, H-10), 11.28 (bs, 1H, NH), 14.00 (bs, 
1H, OH).  
 13C-NMR (DMSO-D6), δ: 118.8, 122.2, 123.8, 128.30, 128.34, 129.0, 129.81, 129.85, 130.2, 131.9, 
134.9 (CH, C-aromatic), 117.1, 132.0, 134.9, 136.0, 140.2 (C, C-aromatic), 170.2 (C, C-17). 
UPLC-MS: Rt 2.12 (100%) MS (ESI)+: 328.1 [M+H]+. 
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2-(Naphthalene-1-sulfonamido)benzoic acid (74) 
(C17H13NO4S; M.W.= 327.35) 
 
Reagent: methyl 2-(naphthalene-1-sulfonamido)benzoate (36) (0.070 g, 0.2 mmol); 
General Procedure 6; 
Yellow Solid; 
T.L.C. System: n-hexane-EtOA: 6:4 v/v, Rf: 0.10; 
Yield: 0.059 g (90%); 
1H-NMR (DMSO-D6), δ: 7.04-7.09 (m, 2H, H-aromatic), 7.48-7.53 (m, 2H, H-aromatic), 7.69-7.74 (m, 
1H, H-aromatic), 7.76-7.80 (m, 1H, H-aromatic), 7.86 (d, J= 7.8 Hz, 1H, H-aromatic), 8.14 (d, J= 8.1 
Hz, 1H, H-aromatic), 8.31 (d, J= 7.8 Hz, 1H, H-aromatic), 8.40 (d, J= 7.2  Hz, 1H, H-aromatic), 8.59 (d, 
J= 8.6 Hz, 1H, H-aromatic), 11.82 (bs, 1H, NH), 14.20 (bs, 1H, OH).  
 13C-NMR (DMSO-D6), δ: 117.5, 123.2, 123.8, 124.9, 127.4, 127.6, 128.9, 131.0, 131.9, 134.9, 135.59 
(CH, C-aromatic), 116.1, 129.8, 134.2, 140.5, 142.0 (C, C-aromatic), 170.3 (C, C-17). 
UPLC-MS: Rt 2.09 (100%) MS (ESI)+: 328.1 [M+H]+. 
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2-(Cyclohexanesulfonamido)benzoic acid (75) 
(C13H17NO4S; M.W.= 283.34) 
 
Reagent: methyl 2-(cyclohexanesulfonamido)benzoate (37) (0.050 g, 0.16 mmol); 
General Procedure 6; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.20; 
Purification: Recrystallisation from DCM/n-hexane; 
Yield: 0.011 g (26%) 
1H-NMR (DMSO-D6), δ: 1.08-1.14 (m, 1H, H-cyclohexane), 1.17-1.26 (m, 2H, H-cyclohexane), 1.38-
1.49 (m, 2H, H-cyclohexane), 1.53-1.60 (m, 1H, H-cyclohexane), 1.74-1.77 (m, 2H, H-cyclohexane), 
1.97-2.00 (m, 2H, H-cyclohexane), 3.19-3.25 (m, 1H, H-1), 7.13-7.17 (m, 1H, H-aromatic), 7.58-7.62 
(m, 1H, H-aromatic), 7.64 (dd, J1= 8.3 Hz, J2= 0.9 Hz, 1H, H-aromatic), 8.01 (dd, J1= 7.9 Hz, J2= 1.4 Hz, 
1H, H-aromatic), 11.01 (bs, 1H, NH). 
13C-NMR (DMSO-D6), δ: 26.4, 25.0, 26.28(CH2, C-cyclohexane), 60.0 (CH, C-1), 117.8, 122.8, 132.1, 
135.0 (CH. C-aromatic), 132.2, 141.5 (C, C-aromatic), 170.5 (C, C- 13). 
UPLC-MS: Rt 2.04 (>99%) MS (ESI)-: 282.1 [M-H]-. 
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2-(Furan-2-sulfonamido)benzoic acid (76) 
(C11H9NO5S; M.W.= 267.02) 
 
Reagent: methyl 2-(furan-2-sulfonamido) benzoate (38) (0.150 g, 0.53 mmol); 
General Procedure 6; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 6:4 v/v, Rf: 0.10; 
Purification: Recrystallisation from EtOH/Water; 
Yield: 0.045 g (32%); 
1H-NMR (DMSO-D6), δ: 6.66-6.68 (m, 1H, H-aromatic), 7.17-7.20 (m, 1H, H-aromatic), 7.35 (dd, J1= 
7.3 Hz, J2= 0.6 Hz, 1H, H-aromatic), 7.52-7.54 (m, 1H, H-aromatic), 7.58-7.62 (m, 1H, H-aromatic) 
7.94-7.97 (m, 2H, H-aromatic), 11.44 (bs, 1H, NH), 13.89 (bs, 1H, OH). 
13C-NMR (DMSO-D6), δ: 112.2, 118.6, 119.0, 124.8, 131.9, 135.0, 148.7 (CH, C-aromatic), 117.4, 
139.5, 146.8 (C, C-aromatic), 170.2 (C, C- 11). 
UPLC-MS: Rt 1.81 (100%) MS (ESI)-: 266.0 [M-H]-. 
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9.2.7 Aryl(alkyl)esters (71, 77, 79) 
Methyl 2-((4-(pentafluorosulfanyl)phenyl)sulfonamido)benzoate (71) 
(C14H12F5NO4S2; M.W.= 417.07) 
 
Reagent: 2-((4-(pentafluorosulfanyl)phenyl)sulfonamido)benzoic acid (70) (0.050 g, 0.12 mmol); 
General Procedure 7; 
White solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.67; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 60:40 in 10CV); 
Yield: 0.022 g (43%); 
1H-NMR (DMSO-D6), δ: 3.74 (s, 3H, H-8), 7.25-7.29 (m, 1H, H-aromatic), 7.41-7.44 (m, 1H, H-
aromatic), 7.58-7.62 (m, 1H, H-aromatic), 7.81-7.83 (dd, J1= 7.9 Hz, J2= 1.3 Hz, 1H, H-aromatic), 7.96 
(d, J=8.6 Hz, 2H, H-aromatic), 8.13 (d, J=8.6 Hz, 2H, H-aromatic), 10.48 (bs, 1H, NH). 
 13C-NMR (DMSO-D6), δ: 52.9 (CH3, C-8), 122.8, 125.6, 127.72, 127.75, 128.6, 131.4 (CH, C-aromatic), 
121.2, 137.4, 143.1, 155.8 (C, C-aromatic), 167.4 (C, C-7). 
 19F-NMR (DMSO-D6), δ: +63.35 (d, J=151.6 Hz, 4F), + 84.78 (m, 1F) ppm. 
UPLC-MS: Rt 2.45 (>97%) MS (ESI)-: 416.1 [M-H]-. 
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Isopropyl 2-aminobenzoate (77) (25) 
(C13H10NO2; M.W.= 179.22) 
 
Reagent: 2-aminobenzoic acid (2) (1.500 g, 10.93 mmol);  
General Procedure 7; 
Yellow oil; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.5; 
Purification: Flash column chromatography (n-hexane:EtOAc 100:0 v/v increasing to n-
hexane:EtOAc 9:1 v/v); 
Yield: 0.374 g (19%); 
1H-NMR (CDCl3), δ: 1.28 (d, J= 6.2 Hz, 6H, H-9,10), 5.14 (m, 1H, H-8), 5.63 (bs, 2H, NH2), 6.54-5.58 
(m, 2H, H-aromatic), 7.15-7.19 (m, 1H, H-aromatic), 7.79 (dd, J1= 7.8 Hz, J2= 1.5 Hz, 1H, H-aromatic). 
13C-NMR (CDCl3), δ: 22.0 (2xCH3, C-9,10), 67.6 (CH, C-8), 116.2, 116.6, 131.2, 133.8 (CH, C-aromatic), 
111.5, 150.4 (C, C-aromatic), 167.7 (C, C-7). 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                      Chapter 9: Experimental 
238 
 
Isopropyl 2-((3-chloro-4-methylphenyl)sulfonamido)benzoate (79) 
(C17H18ClNO4S; M.W.= 367.84) 
 
Reagent: 2-((3-chloro-4-methylphenyl)sulfonamido)benzoic acid  (69) (0.1 g, 0.30 mmol); 
General Procedure 7; 
Colourless oil;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.67; 
Purification1: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 70:30 in 10CV); 
Purification2: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 
10g, n-hexane-EtOAc increasing to n-hexane-EtOAc 70:30 in 20CV); 
Yield: 0.024 g (22%); 
1H-NMR (CDCl3), δ: 1.26 (d, J= 6.2 Hz, 6H, H-16,17), 2.30 (s, 3H, H-7), 5.11-5.14 (m, 1H, H-15), 6.97-
7.00 (m, 1H, H-aromatic), 7.17-7.19 (m, 1H, H-aromatic), 7.37-7.41 (m, 1H, H-aromatic), 7.52 (dd, 
J1= 7.8 Hz, J2= 1.9 Hz, 1H, H-aromatic), 7.59 (dd, J1= 8.3 Hz, J2= 1.0 Hz, 1H, H-aromatic), 7.74-7.76 (m, 
1H, H-aromatic), 7.85 (m, 1H, H-aromatic), 10.68 (bs, 1H, NH) ppm. 
 13C-NMR (CDCl3), δ: 20.2 (CH3, C-7), 21.7 (2xCH3, C-16,17), 69.5 (CH, C-15), 119.4, 123.2, 125.3, 
127.7, 131.1, 131.3, 134.3 (CH, C-aromatic), 116.9, 135.1, 138.3, 140.1, 141.8 (C, C-aromatic), 167.3 
(C, C-14). 
UPLC-MS: Rt 2.77 (100%) MS (ESI)+: 368.8 [M+H]+. 
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9.2.8: Tert-Butyl(arylsulfonamido) benzoate (80-81) 
Tert-Butyl 2-((2,4-dichloro-5-methylphenyl)sulfonamido)benzoate (80) 
(C18H19Cl2NO4S; M.W.= 416.31) 
 
Reagent: 2-((2,4-dichloro-5-methylphenyl)sulfonamido)benzoic acid (3) (0.150 g, 0.416 mmol); 
General Procedure 8; 
Yellow solid;  
T.L.C. System: n-hexane-EtOAc 5:5 v/v, Rf: 0.72; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 60:40 in 15CV); 
Yield: 0.035 g (20%); 
1H-NMR (CDCl3), δ: 1.32 (s, 9H, H-16,17,18), 2.32 (s, 3H, H-7), 6.90-6.93 (m, 1H, H-aromatic), 7.26-
7.30 (m, 1H, H-aromatic), 7.34 (s, 1H, H-6), 7.44 (dd, J1= 7.3 Hz, J2= 1.1 Hz, 1H, H-aromatic), 7.82 (dd, 
J1= 6.3 Hz, J2= 1.6 Hz, 1H, H-aromatic), 7.98 (s, 1H, H-3), 11.32 (bs, 1H, NH). 
13C-NMR (CDCl3), δ: 19.6 (CH3, C-7), 28.1 (3xCH3, C-16,17,18), 117.0, 122.4, 131.5, 131.8, 133.6, 
133.9 (CH, C-aromatic), 83.0 (C, C-15), 129.8, 134.9, 134.5, 135.5, 139.5, 139.9 (C, C-aromatic), 167.0 
(C, C-14).  
UPLC-MS: Rt 2.38 (>97%) MS (ESI)-: 414.1 [M-H]-. 
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Tert-Butyl 2-((3-chloro-4-methylphenyl)sulfonamido)benzoate (81) 
 (C18H20ClNO4S; M.W.= 381.87) 
 
Reagent: 2-((3-chloro-4-methylphenyl)sulfonamido)benzoic acid (69) (0.100 g, 0.30 mmol); 
General Procedure 8; 
White solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.57; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 10g, 
n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 70:30 in 10CV); 
Yield: 0.026 g (22%); 
1H-NMR (CDCl3), δ: 1.48 (s, 9H, H-16,17,18), 2.29 (s, 3H, H-7), 6.95-6.98 (m, 1H, H-aromatic), 7.18-
7.20 (m, 1H, H-aromatic), 7.34-7.38 (m, 1H, H-aromatic), 7.51 (dd, J1= 8.0 Hz, J2= 1.8 Hz, 1H, H-
aromatic), 7.56-7.58 (m, 1H, H-aromatic), 7.74 (d, J1= 1.8 Hz, 1H, H-aromatic), 7.77-7.79 (m, 1H, H-
aromatic), 10.76 (bs, 1H, NH). 
13C-NMR (CDCl3), δ: 20.2 (3xCH3, C-16,17,18), 28.2 (CH3, C-7), 119.6, 125.3, 127.7, 131.2, 131.3, 
131.7, 135. (CH, C-aromatic), 83.1 (C, C-15), 117.9, 131.6, 134.0, 140.0, 141.7 (C, C-aromatic), 167.2 
(C, C-14).  
UPLC-MS: Rt 2.73 (>99%) MS (ESI)-: 380.2 [M-H]-. 
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9.2.9 (1H-Tetrazol-5yl) anilines (84-85) 
2-(1H-Tetrazol-5-yl)aniline (84) 
(C7H7N5; M.W.= 161.17) 
 
Reagent: 2-aminobenzonitrile (82) (1.0 g, 8.46 mmol); 
General Procedure 9; 
Yellow Solid; 
T.L.C. System: n-hexane-EtOAc 5:5 v/v, Rf: 0.58; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP 50g, 
n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 0:100 in 10CV); 
Yield: 0.723 g (53%); 
1H-NMR (DMSO-D6), δ: 6.67-6.70 (m, 1H, H-aromatic), 6.88-6.92 (m, 1H, H-aromatic), 7.22-7.26 (m, 
1H, H-aromatic), 7.72 (dd, J1= 7.8 Hz, J2= 1.3 Hz, 1H, H-aromatic), 9.66 (bs, 1H, NH).  
 13C-NMR (DMSO-D6), δ: 116.0, 116.8, 128.5, 132.3 (CH, C-aromatic), 105.0, 147.9 (C, C-aromatic), 
155.3 (C, C-7). 
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4-(1H-Tetrazol-5-yl)aniline (85) (26) 
(C7H7N5; M.W= 161.17) 
 
Reagent: 4-aminobenzonitrile (83) (1.0 g, 8.46 mmol); 
General Procedure 9; 
Yellow Solid; 
T.L.C. System: n-hexane-EtOAc 2:8 v/v, Rf: 0.30; 
Purification: Trituration with EtOAc; 
Yield: 0.451 g (33%); 
1H-NMR (DMSO-D6), δ: 5.83 (bs, 2H, NH2), 6.69 (d, J= 8.8 Hz, 2H, H-aromatic), 7.69 (d, J= 8.8 Hz, 2H, 
H-aromatic), 16.00 (bs, 1H, NH).  
 13C-NMR (DMSO-D6), δ: 116.0, 116.8, 128.5, 132.3 (CH, C-aromatic), 105.0, 147.9 (C, C-aromatic), 
155.3 (C, C-7). 
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9.2.10 Alkyl(arylsulfonamido) carboxamide (101-105) 
2-((3-Chloro-4-methylphenyl)sulfonamido)-N-methylbenzamide (101) 
(C15H15ClN2O3S; M.W.= 338.81) 
 
Reagent: 2-((3-chloro-4-methylphenyl)sulfonamido)benzoic acid  (69) (0.100 g, 0.30 mmol); 
General Procedure 10; 
White solid;  
T.L.C. System: n-hexane-EtOAc 5:5 v/v, Rf: 0.40; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 10g, 
n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 20:80 in 10CV); 
Yield: 0.03 g (30%); 
1H-NMR (CDCl3), δ: 2.39, (s, 3H, H-7), 2.94 (d, J= 4.8 Hz, 3H, H-15), 6.06 (bs, 1H, NH), 7.07-7.11 (m, 
1H, H-aromatic), 7.26-7.29 (m, 1H, H-aromatic), 7.36 (d, J= 7.9 Hz, 1H, H-3), 7.42-7.46 (m, 1H, H-
aromatic), 7.60 (dd, J1= 8.1 Hz, J2= 1.7 Hz, 1H, H-aromatic), 7.69 (d, J= 7.9 Hz, 1H, H-4), 7.79-7.81 (m, 
1H, H-aromatic), 10.87 (bs, 1H, NH). 
13C-NMR (CDCl3), δ: 20.2 (CH3), 26.7 (CH3), 121.7, 123.8, 125.4, 126.5, 127.7, 131.1, 132.6 (CH, C-
aromatic), 121.8, 135.0, 138.4, 138.5, 141.5 (C, C-aromatic), 168.8 (C, C-14). 
UPLC-MS: Rt 2.11 (>99%) MS (ESI)+: 339.1 [M+H]+. 
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2-((2,4-Dichloro-5-methylphenyl)sulfonamido)-N-methylbenzamide (102) 
(C15H14Cl2N2O3S; M.W.= 373.25) 
 
Reagent: 2-((2,4-dichloro-5-methylphenyl)sulfonamido)benzoic acid (3) (0.100 g, 0.27 mmol); 
General Procedure 10; 
White solid;  
T.L.C. System: n-hexane-EtOAc 5:5 v/v, Rf: 0.43; 
Purification1: Recrystallisation from EtOH/Water; 
Purification2: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 0:100 in 14CV); 
Yield: 0.049 g (49%); 
1H-NMR (CDCl3), δ: 2.41 (s, 3H, H-7), 3.02 (d, J=4.8 Hz, 3H, H-15), 6.17 (bs, 1H, NH), 7.02-7.05 (m, 
1H, H-aromatic), 7.34-7.37 (m, 1H, H-aromatic), 7.40 (dd, J1= 7.8 Hz, J2= 1.0 Hz, 1H, H-aromatic), 7.45 
(s, 1H, H-4), 7.54-7.57 (m, 1H, H-aromatic), 8.05 (s, 1H, H-1), 11.37 (bs, 1H, NH). 
13C-NMR (CDCl3), δ: 19.6 (CH3), 26.8 (CH3), 118.7, 122.9, 126.7, 131.7, 132.5, 133.3 (CH, C-aromatic), 
120.6, 130.0, 135.2, 135.5, 138.0, 139.7 (C, C-aromatic), 168.9 (C, C-14). 
UPLC-MS: Rt 2.23 (100%) MS (ESI)+: 375.1 [M+H]+. 
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2-((2,4-Dichloro-5-methylphenyl)sulfonamido)-N-ethylbenzamide (103) 
(C16H16Cl2N2O3S; M.W.= 387.28) 
 
Reagent: 2-((2,4-dichloro-5-methylphenyl)sulfonamido)benzoic acid (3) (0.100 g, 0.27 mmol); 
General Procedure 10; 
White solid;  
T.L.C. System: n-hexane-EtOAc 6:4 v/v, Rf: 0.40; 
Purification1: Recrystallisation from DCM/n-hexane; 
Purification2: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 
5g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 40:60 in 10CV); 
Yield: 0.047 g (44%); 
1H-NMR (CDCl3), δ: 1.28 (t, J= 7.2 Hz, 3H, H-16), 2.41 (s, 3H, H-7), 3.47-3.52 (m, 2H, H-15), 6.13 (bs, 
1H, NH), 7.02-7.06 (m, 1H, H-aromatic), 7.34-7.37 (m, 1H, H-aromatic), 7.40-7.42 (m, 1H, H-
aromatic), 7.45 (s, 1H, H-4), 7.55-7.57 (m, 1H, H-aromatic), 8.05 (s, 1H, H-1), 11.40 (bs, 1H, NH). 
13C-NMR (CDCl3), δ: 14.6 (CH3), 19.6 (CH3), 35.0 (CH2, C-15), 118.7, 122.9, 126.7, 131.7, 132.5, 133.3 
(CH, C-aromatic), 120.8, 130.0, 135.2, 135.5, 138.1, 139.7 (C, C-aromatic), 168.1 (C, C-14). 
UPLC-MS: Rt 2.33 (>98%) MS (ESI)+: 389.1 [M+H]+. 
 
 
 
 
 
 
                                                                                                                                      Chapter 9: Experimental 
246 
 
2-((2,4-Dichloro-5-methylphenyl)sulfonamido)-N,N-dimethylbenzamide (104) 
(C16H16Cl2N2O3S; M.W.= 387.28) 
 
Reagent: 2-((2,4-dichloro-5-methylphenyl)sulfonamido)benzoic acid (3) (0.100 g, 0.27 mmol); 
General Procedure 10; 
White solid;  
T.L.C. System: n-hexane-EtOAc 4:6 v/v, Rf: 0.50; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 10g, 
n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 30:70 in 11CV); 
Yield: 0.037 g (35%); 
1H-NMR (CDCl3), δ: 2.37 (s, 3H, H-7), 2.79 (s, 3H), 3.10 (s, 3H), 7.09-7.12 (m, 1H, H-aromatic), 7.18-
7.20 (m, 1H, H-aromatic), 7.32-7.36 (m, 1H, H-aromatic), 7.49 (s, 1H, H-4), 7.59-7.60 (m, 1H, H-
aromatic), 7.93 (s, 1H, H-1), 8.88 (bs, 1H, NH) ppm.  
13C-NMR (CDCl3), δ: 19.6 (CH3), 39.4 (CH3), 39.6 (CH3), 122.4, 124.0, 127.9, 130.8, 131.4, 133.2 (CH, 
C-aromatic), 126.1, 129.7, 135.1, 135.2, 135.7, 139.7 (C, C-aromatic), 169.3 (C, C-14) ppm. 
UPLC-MS: Rt 2.18 (>97%) MS (ESI)+: 389.1 [M+H]+. 
 
 
 
 
 
 
 
                                                                                                                                      Chapter 9: Experimental 
247 
 
2-((2,4-Dichloro-5-methylphenyl)sulfonamido)-N-isopropylbenzamide (105) 
(C17H18Cl2N2O3S; M.W.= 401.30) 
 
Reagent: 2-((2,4-dichloro-5-methylphenyl)sulfonamido)benzoic acid (3) (0.100 g, 0.27 mmol); 
General Procedure 10; 
White solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.38; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 10g, 
n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 30:70 in 12CV); 
Yield: 0.060 g (53%); 
1H-NMR (CDCl3), δ: 1.19, d, J=6.5 Hz, 6H, H-16,17), 2.31 (s, 3H-H-7), 4.14-4.20 (m, 1H-H-15), 5.85 
(bs, 1H, NH), 6.92-6.95 (m, 1H, H-aromatic), 7.24-7.27 (m, 1H, H-aromatic), 7.30 (dd, J1= 7.8 Hz, J2= 
1.4 Hz, 1H, H-aromatic), 7.35 (s, 1H, H-aromatic), 7.45 (dd, J1= 1.0 Hz, J2= 8.4 Hz, 1H, H-aromatic), 
7.96 (s, 1H, H-4), 11.32 (bs, 1H, NH).  
13C-NMR (CDCl3), δ: 19.6 (CH3, C-7), 22.6 (2xCH3, C-16,17), 42.1 (CH, C-15), 118.7, 122.9, 126.8, 
131.7, 132.5, 133.4 (CH, C-aromatic), 120.8, 130.0, 135.2, 135.5, 138.1, 139.7 (C, C-aromatic), 167.5 
(C, C-14).  
UPLC-MS: Rt 2.43 (>97%) MS (ESI)+: 403.2 [M+H]+. 
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9.3 Synthesis of amine derivatives 
General Procedure 11: arylamino derivatives (113-120, 129-134, 144-150) (27) 
 
A solution of the appropriate aryl benzaldehyde (1eq) and differently substituted anilines (1eq) in 
MeOH (2.5 mL/mmol) was refluxed overnight. The solvent was then removed under vacuum and 
the resulting residue was dissolved in acetic acid (3 mL/mmol). NaBH4 (2 eq) was then added in 
portions at 20°C and the mixture was then stirred at room temperature for 7 hours. The reaction 
mixture was added of water (4 mL/mmol) and ethyl acetate (4 mL/mmol). The pH of the aqueous 
layer was adjusted to 5 by the addition of 1M NaOH. The water layer was extracted with ethyl 
acetate (3x10 mL/mmol). The combined organic layers were dried over MgSO4 and concentrated 
under vacuum. The desired products were purified by flash column chromatography. 
General Procedure 12: methyl((aryl)amino)benzoates (121-124) (16) 
 
 
The appropriate (arylamino)benzoic acid (1 eq), TBTU (1 eq) and DIPEA (2 eq) was stirred in 
anhydrous DMF (1 mL/mmol eq), and the resulting mixture was stirred at room temperature for 30 
min, under N2 atmosphere. CH3OH (1 eq) was then injected into the reaction mixture via syringe 
and stirring was continued at room temperature until completion of the reaction. The reaction 
mixture was diluted with DCM (10 mL/mmol eq) and the resulting mixture was extracted with sat.aq 
NH4Cl (1x10 mL/mmol eq) and sat.aq NaHCO3 (1x10 mL/mmol eq). The organic layer was dried over 
MgSO4 and the solvent was evaporated under vacuum. The desired products were purified by flash 
column chromatography or recrystallisation.  
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Synthesis of methyl 2-(phenethylamino)benzoate (137) (28) 
(C16H17NO2; M.W.= 255.32) 
 
To a solution of (2-bromoethyl) benzene (0.150 g, 0.81 mmol) in MeCN (5 mL) was added methyl 2-
aminobenzoate (0.122 g, 0.81 mmol) under nitrogen atmosphere. The resulting solution was stirred 
at reflux for 48 h. The formed salt was filtered off and the filtrate was concentrated under vacuum. 
The residue was dissolved in ethyl acetate (15 mL) and washed sequentially with water (10 mL) and 
brine (10 mL) and dried over sodium sulfate. The solvent was evaporated under reduced pressure 
and the residue was purified by flash column chromatography to obtain the pure compound. 
Colourless Oil; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.55; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP 10g, n-
hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 80:20 in 15CV); 
Yield: 0.010 g (5%); 
1H-NMR (CDCl3), δ: 2.90 (t, J= 7.5 Hz, 2H, H-7), 3.37 (t, J= 7.5 Hz, 2H, H-8), 3.76 (s, 3H, H-15), 6.49-
6.52 (m, 1H, H-aromatic), 6.62-6.64 (m, 1H, H-aromatic), 7.12-7.15 (m, 1H, H-aromatic), 7.18-7.20 
(m, 2H, H-aromatic), 7.23-7.29 (m, 3H, H-aromatic), 7.69 (bs, 1H, NH), 7.81-7.83 (m, 1H, H-aromatic). 
 13C-NMR (CDCl3), δ: 51.4 (CH3, C-15), 32.9, 44.5 (CH2, C-7,8), 111.1, 114.5, 128.6, 127.7, 131.5, 
131.7, 134.6 (CH, C-aromatic), 110.0, 139.2, 150.9 (C, C-aromatic), 168.9 (C, C-14). 
UPLC-MS: Rt 2.58 (>97%) MS (ESI)+: 256.1 [M+H]+. 
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Synthesis of methyl 2-((4-trifluoromethyl)phenethylamino)benzoate (138) (29) 
(C17H16F3NO2; M.W.= 323.32) 
 
A mixture of methyl 2-aminobenzoate (0.090 g, 0.59 mmol), 1-(2-bromoethyl)-4-
(trifluoromethyl)benzene (0.150 g, 0.59 mmol), and K2CO3 (0.081 g, 0.59 mmol) in MeCN (2 mL) was 
stirred overnight under reflux. The mixture was extracted between ethylacetate (3 x 10 mL) and 
water (20 mL) and the organic layer was dried over sodium sulfate. The solvent was removed under 
vacuum and the residue was purified by flash column chromatography to obtain the pure 
compound. 
Colourless oil; 
T.L.C. System: n-hexane:EtOAc 9:1 v/v, Rf: 0.54; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 30g, 
n-hexane-DCM 100:0 increasing to n-hexane-DCM 40:60 in 15CV); 
Yield: 0.049 g (26%); 
1H-NMR (CDCl3), δ: 3.06 (t, J= 7.2 Hz, 2H, H-8), 3.49-3.53 (m, 2H, H-9), 3.86 (s, 3H, H-16), 6.61-6.64 
(m, 1H, H-aromatic), 6.70-5.72 (m, 1H, H-aromatic),  7.37-7.40 (m, 3H, H-aromatic), 7.59 (d, J= 8.0 
Hz, 2H, H-aromatic), 7.80 (bs, 1H, NH), 7.93 (dd, J1= 8.0 Hz, J2= 1.6 Hz, 1H, H-aromatic). 
13C-NMR (CDCl3), δ:  35.4, 44.0 (CH2, C-8,9) 51.4 (CH3, C-16), 111.0, 114.8, 125.4, 125.5, 129.1, 
131.78 (CH, C-aromatic), 125.4 (d, J= 37.3 Hz, C), 110.2, 134.6, 143.4, 150.7 (C-aromatic), 168.9 (C, 
C- 15). 
19F-NMR (CDCl3), δ: -62.4 (s, 3F)  
UPLC-MS: Rt 2.68 (100%) MS (ESI)+: 324.2 [M+H]+. 
 
General Procedure 13: (aryl)amino)benzoic acids (139-143, 156) (14) 
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To a solution of the appropriate methyl-(arylamino) benzoate (1 eq) in THF (7 mL/mmol), H2O (3.5 
mL/mmol), MeOH (3.5 mL/mmol) was added LiOH (3 eq). The reaction was stirred ad 70°C 
overnight. After the reaction was allowed to cool to room temperature, the reaction mixture was 
acidified with 2M HCl. The product was extracted with ethyl acetate (3x10 mL/mmol). The organic 
layer was dried over MgSO4 and evaporated under reduced pressure. The product was purified by 
flash column chromatography or recrystallisation. 
Synthesis of: methyl 2-(bromomethyl) benzoate (30, 31) 
(C9H9BrO2; M.W.= 229.07) 
 
To a solution of the starting methyl 2-methylbenzoate (1.0 g, 6.65 mmol) in 7 mL of CHCl3, NBS (1.3 
g, 7.31 mmol) and AIBN (0.013 g, 0.073 mmol) were added and the reaction was stirred at 70°C for 
5 hours.  The reaction was then cooled down to room temperature and the deposit of succinimide 
was filtered. The solvent was evaporated under reduced pressure. The crude product was then 
purified by flash column chromatography to obtain the pure product. 
Yellow oil;  
T.L.C. System: n-hexane-EtOAc 9:1 v/v, Rf: 0.57; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
100g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 80:20 in 15CV); 
Yield: 1.25 g (82%); 
1H-NMR (CDCl3), δ:  3.95 (s, 3H, H-9), 4.98 (s, 2H, H-7), 7.38-7.40 (m, 1H, H-aromatic), 7.46-7.50 (m, 
2H, H-aromatic), 7.98-8.00 (m, 1H, H-aromatic). 
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General Procedure 14: methyl 2-(aryl)amino)methyl)benzoates (162-164) (32) 
 
A mixture of methyl 2-(bromomethyl)benzoate (1 eq), differently substituted anilines (1 eq) and TEA 
(1.5 eq) in methanol (1 mL/mmol) was heated at 85°C. overnight. The mixture was diluted with DCM, 
washed with saturated solution of NaHCO3 (10 mL/mmol), dried over sodium sulfate and 
concentrated in vacuum. The crude products were purified by recrystallisation or flash column 
chromatography. 
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9.3.1 Arylamino derivatives (113-120, 129-134, 144-150) 
2-((4-(Trifluoromethyl)benzyl)amino)benzoic acid (113) 
(C15H12F3NO2, M.W.= 295.26) 
 
Reagent: 4-(trifluoromethyl)benzaldehyde (107) (0.300 g, 1.72 mmol); 
Reagent: 2-aminobenzoic acid (2) (0.236 g, 1.72 mmol); 
General Procedure 10; 
White solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.64; 
Purification1: Biotage Isolera One automated flash column chromatography (cartridge: SNAP ULTRA 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 60:40 in 10CV); 
Purification 2: Recrystallisation from EtOH/water; 
Yield: 0.087 g (17%); 
1H-NMR (CDCl3), δ: 4.59 (s, 2H, H-8), 6.58 (m, 1H, H-aromatic), 6.67-6.70 (m, 1H, H-aromatic), 7.34-
7.38 (m, 1H, H-aromatic), 7.50 (d, J= 7.9 Hz, 2H, H-aromatic), 7.63 (d, J= 7.9 Hz, 2H, H-aromatic), 8.05 
(dd, J1= 8.0 Hz, J2= 1.5 Hz, 1H, H-aromatic), 8.20 (bs, 1H, NH), 11.22 (bs, 1H, OH). 
 13C-NMR (CDCl3), δ: 46.4 (CH2, C-8), 111.7, 115.6, 125.6, 125.7, 129.1, 129.4 (CH, C-aromatic), 109.1, 
125.2, 127.0, 143.0, 151.3 (C, C-aromatic), 173.3 (C, C-15). 
19F-NMR (CDCl3), δ: -62.38 (3F). 
UPLC-MS: Rt 2.29 (>99%) MS (ESI)+: 296.0 [M+H]+. 
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3-((4-(Trifluoromethyl)benzyl)amino)benzoic acid (114) 
(C15H12F3NO2; M.W.= 295.26) 
 
Reagent: 4-(trifluoromethyl)benzaldehyde (107) (0.300 g, 1.72 mmol); 
Reagent: 3-aminobenzoic acid (112) (0.236 g, 1.72 mmol);  
General Procedure 11; 
White solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.45; 
Purification1: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 30:70 in 11CV); 
Purification2: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 40:60 in 10CV); 
Purification 3: Recrystallisation from EtOH; 
Yield: 0.100 g (20%); 
1H-NMR (CDCl3), δ: 4.49 (s, 2H, H-8), 6.83-6.85 (m, 1H, H-aromatic), 7.27-7.30 (m, 1H, H-aromatic), 
7.35 (bs, 1H, NH), 7.39 (s, 1H, H-14), 7.50-7.54 (m, 3H, H-aromatic), 7.64 (d, J= 7.9 Hz, 2H, H-
aromatic), 11.74 (bs, 1H, OH). 
13C-NMR (CDCl3), δ:  47.6 (CH2, C-8), 113.9, 125.2, 125.6, 125.72, 127.5, 129.4 (CH, C-aromatic), 
125.76, 129.8, 130.2, 143.0, 147.70(C, C-aromatic), 171.8 (C, C-8). 
19F-NMR (CDCl3), δ: -62.42 (3F). 
UPLC-MS: Rt 2.12 (99%) MS (ESI)+: 296.0 [M+H]+. 
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2-((3,4-Dimethylbenzyl)amino)benzoic acid (115) 
(C16H17NO2; M.W.= 255.32) 
 
Reagent: 3,4-dimethylbenzaldehyde (108) (0.150 g, 1.12 mmol); 
Reagent: 2-aminobenzoic acid (2) (0.153 g, 1.72 mmol); 
General Procedure 11; 
White solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.50; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 60:40 in 10CV); 
Yield: 0.150 g (52%); 
1H-NMR (CDCl3), δ: 2.18 (d, J= 3.7 Hz, 6H, H-7,8), 4.33 (s, 2H, H-9), 6.52-6.55 (m, 1H, H-aromatic), 
6.58 (d, J= 8.4 Hz, 1H, H-aromatic), 7.00-7.05 (m, 3H, H-aromatic), 7.23-7.27 (m, 1H, H-aromatic), 
7.91 (dd, J1= 7.9 Hz, J2= 1.6 Hz, 1H, H-aromatic), 8.22 (bs, 1H, NH) 11.36 (bs, 1H, OH). 
13C-NMR (CDCl3), δ: 19.4 (CH3), 19.8 (CH3), 46.7 (CH2, C-9), 111.9, 114.9, 124.4, 128.3, 129.9, 132.62, 
135.4 (CH, C-aromatic), 108.8, 135.6, 136.0, 136.9, 151.7 (C, C-aromatic), 173.6 (C, C-16).  
UPLC-MS: Rt 2.34 (100%) MS (ESI)+: 256.1 [M+H]+. 
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3-((3,4-Dimethylbenzyl)amino)benzoic acid (116) 
(C16H17NO2; M.W.= 255.32) 
 
Reagent: 3,4-dimethylbenzaldehyde (108) (0.200 g, 1.5 mmol); 
Reagent: 3-aminobenzoic acid (112) (0.205 g, 1.72 mmol);  
General Procedure 11; 
White solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.48; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP ULTRA 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 50:50 in 10CV); 
Purification2: Recrystallisation from EtOH/Water; 
Yield: 0.097 g (26%); 
1H-NMR (CDCl3), δ: 2.28 (d, J= 3.5 Hz, 6H, H-7,8), 4.32 (s, 2H, H-9), 6.42 (bs, 1H, NH), 6.85-6.88 (m, 
1H, H-aromatic), 7.11-7.15 (m, 2H, H-aromatic), 7.26-7.28 (m, 2H, H-aromatic), 7.40-7.42 (m, 1H, H-
aromatic), 7.47 (d, J= 7.6 Hz, 1H, H-aromatic), 11.71 (bs, 1H, OH). 
13C-NMR (CDCl3), δ: 19.4 (CH3), 19.8 (CH3), 48.0 (CH2, C-9), 113.9, 118.0, 119.2, 125.0, 129.0, 129.31, 
129.9 (CH, C-aromatic), 130.0, 135.7, 136.1, 136.9, 148.2 (C, C-aromatic), 171.5 (C, C-16). 
UPLC-MS: Rt 2.13 (100%) MS (ESI)+: 256.1 [M+H]+. 
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2-((3-Chloro-4-methylbenzyl)amino)benzoic acid (117) 
(C15H14ClNO2; M.W.= 275.53) 
 
Reagent: 3-chloro-4-methylbenzaldehyde (109) (0.150 g, 0.97 mmol); 
Reagent: 2-aminobenzoic acid (2) (0.133 g, 0.97 mmol);  
General Procedure 11; 
White solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.45; 
Purification1: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
50g, n-hexane-EtOAc  100:0 increasing to n-hexane-EtOAc 50:50 in 12CV); 
Purification2: Recrystallisation from EtOH/Water; 
Yield: 0.058 g (21%); 
1H-NMR (CDCl3), δ: 2.38 (s, 3H, H-7), 4.46 (s, 2H, H-8), 6.60-6.63 (m, 1H, H-aromatic), 6.65-6.68 (m, 
1H, H-aromatic), 7.15-7.18 (m, 1H, H-aromatic), 7.21 (d, J= 7.8 Hz, 1H, H-aromatic), 7.34-7.37 (m, 
2H, H-aromatic), 8.02 (dd, J1= 7.8 Hz, J2= 1.4 Hz, 1H, H-aromatic), 8.11 (m, 1H, H-aromatic), 10.77 
(bs, 1H, NH), 12.73 (bs, 1H, OH). 
13C-NMR (CDCl3), δ: 19.7 (CH3), 46.1 (CH2, C-8), 111.8, 115.3, 125.0, 127.4, 131.2, 132.6, 135.6 (CH, 
C-aromatic), 108.9, 134.6, 134.8, 138.1, 151.4 (C, C-aromatic), 172.8 (C-15). 
UPLC-MS: Rt 2.37 (100%) MS (ESI)+: 276.5 [M+H]+. 
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3-((3-Chloro-4-methylbenzyl)amino)benzoic acid (118) 
(C15H14ClNO2; M.W.= 275.73) 
 
Reagent: 3-chloro-4-methylbenzaldehyde (109) (0.114 g, 0.73 mmol); 
Reagent: 3-aminobenzoic acid (112) (0.101 g, 0.73 mmol); 
General Procedure 11; 
Yellow solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.35; 
Purification1: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 20:80 in 12CV); 
Purification2: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 
5g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 0:100 in 11CV); 
Purification3: Recrystallisation from EtOH/Water: 
 Yield: 0.057 g (28%); 
1H-NMR (CDCl3), δ: 2.29 (s, 3H, H-7), 4.25 (s, 2H, H-8), 6.73-6.76 (m, 1H, H-aromatic), 7.08 (dd, J1= 
7.7 Hz, J2= 1.5 Hz, 1H, H-aromatic), 7.13 (d, J= 7.7 Hz, 1H, H-aromatic), 7.16-7.19 (m, 1H, H-aromatic), 
7.27-7.28 (m, 2H, H-aromatic), 7.35 (bs, 1H, NH) 7.38-7.40 (m, 1H, H-aromatic), 11.34 (bs, 1H, OH). 
13C-NMR (CDCl3), δ: 19.7 (CH3, C-7), 47.3 (CH2, C-8), 113.9, 118.0, 119.5, 125.6, 127.9, 129.3, 131.2 
(CH, C-aromatic), 130.0, 134.6, 135.1, 138.1, 147.8 (C, C-aromatic), 171.3 (C, C-15). 
UPLC-MS: Rt 2.16 (>96%) MS (ESI)-: 274.1 [M-H]-. 
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2-((Quinolin-8-ylmethyl)amino)benzoic acid (119) 
(C17H14N2O2; M.W.= 278.31) 
 
Reagent: quinoline-8-carbaldehyde (110) (0.100 g, 0.63 mmol); 
Reagent: 2-aminobenzoic acid (2) (0.086 g, 0.63 mmol); 
General Procedure 11; 
Yellow Solid; 
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.60; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 30g, 
n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 0:100 in 10CV); 
Yield: 0.076 g (43%); 
1H-NMR (DMSO-D6), δ: 5.08 (s, 2H, H-10), 6.52-6.55 (m, 1H, H-aromatic), 6.71 (dd, J1= 8.5 Hz, J2= 0.6 
Hz, 1H, H-aromatic), 7.24-7.29 (m, 1H, H-aromatic), 7.54-7.57 (m, 1H, H-aromatic), 7.60 (dd, J1= 8.2 
Hz, J2= 4.1 Hz, 1H, H-aromatic), 7.68-7.70 (m, 1H, H-aromatic), 7.80 (dd, J1= 7.9 Hz, J2= 1.5 Hz, 1H, H-
aromatic), 7.90 (dd, J1= 7.9 Hz, J2= 1.1 Hz, 1H, H-aromatic), 8.41 (dd, J1= 8.3 Hz, J2= 1.7 Hz, 1H, H-
aromatic), 8.49 (bs, 1H, NH), 8.98 (dd, J1= 4.1 Hz, J2= 1.7 Hz, 1H, H-aromatic), 12.51 (bs, 1H, OH). 
13C-NMR (DMSO-D6), δ: 42.6 (CH2, C-10), 112.0, 114.7, 122.0, 126.8, 127.6, 127.8, 132.2, 134.8, 
136.9, 150.2 (CH, C-aromatic), 110.7, 128.4, 137.0, 146.2, 151.2 (C, C-aromatic), 170.4 (C, C- 17). 
UPLC-MS: Rt 1.95 (100%) MS (ESI)+: 279.1 [M+H]+. 
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2-((Quinoline-3-ylmethyl)amino)benzoic acid (120) 
(C17H14N2O2; M.W.= 278.31) 
 
Reagent: quinoline-3-carbaldehyde (111) (0.100 g, 0.63 mmol); 
Reagent: 2-aminobenzoic acid (2) (0.066 g, 0.63 mmol); 
General Procedure 11; 
Yellow Solid; 
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.25; 
Purification1: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 0:100 in 15CV and EtOAC-MeOH 80:20 in 
10 CV); 
Purification2: Recrystallisation from DCM/n-hexane; 
Yield: 0.025 g (14%); 
1H-NMR (DMSO-D6), δ: 4.72 (s, 2H, H-10), 6.56-6.60 (m, 1H, H-aromatic), 6.72 (d, J= 8.06 Hz, 1H, H-
aromatic), 7.27-7.31 (m, 1H, H-aromatic), 7.57-7.61 (m, 1H, H-aromatic), 7.71-7.75 (m, 1H, H-
aromatic), 7.83 (d, J= 8.1 Hz, 1H, H-aromatic), 7.96 (d, J= 8.1 Hz, 1H, H-aromatic), 8.01 (d, J= 8.1 Hz, 
1H, H-aromatic), 8.24 (s, 1H, H-aromatic), 8.45 (bs, 1H, NH), 8.93 (s, 1H, H-aromatic), 12.76 (bs, 1H, 
OH). 
13C-NMR (DMSO-D6), δ: 112.1, 115.2, 127.2, 128.3, 129.1, 129.6, 132.2, 133.1, 134.9, 151.1 (CH, C-
aromatic), 111.1, 127.9, 133.0, 147.3, 150.8 (C, C-aromatic), 170.4 (C, C- 17). 
UPLC-MS: Rt 1.62 (98%) MS (ESI)+: 279.1 [M+H]+. 
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Methyl 2-((3-chloro-4-methylbenzyl)amino)benzoate (129) 
(C16H16ClNO2; M.W.= 289.76) 
 
Reagent: 3-chloro-4-methylbenzaldehyde (198) (0.100 g, 0.64 mmol); 
Reagent: 2-aminobenzoate (18) (0.098 g, 0.64 mmol); 
General Procedure 11; 
Grey solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.72; 
Purification1: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
50g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 60:40 in 13CV); 
Purification2: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
50g, n-hexane-DCM 100:0 increasing to n-hexane-DCM 30:70 in 10CV); 
Purification3: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-DCM 100:0 increasing to n-hexane-DCM 30:70 in 10CV); 
Yield: 0.049 g (26%); 
1H-NMR (CDCl3), δ: 2.26 (s, 3H, H-7), 3.79 (s, 3H, H-16), 4.31 (d, J= 5.7 Hz, 2H, H-8), 6.50-6.54 (m, 2H, 
H-aromatic), 6.81 (bs, 1H, NH), 7.06 (dd, J1= 7.8 Hz, J2= 1.1 Hz, 1H, H-aromatic), 7.09 (d, J= 7.8 Hz, 
1H, H-aromatic), 7.24 (s, 1H, H-6), 7.84 (dd, J1= 7.9 Hz, J2= 1.6 Hz, 1H, H-aromatic), 8.08 (m, 1H, H-
aromatic).  
13C-NMR (CDCl3), δ: 19.7 (CH3, C-7), 51.5 (CH3, C-16), 46.2 (CH2, C-8), 111.6, 115.1, 125.2, 127.6, 
131.1, 131.6, 134.68 (CH, C-aromatic), 110.3, 134.64, 134.7, 138.3, 150.7 (C, C-aromatic), 169.1 (C, 
C-15). 
UPLC-MS: Rt 2.69 (100%) MS (ESI)+: 290.0 [M+H]+. 
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Methyl 3-((3-chloro-4-methylbenzyl)amino)benzoate (130) 
(C16H16ClNO2; M.W.= 289.76) 
 
Reagent: 3-chloro-4-methylbenzaldehyde (109) (0.100 g, 0.64 mmol); 
Reagent: 3-aminobenzoate (19) (0.098 g, 0.64 mmol); 
General Procedure 11; 
Yellow solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.60; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 40:60 in 13CV); 
Yield: 0.154 g (83%); 
1H-NMR (CDCl3), δ: 2.38 (s, 3H, H-7), 3.91 (s, 3H, H-16), 4.19 (bs, 1H, NH), 4.34 (s, 2H, H-8), 6.78-6.80 
(m, 1H, H-aromatic), 7.17 (dd, J1= 7.8 Hz, J2= 1.5 Hz, 1H, H-aromatic), 7.22 (d, J= 7.9 Hz, 1H, H-
aromatic), 7.25 (d, J= 7.9 Hz, 1H, H-aromatic), 7.32-7.33 (m, 1H, H-aromatic), 7.37-7.38 (m, 1H, H-
aromatic), 7.40-7.42 (m, 1H, H-aromatic). 
13C-NMR (CDCl3), δ: 19.7 (CH3, C-7), 51.5 (CH3, C-16) 47.5 (CH2, C-8), 113.7, 117.4, 119.1, 125.6, 
128.0, 129.2, 13.1 (CH, C-aromatic), 131.8, 134.6, 135.1, 138.0, 147.5 (C, C-aromatic), 167.4 (C, C-
15).  
UPLC-MS: Rt 2.44 (>99%) MS (ESI)+: 290.0 [M+H]+. 
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Methyl 2-((pyridin-3-ylmethyl)amino)benzoate (131) 
(C14H14N2O2; M.W.= 242.28) 
 
Reagent: nicotinaldehyde (125) (0.200 g, 1.86 mmol); 
Reagent: methyl 2-aminobenzoate (18) (0.281 g, 1.86 mmol); 
General Procedure 11; 
Yellow Oil; 
T.L.C. System: n-hexane-EtOAc 6:4 v/v, Rf: 0.30; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP 30g, n-
hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 20:80 in 15CV) ; 
 Yield: 0.427 g (90%); 
1H-NMR (CDCl3), δ: 3.89 (s, 3H, H-14), 4.51 (d, J=5.7 Hz, 2H, H-6), 6.61 (d, J= 8.3 Hz, 1H, H-aromatic), 
6.64-6.67 (m, 1H, H-aromatic), 7.28-7.30 (m, 1H, H-aromatic), 7.31-7.35 (m, 1H, H-aromatic), 7.69-
7.72 (m, 1H, H-aromatic), 7.96 (dd, J1= 8.0 Hz, J2= 1.6 Hz, 1H, H-aromatic), 8.23 (bs, 1H, NH), 8.54-
8.56 (m, 1H, H-aromatic), 8.65 (s, 1H, H-2).  
 13C-NMR (CDCl3), δ: 51.6 (CH3, C-14), 44.5 (CH2, C-6), 111.5, 115.4, 123.6, 134.4, 134.7, 134.8, 148.6, 
149.8 (CH, C-aromatic), 110.6, 131.7, 150.5 (C, C-aromatic), 169.1 (C, C-13). 
UPLC-MS: Rt 1.40 (96%) MS (ESI)+: 243.1 [M+H]+. 
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Methyl 2-((pyridin-4-ylmethyl)amino)benzoate (132) 
(C14H14N2O2; M.W.= 242.28) 
 
Reagent: isonicotinaldehyde (126) (0.200 g, 1.86 mmol); 
Reagent: methyl 2-aminobenzoate (18) (0.282 g, 1.86 mmol); 
General Procedure 11; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 6:4 v/v, Rf: 0.25; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP 80g, n-
hexane-EtOAc  100:0 increasing to n-hexane-EtOAc 40:60 in 15CV); 
 Yield: 0.403 g (89%); 
1H-NMR (CDCl3), δ: 3.92 (s, 3H, H-14), 4.51 (d, J=5.6 Hz, 2H, H-6), 6.50 (d, J= 8.5 Hz, 1H, H-aromatic), 
6.64-6.67 (m, 1H, H-aromatic), 7.29-7.33 (m, 3H, H-aromatic), 7.97 (d, J= 8.1 Hz, 1H, H-aromatic), 
8.31 (bs, 1H, NH), 8.56-8.58 (m, 2H, H-aromatic).  
 13C-NMR (CDCl3), δ: 51.6 (CH3, C-14), 45.9 (CH2, C-6), 111.5, 115.5, 121.8, 131.7, 134.6, 150.0 (CH, 
C-aromatic), 110.6, 148.4, 150.4 (C, C-aromatic), 169.1 (C, C-13). 
UPLC-MS: Rt 1.44 (95%) MS (ESI)+: 243.1 [M+H]+. 
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Methyl 2-((naphthalen-2-ylmethyl)amino)benzoate (133) 
(C19H17NO2; M.W.= 291.35) 
 
Reagent: 2-naphthaldehyde (127) (0.200 g, 1.28 mmol); 
Reagent: methyl 2-aminobenzoate (18) (0.193 g, 1.28 mmol); 
General Procedure 11; 
Yellow Solid; 
T.L.C. System: n-hexane-DCM 6:4 v/v, Rf: 0.64; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP 45g, n-
hexane-DCM 100:0 increasing to n-hexane-DCM 20:80 in 15CV); 
 Yield: 0.285 g (76%); 
1H-NMR (CDCl3), δ: 3.80 (s, 3H, H-19), 4.54 (d, J= 5.9 Hz, 2H, H-11), 6.50-6.54 (m, 1H, H-aromatic), 
6.59 (d, J= 8.5 Hz, 1H, H-aromatic), 7.19-7.21 (m, 1H, H-aromatic), 7.35-7.37 (m, 1H, H-aromatic), 
7.38-7.41 (m, 2H, H-aromatic), 7.70-7.72 (m, 2H, H-aromatic), 7.73-7.76 (m, 2H, H-aromatic), 7.86 
(dd, J1= 8.2 Hz, J2= 1.6 Hz, 1H, H-aromatic), 8.20 (bs, 1H, NH).  
 13C-NMR (CDCl3), δ: 51.5 (CH3, C-19), 47.2 (CH2, C-11), 111.8, 114.9, 125.3, 125.5, 125.6, 126.1, 
127.70, 127.79, 128.4, 131.6, 134.6 (CH, C-aromatic), 110.3, 132.7, 133.5, 136.4, 151.0 (C, C-
aromatic), 169.1 (C, C-18). 
UPLC-MS: Rt 2.66 (100%) MS (ESI)+: 292.0 [M+H]+. 
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Methyl 2-((naphthalen-1-ylmethyl)amino)benzoate (134) 
(C19H17NO2; M.W.= 291.35) 
 
Reagent: 1-naphthaldehyde (128) (0.200 g, 1.28 mmol); 
Reagent: methyl 2-aminobenzoate (18) (0.193 g, 1.28 mmol); 
General Procedure 11; 
White Solid; 
T.L.C. System: n-hexane-DCM 6:4 v/v, Rf: 0.51; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP 45g, n-
hexane-DCM 100:0 increasing to n-hexane-DCM 20:80 in 10CV); 
Yield: 0.295 g (79%); 
1H-NMR (CDCl3), δ: 3.76 (s, 3H, H-19), 4.81 (d, J= 5.2 Hz, 2H, H-11), 6.53-6.57 (m, 1H, H-aromatic), 
6.63 (d, J= 8.5 Hz, 1H, H-aromatic), 7.22-7.26 (m, 1H, H-aromatic), 7.32-7.35 (m, 1H, H-aromatic), 
7.42-7.49 (m, 3H, H-aromatic), 7.71 (d, J= 8.3 Hz, 1H, H-aromatic), 7.81-7.83 (m, 1H, H-aromatic), 
7.87 (dd, J1= 8.0 Hz, J2= 1.7 Hz, 1H, H-aromatic), 7.97 (d, J= 8.3 Hz, 1H, H-aromatic), 8.09 (bs, 1H, 
NH).  
13C-NMR (CDCl3), δ: 51.5 (CH3, C-19), 44.9 (CH2, C-11), 111.6, 114.9, 123.0, 125.1, 125.5, 125.7, 
126.2, 127.9, 128.8, 131.6, 134.6 (CH, C-aromatic), 110.2, 131.3, 133.5, 133.8, 151.0 (C, C-aromatic), 
169.0 (C, C-18). 
UPLC-MS: Rt 2.66 (100%) MS (ESI)+: 292.0 [M+H]+. 
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2-(1H-Tetrazol-5-yl)-N-(4-(trifluoromethyl)benzyl)aniline (144) 
(C15H12F3N5; M.W.= 319.29) 
 
Reagent: 4-(trifluoromethyl)benzaldehyde (107) (0.100 g, 0.57 mmol); 
Reagent: 2-(1H-tetrazol-5-yl)aniline (84) (0.092 g, 0.57 mmol); 
General Procedure 11; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 6:4 v/v, Rf: 0.66; 
Purification: Recrystallisation from EtOH/Water; 
Yield: 0.059 g (32%); 
1H-NMR (DMSO-D6), δ: 4.70 (s, 2H, H-8), 6.73-6.78 (m, 2H, H-aromatic), 7.28-7.31 (m, 1H, H-
aromatic), 7.59 (d, J= 8.1 Hz, 2H, H-aromatic), 7.71 (d, J= 8.1 Hz, 2H, H-aromatic), 7.82-7.84 (m, 1H, 
H-aromatic)  
13C-NMR (DMSO-D6), δ: 46.1 (CH2, C-8), 112.4, 116.3, 125.8, 128.1, 129.0, 132.7 (CH, C-aromatic), 
106.3, 123.7, 127.9, 145.1, 146.7 (C-aromatic). 
19F-NMR (DMSO-D6), δ: -60.71 (s, 3F). 
UPLC-MS: Rt 1.95 (>99%) MS (ESI)+: 320.1 [M+H]+. 
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N-(3-Chloro-4-methylbenzyl)-2-(1H-tetrazol-5-yl)aniline (145) 
(C15H14ClN5; M.W.= 299.76) 
 
Reagent: 3-chloro-4-methylbenzaldehyde (109) (0.096 g, 0.62 mmol); 
Reagent: 2-(1H-tetrazol-5-yl)aniline (84) (0.100 g, 0.62 mmol); 
General Procedure 11; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 6:4 v/v, Rf: 0.37; 
Purification1: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 20:80 in 15CV); 
Purification2: Recrystallisation from DCM; 
Purification3: Recrystallisation from EtOH/Water; 
Yield: 0.036 g (25%); 
1H-NMR (DMSO-D6), δ: 2.30 (s, 3H, H-7), 4.54 (s, 2H, H-8), 6.74-6.78 (m, 2H, H-aromatic), 7.25 (d, J= 
7.5 Hz, 1H, H-aromatic), 7.30-7.32 (m, 2H, H-aromatic), 7.41 (s, 1H, H-6), 7.81 (d, J= 7.5 Hz, 1H, H-
aromatic).  
 13C-NMR (DMSO-D6), δ: 19.6 (CH3, C-7), 45.8 (CH2, C-8), 112.4, 116.2, 126.2, 127.7, 128.9, 131.8, 
132.7 (CH, C-aromatic), 133.0, 133.7, 134.3, 138.7, 139.8 (C, C-aromatic), 149.7 (C, C-15). 
UPLC-MS: Rt 2.33 (100%) MS (ESI)+: 300.0 [M+H]+. 
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N-(3-Chloro-4-methylbenzyl)-4-(1H-tetrazol-5-yl)aniline (146) 
(C15H14ClN5; M.W.= 299.76) 
 
Reagent: 3-chloro-4-methylbenzaldehyde (109) (0.096 g, 0.62 mmol); 
Reagent: 4-(1H-tetrazol-5-yl)aniline (85) (0.100 g, 0.62 mmol); 
General Procedure 11; 
White Solid; 
T.L.C. System: DCM-MeOH 95:5 v/v, Rf: 0.75; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP 25g, 
DCM-MeOH 100:0 increasing to DCM-MeOH 90:10 in 10CV); 
Yield: 0.027 g (15%); 
1H-NMR (DMSO-D6), δ: 2.29 (s, 3H, H-7), 4.33 (d, J= 5.9 Hz, 2H, H-8), 6.72 (d, 2H, J= 8.7 Hz, H-
aromatic), 6.94 (t, J= 5.9 Hz, 1H, NH), 7.23 (d, J= 7.9 Hz, 1H, H-3), 7.31 (d, J= 7.9 Hz, 1H, H-2), 7.40 (s, 
1H, H-6), 7.72 (d, J= 8.7 Hz, 2H, H-aromatic).  
 13C-NMR (DMSO-D6), δ: 19.6 (CH3, C-7), 45.4 (CH2, C-8), 112.8, 126.4, 127.8, 128.6, 131.6 (CH, C-
aromatic), 118.4, 133.8, 134.1, 140.0 (C, C-aromatic), 151.1 (C, C-14). 
UPLC-MS: Rt 2.05 (>98%) MS (ESI)+: 300.1 [M+H]+. 
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N-(Quinolin-8-ylmethyl)-2-(1H-tetrazol-5-yl)aniline (147) 
(C17H14N6; M.W.= 302.34) 
 
Reagent: quinoline-8-carbaldehyde (110) (0.098 g, 0.62 mmol); 
Reagent: 2-(1H-tetrazol-5-yl)aniline (84) (0.100 g, 0.62 mmol); 
General Procedure 11; 
Yellow Solid; 
T.L.C. System: n-hexane-EtOAc 5:5 v/v, Rf: 0.41; 
Purification1: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 0:100 in 15CV); 
Purification2: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP 
10g, DCM-MeOH 100:0 increasing to DCM-MeOH 98:2 in 15CV); 
Purification3: Recrystallisation from EtOH/Water; 
Yield: 0.023 g (12%); 
1H-NMR (DMSO-D6), δ: 5.18 (s, 2H, H-10), 6.71-6.74 (m, 1H, H-aromatic), 6.75-6.78 (m, 1H, H-
aromatic), 7.27-7.30 (m, 1H, H-aromatic), 7.55-7.58 (m, 1H, H-aromatic), 7.59-7.62 (m, 1H, H-
aromatic), 7.73-7.75 (m, 1H, H-aromatic), 7.80-8.82 (m, 1H, H-aromatic), 7.90-7.92 (m, 1H, H-
aromatic), 8.40-8.42 (m, 1H, H-aromatic), 8.98-9.00 (m, 1H, H-aromatic). 
 13C-NMR (DMSO-D6), δ: 43.0 (CH2, C-10), 112.3, 115.9, 122.0, 126.8, 127.7, 127.9, 128.9, 132.8, 
136.9, 150.3 (CH, C-aromatic), 128.4, 146.2, 147.1 (C-aromatic). 
UPLC-MS: Rt 1.68 (>96%) MS (ESI)+: 303.3 [M+H]+. 
 
                                                                                                                                      Chapter 9: Experimental 
271 
 
N-(Quinolin-3-ylmethyl)-2-(1H-tetrazol-5-yl)aniline (148) 
(C17H14N6; M.W.= 302.34) 
 
Reagent: quinoline-3-carbaldehyde (111) (0.097 g, 0.62 mmol); 
Reagent: 2-(1H-tetrazol-5-yl)aniline (84) (0.100 g, 0.62 mmol); 
General Procedure 11; 
Yellow Solid; 
T.L.C. System: DCM-MeOH 98:2 v/v, Rf: 0.32; 
Purification1: Trituration from MeOH; 
Purification2: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP 
10g, DCM-MeOH 100:0 increasing to DCM-MeOH 90:10 in 20CV); 
Yield: 0.0084 g (11%); 
1H-NMR (DMSO-D6), δ: 4.82 (s, 2H, H-10), 6.5-6.78 (m, 1H, H-aromatic), 6.86-6.88 (m, 1H, H-
aromatic), 7.29-31  (m, 1H, H-aromatic), 7.58-7.61 (m, 1H, H-aromatic), 7.72-7.75 (m, 1H, H-
aromatic),  7.83-7.85 (m, 1H, H-aromatic), 7.92-7.95 (m, 1H, H-aromatic), 8.01-8.03 (m, 1H, H-
aromatic), 8.29 (s, 1H, H-1), 8.97 (s, 1H, H-3).  
 13C-NMR (DMSO-D6), δ: 49.0 (CH2, C-10), 112.4, 116.3, 127.2, 128.3, 129.0, 129.1, 129.6, 132.6, 
133.8, 151.2 (CH, C-aromatic), 106.7, 127.9, 132.9, 146.6, 147.3 (C-aromatic). 
UPLC-MS: Rt 1.59 (>96%) MS (ESI)+: 303.1 [M+H]+. 
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N-(Naphthalen-2-ylmethyl)-2-(1H-tetrazol-5-yl)aniline (149) 
(C18H15N5; M.W.= 301.35) 
 
Reagent: 2-naphthaldehyde (127) (0.100 g, 0.64 mmol); 
Reagent: 2-(1H-tetrazol-5-yl)aniline (84) (0.103 g, 0.64 mmol); 
General Procedure 11; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 6:4 v/v, Rf: 0.57; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP 25g, 
n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 30:70 in 15CV); 
Yield: 0.144 g (75%); 
1H-NMR (DMSO-D6), δ: 4.74 (s, 2H, H-11), 6.74-6.77 (m, 1H, H-aromatic), 6.85 (d, J=8.3 Hz, 1H, H-
aromatic), 7.28-7.31 (m, 1H, H-aromatic), 7.47-7.52 (m, 2H, H-aromatic), 7.54 (d, J= 8.3 Hz, 1H, H-
aromatic), 7.81-7.87 (m, 2H, H-aromatic), 7.90-7.92 (m, 3H, H-aromatic). 
 13C-NMR (DMSO-D6), δ: 46.9 (CH2, C-11), 112.5, 116.1, 125.8, 126.1, 126.1, 126.7, 128.0, 128.0, 
128.6, 128.9, 132.70 (CH, C-aromatic), 132.72, 133.4, 137.8, 147.0 (C, C-aromatic). 
UPLC-MS: Rt 1.97 (>98%) MS (ESI)-: 300.2 [M-H]-. 
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3-(2-((3-Chloro-4-methylbenzyl)amino)phenyl)-1,2,4-oxadiazol-5(4H)-one (150) 
(C16H14ClN3O2; M.W.= 315.76) 
 
Reagent: 3-chloro-4-methylbenzaldehyde (109) (0.070 g, 0.45 mmol); 
Reagent: 3-(2-aminophenyl)-1,2,4-oxadiazol-5(4H)-one (96) (0.080 g, 0.45 mmol); 
General Procedure 11; 
Off-White Solid; 
T.L.C. System: n-hexane-EtOAc 6:4 v/v, Rf: 0.57; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP 25g, 
n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 20:80 in 12CV); 
Yield: 0.057 g (40%); 
1H-NMR (DMSO-D6), δ: 2.37 (s, 3H, H-7), 4.50 (s, 2H, H-8), 6.70-6.73 (m, 2H, H-aromatic), 7.08 (bs, 
1H, NH), 7.21 (d, J= 7.2 Hz, 1H, H-aromatic), 7.30-7.33 (m, 2H, H-aromatic), 7.39 (s, 1H, H-2), 7.55 (d, 
J= 7.2 Hz, 1H, H-aromatic), 12.79 (bs, 1H, NH).  
 13C-NMR (DMSO-D6), δ: 19.6 (CH3, C-7), 45.7 (CH2, C-8), 112.3, 116.1, 126.2, 127.7, 129.0, 131.8, 
133.3 (CH, C-aromatic), 105.5, 133.7, 134.3, 139.5, 146.9, 158.7 (C, C-aromatic), 159.5 (C, C-15). 
UPLC-MS: Rt 2.35 (>99%) MS (ESI)-: 314.1 [M-H]-. 
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9.3.2 Methyl((aryl)amino)benzoates (121-124) 
Methyl 2-((4-(trifluoromethyl)benzyl)amino)benzoate (121) 
(C16H14F3NO2; M.W.= 309.29) 
 
Reagent: 2-((4-(trifluoromethyl)benzyl)amino)benzoic acid (113) (0.050 g, 0.17 mmol); 
General Procedure 12; 
Yellow solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.40; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 70:30 in 15CV); 
Yield: 0.023 g (44%); 
1H-NMR (CDCl3), δ: 3.81 (s, 3H, H-16), 4.45 (d, J= 5.8 Hz, 2H, H-8), 6.45-6.48 (m, 1H, H-aromatic), 
6.54-6.57 (m, 1H, H-aromatic), 7.20-7.24 (m, 1H, H-aromatic), 7.39 (d, J= 8.0 Hz, 2H, H-aromatic), 
7.52 (d, J= 8.0 Hz, 2H, H-aromatic), 7.85-7.88 (m, 1H, H-aromatic), 8.18 (bs, 1H, NH). 
13C-NMR (CDCl3), δ: 51.6 (CH3, C-16), 46.5 (CH2, C-8), 111.5, 115.3, 125.6, 125.7, 131.7, 134.6 (CH, 
C-aromatic), 110.5, 125.6, 129.3, 143.1, 150.6 (C, C-aromatic), 169.1 (C, C-15). 
19F-NMR (CDCl3), δ: -62.43 (s, 3F). 
UPLC-MS: Rt 2.60 (>98%) MS (ESI)+: 310.1 [M+H]+. 
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Methyl 3-((4-(trifluoromethyl)benzyl)amino)benzoate (122) 
(C16H14F3NO2; M.W.= 309.29) 
 
Reagent: 3-((4-(trifluoromethyl)benzyl)amino)benzoic acid (114) (0.050 g, 0.17 mmol); 
General Procedure 12; 
White solid;  
T.L.C. System: n-hexane-EtOAc 5:5 v/v, Rf: 0.61; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 10g, 
n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 50:50 in 10CV); 
Yield: 0.020 g (38%); 
1H-NMR (CDCl3), δ: 3.81 (s, 3H, H-16), 4.19 (bs, 1H, NH), 4.38 (s, 2H, H-8), 6.68-6.71 (m, 1H, H-
aromatic), 7.13-7.17 (m, 1H, H-aromatic), 7.23-7.25 (m, 1H, H-aromatic), 7.31-7.34 (m, 1H, H-
aromatic), 7.41 (d, J= 8.0 Hz, 2H, H-aromatic), 7.53 (d, J= 8.0 Hz, 2H, H-aromatic).  
13C-NMR (CDCl3), δ: 52.0 (CH3, C-16), 47.7 (CH2, C-8), 113.6, 117.3, 119.2, 125.6, 127.5, 129.3 (CH, 
C-aromatic), 123.0, 129.2, 131.2, 143.0, 147.5 (C, C-aromatic), 167.3 (C, C-15). 
 19F-NMR (CDCl3), δ: -62.51 (s, 3F). 
UPLC-MS: Rt 2.38 (>99%) MS (ESI)+: 310.1 [M+H]+. 
 
 
 
 
 
 
                                                                                                                                      Chapter 9: Experimental 
276 
 
Methyl 2-((3,4-dimethylbenzyl)amino)benzoate (123) 
(C17H19NO2; M.W.= 269.34) 
 
Reagent: methyl 2-((3,4-dimethylbenzyl)amino)benzoate (115) (0.070 g, 0.27 mmol); 
General Procedure 12; 
Yellow solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.65; 
Purification1: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 70:30 in 10CV); 
Purification2: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 80:20 in 10CV); 
Purification3: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 90:10 in 10CV); 
Yield: 0.010 g (13%); 
1H-NMR (CDCl3), δ: 2.17 (d, J= 3.7 Hz, 6H, H-7,8), 3.77 (s, 3H, H-17), 4.30 (d, J=5.4 Hz, 2H, H-9), 6.49-
6.52 (m, 1H, H-aromatic), 6.56-6.59 (m, 1H, H-aromatic), 7.00-7.02 (m, 2H, H-aromatic), 7.04 (s, 1H, 
H-aromatic), 7.20-7.23 (m, 1H, H-aromatic), 7.83 (dd, J1= 8.0 Hz, J2= 1.6 Hz, 1H, H-aromatic), 8.01 
(bs, 1H, NH). 
13C-NMR (CDCl3), δ: 19.4 (CH3), 19.8 (CH3), 51.4 (CH3, C-17), 46.83(CH2, C-9), 111.6, 114.7, 124.5, 
128.5, 129.9, 131.5, 134.6 (CH, C-aromatic), 110.1, 135.4, 136.2, 136.8, 151.0 (C, C-aromatic), 169.1 
(C-16). 
UPLC-MS: Rt 2.68 (>99%) MS (ESI)+: 270.1 [M+H]+. 
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Methyl 3-((3,4-dimethylbenzyl)amino)benzoate (124) 
(C17H19NO2; M.W.= 269.34) 
 
Reagent: methyl 3-((3,4-dimethylbenzyl)amino)benzoate (116) (0.070 g, 0.27 mmol); 
General Procedure 12; 
Yellow solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.60; 
Purification1: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 60:40 in 10CV); 
Purification2: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 70:30 in 10CV); 
Yield: 0.019 g (26%); 
1H-NMR (CDCl3), δ: 2.18 (d, J= 2.5 Hz, 6H, H-7,8), 3.80 (s, 3H, H-17), 4.01 (bs, 1H, NH), 4.20 (s, 2H, H-
9), 6.71 (dd, J1= 8.0 Hz, J2= 2.2 Hz, 1H, H-aromatic), 7.00-7.04 (m, 2H, H-aromatic), 7.06 (s, 1H, H-6), 
7.11-7.15 (m, 1H, H-aromatic), 7.17 (s, 1H, H-15), 7.29 (d, J= 7.7 Hz, 1H, H-aromatic). 
13C-NMR (CDCl3), δ: 19.4 (CH3), 19.8 (CH3), 52.0 (CH3, C-17), 48.0 (CH2, C-9), 113.5, 117.2, 117.5, 
118.6, 125.9, 129.0, 129.9 (CH, C-aromatic), 131.0, 135.7, 136.2, 136.9, 148.2 (C, C-aromatic), 167.5 
(C, C-16). 
UPLC-MS: Rt 2.42 (>99%) MS (ESI)+: 270.1 [M+H]+. 
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9.3.3 (Aryl)amino)benzoic acids (139-143, 156) 
2-((Pyridin-3-ylmethyl)amino)benzoic acid (139) 
(C13H12N2O2; M.W.= 228.25) 
 
Reagent: methyl 2-((pyridin-3-ylmethyl)amino)benzoate (131) (0.100 g, 0.41 mmol); 
General Procedure 13; 
White Solid; 
T.L.C. System: n-hexane-EtOA: 5:5 v/v, Rf: 0.30; 
Purification: Recrystallisation from EtOH; 
Yield: 0.026 g (28%); 
1H-NMR (DMSO-D6), δ: 4.52 (S, 2H, H-6), 6.56-6.60 (m, 1H, H-aromatic), 6.69 (d, J= 8.4 Hz, 1H, H-
aromatic), 7.29-7.30 (m, 1H, H-aromatic), 7.34 (dd, J1= 7.7 Hz, J2= 4.7 Hz, 1H, H-4), 7.73 (d, J= 7.7 Hz, 
1H, H-5), 7.81 (dd, J1= 8.0 Hz, J2= 1.4 Hz, 1H, H-aromatic), 8.30 (bs, 1H, NH), 7.47 (d, J= 4.7 Hz, 1H, H-
3), 8.59 (s, 1H, H-2), 12.76 (bs, 1H, OH).  
 13C-NMR (DMSO-D6), δ: 43.7 (CH2, C-6), 112.1, 115.2, 124.1, 132.2, 134.8, 135.3, 148.6, 149.1 (CH, 
C-aromatic), 111.1, 135.4, 150.8 (C, C-aromatic), 170.4 (C, C-13). 
UPLC-MS: Rt 1.20 (>98%) MS (ESI)+: 229.1 [M+H]+. 
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2-((Pyridin-4-ylmethyl)amino)benzoic acid (140) 
(C13H12N2O2; M.W.= 228.25) 
 
Reagent: methyl 2-((pyridin-4-ylmethyl)amino)benzoate (132) (0.100 g, 0.41 mmol); 
General Procedure 13; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 5:5 v/v, Rf: 0.20; 
Purification1: Recrystallization from EtOH; 
Purification2: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 0:100 in 6CV and EtOAc-MeOH 80:20 in 
10CV); 
Yield: 0.025 g (26%); 
1H-NMR (DMSO-D6), δ: 4.54 (s, 2H, H-6), 6.53-6.56 (m, 1H, H-aromatic), 6.57-6.59 (m, 1H, H-
aromatic), 7.24-7.28 (m, 1H, H-aromatic), 7.32 (d, J= 7.8 Hz, 2H, H-aromatic), 7.82 (d, J= 7.8 Hz, 2H, 
H-aromatic), 8.48-8.53 (m, 2H, H-aromatic + NH), 12.74 (bs, 1H, OH).  
 13C-NMR (DMSO-D6), δ: 45.1 (CH2, C-6), 112.0, 115.6, 129.4, 132.2, 135.0, 150.6 (CH, C-aromatic), 
118.6, 136.5, 149.8 (C, C-aromatic), 151.1 (C, C-13). 
UPLC-MS: Rt 1.23 (100%) MS (ESI)+: 229.1 [M+H]+. 
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2-((Naphthalen-2-ylmethyl)amino)benzoic acid (141) 
(C18H15NO2; M.W.= 277.32) 
 
Reagent: methyl 2-((naphthalen-2-ylmethyl)amino)benzoate (133) (0.100 g, 0.34 mmol); 
General Procedure 13; 
White Solid; 
T.L.C. System: n-hexane-EtOA: 6:4 v/v, Rf: 0.84; 
Yield: 0.084 g (89%); 
1H-NMR (DMSO-D6), δ: 4.64 (S, 2H, H-11), 6.54-6.58 (m, 1H, H-aromatic), 6.72 (d, J= 8.2 Hz, 1H, H-
aromatic), 7.27-7.30 (m, 1H, H-aromatic), 7.47-7.53 (m, 3H, H-aromatic), 7.82 (dd, J1= 7.9 Hz, J2= 1.5 
Hz, 1H, H-aromatic), 7.85-7.88 (m, 2H, H-aromatic), 7.89-7.92 (m, 2H, H-aromatic), 8.41 (bs, 1H, NH), 
12.68 (bs, 1H, OH).  
 13C-NMR (DMSO-D6), δ: 45.5 (CH2, C-11), 112.2, 115.0, 125.6, 126.0, 126.1, 126.7, 128.01, 128.04, 
128.6, 132.1, 134.8 (CH, C-aromatic), 110.8, 132.7, 133.4, 137.5, 151.1 (C, C-aromatic), 170.5 (C, C-
18). 
UPLC-MS: Rt 2.32 (99%) MS (ESI)+: 278.0 [M+H]+. 
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2-((|Naphthalen-1-ylmethyl)amino)benzoic acid (142) 
(C18H15NO2; M.W.= 277.32) 
 
Reagent: methyl 2-((naphthalen-1-ylmethyl)amino)benzoate (134) (0.1 g, 0.34 mmol); 
General Procedure 13; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.50; 
Purification: Recrystallisation from EtOH; 
Yield: 0.039 g (41%); 
1H-NMR (DMSO-D6), δ: 4.91 (s, 2H, H-11), 6.51-6.61 (m, 1H, H-aromatic), 6.78 (dd, J1= 8.7 Hz, J2= 0.4 
Hz, 1H, H-aromatic), 7.32-7.35 (m, 1H, H-aromatic), 7.46-7.50 (m, 2H, H-aromatic), 7.55-7.61 (m, 2H, 
H-aromatic), 7.83 (dd, J1= 7.9 Hz, J2= 1.6 Hz, 1H, H-aromatic), 7.87 (dd, J1= 7.4 Hz, J2= 1.3 Hz, 1H, H-
aromatic), 7.97-8.00 (m, 1H, H-aromatic), 8.11-8.12 (m, 1H, H-aromatic), 8.26 (bs, 1H, NH), 12.63 
(bs, 1H, OH). 
13C-NMR (DMSO-D6), δ: 44.4 (CH2, C-11), 112.1, 115.0, 123.8, 125.3, 126.0, 126.3, 126.7, 128.1, 
129.0, 132.1, 134.9 (CH, C-aromatic), 110.7, 131.3, 133.9, 134.6 (C, C-aromatic), 170.4 (C, C- 18). 
UPLC-MS: Rt 2.33 (99%) MS (ESI)+: 278.1 [M+H]+. 
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2-((4-(Trifluoromethyl)phenethyl)amino)benzoic acid (143) 
(C16H14F3NO2; M.W.= 309.29) 
 
Reagent: methyl 2-((4-(trifluoromethyl)phenethyl)amino)benzoate (136) (0.035 g, 0.1 mmol); 
General Procedure 13; 
Pale Yellow Solid; 
T.L.C. System: n-hexane-EtOAc 6:4 v/v, Rf: 0.10; 
Purification: Recrystallisation from EtOH/Water; 
Yield: 0.005 g (16%); 
1H-NMR (CDCl3), δ: 3.07 (t, J= 7.06 Hz, 2H, H-alkyl), 3.54 (t, J= 7.06 Hz, 2H, H-alkyl), 6.66-6.69 (m, 1H, 
H-aromatic), 6.74-6.76 (m, 1H, H-aromatic), 7.41 (d, J= 7.7 Hz, 2H, H-aromatic), 7.44-7.46 (m, 1H, H-
aromatic), 7.62 (d, J= 7.7 Hz, 2H, H-aromatic), 7.72 (bs, 1H, NH), 8.01 (dd, J1= 7.9 Hz, J2= 1.3 Hz, 1H, 
H-aromatic), 11.24 (bs, 1H, OH). 
13C-NMR (CDCl3), δ: 35.3, 43.9 (2xCH2, C-8,9), 111.2, 115.0, 125.5, 129.1, 132.7, 135.7 (CH, C-
aromatic), 128.8 (d, J= 32.42 Hz, C) 102.5, 108.7, 143.1, 151.3 (C, C-aromatic), 173.2 (C, C- 15). 
19F-NMR (CDCl3), δ: -62.3 (s, 3F). 
UPLC-MS: Rt 2.37 (100%) MS (ESI)+: 310.1 [M+H]+. 
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2-(((5-Chloro-2-methylphenyl)amino)methyl)benzoic acid (156) 
(C15H14ClNO2; M.W.= 275.73) 
 
Reagent: methyl 2-(((5-chloro-2-methylphenyl)amino)methyl)benzoate (163) (0.040 g, 0.13 mmol); 
General Procedure13; 
White Solid; 
T.L.C. System: DCM-MeOH 98:2 v/v, Rf: 0.47; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
10g, DCM-MeOH 100:0 increasing to DCM-MeOH 95:5 in 10CV) ; 
Yield: 0.018 g (53%); 
1H-NMR (DMSO-D6), δ: 2.14 (s, 3H, H-7), 4.68 (s, 2H, H-8), 5.94 (bs, 1H, NH), 6.23 (d, J= 2.0 Hz, 1H, 
H-2), 6.47 (dd, J1= 7.8 Hz, J2= 2.0 Hz, 1H, H-4), 6.97 (d, J= 7.8 Hz, 1H, H-5), 7.33-7.37 (m, 1H, H-
aromatic), 7.42 (d, J= 7.3 Hz, 1H, H-aromatic), 7.49-7.52 (m, 1H, H-aromatic), 7.89 (dd, J1= 7.7 Hz, J2= 
1.2 Hz, 1H, H-aromatic), 13.09 (bs, 1H, OH). 
13C-NMR (DMSO-D6), δ: 17.6 (CH3, C-7), 45.2 (CH2, C-8), 109.0, 115.3, 127.2, 128.0, 131.0, 131.4, 
132.4 (CH, C-aromatic), 121.1, 130.1, 131.6, 141.3, 147.9 (C, C-aromatic), 169.1 (C, C- 15). 
UPLC-MS: Rt 2.19 (100%) MS (ESI)+: 276.0 [M+H]+. 
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9.3.4 Methyl 2-(aryl)amino)methyl)benzoates (162-164) 
Methyl 2-(((3-chloro-4-methylphenyl)amino)methyl)benzoate (162) 
(C16H16ClNO2; M.W.= 289.76) 
 
Reagent: 3-chloro-4-methylaniline (152) (0.062 g, 0.43 mmol); 
Reagent: methyl 2-(bromomethyl)benzoate (61) (0.200 g, 0.87 mmol); 
General Procedure14; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 90:10 v/v, Rf: 0.40; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 30g, 
n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 80:20 in 15CV) ; 
Yield: 0.087 g (74%); 
1H-NMR (CDCl3), δ: 2.24 (s, 3H, H-16), 3.93 (s, 3H, H-8), 4.46 (bs, 1H, NH),  4.65 (s, 2H, H-9), 6.24 (dd, 
J1= 8.1 Hz, J2=2.2 Hz, 1H, H-11), 6.65 (d, J= 2.2 Hz, 1H, H-15),  6.99 (d, J= 8.1 Hz, 1H, H-12), 7.34-7.37 
(m, 1H, H-aromatic), 7.48-7.52 (m, 2H, H-aromatic), 7.99-8.01 (m, 1H, H-aromatic). 
UPLC-MS: Rt 2.49 (90%) MS (ESI)+: 291.1 [M+H]+. 
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Methyl 2-(((5-chloro-2-methylphenyl)amino)methyl)benzoate (163) 
(C16H16ClNO2; M.W.= 289.76) 
 
Reagent: 5-chloro-2-methylaniline (153) (0.062 g, 0.43 mmol); 
Reagent: methyl 2-(bromomethyl)benzoate (61) (0.200 g, 0.87 mmol); 
General Procedure14; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 90:10 v/v, Rf: 0.40; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 80:20 in 15CV) ; 
Yield: 0.047 g (38%); 
1H-NMR (CDCl3), δ: 2.03 (s, 3H, H-16), 3.83 (s, 3H, H-8), 4.39 (bs, 1H, NH),  4.61 (d, J= 6.1 Hz, 2H, H-
9), 6.48 (d, J= 2.0 Hz, 1H, H-15),  6.51 (dd, J1= 7.8 Hz, J2=2.0 Hz, 1H, H-13), 6.86 (dd, J1= 7.8 HZ, J2= 
0.7 Hz, 1H, H-aromatic), 7.26-7.29 (m, 1H, H-aromatic), 7.40-7.42 (m, 2H, H-aromatic), 7.90-7.92 (m, 
1H, H-aromatic). 
UPLC-MS: Rt 2.49 (97%) MS (ESI)+: 291.8 [M+H]+. 
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Methyl 2-(((4-(trifluoromethyl)phenyl)amino)methyl)benzoate (164) 
(C16H14F3NO2; M.W.= 309.10) 
 
Reagent: 1-methyl-4-(trifluoromethyl)benzene (154) (0.046 g, 0.28 mmol); 
Reagent: methyl 2-(bromomethyl)benzoate (61) (0.066 g, 0.28 mmol); 
General Procedure14; 
White Solid; 
T.L.C. System: n-hexane-EtOAc 90:10 v/v, Rf: 0.40; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 60:40 in 15CV); 
Yield: 0.037 g (43%); 
1H-NMR (CDCl3), δ: 3.84 (s, 3H, H-8), 4.63 (d, J= 6.2 Hz, 2H, H-9), 4.79 (bs, 1H, NH),  6.53 (d, J= 8.5 
Hz, 2H, H-aromatic), 7.16-7.30 (m, 3H, H-aromatic), 7.40-7.41 (m, 2H, H-aromatic), 7.92-7.94 (m, 1H, 
H-aromatic). 
19F-NMR (CDCl3), δ: -62.06 (s, 3F)  
UPLC-MS: Rt 2.44 (>96%) MS (ESI)+: 310.1 [M+H]+. 
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Lactam Derivatives (158-160) 
2-(3-Chloro-4-methylphenyl)isoindolin-1-one (158) 
(C15H12ClNO; M.W.= 257.72) 
 
Reagent: 3-chloro-4-methylaniline (152) (0.108 g, 0.76 mmol); 
Reagent: 2-(bromomethyl)benzoic acid (151) (0.150 g, 0.69 mmol); 
Off-White Solid; 
T.L.C. System: n-hexane-EtOAc 6:4 v/v, Rf: 0.40; 
Purification: Recrystallisation from EtOH;   
Yield: 0.063 g (37%); 
1H-NMR (DMSO-D6), δ: 2.34 (s, 3H, H-7), 5.03 (s, 2H, H-8), 7.41-7.43 (m, 1H, H-aromatic), 7.54-7.57 
(m, 1H, H-aromatic), 7.66-7.71 (m, 2H, H-aromatic), 7.72 (dd, J1= 8.5 Hz, J2= 2.3 Hz, 1H, H-6), 7.79-
7.80 (m, 1H, H-aromatic), 8.09 (d, J= 2.3 Hz, 1H, H-2). 
 13C-NMR (DMSO-D6), δ: 19.4 (CH3, C-7), 50.8 (CH2, C-8), 118.1, 119.7, 123.7, 123.8, 128.7, 131.8, 
132.9 (CH, C-aromatic), 131.2, 132.6, 135.8, 139.0, 141.4 (C, C-aromatic), 167.2 (C, C-15). 
UPLC-MS: Rt 2.32 (100%) MS (ESI)+: 258.0 [M+H]+. 
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2-(5-Chloro-2-methylphenyl)isoindolin-1-one (159) 
(C15H12ClNO; M.W.= 257.72) 
 
Reagent: 5-chloro-2-methylaniline (153) (0.108 g, 0.76 mmol); 
Reagent: 2-(bromomethyl)benzoic acid (151) (0.150 g, 0.69 mmol); 
Colourless oil; 
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.6; 
Purification1: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 60:40 in 10CV); 
Purification2: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP 
10g, n-hexane-DCM 100:0 increasing to n-hexane-DCM 0:100 in 15CV);   
Yield: 0.073 g (38%); 
1H-NMR (DMSO-D6), δ: 2.16 (s, 3H, H-7), 4.89 (s, 2H, H-8), 7.36-7.40 (m, 2H, H-aromatic), 7.55-7.59 
(m, 2H, H-aromatic), 7.66-7.71 (m, 2H, H-aromatic), 7.79 (d, J= 7.4 Hz, 1H, H-aromatic). 
 13C-NMR (DMSO-D6), δ: 17.9 (CH3, C-7), 52.8 (CH2, C-8), 123.7, 123.9, 127.8, 128.0, 128.6, 132.4, 
132.6 (CH, C-aromatic), 130.8, 131.9, 135.6, 139.2, 142.9 (C, C-aromatic), 166.8 (C, C-15). 
UPLC-MS: Rt 2.10 (100%) MS (ESI)+: 258.0 [M+H]+. 
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2-(4-(Trifluoromethyl)phenyl)isoindolin-1-one (160) 
(C15H10F3NO; M.W.= 277.25) 
 
Reagent: 4-(trifluoromethyl)aniline (154) (0.165 g, 1.02 mmol); 
Reagent: 2-(bromomethyl)benzoic acid (151) (0.2 g, 0.93mmol); 
White Solid; 
T.L.C. System: n-hexane-EtOAc 9:1 v/v, Rf: 0.20; 
Purification: Recrystallisation from EtOH; 
Yield: 0.087 g (32%); 
1H-NMR (CDCl3), δ: 4.92 (s, 2H, H-8), 7.54-7.57 (m, 2H, H-aromatic), 7.64-7.68 (m, 1H, H-aromatic), 
7.71 (d, J= 8.5 Hz, 2H, H-aromatic), 7.96-7.98 (m, 1H, H-aromatic), 8.05 (d, J= 8,5 Hz, 2H, H-aromatic). 
13C-NMR (CDCl3), δ: 50.5 (CH2, C-8), 118.5, 122.7, 124.4, 126.4, 128.6, 132.6 (CH, C-aromatic), 126.3 
(d, J= 27.5 Hz, C, C-aromatic), 126.3, 126.4, 139.8, 142.0 (C, C-aromatic), 198.0 (C, C- 11). 
19F-NMR (CDCl3), δ: -62.06 (s, 3F)  
UPLC-MS: Rt 2.28 (100%) MS (ESI)+: 278.0 [M+H]+. 
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9.4 Synthesis of methylene derivatives 
General Procedure 15: methyl(benzyl)benzoates (169-170) (33) 
 
A round bottom flask was charged with Pd(OAc)2 (0.001 eq), PPh3 (0.002 eq), the appropriate 
arylboronic acid (1.5 eq), and K3PO4 (2 eq), under N2 atmosphere. Then the appropriate benzyl 
bromide (1 eq) and toluene (4.5 mL/mmol) were added. The reaction was stirred at 80°C for 48 
hours.  The solution was diluted with diethyl ether (15 mL/mmol) and washed with NaOH 1M 
solution (10 mL/mmol), brine (10 mL/mmol) and then dried over MgSO4. The residue obtained were 
purified by flash column chromatography. 
Synthesis of methyl 2-(3-chloro-4-methylbenzyl)benzoate (171) (34) 
((C16H15ClO2; M.W.=274.74) 
 
To a solution of (3-chloro-4-methylphenyl)boronic acid (0.111 g, 0.94 mmol) and (2-
bromomethyl)benzoate (0.150 g, 0.65 mmol) in EtOH (1.5 mL), water (0.4 mL) and toluene (1.2 mL) 
was added Na2CO3 1M (0.075 g, 0.72 mmol) and catalytic amount of  Pd(PPh3)4. The reaction was 
stirred at 80°C for 2 days. The solution was then filtered through celite and the solvent was 
evaporated. The residue diluted with water and extracted with diethyl ether (3x10 mL). The organic 
layer was dried over MgSO4 and evaporated under reduced pressure. The crude product was used 
for the next step without further purification. 
Colourless oil;  
T.L.C. System: n-hexane-DCM 6:4 v/v, Rf: 0.51; 
Yield: 0.100 g (56%) 
1H-NMR (CDCl3), δ: 2.24 (s, 3H, H-7), 3.76 (s, 3H, H-16), 4.24 (s, 2H), 6.85-6.87 (m, 1H, H-aromatic), 
7.03 (d, J= 7.9 Hz, 1H, H-aromatic), 7.04-7.06 (m, 1H, H-aromatic), 7.13 (d, J= 7.9 Hz, 1H, H-aromatic), 
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7.20-7.24 (m, 1H, H-aromatic), 7.35-7.38 (m, 1H, H-aromatic), 7.83 (dd, J1= 7.8 Hz, J2= 1.3 Hz, 1H, H-
aromatic). 
13C-NMR (CDCl3), δ: 19.6 (CH3), 51.8 (CH3), 38.9 (CH2), 126.7, 127.1, 129.4, 130.8, 131.0, 131.6, 
132.30 (CH, C-aromatic), 129.80, 133.49, 134.19, 140.24, 141.71 (C, C-aromatic), 167.9 (C, C-15). 
General Procedure 16: benzyl benzoic acids (172-173) (14) 
 
To a solution of the appropriate methyl-(arylamino) benzoate (1 eq) in THF (7 mL/mmol), H2O (3.5 
mL/mmol), MeOH (3.5 mL/mmol) was added LiOH (3 eq). The reaction was stirred ad 70°C 
overnight. After the reaction was allowed to cool to room temperature, the reaction mixture was 
acidified with 2M HCl. The product was extracted with ethyl acetate (3x10 mL/mmol). The organic 
layer was dried over MgSO4 and evaporated under reduced pressure. The product was purified by 
flash column chromatography or recrystallisation. 
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9.4.1 Methyl(benzyl)benzoates (169-170) 
Methyl 2-(4-(trifluoromethyl)benzyl)benzoate (169) 
(C16H13F3O2; M.W.= 294.09) 
 
Reagent: 1-(bromomethyl)-4-(trifluoromethyl)benzene (165) (0.150 g, 0.67 mmol); 
Reagent: (2-(methoxycarbonyl)phenyl)boronic acid (167) (0.170 g, 0.94 mmol); 
General Procedure 15; 
Colourless oil;  
T.L.C. System: n-hexane-EtOAc 9:1 v/v, Rf: 0.61; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-DCM 100:0 increasing to n-hexane-DCM 60:40 in 15CV); 
Yield: 0.074 g (37%); 
1H-NMR (CDCl3), δ: 3.84 (s, 3H, H-16), 4.47 (s, 2H, H-8), 7.24-7.26 (m, 1H, H-aromatic), 7.27 (d, J= 
8.2 Hz, 2H, H-aromatic), 7.33-7.37 (m, 1H, H-aromatic), 7.47-7.51 (m, 1H, H-aromatic), 7.53 (d, J= 
8.2 Hz, 2H, H-aromatic), 7.97 (dd, J1= 7.8 Hz, J2= 1.4 Hz, 1H, H-aromatic). 
13C-NMR (CDCl3), δ: 52.0 (CH3, C-16), 39.5 (CH2, C-8), 125.4, 126.7, 128.1, 128.8, 129.0, 129.7 (CH, 
C-aromatic), 125.5, 128.3, 128.7, 141.1, 145.1 (C, C-aromatic), 167.7 (C, C-15). 
19F-NMR (CDCl3), δ:  -62.40 (s, 3F). 
UPLC-MS: Rt 2.54 (100%) MS (ESI)+: 295.9 [M+H]+. 
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Methyl 3-(3-chloro-4-methylbenzyl)benzoate (170) 
(C16H15ClO2; M.W.=274.74) 
 
Reagent: methyl 3-(bromomethyl)benzoate (166) (0.100 g, 0.44 mmol); 
Reagent: (3-chloro-4-methylphenyl)boronic acid (168) (0.170 g, 0.94 mmol); 
General Procedure 15; 
Colourless oil;  
T.L.C. System: n-hexane-EtOAc 9:1 v/v, Rf: 0.48; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-EtOAC 100:0 increasing to n-hexane-EtOAC 80:20 in 15CV); 
Yield: 0.070 g (58%); 
1H-NMR (CDCl3), δ: 2.25 (s, 3H, H-7), 3.83 (s, 3H, H-16), 3.88 (s, 2H, H-8), 6.89 (dd, J1= 7.7 Hz, J2= 1.3 
Hz, 1H, H-aromatic), 7.06 (d, J= 7.7 Hz, 1H, H-aromatic), 7.08-7.10 (m, 1H, H-aromatic), 7.14-7.16 
(m, 1H, H-aromatic), 7.27-7.30 (m, 1H, H-aromatic), 7.40-7.44 (m, 1H, H-aromatic), 8.01 (dd, J1= 7.8 
Hz, J2= 1.3 Hz, 2H, H-aromatic), 7.79-7.83 (m, 2H, H-aromatic). 
13C-NMR (CDCl3), δ: 19.6 (CH3), 52.1 (CH3), 40.9 (CH2), 127.1, 127.6, 128.6, 129.31, 131.0, 133.9, 
140.9 (CH, C-aromatic), 129.33, 130.4, 133.4, 134.4, 139.7 (C, C-aromatic), 161.1 (C, C-15). 
UPLC-MS: Rt 2.62 (>95%) MS (ESI)+: 275.0 [M+H]+. 
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9.4.2 Benzyl benzoic acids (172-173) 
3-(3-Chloro-4-methylbenzyl)benzoic acid (172) 
(C15H13ClO2; M.W.= 260.72) 
 
Reagent: methyl 3-(3-chloro-4-methylbenzyl)benzoate (170) (0.050 g, 0.18 mmol); 
General Procedure 16; 
White solid;  
T.L.C. System: n-hexane-EtOAc 6:4 v/v, Rf: 0.20; 
Purification: Precipitation in acid aqueous solution; 
Yield: 0.032 g (74%); 
1H-NMR (CDCl3), δ: 2.36 (s, 3H, H-7), 4.00 (s, 2H, H-8), 6.99-7.01 (m, 1H, H-aromatic), 7.12 (d, J= 7.6 
Hz, 1H, H-aromatic), 7.18-7.20 (m, 1H, H-aromatic), 7.42 (d, J= 7.6 Hz, 1H, H-aromatic), 7.43-7.45 
(m, 1H, H-aromatic), 7.96 (s, 1H, H-aromatic), 7.98-7.80 (m, 1H, H-aromatic), 11.31 (bs, 1H, OH). 
13C-NMR (CDCl3), δ: 19.6 (CH3, C-7), 40.8 (CH2, C-8), 127.1, 128.2, 128.8, 129.3, 130.5, 131.1, 134.0 
(CH, C-aromatic), 129.4, 134.3, 134.4, 139.5, 141.1 (C, C-aromatic), 171.3 (C, C-15). 
UPLC-MS: Rt 2.30 (>98%) MS (ESI)-: 259.56 [M-H]-. 
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2-(3-Chloro-4-methylbenzyl)benzoic acid (173) 
(C15H13ClO2; M.W.= 260.72) 
 
Reagent: methyl 2-(3-chloro-4-methylbenzyl)benzoate (171) (0.096 g, 0.35 mmol); 
General Procedure 16; 
White solid;  
T.L.C. System: n-hexane-EtOAc 6:4 v/v, Rf: 0.40; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: ZIP KP SIL 10g, 
n-hexane-EtOAc  100:0 increasing to n-hexane-EtOAc 40:60 in 14CV); 
Yield: 0.061 g (67%); 
1H-NMR (CDCl3), δ: 2.24 (s, 3H, H-7), 4.31 (s, 2H, H-8), 6.88 (dd, J1= 7.7 Hz, J2= 1.5 Hz, 1H, H-4), 7.03 
(d, J= 7.7 Hz, 1H, H-3), 7.06 (d, J= 1,5 Hz, 1H, H-6), 7.14-7.16 (m, 1H, H-aromatic), 7.25-7.28 (m, 1H, 
H-aromatic), 7.40-7.44 (m, 1H, H-aromatic), 8.01 (dd, J1= 7.8 Hz, J2= 1.3 Hz, 1H, H-aromatic), 11.36 
(bs, 1H, OH). 
13C-NMR (CDCl3), δ: 19.6 (CH3, C-7), 38.9 (CH2, C-8), 126.6, 127.3, 129.4, 130.8, 131.7, 131.8, 133.1 
(CH, C-aromatic), 128.2, 133.5, 134.2, 140.0, 142.8 (C, C-aromatic), 172.1 (C, C-15). 
UPLC-MS: Rt 2.31 (>98%) MS (ESI)-: 259.1 [M-H]-. 
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9.5 Synthesis of amide derivatives 
General Procedure 17: alkyl 2-arylamido benzoates (178-183) (35) 
 
A solution of differently substituted benzoyl chloride (1 eq) in THF (1.5 mL/mmol) was slowly added 
at 0°C to a solution of the appropriate alkyl aminobenzoate (1.1 eq) and NEt3 (1.1 eq) in THF (6.5 
mL/mmol). The reaction was stirred at room temperature for 6 hours. The formed salt was removed 
by filtration and washed with THF. The solvent was removed under reduced pressure. The crude 
product was purified by flash column chromatography or recrystallization. 
Synthesis of 3-chloro-2-methy benzoyl chloride (177) (36) 
(C8H6Cl2O; M.W.= 189.04) 
 
To a solution of 3-chloro-2-methyl carboxylic acid (0.3 g, 1.75 mmol) in dry DCM (5 mL) was added 
dropwise at 0°C oxalyl chloride (0.18 mL, 2.11 mmol), followed by addition of a catalytic amount (3 
drops) of DMF. The reaction was stirred at room temperature, under nitrogen atmosphere for 4 
hours. The solvent was then removed under vacuum to afford the desired product. 
Yellow oil;  
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.60; 
Yield: 0.303 g (92%); 
1H-NMR (CDCl3), δ: 2.51 (s, 3H, H-7), 7.18-7.22 (m, 1H, H-aromatic), 7.53 (dd, J1= 1.2 Hz, J2= 7.0 Hz, 
1H, H-aromatic), 7.93 (m, 1H, H-aromatic). 
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Synthesis of 3-chloro-4-methyl benzoyl chloride (185) (37) 
(C8H6Cl2O; M.W.= 189.04) 
 
SOCl2 (0.696 g, 5.85 mmol) was added to a solution of 3-chloro-4-methyl benzoic acid (0.200 g, 1.17 
mmol) in CH2Cl2 (2 mL). The mixture was stirred and refluxed for 24 hours, then evaporated until 
dryness to afford the desired product. 
Yellow oil;  
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.60; 
Yield: 0.110 g (50%); 
1H-NMR (CDCl3), δ: 2.09 (s, 3H, H-7), 7.30 (d, J= 8.3 Hz, 1H, H3), 7.83 (dd, J1= 8.3 Hz, J2= 1.9 Hz, 1H, 
H-2), 8.01 (d, J= 1.9 Hz, 1H, H-aromatic). 
13C-NMR (CDCl3), δ: 20.6 (CH3, C-7), 129.4, 131.3, 131.7 (CH, C-aromatic), 99.0, 124.2, 134.2 (C, C-
aromatic), 144.6 (C, C-8). 
Synthesis of 2-(3-chloro-4-methylbenzamido)benzoic acid (186) (38) 
(C15H12ClNO3; M.W.= 289.72) 
 
A mixture of anthranilic acid (0.020 g, 0.14 mmol), NEt3 (0.018 g, 0.18 mmol) and CH2Cl2 (4 mL) was 
stirred at room temperature. 3-chloro-4-methyl benzoyl chloride (0.030 g, 0.15 mmol) was then 
added slowly at 0oC. The reaction was stirred overnight. The reaction mixture was washed with 
water and extracted with CH2Cl2 (20 mL x 2). The organic layers were combined, dried over sodium 
sulfate, and concentrated under reduced pressure. The product was purified by recrystallisation 
from EtOH/Water. 
White solid;  
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T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.50; 
Purification: Recrystallisation from EtOH; 
Yield: 0.021 g (52%); 
1H-NMR (DMSO-D6), δ: 2.48 (s, 3H, H-7), 7.19-7.22 (m, 1H, H-aromatic), 7.40 (d, J= 7.9 Hz, 1H, H-13), 
7.68-7.72 (m, 1H, H-aromatic), 7.82 (dd, J1= 7.9 Hz, J2= 1.6 Hz, 1H, H-14), 7.83 (d, J= 1.6 Hz, 1H, H-
10), 8.20 (dd, J1= 8.0 Hz, J2= 1.4 Hz, 1H, H-aromatic), 8.94-8.96 (m, 1H, H-aromatic), 11.85 (bs, 1H, 
NH). 
13C-NMR (DMSO-D6), δ: 20.2 (CH3, C-15), 120.5, 122.9, 125.3, 128.4, 131.2, 131.9, 135.9 (CH, C-
aromatic), 113.8, 134.0, 135.1, 140.5, 142.3 (C, C-aromatic), 164.5, 171.2 (C, C-carbonyl). 
UPLC-MS: Rt 2.25 (99%) MS (ESI)+: 290.1 [M+H]+. 
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9.5.1 Alkyl 2-arylamido benzoates (178-183) 
Ethyl 3-(4-(trifluoromethyl)benzamido)benzoate (178) 
(C17H14F3NO3; M.W.= 337.30) 
 
Reagent: 4-(trifluoromethyl)benzoyl chloride  (174) (0.150 g, 0.72 mmol); 
Reagent: ethyl 3-aminobenzoate (45) (0.130 g, 0.72 mmol); 
General Procedure 17; 
White solid;  
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.44; 
Purification1: Recrystallisation from EtOH; 
Purification 2: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 60:40 in 10CV); 
Purification 3: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
10g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 65:30 in 10CV); 
Yield: 0.117 g (44%); 
1H-NMR (DMSO-D6), δ: 1.34 (t, J= 7.1 Hz, 3H, H-17), 4.35 (q, J= 7.1 Hz, 2H, H-16), 7.52-7.55 (m, 1H, 
H-aromatic), 7.72-7.74 (m, 1H, H-aromatic), 7.94 (d, J= 8.1 Hz, 2H, H-aromatic), 8.08-8.11 (m, 1H, H-
aromatic), 8.19 (d, J= 8.1 Hz, 2H, H-aromatic), 8.43-8.45 (m, 1H, H-aromatic), 10.68 (bs, 1H, NH). 
13C-NMR (DMSO-D6), δ: 14.6 (CH3, C-17), 61.3 (CH2, C-16), 121.3, 124.3, 125.0, 125.2, 125.90, 125.93 
(CH, C-aromatic), 129.1, 129.6, 130.8, 138.8, 139.6 (C, C-aromatic), 165.0, 166.0(C, C-8,15). 
19 F-NMR (DMSO-D6), δ: -61.33 (s, 3F). 
UPLC-MS: Rt 2.31 (100%) MS (ESI)+: 338.2 [M+H]+. 
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Methyl 2-(4-(trifluoromethyl)benzamido)benzoate (179) 
(C16H12F3NO3; M.W.= 323.27) 
 
Reagent: 4-(trifluoromethyl)benzoyl chloride (174) (0.500 g, 2.39 mmol); 
Reagent: methyl 2-aminobenzoate (18) (0.362 g, 2.39 mmol); 
General Procedure 17; 
White solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.59; 
Purification: Recrystallisation from EtOH; 
Yield: 0.275 g (37%); 
1H-NMR (DMSO-D6), δ: 3.84 (s, 3H, H-16), 7.28-7.31 (m, 1H, H-aromatic), 7.69-7.33 (m, 1H, H-
aromatic), 7.99 (d, J= 8.2 Hz, 2H, H-aromatic), 8.01-8.03 (m, 1H, H-aromatic), 8.16 (d, J= 8.2 Hz, 2H, 
H-aromatic), 8.46 (dd, J1= 7.3 Hz, J2= 1.0 Hz, 1H, H-aromatic), 11.59 (bs, 1H, NH). 
13C-NMR (DMSO-D6), δ: 53.1 (CH3, C-16), 121., 125.3, 126.5, 128.5, 131.1, 134.7 (CH, C-aromatic), 
118.6, 132.4, 138.6, 139.3, 140.8, (C, C-aromatic), 164.1, 168.3 (C, C-8,15). 
19 F-NMR (DMSO-D6), δ: -61.41 (s, 3F). 
UPLC-MS: Rt 2.52 (100%) MS (ESI)+: 324.2 [M+H]+. 
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Methyl 3-(4-(trifluoromethyl)benzamido)benzoate (180) 
(C16H12F3NO3; M.W.= 323.27) 
 
Reagent: 4-(trifluoromethyl)benzoyl chloride (174) (0.500 g, 2.39 mmol); 
Reagent: methyl 3-aminobenzoate (19) (0.362 g, 2.39 mmol); 
General Procedure 17; 
White solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.50; 
Purification: Recrystallisation from EtOH; 
Yield: 0.700 g (90%); 
1H-NMR (CDCl3), δ: 3.93 (s, 3H, H-16), 7.47-7.50 (m, 1H, H-aromatic), 7.70 (d, J= 8.3 Hz, 2H, H-
aromatic), 7.85-7.87 (m, 1H, H-aromatic), 8.02 (d, J= 8.3 Hz, 2H, H-aromatic), 8.05-8.07 (m, 1H, H-
aromatic), 8.15-8.17 (m, 1H, H-aromatic), 8.23 (bs, 1H, NH). 
13C-NMR (CDCl3), δ: 53.3 (CH3, C-16), 121.9, 124.8, 125.9, 126.0, 127.6, 129.3 (CH, C-aromatic), 
122.6, 124.6, 131.0, 133.7, 135.8, (C, C-aromatic), 164.6, 166.6 (C, C-8,15). 
19 F-NMR (CDCl3), δ: -62.99 (s, 3F). 
UPLC-MS: Rt 2.21 (100%) MS (ESI)+: 324.2 [M+H]+. 
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Ethyl 3-(4-iodobenzamido)benzoate (181) 
(C16H14INO3; M.W.= 395.20) 
 
Reagent: 4-iodobenzoyl chloride (175) (0.500 g, 1.88 mmol); 
Reagent: ethyl 3-aminobenzoate (45) (0.309 g, 1.88 mmol);  
General Procedure 17; 
White solid;  
T.L.C. System: n-hexane-EtOAc 8:2 v/v, Rf: 0.40; 
Purification1: Recrystallisation from EtOH; 
Purification 2: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 60:40 in 10CV); 
Yield: 0.270 g (37%); 
1H-NMR (CDCl3), δ: 1.32 (t, J=7.1 Hz, 3H, H-16), 4.30 (q, J= 7.1 Hz, 2H, H-15), 7.37-7.40 (m, 1H, H-
aromatic), 7.53 (d, J= 8.5 Hz, 2H, H-aromatic), 7.77 (d, J= 8.5 Hz, 2H, H-aromatic), 7.79-7.82 (m, 1H, 
H-aromatic),7.85 (bs, 1H, NH), 7.97-7.99 (m, 1H, H-aromatic), 8.02-8.03 (m, 1H, H-aromatic), 
13C-NMR (CDCl3), δ: 14.3 (CH3, C-16), 61.2 (CH2, C-15), 121.0, 124.6, 125.8, 128.6, 129.3, 138.1 (CH, 
C-aromatic), 99.1, 131.4, 134.0, 137.8, (C, C-aromatic), 165.0, 166.1 (C, C-7,14). 
UPLC-MS: Rt 2.21 (>99%) MS (ESI)-: 398.2 [M-H]-. 
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Methyl 2-(3-chloro-2-methylbenzamido)benzoate (182) 
(C16H14ClNO3; M.W.= 303.74) 
 
Reagent: 3-chloro-2-methylbenzoyl chloride (177) (0.150 g, 0.79 mmol); 
Reagent: methyl 2-aminobenzoate (18) (0.120 g, 0.79 mmol);  
General Procedure 17; 
White solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.50; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 80:20 in 15CV); 
Yield: 0.067 g (28%); 
1H-NMR (CDCl3), δ: 2.57 (s, 3H, H-7), 3.93 (s, 3H, H-16), 7.16-7.20 (m, 1H, H-aromatic), 7.24-7.28 (m, 
1H, H-aromatic), 7.48-7.51 (m, 2H, H-aromatic), 7.63-7.66 (m, 1H, H-aromatic), 8.11 (dd, J1= 6.3 Hz, 
J2= 1.5Hz, 1H, H-aromatic), 8.90-8.93 (m, 1H, H-aromatic), 11.45 (bs, 1H, NH). 
13C-NMR (CDCl3), δ: 17.1 (CH3), 52.4 (CH3), 123.0, 125.3, 126.0, 127.0, 131.0, 131.1, 134.3 (CH, C-
aromatic), 115.3, 134.5, 136.1, 139.0, 141.4 (C, C-aromatic), 167.7, 168.7 (C, C-8, 15). 
UPLC-MS: Rt 2.50 (>98%) MS (ESI)+: 304.1 [M+H]+. 
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Methyl 3-(3-chloro-2-methylbenzamido)benzoate (183) 
(C16H14ClNO3; M.W.= 303.74) 
 
Reagent: 3-chloro-2-methylbenzoyl chloride (177) (0.150 g, 0.79 mmol); 
Reagent: methyl 3-aminobenzoate (18) (0.120 g, 0.79 mmol); 
General Procedure 17; 
White solid;  
T.L.C. System: n-hexane-EtOAc 7:3 v/v, Rf: 0.50; 
Purification: Biotage Isolera One automated flash column chromatography (cartridge: SNAP KP SIL 
25g, n-hexane-EtOAc 100:0 increasing to n-hexane-EtOAc 80:20 in 15CV); 
Yield: 0.073 g (30%); 
1H-NMR (CDCl3), δ: 2.40 (s, 3H, H-7), 3.77 (s, 3H, H-16), 7.08-7.12 (m, 1H, H-aromatic), 7.25-7.27 (m, 
1H, H-aromatic), 7.36-7.39 (m, 2H, H-aromatic), 7.72-7.75 (m, 1H, H-aromatic), 7.80 (bs, 1H, NH), 
7.95-7.97 (m, 1H, H-aromatic), 8.05 (s, 1H, H-10). 
13C-NMR (CDCl3), δ: 17.0 (CH3), 52.2 (CH3), 120.8, 124.4, 124.9, 125.8, 126.9, 129.3, 131.0 (CH, C-
aromatic), 131.0, 134.2, 136.0, 138.0, 138.4 (C, C-aromatic), 166.6, 167.4 (C, C-8,15). 
UPLC-MS: Rt 2.17 (100%) MS (ESI)+: 304.1 [M+H]+. 
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